<SEC-DOCUMENT>0001493152-22-034990.txt : 20221209
<SEC-HEADER>0001493152-22-034990.hdr.sgml : 20221209
<ACCEPTANCE-DATETIME>20221209105709
ACCESSION NUMBER:		0001493152-22-034990
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20221209
DATE AS OF CHANGE:		20221209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268675
		FILM NUMBER:		221453977

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>formf-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As filed with the Securities and Exchange Commission
on December 9, 2022. </B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Statement No. 333-268675 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Amendment No. 1 to</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
F-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
Applicable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Translation
of Registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Martello
Court</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Admiral
Park</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>St.
Peter Port</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
GY1 3HB</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+44
(0)20 7495 2379</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including area code, of Registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
    </B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2836</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other Jurisdiction of</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
    or Organization)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma US, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>420
Lexington Avenue, Suite 1405</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10170</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(917)
225-9646</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jeffrey
    Fessler</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sheppard,
    Mullin, Richter &amp; Hampton LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30
    Rockefeller Plaza</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10112-0015</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    653 8700 </B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ed
    Lukins</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ed
    Dyson</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Orrick,
    Herrington &amp; Sutcliffe (UK) LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>107
    Cheapside</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>London
    EC2V 6DN</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>United
    Kingdom</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+44
    (0) 207 862 4620 </B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anthony
    J. Marsico</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dorsey
    &amp; Whitney LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>51
    West 52nd Street</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, New York 10019</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    415-9200</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, check
the following box and list the Securities Act of 1933 registration statement number of the earlier effective registration statement for
the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list
the Securities Act of 1933 registration statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act of 1933, check the following box and list
the Securities Act of 1933 registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 21%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period* for complying with any new or revised financial accounting standards provided
pursuant to Section 7(a)(2)(B) of the Securities Act of 1933. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT
    TO COMPLETION</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>DATED
    DECEMBER 9, 2022</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>6,315,789
</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>American Depositary Shares</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Representing
410,526,285 Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formf-1a_001.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV>

<DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are offering 6,315,789 American Depositary
Shares, or ADSs, of OKYO Pharma Limited. Each ADS represents 65 ordinary shares. Our ADSs are currently trading on the Nasdaq Capital
Market, or Nasdaq, under the ticker symbol &ldquo;OKYO&rdquo;. On December 7, 2022, the closing sale price of our ADSs was $1.90
per share. The public offering price per ADS will be determined through negotiation between us and the underwriters in the offering
and the recent market price used throughout this prospectus may not be indicative of the actual offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ordinary shares are admitted
to listing on the standard segment of Official List of the United Kingdom Financial Conduct Authority, or FCA, and to trading on the
main market for listed securities, or Main Market,of London Stock Exchange plc, or LSE, under the symbol &ldquo;OKYO.&rdquo; On December
7, 2022, the last reported sale price of our ordinary shares was &pound; 0.0275 per share (equivalent to $0.034 per ADS
based on an exchange rate of &pound;1.00 to $1.2292). For a discussion of the factors considered in determining the public offering
price of our ADSs, see &ldquo;Underwriting&rdquo;.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our ADSs involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 10 of this prospectus for a discussion
of information that you should consider before investing in our ADSs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are an &ldquo;emerging growth company,&rdquo; or EGC, as defined under applicable Securities and Exchange Commission, or SEC, rules and,
as such, have elected to comply with certain reduced public company reporting requirements for this and future filings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are also a &ldquo;foreign private issuer,&rdquo; as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act,
and are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy
solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the
reporting and &ldquo;short-swing&rdquo; profit recovery provisions under Section 16 of the Exchange Act. Moreover, we are not required
to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    ADS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions (1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
    before expenses, to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We refer you to &ldquo;Underwriting&rdquo; beginning on page 126 of
this prospectus for additional information regarding underwriting compensation.</P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the representative of the underwriters an over-allotment option to purchase up to an additional 947,369 ADSs from
us at the public offering price, less the underwriting discounts and commissions, within 45 days from the date of this prospectus to
cover over-allotments, if any. If the representative of the underwriters exercises their over-allotment option in full, the total underwriting
discounts and commissions payable will be $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before
expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver our ADSs to purchasers in this offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formf-1a_002.jpg" ALT="" STYLE="height: 552px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center">Page</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presentation of Financial Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">ii</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">40</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market and Industry Data</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">41<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademarks, Service Marks and Tradenames</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">41<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Rate Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">41</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price Range of Our Ordinary Shares</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">42</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">43</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">44</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Consolidated Financial Data</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">46</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ba_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">47</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">58</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">79</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Party Transactions</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">88</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Shareholders</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">89</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Share Capital and Memorandum and Articles of Incorporation</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">90</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ak_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of the American Depositary Shares</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">110</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares and ADSs Eligible For Future Sale</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">121</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain U.S. and Guernsey Tax Considerations</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">122</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">126</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of This Offering</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">133</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">133</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">133</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service of Process and Enforcement of Liabilities</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">133</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional Information</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">134</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
are responsible for the information contained in this prospectus and any free-writing prospectus we prepare or authorize. We have not
authorized anyone to provide you with different information, and we take no responsibility for any other information others may give
you. We are not making an offer to sell our ADSs in any jurisdiction where the offer or sale is not permitted. For the avoidance of doubt,
we are not, making an offer to sell our ordinary shares in any jurisdiction. You should not assume that the information contained in
this prospectus is accurate as of any date other than the date on the front cover of this prospectus, regardless of the time of delivery
of this prospectus or the sale of any ADSs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States, we have not done anything that would permit this offering or possession or distribution of this
prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United States
who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering and
the distribution of this prospectus outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a non-cellular company limited by shares incorporated under the Companies (Guernsey) Law 2008, or the Guernsey Companies Law, and
a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the SEC, we are currently eligible for treatment
as a &ldquo;foreign private issuer,&rdquo; or FPI. As an FPI, we will not be required to file periodic reports and financial statements
with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the  Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>About
This Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, all references in this registration statement to the terms &ldquo;OKYO,&rdquo;
&ldquo;OKYO Pharma Limited,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to
OKYO Pharma Limited and our wholly owned subsidiary OKYO Pharma US Inc..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks and trade names in this registration statement may be referred to without the &reg; and
&trade; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest
extent under applicable law, their rights thereto. This registration statement contains additional trademarks, service marks and trade
names of others, which are the property of their respective owners. We do not intend to use or display other companies&rsquo; trademarks,
service marks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this registration statement, unless otherwise stated, all references to &ldquo;U.S. dollars&rdquo; or &ldquo;US$&rdquo; or &ldquo;$&rdquo;
or &ldquo;cents&rdquo; are to the currency of the United States of America, and all references to &ldquo;Pounds Sterling&rdquo; or &ldquo;&pound;&rdquo;
or &ldquo;pence&rdquo; are to the currency of the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this registration statement, any reference to any provision of any legislation shall include any amendment, modification, re-enactment
or extension thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender
shall include the feminine or neutral gender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
discusses in this prospectus its business strategy, market opportunity, capital requirements, product introductions and development plans
and the adequacy of the Company&rsquo;s funding. Other statements contained in this prospectus, which are not historical facts, are also
forward-looking statements. OKYO has tried, wherever possible, to identify forward-looking statements by terminology such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates&rdquo; and other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
cautions investors that any forward-looking statements presented in this prospectus, or that OKYO may make orally or in writing from
time to time, are based on the beliefs of, assumptions made by, and information currently available to, OKYO. These statements are based
on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond
its control or ability to predict. Although OKYO believes that its assumptions are reasonable, they are not a guarantee of future performance,
and some will inevitably prove to be incorrect. As a result, its actual future results can be expected to differ from its expectations,
and those differences may be material. Accordingly, investors should use caution in relying on forward-looking statements, which are
based only on known results and trends at the time they are made, to anticipate future results or trends. Certain risks are discussed
in this prospectus and also from time to time in OKYO&rsquo;s other filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus and all subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf
are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. The Company does not
undertake any obligation to release publicly any revisions to its forward-looking statements to reflect events or circumstances after
the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, you should consider the risks provided under &ldquo;Risk factor summary&rdquo; in this prospectus and in the Form 20-F for
the fiscal year ended March 31, 2022 as filed with the SEC (the &ldquo;2022 Form 20-F&rdquo;) incorporated by reference
in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Presentation
of Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus includes our audited consolidated financial statements as of March 31, 2022 and 2021 and for the years ended March
31, 2022, 2021 and 2020 which are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued
by the International Accounting Standards Board, or IASB. None of our financial statements were prepared in accordance with generally
accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Our financial information is
presented in U.S. dollars. For the convenience of the reader, in this prospectus, unless otherwise indicated, translations from Pounds
Sterling into U.S. dollars were made at the rate of &pound;1.00 to $1.2292 which was the noon buying rate of the Federal Reserve
Bank of New York on December 2, 2022. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that
could actually have been purchased upon exchange of Pounds Sterling at the dates indicated.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in
some tables may not be an arithmetic aggregation of the figures that preceded them.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider
in making your investment decision. Before investing in our ADSs or ordinary shares, you should carefully read this entire prospectus,
including our consolidated financial statements and the related notes and the information set forth under the sections titled &ldquo;Risk
Factors,&rdquo; &ldquo;Special Note Regarding Forward-Looking Statements,&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; in each case included elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I>&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory
eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays
a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting
inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product
candidate, for the treatment of dry eye disease (&ldquo;DED&rdquo;). We also plan to evaluate its potential in benefiting patients with
ocular neuropathic pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM,
lipidated-peptide preclinical analogue candidate that is currently in developmental stage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Ltd., a related party) a license
from On Target Therapeutics LLC, or OTT, to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed
by OTT from Tufts Medical Center Inc., or TMC, to support our ophthalmic disease drug programs. These licenses gave us the right to exploit
the intellectual property, or IP estate which is directed to compositions-of-matter and methodologies for treating ocular inflammation,
DED, with chemerin or lipid-linked chemerin analogues. We also have a license from TMC to a separate IP estate for treating symptoms
of ocular neuropathic pain and uveitis associated pain. On August 6, 2019, we signed a collaborative agreement with TMC on a research
program focused on ocular neuropathic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2021, we announced the appointment of Mr. Gabriele Cerrone as Non-Executive Chairman and Director, and Gary S. Jacob, Ph.D.
as Chief Executive Officer and Director. The addition of these two individuals was a significant step for us, highlighting a careful
realignment of the strategic focus of our research and development program, with the aim of facilitating advancement of both of our preclinical
programs. We believed this realignment would allow us to file investigational new drug, or IND, applications on our drug
candidates with the U.S. Food and Drug Administration, or FDA, in the shortest time possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OK-101</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101,
our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one
of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation
accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. There are presently
approximately 20 million people suffering from DED in the U.S. alone (Farrand et al. AJO 2017; 182:90), with the disease affecting approximately
up to 34% of the population aged 50+ (Dana et al. AJO 2019; 202:47), and with women representing approximately two-thirds of those affected
(Matossian et al. J Womens Health (Larchmt) 2019; 28:502&ndash;514). Prevalence of DED is anticipated to increase substantially in the
next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We
believe this increase in prevalence of DED represents a major expanding economic burden to public healthcare. According to Market
Research Report, Dry Eye Disease, December 2020, the global DED market in 2019 was approximately $5.22 billion, with the market size
expected to reach $6.54 billion by 2027. In addition, DED causes approximately $3.8 billion annually in healthcare costs and represents
a major economic burden to public healthcare, accounting for more than $50 billion to the U.S. economy annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, there are 5 prescription drugs available to treat DED: 1) Restasis (0.05% cyclosporine), 2) Cequa (0.09% cyclosporine), 3) Xiidra
(5% lifitegrast), 4) Tyrvaya (0.03 mg varenicline), and 5) Eysuvis (0.25% loteprednol &ndash; a corticosteroid for short term use only).
However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments available
to them through the medical community.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient population suffering
from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical
trials. The evidence from over 40 years of scientific literature, however, suggests inflammation as the most common underlying element
of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is looking to be an attractive approach
in improving symptoms in DED patients. Moreover, large number of dry eye patients suffer from ocular neuropathic pain, making their condition
more resistant to topical anti-inflammatory therapy, and a drug capable of targeting both of these aspects of DED would be a significant
addition to the ocular-care practitioner&rsquo;s arsenal for the treatment of DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chemerin receptor (CMKLR1 or ChemR23) is a chemokine like GCPR expressed on select populations of cells including inflammatory mediators,
epithelial and endothelial cells as well as neurons and glial cells in the dorsal root ganglion, spinal cord, and retina. Activation
of CMKLR1 by chemerin has been shown to resolve the inflammation and pain in animal models of asthma and pain, respectively. We have
been pioneering the development of OK-101, a lipidated-chemerin analogue, which is an agonist of CMKLR1, in treating DED and other ocular
inflammatory conditions. OK-101 was first identified in a program developed by OTT using membrane-tethered ligand technology.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
expand our understanding of the structure-activity relationships of the lipidated-chemerin analogues, such as OK-101, as agonists of
the chemerin receptor, we synthesized a small library of analogues of OK-101. We screened these analogues in a cell-line based receptor
binding assay to characterize the agonist potency of these lipidated-chemerin analogues. This work has also been coupled to an evaluation
of a subset of these analogues&rsquo; potential in treating DED by using a variety of preclinical studies and dry eye animal model studies.
After evaluating a number of our analogues in a mouse model of acute DED by looking at their ability to reduce corneal permeability,
a measure of dry-eye effectiveness, as well as the analogues&rsquo; impact on immune response, we determined that OK-101 was in fact
the most potent analogue in reducing corneal permeability and down-regulating immune response. In addition, in a separate set of animal
model experiments, OK-101 was shown to exhibit potent ocular pain-reducing activity in a ciliary nerve ligation mouse model of corneal
neuropathic pain. Following these studies, we evaluated the ocular tolerance of OK-101 <I>via</I> repeated ocular instillation in rabbits
followed by clinical ophthalmic observations. Rabbit ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis
or hyperemia and no signs of local irritation. With potential anti-inflammatory and neuropathic pain reducing characteristics, we are
developing OK-101 for the treatment of DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Based on the results from the
DED animal model, the neuropathic corneal pain model as well as the rabbit ocular tolerance studies, we moved forward over
the past 18 months with plans to file an IND on OK-101 to treat DED to enable us to begin clinical trials soon thereafter. During
the fourth quarter of 2021 we successfully manufactured a 200-gram batch of OK-101 drug substance needed for initiating the IND-enabling
studies that were begun during the first quarter of 2022. In support of this work, we also had previously signed an agreement on April
13, 2021, with Ora, Inc., or Ora, a major clinical research organization, or CRO, specializing in ophthalmic drug development who have
been providing us with the following services over the past 18 months:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
                                            of the OK-101 pre-IND briefing document used in the successful pre-IND meeting with FDA in
                                            February of this year</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            with the OK-101 pre-IND meeting OKYO accomplished with FDA earlier this year</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            for the planned regulatory publishing and submission of the OK-101 IND in electronic common
                                            technical document, or eCTD, format</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
                                            oversight for the recent successful development of the topical OK-101 formulation for future
                                            human studies</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
                                            oversight of the successful development and qualification of the drug stability analysis
                                            method for OK-101 along with successfully conducting stability studies to establish formulated
                                            drug product is stable for at least 90 days</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            for the recently completed 90 days animal toxicology studies in rabbit and dog</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the past nine months we accomplished the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            topical formulation of the OK-101 drug product as well as initial stability studies</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalized
                                            the bioanalytical method development to support the OK-101 clinical program</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            batch manufacture of cGMP OK-101 for clinical trials</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            toxicokinetic method development</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            toxicology studies in rabbits and dogs</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            stability studies of formulated OK-101</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We recently completed the
final stages of a concerted effort to complete all IND enabling activities and filed with FDA the IND on OK-101 to treat DED on November
18, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on recent consultations with Ora, we are now planning to commence the first human study with OK-101 in the first quarter of 2023, and
because the drug is designed to be administered topically, we plan to skip the standard Phase 1 studies typically expected with orally
delivered or injectable drug candidates in non-life-threatening conditions and open the first trial as a Phase 2 clinical trial in DED
patients (See OKYO Pipeline below). This trial is anticipated to be conducted in approximately 200 to 250 DED patients. The study is
being designed in conjunction with, and will be managed and monitored by Ora, well known for its leadership of ophthalmic clinical trial
activities. The Phase 2 trial is expected to be completed in 6-9 months from enrollment of the first patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OKYO
Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_003.jpg" ALT="" STYLE="height: 355px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, we announced the successful completion of the pre-IND meeting facilitated by Ora with the FDA regarding development
plans for OK-101 to treat DED. Both nonclinical and clinical development milestones were covered in the pre-IND meeting, with the FDA
agreeing that our first human trial would be a Phase 2 safety and efficacy trial in DED patients. The FDA also provided guidance on the
planned protocol for this trial in DED patients, concurring with one particular option OKYO has considered for the protocol which is
to designate co-primary efficacy endpoints covering both a sign and a symptom of DED in the clinical trial. Notably, the final decision
to designate any efficacy endpoints as primary endpoints in this trial would be highly significant as should this phase 2 trial then
meet any prespecified primary endpoints, the trial should considerably affect the timeline to an NDA filing with the FDA for OK-101 to
treat DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Applicable Disease Indications for OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second related ophthalmic disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading
cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis
can damage vital eye tissue, leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections
that reduce inflammation, however, the long-term use of corticosteroids causes risk of cataract and glaucoma, requiring close monitoring
for their potential side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that OK-101, in addition to its potential to treat DED, should also be evaluated to treat allergic conjunctivitis and uveitis.
Correspondingly, once we have an IND on OK-101 in place and are clinically evaluating OK-101 to treat DED, we also plan to explore the
drug candidate&rsquo;s potential to suppress the inflammation associated with allergic conjunctivitis and uveitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OK-201</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAS-Related
G Protein-Coupled Receptors, or MRGPRs, mainly expressed in the sensory neurons, are involved in the perception of pain, thus making
them a promising analgesic target. Activation of MRGPR by Bovine Adrenal Medulla, or BAM, peptide inhibits pain perception by modulating
Ca2+ influx. OK-201, a BAM peptide analogue, licensed from TMC on May 1, 2018, is a potent agonist of human MRGPR and a promising candidate
for the treatment of neuropathic and inflammatory pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2019, we signed a collaborative agreement with TMC and Pedram Hamrah, MD, Professor of Ophthalmology at Tufts University School
of Medicine, Boston, MA as Principal Investigator to evaluate OK-201 and other proprietary lead compounds to suppress corneal neuropathic
pain using a mouse ocular pain model recently developed in Dr. Hamrah&rsquo;s laboratory. Our goal was to further develop this lipidated
peptide, as well as explore additional analogues, for their potential use in treating ocular pain, and for potentially treating long-term
chronic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, we announced positive results of OK-201, a non-opioid analgesic drug candidate delivered topically in Dr. Hamrah&rsquo;s
mouse neuropathic corneal pain model, as a potential drug to treat acute and chronic ocular pain. Importantly, OK-201 demonstrated a
reduced corneal pain response equivalent to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations demonstrated
preclinical &lsquo;proof-of-concept&rsquo; for the topical administration of OK-201 as a potential non-opioid analgesic for ocular pain.
Current treatments for corneal pain are limited to short term non-steroidal anti-inflammatory drugs, or NSAIDs, steroids, and oral gabapentin
and opioids in severe cases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results with OK-201 were encouraging, due to subsequent success obtained with OK-101 (see section above on OK-101) in follow-on animal
model studies utilizing the same mouse corneal neuropathic pain model as for OK-201, we have decided to maintain this drug candidate
at the exploratory level while we focus our primary energy on the OK-101 program to treat DED, based on OK-101&rsquo;s combination of
anti-inflammatory and corneal pain-reducing activities in animal models of these conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
OF RISKS AFFECTING OUR BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks of which you should be aware before making an investment decision. You should carefully consider
all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth in the section
titled &ldquo;Risk Factors&rdquo; before deciding whether to invest in our ADSs. These important risks include, but are not limited to,
the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-left: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
We have only recently committed to our new business and our product candidates are in the early stages of development and it may be some
years until we generate revenue, if at all.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Our product candidates have not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a high degree of failure for product candidates as they progress through clinical trials and clinical trial data may be
interpreted in varying ways which may delay, limit or prevent future regulatory approvals.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of pharmaceutical products carries significant risk of failure in early and late stage development programs.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will continue to incur significant losses for the foreseeable future.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to spend extensively on further research activities and there can be no guarantee that we will have access to sufficient funds to fully realize our research and development plan or to commercialize any products derived from research activities.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we successfully develop a product which shows efficacy in human subjects there remain high barriers to commercial success.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face significant competition from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical companies, universities and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number of established companies engaged in the development and marketing of preparations addressing the DED market. In addition, there are a wide range of products addressing the DED market currently approved and marketed by a number of large and small pharmaceutical companies.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property rights for products that are marketed or in development may result in additional competition from other third-party products. Third parties may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation be paid to such third parties.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates could infringe patents and other intellectual property rights of third parties.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19 has adversely affected our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect our business.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relationship of the UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our product candidates and the approval may be for a more narrow indication than we seek.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from competition.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never obtain approval for our product candidates in other major markets.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may seek a conditional marketing authorization in the United Kingdom and EU for some or all of our current product candidates, but we may not be able to obtain or maintain such designation.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to governmental regulation and other legal obligations related to privacy, data protection and data security. Our actual or perceived failure to comply with such obligations could harm our business.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not know whether an active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will be. As a result, it may be difficult for ADS holders to sell their ADSs.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If you purchase ADSs in this offering, you will suffer immediate dilution of your investment.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of our ADSs may experience substantial dilution upon the exercise of outstanding options and warrants.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#9679; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on July 4, 2007 under the BVI
Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc.. Our legal and commercial name was changed
to Minor Metals &amp; Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation
on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of
our AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry, we were registered
under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability, an indefinite life
and company number 65220. We are domiciled in Guernsey. On July 17, 2018, our Ordinary Shares were admitted to listing on the standard
segment of the Official List of the FCA and admitted to trading on the Main Market of the London Stock Exchange. We are subject to the
Takeover Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB and our telephone number is +44 (0) 20
7495 2379. Our website address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information
contained in, or that can be accessed through, our website is not a part of this registration statement. Our agent for service of process
in the United States is OKYO Pharma US, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;OKYO,&rdquo;
the OKYO logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property of OKYO or our
subsidiary. This prospectus contains additional trade names, trademarks and service marks of others, which are the property of their
respective owners. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the &reg; or
<SUP>TM</SUP> symbols.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of certain
exemptions from various reporting requirements that are applicable to other publicly traded entities that are not EGCs. These exemptions
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    option to present only two years of audited financial statements and related discussion in the section titled &ldquo;Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations&rdquo; in this prospectus;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley
    Act;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory
    audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial
    statements (i.e., an auditor discussion and analysis);</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to submit certain executive compensation matters to stockholder advisory votes, such as &ldquo;say-on-pay,&rdquo;
    &ldquo;say-on-frequency,&rdquo; and &ldquo;say-on-golden parachutes;&rdquo; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to disclose certain executive compensation related items such as the correlation between executive compensation and
    performance and comparisons of the chief executive officer&rsquo;s compensation to median employee compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
107 of the JOBS Act also provides that an EGC can take advantage of the extended transition period provided in Section 13(a) of the Exchange
Act, for complying with new or revised accounting standards. As a result, an EGC can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will remain an EGC until the earliest of: (1) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion;
(2) the last day of 2023; (3) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Exchange
Act, which would occur on the last day of any fiscal year that the aggregate worldwide market value of our common equity held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or (4) the date on which we have
issued more than $1.0 billion in non-convertible debt securities during any three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Foreign Private Issuer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> report under the Exchange Act as a non-U.S.
company with FPI status. Even after we no longer qualify as an EGC, as long as we qualify as an FPI under the Exchange Act we will be
exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
    under the Exchange Act;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability
    for insiders who profit from trades made in a short period of time; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and
    other specific information, and current reports on Form 8-K upon the occurrence of specified significant events.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FPIs
are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an EGC, but
remain an FPI, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither
an EGC nor an FPI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>The
Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: justify"><FONT STYLE="font-size: 10pt">ADSs offered by us</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 64%; text-align: justify"> <FONT STYLE="font-size: 10pt">6,315,789</FONT> <FONT STYLE="font-size: 10pt"> ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ordinary shares to be outstanding after this offering (1)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,825,566,753 ordinary shares, including ordinary shares represented
    by ADSs (or 1,887,145,738 ordinary shares if the underwriters exercise in full their over-allotment option to purchase 947,369
    ADSs)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Over-allotment option</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-size: 10pt">947,369</FONT> <FONT STYLE="font-size: 10pt"> ADSs.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ADSs</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Each ADS represents 65 ordinary shares of no par value. The depositary will hold the ordinary shares underlying your ADSs and you will have rights as provided in the deposit agreement among us, the depositary, and holders and beneficial owners of ADSs from time to time. To better understand the terms of our ADSs, see &ldquo;Description of the American Depositary Shares.&rdquo; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Depositary</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">JPMorgan Chase Bank, N.A..</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We estimate that the net proceeds from our sale
    of ADSs in this offering will be approximately $10.7 million (or approximately $12.3 million if the underwriters exercise
    their over-allotment option in full), assuming a public offering price of $1.90 per ADS, which reflects the closing trade
    price on Nasdaq on December 7, 2022 after deducting the underwriting discounts and commissions and estimated offering expenses
    payable by us.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to use the net proceeds we receive from
    this offering to fund the initial Phase 2 clinical trial of OK-101 in DED patients and for working capital and other general corporate
    purposes.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &ldquo;Use of Proceeds&rdquo; for additional information.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">See &ldquo;Risk Factors&rdquo; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ADSs</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Nasdaq symbol</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;OKYO&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The number of ordinary shares to be outstanding after this offering is based on 1,415,040,468 ordinary shares outstanding as of December
7, 2022, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">81,820,000 ordinary shares
    issuable upon the exercise of share options at exercise prices of between $0.055 and $0.191 per ordinary share of which
    24,375,000 ordinary shares are currently exercisable and 57,445,000 are exercisable between January 6, 2023 and January 31, 2032;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,909,090
    ordinary shares that currently may be issued upon the exercise of warrants to purchase ordinary shares at exercise prices of between
    $0.034 and $0.055 per ordinary share.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise indicated, this prospectus reflects and assumes the following:</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of outstanding share options or warrants after December 7, 2022; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the underwriters&rsquo; over-allotment option.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Summary
Consolidated Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our summary consolidated financial data for the periods indicated. We have derived the consolidated statement
of operations data for the years ended March 31, 2022, 2021 and 2020 and the consolidated balance sheet data as of March
31, 2022 from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily
indicative of the results that should be expected for any future period. You should read the following summary consolidated financial
data together with the audited consolidated financial statements included elsewhere in this prospectus and the sections titled &ldquo;Exchange
Rate Information&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB.
We report our financial results in U.S. dollars.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statement of Operations and Comprehensive Loss Data: </B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in thousands except share and per share data)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: justify">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,301</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(174</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(518</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,917</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,192</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,017</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,535</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,535</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">787</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net loss attributable to ordinary shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,457</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic and diluted net loss per ordinary share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheet Data:</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Ended March 31, 2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As<BR>
Adjusted(1)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(in thousands except share and per share data)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">2,701</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"> <FONT STYLE="font-size: 10pt">13,364</FONT> </TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Working capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,942</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13,606</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,301</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">14,964</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Total shareholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,947</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">13,611</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1)
                                            As adjusted to give effect to the sale by us of 6,315,789 ADSs (representing 410,526,285
                                            ordinary shares) at an assumed public offering price of $1.90 per ADS in this
                                            offering, which reflects the closing trade price on Nasdaq on December 7, 2022 after
                                            deducting the underwriting discounts and commissions and estimated offering expenses payable
                                            by us in connection with this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should carefully consider the risks described below, together with all of the other information in this registration statement. The risks
and uncertainties below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we believe
to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition and results
of operations could be seriously harmed and potential future investors in our ADSs could lose all or part of their investment. Further,
if we fail to meet the expectations of the public market in any given period, the potential market price of our ADSs could decline. We
operate in a highly competitive environment that involves significant risks and uncertainties, some of which are outside of our control.
If any of these risks actually occurs, our business and financial condition could suffer and the potential market price of our ADSs could
decline.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have only recently committed to our new business and our product candidates are in the early stages of development and it may be some
years until we generate revenue, if at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates, OK-101 and OK-201, are both very early in the development stage and even the lead product candidate, OK-101, is still
in the pre-clinical stage. Through our scientific collaborators, we have only recently completed initial pre-clinical studies with respect
to OK-101 and OK-201 and our ability to generate product revenue, which is not expected to occur for several years, if ever, will depend
heavily on the successful development of the product candidates, many stages of clinical trials, regulatory approval and eventual commercialization.
We have only recently committed to our new business operating as a life sciences and biotechnology business. We currently generate no
revenue from sales of any product and may never be able to develop or commercialize a marketable product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates have not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
early stages of our business strategy carry significant risks associated with product candidates which have not been evaluated in human
clinical trials. Not only may encouraging results seen in pre-clinical trials not be indicative of results in later clinical trials but
given that the product candidates have only been evaluated in mouse models to date, unexpected or adverse effects may be seen once the
product candidates enter the human clinical trials stage which in turn may create significant hurdles to further development or lead
to the abandonment of further development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is a high degree of failure for product candidates as they progress through clinical trials and clinical trial data may be interpreted
in varying ways which may delay, limit or prevent future regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies in the life sciences and biotechnology sector have made significant initial progress only to suffer significant setbacks in
later stage clinical trials and there is a high failure rate for product candidates as they proceed through clinical trials. Data obtained
from pre-clinical and clinical activities is subject to varying interpretations which may delay, limit or prevent applications for regulatory
approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
development of pharmaceutical products carries significant risk of failure in early and late stage development programs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of pharmaceutical products is inherently uncertain, even in late-stage product development programs. There is a high failure
rate in the development of pharmaceutical products and there is a substantial risk of adverse, undesirable, unintended or inconclusive
results from testing or pre-clinical or clinical trials, which may substantially delay, or halt entirely, or make uneconomic, any further
development of our products and may prevent or limit the commercial use of such products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pre-clinical development of OK-101 and initial studies in animal models have been encouraging, the scope of these studies is limited,
and significant risks exist that OK-101 may never progress to a commercially viable product. Laboratory studies in animal models carry
the risk that similar results may not be seen or reproduced in future tests and trials, and there can be no guarantee that a successful
test in a mouse or other animal model will be capable of being reproduced in a human clinical trial. Small scale trials and the results
thereof, can be misleading as to efficacy, safety and other findings, as the outcome may be influenced by laboratory or demographic factors
and not due to the chemistry or biological effect of the drug candidate being evaluated. Larger scale trials often fail to produce the
same positive results seen in small scale trials for a variety of reasons and clinical trials in humans frequently fail to reproduce
efficacy seen in animal trials in the laboratory. Failure can often result after significant sums have been expended on research and
often where initial trial results (both in animals and in humans) have shown very encouraging results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
initially intends to conduct laboratory and pre-clinical trials to establish safety and efficacy of our products. Due to the inherent
risks involved in developing pharmaceutical products, there is a risk that some or all of our products will not ultimately be successfully
developed or launched. In addition, the planned clinical trials may fail to show the desired safety and efficacy. This may be the case
even if the FDA approves an IND application as positive data in animal studies may not be reflected or reproduced in human trials. Successful
completion of one stage of development of a pharmaceutical product does not ensure that subsequent stages of development will be successful.
Our inability to market any of our products currently under development would adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently primarily dependent for our short to medium-term success on a single early-stage product, OK-101, which is a research product
that has shown pre-clinical potential but has not yet been tested on humans and has not obtained the necessary approvals required to
conduct Phase I clinical trials in humans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
commercial development of OK-101 is highly dependent on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71.45pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful conduct of human trials in the initial indications of DED;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals for OK-101 in the United States and other jurisdictions where separate approval is required and where we subsequently
    choose to market OK-101;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of OK-101, if and when approved;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of OK-101 by patients, the medical community and third-party payers;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    competing effectively with existing therapies and in particular with established products addressing the same clinical needs;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    influencing the treatment guidelines in relevant territories; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    clinical trials to provide additional data to support commercialization of OK-101 and to permit wider label claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these milestones are not met, our business, financial condition, prospects and results of operations could be materially adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to raise substantial additional capital to develop and commercialize our product candidates and our failure to obtain funding
when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, our cash and cash equivalents balance was approximately $2.7 million and our working capital was approximately $2.9
million. Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will
be required to raise additional capital to complete the development and commercialization of our current product candidates. We have
historically relied upon private and public sales of our equity, as well as debt financings to fund our operations. In order to raise
additional capital, we may seek to sell additional equity and/or debt securities or obtain a credit facility or other loan, which we
may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors,
including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required
or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our
product candidate, restrict our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional
capital at acceptable terms would result in a material and adverse impact on our operations.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
may hinder our ability to obtain future financing.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP, our independent registered public accounting firm for the fiscal year ended March 31, 2022, has included an explanatory paragraph
in their opinion that accompanies our audited consolidated financial statements as of and for the year ended March 31, 2022, indicating
that liquidity position post November 2022 raises substantial doubt about our ability to continue as a going concern. If we are unable
to improve our liquidity position by December 2022, we may not be able to continue as a going concern. The accompanying consolidated
financial statements do not include any adjustments that might result if we are unable to continue as a going concern and, therefore,
be required to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors
to suffer the loss of all or a substantial portion of their investment.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
anticipate that we will continue to incur significant losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of our future net losses will depend, in part, on the rate of our future expenditures, including further research and development
activity. The amount of net losses will also depend on our success in developing and commercializing OK-101 and other products that generate
significant revenue. Any failure by us to become and remain profitable could depress the value of the ADSs and could impair our ability
to expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to spend extensively on further research activities and there can be no guarantee that we will have access to sufficient funds
to fully realize our research and development plan or to commercialize any products derived from research activities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur further significant expenses in connection with our ongoing research and development activities in relation to our products
in development, including the future funding of clinical studies, registration, manufacturing, marketing, sales and distribution. To
finance fully our strategy, we may require more capital than is available from our existing cash balances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
to adequate additional financing, whether through debt financing, an equity capital raise or a suitable partnering transaction may not
be available to us on acceptable terms, or at all. Further, while the potential economic impact brought by, and the duration of the COVID-19
pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability
to access capital, which could negatively impact our short-term and long-term liquidity. If we are unable to raise capital, we could
be forced to delay, reduce or eliminate our research and development programs or commercialization efforts. Any additional equity fundraising
may be dilutive for our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could have a material adverse effect on our business financial condition, prospects and results of operation and may
lead us to delay, reduce or abandon research and development programs or commercialization of some of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Commercialization of Our Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we successfully develop a product which shows efficacy in human subjects there remain high barriers to commercial success</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we were to receive regulatory approval for OK-101 or any other products, we may be unable to commercialize them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of factors that may inhibit our efforts to commercialize OK-101 or any other products on our own, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to or persuade adequate numbers of potential practitioners to prescribe any future
    products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of marketing and promotion above those anticipated by us; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to secure a suitable level of pricing and/or reimbursement approval from the relevant regulatory authorities in the countries
    we are targeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we may only seek to enter into arrangements with third parties to perform sales and marketing services in non-core territories, any such
arrangements could result in our product revenues (or the profitability of such product revenues) being lower than if we were to market
and sell the products itself. In addition, we may not be successful in entering into arrangements with third parties to sell and market
our products or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources
and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either
on our own or in collaboration with third parties, we will not be successful in commercializing our products, which in turn would have
a material adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also invested and will continue to invest resources into the development of other products, such as OK-201. Even where these products
are successfully developed and marketing approval is secured from relevant regulatory authorities, these products might not achieve commercial
success. Factors which could limit commercial success of a product include but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    market acceptance or a lack of recognition of the unmet medical need for the product amongst prescribers;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    competitor products entering the market;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and relative efficacy, safety or cost of competitive products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to supply a sufficient amount of the product to meet market demand;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    funding being available to market the product adequately;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to enforce intellectual property rights, or the existence of third-party intellectual property rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    concerns arising pre- or post-launch resulting in negative publicity or product withdrawal or narrowing of the product label and
    the group of persons who may receive the product;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labelling
    being restricted/narrowed in the future and in the future by regulatory agencies; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusals
    by government or other healthcare payors to fund the purchase of the products by healthcare providers at a commercially viable level
    (or at all) or otherwise to restrict the availability of approved products on other grounds.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the foregoing were to occur, it could materially and adversely affect our business, financial condition, prospects and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face significant competition from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical
companies, universities and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number
of established companies engaged in the development and marketing of preparations addressing the DED market. In addition, there are a
wide range of products addressing the DED market currently approved and marketed by a number of large and small pharmaceutical companies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technical and other resources, such as larger research and development teams,
proven marketing and manufacturing organizations and well-established sales forces. Our competitors may succeed in developing, acquiring
or licensing drug products that are more effective or less costly than products which we are currently developing or which it may develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical companies may invest heavily to accelerate the discovery and development of products that could make our products less
competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy,
convenience, tolerability or safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors
may succeed in obtaining patent protection, receiving approval from the FDA, the European Medicines Agency, or EMA, or that of another
relevant regulatory authority or discovering, developing and commercializing pharmaceutical products before we do, which would have a
material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and price of our competitors&rsquo; products could limit the demand, and the price we are able to charge, for any of our
products, if approved for sale. We will not achieve our business plan if acceptance is inhibited by price competition or the reluctance
of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to
reserve our products for use in limited circumstances. Competition from lower-cost generic pharmaceuticals may also result in significant
reductions in sales volumes or prices for our products, which could materially adversely affect our business, prospects, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third party supply, development and manufacturing and clinical service relationships and on single manufacturing sites
for certain products. Our business strategy utilizes the expertise and resources of third parties in a number of areas, including the
conduct of clinical trials, other product development, manufacture and the protection of our intellectual property rights in various
geographical locations. This strategy creates risks for us by placing critical aspects of our business in the hands of third parties
whom we may not be able to manage or control adequately and who may not always act in our best interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
we are dependent upon third parties for the development or manufacture of certain products, our ability to procure our development or
manufacture in a manner which complies with regulatory requirements may be constrained, and our ability to develop and deliver such material
on a timely and competitive basis may be materially adversely affected, which may impact revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements for pharmaceutical products tend to make the substitution of suppliers and contractors costly and time-consuming. Alternative
suppliers may not be able to manufacture products effectively or obtain the necessary manufacturing licenses from relevant regulatory
authorities. The unavailability of adequate commercial quantities, the inability to develop alternative sources, a reduction or interruption
in supply of contracted services, or a significant increase in the price of materials and services, could have a material adverse effect
on our ability to manufacture and market our products or to fulfill orders from our distributors or licensees, which in turn would have
a material adverse impact on our cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insurance
coverage and reimbursement may be limited, unavailable or may be reduced over time in certain market segments for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and third-party payers, such as private health insurers, decide which pharmaceutical products they will cover and the amount
of reimbursement. Reimbursement may depend upon a number of factors, including the payer&rsquo;s determination that use of a product
is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under the payor&rsquo;s health plan;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third- party payer is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement, or to demonstrate commercial
value compared to existing established treatments. Even if we are able to furnish the requested data, there is no guarantee that a third-party
payor will cover a product. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, we may be unable to achieve or sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in the future, seek approval to market our products in the EU, the US and in selected other jurisdictions. In the EU, the pricing
of prescription pharmaceuticals is subject to national governmental control and pricing negotiations with governmental authorities can,
in some circumstances, take several years after obtaining marketing approval for a product. In addition, market acceptance and sales
of our products will depend significantly on the availability of adequate coverage and reimbursement from third-party payers and may
be affected by existing and future healthcare reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing efforts of governments, insurance companies, managed care organizations and other payers of healthcare services to contain
or reduce costs of healthcare and/or impose price controls may materially adversely affect our ability to set prices for our products,
generate revenues and achieve or maintain profitability. Any reduction in government reimbursement programs may result in a similar reduction
in payments from private payers, which may materially adversely affect our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property rights
for products that are marketed or in development may result in additional competition from other third-party products. Third parties
may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation be paid to
such third parties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of our success will, to a significant degree, depend on our ability to establish, maintain, defend and enforce adequate intellectual
property rights and to operate without infringing the proprietary or intellectual property rights of third parties. We have been granted,
or have in-licensed rights under, a number of key patent families for OK-101 (or other proprietary rights), and patent applications are
pending in the U.S., the EU, and certain other jurisdictions. We may develop or acquire further technology or products that are not patentable
or otherwise protectable. The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can
be uncertain. Patents or other rights might not be granted under any pending or future applications filed or in-licensed by us and any
claims allowed might not be sufficiently broad to protect our technologies and products from competition. Competitors may also successfully
design around key patents held by us, thereby avoiding a claim of infringement. There is a risk that not all relevant prior art has been
identified with respect to any particular patent or patent application and the existence of such prior art may invalidate any patents
granted (or result in a patent application not proceeding to grant). Patents or other registerable rights might also be revoked for other
reasons after grant. Third parties may challenge the validity, enforceability or scope of any granted patents. Our defense of our proprietary
rights could involve substantial costs (even if successful) and could result in declarations of invalidity or significantly narrow the
scope of those rights, limiting their value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have filed applications or been granted patents, or obtained additional patents and proprietary rights, which relate to and could
be infringed by our products. An adverse outcome with respect to third party rights such as claims of infringement of patents or third-party
proprietary rights by us could subject us to significant liabilities or require us to obtain a license for the continued use of the affected
rights, which may not be available on acceptable terms or at all, or require us to cease commercialization and development efforts, or
the sale of the relevant products, in whole or in part in the relevant jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to claims for compensation by third parties claiming an ownership interest in the intellectual property rights relating
to a commercially successful product. This may include claims from employee inventors in territories which permit such claims even where
we own the intellectual property rights in question. Any such failure to defend our proprietary intellectual property could have a material
adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain, maintain, defend or enforce the intellectual property rights covering our products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have had certain patents licensed to us in jurisdictions we consider to be important to our business. However, we cannot predict:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree and range of protection any patents will afford against competitors and competing technologies, including whether third parties
    will find ways to invalidate or otherwise circumvent the patents by developing a competitive product that falls outside its scope;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    or when any patents will be granted;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    granted patents will not be contested, invalidated or found unenforceable;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not others will obtain patents claiming aspects similar to those covered by the Company&rsquo;s patents and patent applications;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will need to initiate litigation or administrative proceedings, or whether such litigation or proceedings will be initiated by
    third parties against us, which may be costly and time consuming; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    third parties will claim that our technology infringes upon their rights.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe that we have novel composition of matter on the OK-101 peptide and novel methods of its use in treating DED, we cannot be
sure that these patent applications will issue as patents. Each patent office has different patentability requirements, but we believe
that the license patent applications contain patentable subject matter. The process for issuance of a patent involves correspondence
with each local patent office in the jurisdictions in which the patent application is filed. That process, patent prosecution, involves
a discussion of any relevant prior art and typically a discussion of the scope of the claims. The patent prosecution process can take
several years depending on the jurisdiction and is not in the control of the patent owner, but in the control of the local patent office.
We cannot be sure the outcome of the patent prosecution will be successful and result in issued patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
protection is of importance to us in maintaining our competitive position in our planned product lines and a failure to obtain or retain
adequate protection could have a material adverse effect on our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to prevent disclosure of our trade secrets, know-how or other proprietary information.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to
obtain or enforce. If we are unable to protect our trade secrets adequately the value of our technology and products could be significantly
diminished. Furthermore, our employees, consultants, contract personnel or third-party partners, either accidentally or through willful
misconduct, may cause serious damage to our programs and/or our strategy by disclosing confidential information to third parties. It
is also possible that confidential information could be obtained by third parties as a result of breaches of our physical or electronic
security systems. Any disclosure of confidential data into the public domain or to third parties could allow third parties to access
confidential information and use it in competition with us. In addition, others may independently discover the confidential information.
Any action to enforce our rights against any misappropriation or unauthorized use and/or disclosure of confidential information is likely
to be time-consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.
Any such loss of confidential information or failure to enforce our rights in relation to such confidential information, or unsatisfactory
outcome of any related litigation could have a material adverse effect on our business, prospects, financial condition or results of
operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates could infringe patents and other intellectual property rights of third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of any third party with which we may partner to develop, manufacture, market
and sell our products and use our patent- protected technologies without infringing the patents of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may infringe or may be alleged to infringe existing patents or patents that may be granted in the future which may result in
costly litigation and could result in our having to pay substantial damages or limit our ability to commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
some patent applications in Europe, the U.S. and many foreign jurisdictions may be maintained in secrecy until the patents are issued,
patent applications in such jurisdictions are typically not published until 18 months after filing, and publications in the scientific
literature often lag behind actual discoveries. Accordingly, we cannot be certain that others have not filed patents that may cover our
technologies, our products or the use of our products. Additionally, pending patent applications which have been published can, subject
to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As a
result, we may become party to, or threatened with, future adversarial proceedings or litigation regarding patents with respect to our
products and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims
of the relevant patent or that the patent claims are invalid, and we may not be able to do this. If we are found to infringe a third
party&rsquo;s patent, we could be required to obtain a license from such third party to continue developing and marketing our products
and technology or we may elect to enter into such a license in order to settle litigation or in order to resolve disputes prior to litigation.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain
a license, it could be non- exclusive, thereby giving our competitors access to the same technologies that are licensed to us and could
require us to make substantial royalty payments. We could also be forced, including by court order, to cease commercializing the infringing
technology or products. A finding of infringement could prevent us from commercializing our products or force us to cease some of our
business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade
secrets of third parties could have a similarly negative impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such claims are likely to be expensive to defend, and some of our competitors may be able to sustain the costs of complex patent litigation
more effectively than us can because they have substantially greater resources. Moreover, even if we are successful in defending any
infringement proceedings, we may incur substantial costs and divert management&rsquo;s time and attention in doing so, which could materially
adversely affect our business, prospects, results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
relating to managing growth, employee matters and other risks relating to our business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Growth
may place significant demands on our management and resources. We expect to experience growth in the number of our employees and the
scope of our operations in connection with the continued development and, in due course, the potential commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
potential growth will place a significant strain on our management and operations, and we may have difficulty managing this future potential
growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our current executive officers and their services are critical to the successful implementation of our product
development and regulatory strategies. While suitable contracts of employment are in place including six to 12 months&rsquo; notice periods
for all executive officers, they may give notice to terminate their employment with us at any time. The loss of the services of any of
our executive officers and our inability to find suitable replacements could harm our business, prospects, financial condition, results
of operations and ability to achieve the successful development or commercialization of our products.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Challenges
in identifying and retaining key personnel could impair our ability to conduct and grow our operations effectively. Our ability to compete
in the highly competitive pharmaceutical industry depends upon our ability to attract and retain highly qualified management and sales
teams. We are intending to recruit our own commercial team and expand our existing central infrastructure team. Many of the other pharmaceutical
companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. We might not be able to attract or retain these key persons on conditions
that are economically acceptable. Our inability to attract and retain these key persons could have a material adverse effect on our business,
prospects, financial conditions and results of operation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>COVID-19
has adversely affected our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect
our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, spread globally, substantially impacting the global economy and our operations,
including interrupting preclinical and clinical trial activities and disrupting our supply chain. The spread of an infectious disease,
including COVID-19, may also result in the inability of our suppliers to source or deliver components or raw materials necessary for
our clinical supply on a timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments
in response to the spread of an infectious disease. Such events may result in a period of business disruption, and in reduced operations,
or doctors and medical providers may be unwilling to participate in our clinical trials, any of which could materially affect our business,
financial condition and results of operations. The extent to which COVID-19 impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus
and the actions to contain the coronavirus or treat its impact, among others. A significant pandemic as with COVID-19, or any other infectious
disease, could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting
in an economic downturn that could impact our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become subject to product liability claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability and associated adverse publicity as a result of the clinical testing of our products and sales
of our products once marketing approval is received from relevant regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
or civil proceedings might be filed against us any by study subjects, patients, relevant regulatory authorities, pharmaceutical companies,
and any other third party using or marketing our products. Any such product liability claims may include allegations of defects in manufacturing
or design, negligence, strict liability, a breach of warranties and a failure to warn of dangers inherent in the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our products, if approved. Even if we successfully defend ourselves against such product liability claims it could
require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result
in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our products due to negative public perception;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical study participants or difficulties in recruiting new study participants;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend or settle the related litigation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management&rsquo;s time and our resources;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients, study participants or subjects;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labelling, marketing or promotional restrictions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues from product sales; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any of our products, if approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we will maintain levels of insurance customary for our sector to cover our current and future business operations, any claim that may
be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance
or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. In such cases, we would have to pay any amounts awarded by a court or negotiated
in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our partners, licensees and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost,
or to protect ourselves in any way against actions for damages, this would seriously affect the marketing of our products and, more generally,
be detrimental to our business, prospects, results of operations or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
employees, contractors, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging
in fraud or other misconduct. Misconduct could include intentional failures to comply with FDA or EMA regulations or those of other relevant
regulatory authorities, to provide accurate information to the FDA, EMA or other relevant regulatory authorities, or to comply with manufacturing
standards we have established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, sales, marketing and business arrangements in the life sciences and biotechnology sector are subject to extensive laws and
regulations intended to prevent fraud, misconduct, bribery and other abusive practices. These laws and regulations may restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory
sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental or relevant regulatory authority investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions,
and our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be vulnerable to disruptions of information technology systems or breaches of data security. We are dependent on information technology
systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit confidential
information, including intellectual property, proprietary business information and personal information. It is important that we do so
in a secure manner to maintain confidentiality and integrity of such confidential information. Any failure to do so could adversely affect
our business, prospects, results of operation or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
relationship of the UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
UK formally exited the EU on January 31, 2020, which is commonly known as Brexit. Under the terms of its departure, the UK entered a
transition period during which it continued to follow all EU rules until December 31, 2020, or the Transition Period. On December 30,
2020, the UK and EU signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is considerable uncertainty resulting from a lack of precedent and the complexity of the UK and EU&rsquo;s intertwined legal regimes
as to how Brexit (following the Transition Period) will impact the medical devices industry in Europe. Since a significant proportion
of the regulatory framework in the UK applicable to our business and product candidates is derived from EU directives and regulations,
Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization
of our product candidates in the UK or the EU. The impact will largely depend on the model and means by which the UK&rsquo;s relationship
with the EU is governed post-Brexit and the extent to which the UK chooses to diverge from the EU regulatory framework. For example,
following the Transition Period, the UK will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorizations
and our product candidates will therefore require a separate marketing authorization for such products to be marketed in the UK. It is
also unclear as to whether the relevant authorities in the EU and the UK are adequately prepared for the additional administrative burden
caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would
prevent us from, or delay commercialization of, product candidates in the UK and/or the EEA and restrict our ability to generate revenue
and achieve and sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK for its product candidates,
which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit
will have on process to obtain regulatory approval in the UK for product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the UK&rsquo;s withdrawal from the EU has resulted in the relocation of the EMA from the UK to the Netherlands. This relocation has caused,
and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the UK Medicines and Healthcare
Products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of importation
and export of medical devices, active substance and other components of new drug formulations, and disruption of the supply chain for
clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add
considerably to the development lead time to marketing authorization and commercialization of product candidates in the EU and/or the
UK. Brexit may also result in a reduction of funding to the EMA once the UK no longer makes financial contributions to EU institutions,
such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product
candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our
product candidates and whether the approval may be for a narrower indication than we seek.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
The FDA must review and approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory
review and approval process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed
labeling, as well as the evaluation of the manufacturing process and manufacturers&rsquo; facilities, all of which is lengthy, expensive
and uncertain. To obtain approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials
that the product candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet
the FDA&rsquo;s safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner,
or we may not be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse
to file our application for substantive review or may determine after review of our data that our application is insufficient to allow
approval of our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing
validation studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee
or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections
based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy
during the period of product development, clinical trials and the review process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, EMA or other regulatory authorities also may approve a product candidate for more limited indications than requested or may impose
significant limitations in the form of narrow indications, warnings or a risk evaluation and mitigation strategy, or REMS. These regulatory
authorities may require precautions or contraindications with respect to conditions of use or may grant approval subject to the performance
of costly post-marketing clinical trials. In addition, the FDA, EMA or other regulatory authorities may not approve the labeling claims
that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could
harm the commercial prospects for our product candidates and negatively impact our business, financial condition, results of operations
and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delays
in obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt
our product development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin
to commercially manufacture our product candidates, whether in a third-party facility or in our own facility, if and when established,
we must obtain regulatory approval from the FDA for our manufacturing process and facility. A manufacturing authorization must also be
obtained from the appropriate European Union regulatory authorities and from other foreign regulatory authorities, as applicable. In
order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with cGMP, and perform
extensive audits of vendors, contract laboratories and suppliers. If any of our vendors, contract laboratories or suppliers are found
to be non-compliant with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy
the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing
process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production,
record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply
with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that
we may develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third-party manufacturers fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can
impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension
or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects
to be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the supply of our products from our third-party manufacturers to us is interrupted for any reason, including due to regulatory requirements
or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMP
requirements, contamination, business interruptions or labor shortages or disputes, there could be a significant disruption in commercial
supply of our products. We do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial
sale. An alternative manufacturer would need to be qualified through a supplement to its regulatory filing, which could result in further
delays. The regulatory authorities also may require additional clinical trials if a new manufacturer is relied upon for commercial production.
Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications
as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant
period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from
competition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States and the European Union, may designate products for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is
intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals
in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that
the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles
a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.
In the European Union, the EMA&rsquo;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing
the drug or biologic product. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance
and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
designation as an orphan product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve,
that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates
of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another
marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period,
except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation),
we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is
seven years in the United States and 10 years in the European Union. The exclusivity period in the European Union can be reduced to six
years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market
exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients
with the rare disease or condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from
competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved,
the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or
is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European
Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already
    authorized, is safer, more effective or otherwise clinically superior;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal
    product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses
for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our product candidates are classified as biologics in the United States, and therefore, can only be sold if we obtain a biologics
license application, or BLA, from the FDA. The holder of an approved BLA also must submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling or manufacturing process. In addition, the holder of a BLA
approval must comply with the FDA&rsquo;s advertising and promotion requirements, such as those related to the prohibition on promoting
products for uses or in patient populations that are not described in the product&rsquo;s approved labeling (known as &ldquo;off-label
use&rdquo;). Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially
applicable federal and state laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign
marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events
of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority
disagrees with the promotion, marketing or labeling of that product (in addition to our being obligated as holder of a BLA to monitor
and report adverse events and any failure of a product to meet the BLA specifications), a regulatory authority may impose restrictions
relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority
may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning letter asserting that we are in violation of the law;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise require the withdrawal of the product from the market;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of the product; or</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA&rsquo;s policies, and those of the EMA and other regulatory authorities, may change and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability, which would negatively impact our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never
obtain approval for our product candidates in other major markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements
of such countries or territories regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained
in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional
administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and
costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries.
For example, in many jurisdictions outside of the United States, a product candidate must be approved for reimbursement before it can
be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products would also be subject to
approval. Satisfying these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays.
In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory
approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the United
States, Europe or any other international markets, and we do not have experience in obtaining regulatory approval in international markets.
If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market
will be reduced and our ability to realize the full market potential of our product candidates will be compromised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek a conditional marketing authorization in Europe for some or all of our current product candidates, but we may not be able to
obtain or maintain such designation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of its marketing authorization process, the EMA may grant marketing authorizations for certain categories of medicinal products
on the basis of less complete data than is normally required, when doing so may meet unmet medical needs of patients and serve the interest
of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting
of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional
marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment,
the prevention, or the medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety
and therapeutic utility of the medicinal product have not been supplied, all the following requirements are met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk-benefit balance of the medicinal product is positive;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is likely that the applicant will be in a position to provide the comprehensive clinical data;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unmet
    medical needs will be fulfilled; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent
    in the fact that additional data is still required.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not
yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended
to be used in emergency situations in response to public health threats. Conditional marketing authorizations are valid for one year,
on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that
the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance
data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granting
a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the
case and will ensure that additional data on a product is generated, submitted, assessed and acted upon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
legislative reform measures may have a negative impact on our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or
regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers
and pays for pharmaceutical products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part
D program and introduced a new reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs.
In addition, the MMA authorized Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic
class in their formularies. The MMA&rsquo;s cost reduction initiatives and other provisions could decrease the coverage and price that
we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement
that results from the MMA may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies
may be enacted in international markets, which could similarly impact our business.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the PPACA (as amended by the Health Care and Education Reconciliation Act of 2010) was passed, which substantially changes
the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.
The PPACA, among other things: (i) addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate
Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; (ii) increases the minimum Medicaid rebates
owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed
care organizations; (iii) establishes annual fees and taxes on manufacturers of certain branded prescription drugs; (iv) expands the
availability of lower pricing under the 340B drug pricing program by adding new entities to the program; and (v) establishes a new Medicare
Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient
drugs to be covered under Medicare Part D. Additionally, in the United States, the Biologics Price Competition and Innovation Act of
2009 created an abbreviated approval pathway for biologic products that are demonstrated to be biosimilar or &ldquo;interchangeable&rdquo;
with an FDA-approved biologic product. This new pathway could allow competitors to reference data from biologic products already approved
after 12 years from the time of approval. This could expose us to potential competition by lower-cost biosimilars even if we commercialize
a product candidate faster than our competitors. Moreover, the creation of this abbreviated approval pathway does not preclude or delay
a third party from pursuing approval of a competitive product candidate via the traditional approval pathway based on their own clinical
trial data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
changes that may affect our business include those changes governing enrollment in federal healthcare programs, reimbursement changes,
rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation
of the PPACA and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment
for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting
system and feedback program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each state that does not choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact
the sales, business and financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage
under any of the new options made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting
drug utilization. The U.S. federal government also has announced delays in the implementation of key provisions of the PPACA. The implications
of these delays for our and our potential partners&rsquo; business and financial condition, if any, are not yet clear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration
and Congress will likely continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions
of the PPACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities
under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a
fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical
devices. More recently, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017, and Senate
Republicans have released a draft bill known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects
of the PPACA if ultimately enacted. The prospects for enactment of these legislative initiatives remain uncertain. Further, Congress
also could consider other legislation to replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or
any future healthcare reform legislation will impact our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services Office of Inspector General issued final regulations on November 30, 2020 to eliminate safe harbor
protection under the anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and Medicaid plan
sponsors and their pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current drug discount
and services compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations and their
pharmacy benefit managers. The proposal also reflects a skepticism that current drug discount and compensation practices among manufacturers
and pharmacy benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions and value is
passed through to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. The Biden Administration
has delayed the effective date of this rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care Management Administration
has challenged this final rule. If the regulation becomes effective it could result in lower prices for pharmaceutical products in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Centers for Medicare and Medicaid Services issued an interim final rule on November 20, 2020 that would tie prices for certain drugs
under Medicare Part B to the lowest price for those drugs available in certain countries that are members of the Organization for Economic
Co-operation and Development. This &ldquo;most favored nation&rdquo; drug pricing rule is also the subject of lawsuits, and a federal
court has placed an injunction on the implementation of the rule. This rule, if finalized, could also result in lower prices for pharmaceutical
products in general.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden Administration will have the opportunity to address these regulations as well as drug pricing, health care access, and other health
care reform issues. Any further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under
the Medicare or Medicaid program could affect the payment we could collect from sale of any product in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to stringent and changing privacy laws, regulations and standards as well as contractual obligations related to data privacy
and security. Our actual or perceived failure to comply with such obligations could harm our reputation, subject us to significant fines
and liability, or otherwise adversely affect our business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>or
prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to data privacy and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission,
storage, processing and use of personal information or personal data, which among other things, impose certain requirements relating
to the privacy, security and transmission of personal information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been
an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with laws, regulations
and other obligations governing personal information could result in enforcement actions against us, including fines, imprisonment of
company officials and public censure, processing penalties, claims for damages by affected individuals, damage to our reputation and
loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory framework for the collection, use, retention, safeguarding, disclosure, sharing, transfer and other processing of personal
information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction
in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection,
use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health
data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member
states of the European Union, or EU, in May 2018 and similar legislation in the United Kingdom. The GDPR is wide-ranging in scope and
imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing
information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data that requires the adoption of administrative, physical and technical safeguards, providing notification of data breaches
to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their
personal data and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical
trials conducted in the EU by expanding the definition of personal data to include coded data and requiring changes to informed consent
practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on
the transfer of personal data to countries outside the European Economic Area, or EEA, including the United States and, as a result,
increases the scrutiny for transfers of personal data from clinical trial sites located in the EU to the United States. The United Kingdom
and Switzerland have adopted similar restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Brexit and ongoing developments in the United Kingdom have created uncertainty with regard to data protection regulation in the United
Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy
and data security requirements are also either in place or underway in the United States. There are a broad variety of data protection
laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review
companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state attorneys
general can all be aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or
have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which
became effective on January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers
about their data collection, use and sharing practices, provides such individuals with new data privacy rights (including the ability
to opt out of certain disclosures of personal information), imposes new operational requirements for covered businesses, provides a private
right of action for data breaches and creates a statutory damages framework. Virginia became the second state to adopt a comprehensive
privacy legislation on March 2, 2021 with enactment of the Virginia Consumer Data Protection Act. Many other states are considering similar
legislation, and a broad range of legislative measures also have been introduced at the federal level. Although there are limited exemptions
for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted
and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
regulations promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, establish
privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health
information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected
health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions
may be applicable to our business or that of our collaborators, service providers, contractors or consultants. Determining whether protected
health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and
may be subject to changing interpretation. If we are unable to properly protect the privacy and security of protected health information,
we could be found to have violated these privacy and security laws and/or breached certain contracts with our business partners (including
as a business associate). Further, if we fail to comply with applicable privacy laws, such as, to the extent applicable, HIPAA privacy
and security standards, we could face significant civil and criminal penalties. In the United States, the Department of Health and Human
Services&rsquo; and state attorney&rsquo;s general enforcement activity can result in financial liability and reputational harm, and
responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized
to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents.
We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated
with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at
the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR, CCPA and similar laws&rsquo;
requirements are rigorous and time-intensive and require significant resources and a review of our technologies, systems and practices,
as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data.
Changes involving the GDPR, CCPA or other laws or regulations associated with the enhanced protection of certain types of sensitive data,
such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and
put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and
increase our cost of doing business, and could expose us to government enforcement actions, regulatory investigations, private litigation
and significant fines, penalties and remediation costs and could have a material adverse effect on our business, financial condition
or results of operations. Additionally, any failure by our third-party collaborators, service providers, contractors or consultants to
comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against
us by governmental entities or others, fines, reputational harm and other liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information
and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at
times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving
compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to
potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices.
Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may
contractually limit our ability to use and disclose the information. Claims that we have violated individuals&rsquo; privacy rights or
failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming
to defend and could result in adverse publicity that could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts
to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines, or penalties
or orders requiring that we change our practices, which could adversely affect our business. We must devote significant resources to
understanding and complying with this changing landscape. Failure to comply with federal, state and foreign laws regarding privacy and
security of personal information could expose us to government-imposed fines and penalties under such laws, penalties or orders requiring
that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement actions, litigation
and significant costs for remediation, reputational harm, diminished profits and earnings, additional reporting requirements and/or oversight,
any of which could adversely affect our business, our results of operations or prospects. We also face a threat of consumer class actions
related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government
investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Any of the
foregoing could have a materially adverse effect on our reputation and our business, financial condition, results of operations or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control
laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt
Practices Act of 1977, or the FCPA, the U.S. domestic bribery statute contained in 18 &sect;201, the U.S. Travel Act, and other anti-corruption
laws that apply in countries where we do business. The U.K. Bribery Act, the FCPA and these other laws generally prohibit us and our
employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments,
or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage.
Under the U.K. Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.
We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential U.K. Bribery Act or FCPA violations,
and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject
us to liability under the U.K. Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual
knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our
international operations might be subject or the manner in which existing laws might be administered or interpreted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the governments
of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency
exchange regulations, collectively referred to as the Trade Control laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the
U.K. Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery
Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and
other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results
of operations and liquidity. Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti-corruption
laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation,
our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
relationships with customers, physicians and third-party payors will be subject, directly or indirectly, to federal and state healthcare
fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we
are found in violation of these laws and regulations, we may be required to pay a penalty or be suspended from participation in federal
or state healthcare programs, which may adversely affect our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for our product candidates and begin commercializing them in the United States, our operations will be directly,
or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations,
including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and Physician Payments
Sunshine Act of 2010 and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs.
In addition, we may be subject to patient privacy laws by both the U.S. federal government and the states in which we conduct our business.
The laws that will affect our operations include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the
    purchase, lease or order of a good, facility, item or service reimbursable under a federal healthcare program, such as the Medicare
    and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one
    hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback
    Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government
    payors that are false or fraudulent. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers
    support the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may
    implicate the False Claims Act of 1863;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit,
    among other things, a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud
    any healthcare benefit program, regardless of the payor (e.g., public or private);</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    (as amended by the Health Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations,
    which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information
    without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care
    providers, and their respective business associates that perform certain functions or activities that involve the use or disclosure
    of protected health information on their behalf;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics
    and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with
    specific exceptions, to report annually to the CMS information related to: (i) payments or other &ldquo;transfers of value&rdquo;
    made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family
    members;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
    consumers; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, state and local laws that require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state
    and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each
    other in significant ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it
is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions
including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded
healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required
to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the
regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s
attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable
systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that
a healthcare company may run afoul of one or more of the requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
substantial costs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and
wastes, as well as laws and regulations relating to occupational health and safety. We contract with third parties that conduct operations
on our behalf that involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors
also produce and dispose of hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In
the event of contamination or injury resulting from our contractors&rsquo; use of hazardous materials, we could be held liable for any
resulting damages and any liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We
also could incur significant costs associated with civil or criminal fines and penalties. Our third-party contractors may not carry specific
biological or hazardous waste insurance coverage, and their property, casualty and general liability insurance policies specifically
exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&rsquo; compensation insurance for certain costs and expenses that we may incur due to injuries to our employees resulting
from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal
of biologic, hazardous or radioactive materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations,
which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development
or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions
or liabilities, which could adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Computer
system failures, cyber-attacks or deficiencies in our or related parties&rsquo; cyber security could result in a material disruption
of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations,
any of which could potentially expose us to liability or reputational harm or otherwise adversely affect our business and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented our security measures designed to protect the information (including but not limited to intellectual property, proprietary
business information and personal information) in our possession, custody or control. Our internal computer systems and those of current
and future third parties (such as vendors, CROs, collaborators or others) on which we rely may fail and are vulnerable to breakdown,
breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse,
denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism,
war, telecommunication and electrical failures or other compromise. Despite our security practices, there is a risk that we may be subject
to phishing and other cyberattacks in the future. The risk of a security breach or disruption, particularly through cyber-attacks or
cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity
and sophistication of attempted attacks and intrusions from around the world have increased.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against
all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate
from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations
or hostile foreign governments or agencies. Our information technology and other internal infrastructure systems, including corporate
firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development
programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result
in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely
on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar
events relating to their computer systems could also have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
use, disclosure of or access to confidential or proprietary information, we could incur liability, our competitive position could be
harmed and the further development and commercialization of our product candidates or any future product candidates could be hindered
or delayed. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with
the investigation, remediation and potential notification of the breach to counterparties, data subjects, regulators or others could
be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors,
CROs, collaborators or other contractors or consultants become subject to disruptions or security breaches, we may have insufficient
recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop
and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources
necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption,
including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage
to intellectual property or other proprietary information. Furthermore, any such event that leads to unauthorized access, use, or disclosure
of personal information, including personal information regarding clinical trial participants or employees, could harm our reputation,
compel us to comply with federal and/or state breach notification laws and foreign law equivalents, cause us to breach our contractual
obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that
protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational
damages. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to enhance our protective
measures or to remediate any information security vulnerability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance
that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would
otherwise protect us from liabilities or damages as a result of the events referenced above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in response to the ongoing COVID-19 pandemic, varying parts of our workforce are currently working remotely on a part- or full-time
basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication
disruptions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our ADSs may experience substantial dilution upon the exercise of outstanding options, warrants and convertible loan notes.</I></B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 7, 2022,
there were 81,820,000 ordinary shares issuable upon the exercise of share options at exercise prices of between $0.055 and $0.191
per ordinary share of which 24,375,000 ordinary shares are currently exercisable and 57,445,000 are exercisable between January 6,
2023 and January 31, 2032. In addition, there were 35,909,090 ordinary shares that currently may be issued upon the exercise of warrants
to purchase ordinary shares at exercise prices of between $0.034 and $0.055 per ordinary share. The exercise of such options
and warrants will result in dilution of your investment. As a result of this dilution, you may receive significantly less than the full
purchase price you paid for our securities in the event of liquidation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our ADSs do not have the same rights as our shareholders and may only exercise their voting rights with respect to the underlying
ordinary shares in accordance with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee
as their representative to exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting
is convened, if you hold ADSs, you may not receive sufficient notice of a shareholders&rsquo; meeting to permit you to withdraw the ordinary
shares underlying your ADSs to allow you to vote with respect to any specific matter. We will make all commercially reasonable efforts
to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials
in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other
third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure
to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you
may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your
capacity as an ADS holder, you will not be able to call a shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. The rights of holders of ordinary shares and, therefore, certain of the rights of any potential
future holders of ADSs, are governed by the laws of Guernsey, including the provisions of the Guernsey Companies Law, and by our Memorandum
and Articles of Incorporation, or Articles. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations.
See &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation &mdash;-Differences in Corporate Law&rdquo; in this
report for a description of the principal differences between the provisions of the Guernsey Companies Law applicable to us and, for
example, the Delaware General Corporation Law relating to stockholders&rsquo; rights and protections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause
us to incur debt or assume contingent liabilities and subject us to other risks.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs,
intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&rsquo;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
    merger or acquisition;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    drugs or drug candidates and regulatory approvals; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an FPI, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than
U.S. public companies</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FPI, as defined in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable
to companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate
disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a
security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &ldquo;short-swing&rdquo;
profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public
companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we will file an annual report on Form 20-F within four months of the close of each fiscal year ended March 31 and reports on
Form 6-K relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions
for FPIs, our ADS holders will not be afforded the same protections or information generally available to investors holding shares in
public companies organized in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>While
we are an FPI, we are not subject to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are entitled to rely on a provision in Nasdaq&rsquo;s corporate governance rules that allows us to follow the laws of Guernsey and rules
applicable to companies admitted to listing on the standard segment of the Official List of the FCA and to trading on the Main Market
of the London Stock Exchange, including, but not limited to, the Listing Rules and the Disclosure Guidance and Transparency Rules, or
DTRs, of the FCA with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices
that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we have elected to rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted
to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange instead
of Nasdaq regulations that require a listed U.S. company to (i) have a majority of the board of directors consist of independent directors,
(ii) require non-management directors to meet on a regular basis without management present and (iii) promptly disclose any waivers of
the code for directors or executive officers that should address certain specified items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Nasdaq listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley
Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to Nasdaq-listed U.S. companies. Because we have elected to
rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard
segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange, however, our audit committee
is not subject to additional Nasdaq requirements applicable to listed U.S. companies, including an affirmative determination that all
members of the audit committee are &ldquo;independent,&rdquo; using more stringent criteria than those applicable to us as an FPI. Furthermore,
Nasdaq&rsquo;s corporate governance rules require listed U.S. companies to, among other things, seek shareholder approval for the implementation
of certain equity compensation plans and issuances of ordinary shares, however as an FPI, we may elect to follow the laws of Guernsey
and rules applicable to companies admitted to listing on the Main Market of the London Stock Exchange in lieu of these Nasdaq requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may lose our FPI status, which would then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to
incur significant legal, accounting and other expenses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to U.S. domestic issuers. We may no longer be an FPI as early as September 30, 2023 (the end of our second fiscal quarter in the fiscal
year following this Nasdaq listing), which would require us to comply with all of the periodic disclosure and current reporting requirements
of the Exchange Act applicable to U.S. domestic issuers as of April 1, 2024. In order to maintain our current status as an FPI, either
(a) a majority of our outstanding voting securities must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i) a majority of our executive officers or directors cannot be U.S. citizens or residents, (ii) more than 50% of our assets
must be located outside the United States and (iii) our business must be administered principally outside the United States. If we lose
our status as an FPI, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic
issuers, which are more detailed and extensive than the requirements for FPIs. We may also be required to make changes in our corporate
governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities
laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than
the cost we would incur as an FPI. As a result, we expect that a loss of FPI status would increase our legal and financial compliance
costs and is likely to make some activities highly time-consuming and costly. We also expect that if we were required to comply with
the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director
and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.
These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an emerging growth company within the meaning of the Securities Act of 1933, or the Securities Act, and will take advantage of certain
reduced reporting requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC, as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting
requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404, exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an EGC,
we are required to report only two years of financial results and selected financial data compared to three and five years, respectively,
for comparable data reported by other public companies. We may take advantage of these exemptions until we are no longer an EGC. We could
be an EGC for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market
value of our ADSs held by non-affiliates exceeds $700 million as of any September 30 (the end of our second fiscal quarter) before that
time, in which case we would no longer be an EGC as of the following December 31 (our fiscal year-end). We cannot predict if investors
will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result,
there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile in the event that we decide to
make an offering of our ADSs following our Nasdaq listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable
regulations could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404(a) of the Sarbanes-Oxley Act, or Section 404(a), requires that beginning with our second annual report following our IPO, management
assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses
in our internal control over financial reporting. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our
independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over
financial reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply
with SEC rules that implement Section 404(b) until such time as we are no longer an EGC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our first Section 404(a) assessment will take place for our annual report for the fiscal year ending March 31, 2023. The presence
of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports, delays
in our financial reporting, which could require us to restate our operating results or our auditors may be required to issue a qualified
audit report. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance
with Section 404 (a). In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control
over financial reporting, we will need to expend significant resources and provide significant management oversight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementing
any appropriate changes to our internal control may require specific compliance training of our directors and employees, entail substantial
costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&rsquo;s
attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either we are unable to conclude that we have effective internal control over financial reporting or, at the appropriate time, our independent
auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal control over financial
reporting as required by Section 404(b), then in the event we have decided to make an offering of our ADSs following our Nasdaq listing,
investors may lose confidence in our operating results, the price of our ADSs could decline and we may be subject to litigation or regulatory
enforcement actions. In addition, if we are unable to meet the requirements of Section 404, we may not be able to remain listed on Nasdaq.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will incur significant increased costs as a result of operating as a company that publicly listed on Nasdaq in the United States, and
our management will be required to devote substantial time to new compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.S. public company, and particularly after we no longer qualify as an EGC, we will incur significant legal, accounting and other expenses
that we did not incur previously. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 1987, the
listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting
public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. Our senior management and other personnel will need to devote a substantial amount of time to these compliance initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director
and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management
personnel or members for our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404, we will be required to furnish a report by our senior management on our internal control over financial reporting. However,
while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, once we no longer qualify
as an EGC, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly
and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and
adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve
control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting
and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able
to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by
Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a
loss of confidence in the reliability of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ADSs
holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less favorable
results to the plaintiff(s) in any such action.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement governing the ADSs representing our ordinary shares provides that holders and beneficial owners of ADSs irrevocably
waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including
claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial
waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with
a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated
by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New
York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction
over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision,
New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently
prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit
agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or
counterclaim sounding in fraud or one which is based upon a creditor&rsquo;s negligence in failing to liquidate collateral upon a guarantor&rsquo;s
demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the
case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver
by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws.
If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising
under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect
to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought
against us and / or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court,
which would be conducted according to different civil procedures and may augur different results than a trial by jury would have had,
including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of
the claims, the judge or justice hearing such claims, and the venue of the hearing.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Claims
of U.S. civil liabilities may not be enforceable against us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. Certain members of our board of directors and senior management are non-residents of the
United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As
a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S.
courts against them or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be
possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S.
courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo; Additionally,
it may be difficult to assert securities law claims in actions originally instituted outside of the United States. Foreign courts may
refuse to hear a securities law claim because foreign courts may not be the most appropriate forum in which to bring such a claim. Even
if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and
not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be
proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law
of the jurisdiction in which the foreign court resides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
rights afforded to shareholders are governed by Guernsey law. Not all rights available to shareholders under English law or U.S. law
will be available to shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights afforded to shareholders will be governed by Guernsey law and by our Articles, and these rights differ in certain respects from
the rights of shareholders in typical English companies and U.S. corporations. In particular, Guernsey law significantly limits the circumstances
under which shareholders of companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant
or plaintiff for the purposes of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor
any group of shareholders has any right of action in such circumstances. In addition, Guernsey law does not afford appraisal rights to
dissenting shareholders in the form typically available to shareholders of a U.S. corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
insolvency laws of Guernsey and other jurisdictions may not be as favorable to you as the U.S. bankruptcy laws.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. In the event of a bankruptcy, insolvency or similar event, proceedings could be initiated
in Guernsey or another relevant jurisdiction. The bankruptcy, insolvency, administrative and other laws of our and our subsidiaries&rsquo;
jurisdictions of organization or incorporation may be materially different from, or in conflict with, each other and those of the United
States, including in the areas of rights of creditors, shareholders, priority of governmental and other creditors and duration of the
proceeding. The application of these laws, or any conflict among them, could call into question whether any particular jurisdiction&rsquo;s
law should apply, adversely affecting your ability to enforce your rights under the ordinary shares underlying our ADSs in those jurisdictions
or limit any amounts that you may receive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Internal Revenue Code of 1986, or the Internal Revenue Code, we will be a PFIC for any taxable year in which (1) 75% or more of our
gross income consists of passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce,
or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from
the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S.
corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its
proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a
PFIC for any taxable year during which a U.S. Holder (as defined below under &ldquo;Certain U.S. and Guernsey Tax Considerations-Material
U.S. Federal Income Tax Considerations for U.S. Holders&rdquo;) holds our shares, the U.S. Holder may be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual
or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that we were a PFIC for our taxable year ended March 31, 2022 but cannot provide any assurances regarding our PFIC status
for any past, current or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an
annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In
particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans,
which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes
may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably.
Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into
in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend
the cash we raise in any offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making,
where available, a qualified electing fund, or QEF, election to include in income its pro rata share of the corporation&rsquo;s income
on a current basis or a mark-to-market election. A U.S. Holder may make a QEF election with respect to our ordinary shares or ADSs only
if we agree to furnish such U.S. Holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury
Regulations. We currently do not intend to prepare or provide the information that would enable U.S. Holders to make a QEF election if
we are treated as a PFIC for any taxable year, and prospective investors should assume that a QEF election will not be available. A U.S.
Holder may be able to make a mark-to-market election with respect to our ADSs if our ADSs are treated as &ldquo;marketable stock.&rdquo;
Generally, stock will be considered marketable stock if it is &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo; within
the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Our ADSs will be marketable
stock as long as they remain listed on Nasdaq and are regularly traded. There can be no assurance that out ADSs will be regularly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see
the section of this report entitled &ldquo;Certain U.S. and Guernsey Tax Considerations-Material U.S. Federal Income Considerations for
U.S. Holders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
change in our tax residence could have a negative effect on our future profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are incorporated under the laws of Guernsey, our affairs are, and are intended to continue to be, managed and controlled in the United
Kingdom for tax purposes and therefore we are resident in the United Kingdom for U.K. and Guernsey tax purposes. It is possible that
in the future, whether as a result of a change in law or the practice of any relevant tax authority or as a result of any change in the
conduct of our affairs or for any other reason, we could become, or be regarded as having become, a resident in a jurisdiction other
than the United Kingdom. If we cease to be a U.K. tax resident, we may be subject to a charge to U.K. corporation tax on chargeable gains
on our assets and to unexpected tax charges in other jurisdictions on our income. Similarly, if the tax residency of any of our subsidiaries
were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains
tax on the assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit
from favorable U.K. tax legislation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.K. resident trading entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses
since inception. As of March 31, 2022, we had cumulative carryforward tax losses of $15,870,525. Subject to any relevant restrictions,
we expect these to be available to carry forward and offset against future operating profits. As a company that carries out extensive
research and development activities, we benefit from the U.K. research and development tax credit regime for small and medium-sized companies,
whereby we are able to surrender the trading losses that arise from our qualifying research and development activities for a payable
tax credit of up to 33.35% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs
for research staff, consumables and certain internal overhead costs incurred as part of research projects. Certain subcontracted qualifying
research expenditures are eligible for a cash rebate of up to 21.67%. The majority of our pipeline research, clinical trials management
and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our ability to continue
to claim payable research and development tax credits in the future may be limited because we may no longer qualify as a small or medium-sized
company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may benefit in the future from the United Kingdom&rsquo;s &ldquo;patent box&rdquo; regime, which allows certain profits attributable
to revenues from patented products to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent
applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues
and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our research and development
expenditures, we expect a long-term lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to
the U.K. research and development tax credit regime or the &ldquo;patent box&rdquo; regime, or for any reason we are unable to qualify
for such advantageous tax legislation, or we are unable to use net operating loss and tax credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition
and results of operations and reduce net returns to our shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes
in the interpretation thereof by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being
affected by certain changes currently proposed by the Organization for Economic Co-operation and Development and their action plan on
Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which
we operate, particularly if such trends continue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future
effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues
arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities;
(4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with
acquisitions; (5) changes in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws,
and changes in generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&rsquo;s
Revenue &amp; Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of
income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer
pricing policies, including methodologies for valuing developed technology and amounts paid with respect to our intellectual property
development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established
a taxable connection, often referred to as a &ldquo;permanent establishment&rdquo; under international tax treaties, and such an assertion,
if successful, could increase our expected tax liability in one or more jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where
there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive
review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable
to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher
taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in
disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
registration statement contains forward-looking statements that involve substantial risks and uncertainties. All statements contained
in this registration statement, other than statements of historical fact, including statements regarding our strategy, future operations,
future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements.
The words &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;objective,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or the negative
of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and
unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements
and opinions contained in this registration statement are based upon information available to us as of the date of this registration
statement and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete,
and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available
relevant information. Forward-looking statements include statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical
    studies or trials and related preparatory work, the period during which the results of the trials will become available and our research
    and development programs;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them,
    and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to research, develop, manufacture and commercialize our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of our regulatory filings for our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size and growth potential of the markets for our product candidates;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise additional capital;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    impact of COVID-19 on our business and operations;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    commercialization, marketing and manufacturing capabilities and strategy;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding our ability to obtain and maintain intellectual property protection;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified employees and key personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third party suppliers and manufacturers and their ability to perform adequately;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding future revenue, expenses and needs for additional financing; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments in the United States, European Union and other jurisdictions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should refer to the section titled &ldquo;Risk Factors&rdquo; for a discussion of important factors that may cause our actual results
to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure
you that the forward-looking statements in this registration statement will prove to be accurate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in
these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that
we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this registration statement and the documents that we have filed as exhibits to this registration statement completely and
with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking
statements by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>MARKET
and industry DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
industry data and market data included in this prospectus were obtained from independent third-party surveys, market research, publicly
available information, reports of governmental agencies, and industry publications and surveys. All of the market data used in this prospectus
involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the
information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is
subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &ldquo;Risk Factors.&rdquo;
These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRADEMARKS,
SERVICE MARKS AND TRADENAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &reg; and &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names. For the avoidance of doubt,
&ldquo;OKYO,&rdquo; the OKYO logo and other trademarks or service marks of OKYO Pharma Limited appearing in this prospectus are the property
of OKYO or our subsidiary. This prospectus contains additional trademarks, service marks, and trade names of others, which are the property
of their respective owners. All trademarks, service marks, and trade names appearing in this prospectus are, to our knowledge, the property
of their respective owners. We do not intend our use or display of other companies&rsquo; trademarks, service marks, copyrights, or trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>EXCHANGE
RATE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fluctuations
in the exchange rate between Pounds Sterling and the U.S. dollar will affect the U.S. dollar amounts received by potential future owners
of our ADSs on conversion of dividends, if any, paid in Pounds Sterling on the ordinary shares and will affect the potential future U.S.
dollar price of our ADSs on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below shows the period end, average, high and low exchange rates of U.S. dollars per Pound Sterling for the periods shown. Average
rates are computed by using the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the last business day
of each month during the relevant year indicated or each business day during the relevant month indicated. The rates set forth below
are provided solely for your convenience and may differ from the actual rates used in the preparation of our consolidated financial statements
included in this registration statement and other financial data appearing in this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Year Ended March 31,</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Period End</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Rate for Period</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="13" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(U.S. dollars per pound Sterling)</B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: justify">2017</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.2537</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.3087</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.4800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.2118</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4027</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3032</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2524</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Month, 2022</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Period End</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">High</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Low</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="9" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>(U.S.
dollars per Pound Sterling)</B></FONT></TD><TD STYLE="font-size: 12pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%">April 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">1.3838</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">1.3977</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">1.3734</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3873</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3806</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4179</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3806</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3913</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>August 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3470</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3862</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3439</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3569</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3252</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>December 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3188</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>January 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3385</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>February 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3636</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3360</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>March 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3152</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3044</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>April 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>May 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>June 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2011</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>July 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1647</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2278</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>September 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1473</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>October 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>November 2022 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1.1962 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1183</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>December 2022 (to December 2, 2022)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 1.2292 </P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 1.2292 </P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 1.2252 </P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>On
December 2 2022 the exchange rate published by the Federal Reserve Bank of New York was $1.2292 per &pound;1.00.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
presented on a constant currency basis in this prospectus is calculated by translating current year results at prior year average exchange
rates. Management reviews and analyzes business results excluding the effect of foreign currency translation because they believe this
better represents our underlying business trends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRICE
RANGE OF OUR ORDINARY SHARES AND ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The principal trading market
for our ordinary shares is the Main Market of the LSE, where our ordinary shares have been listed since July 17, 2018 under the symbol
&ldquo;OKYO.&rdquo; Prior to this date we were listed on the AIM market of the London Stock Exchange since 2014. The following table
sets forth, for the periods indicated, the reported high and low closing prices on the LSE for our ordinary shares in Pounds Sterling.
See &ldquo;Exchange Rate Information&rdquo; on page 41 for the exchange rates applicable to the periods set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The following table presents,
for the periods indicated, the reported high and low sale prices, including intra-day sales, of our ordinary shares on the LSE in Pounds
Sterling and U.S. dollars. For the convenience of the reader, we have translated Pounds Sterling amounts in the table below into U.S.
dollars at the noon buying rate of the Federal Reserve Bank of New York on December 2, 2022 which was &pound;1.00 to $1.2292. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Price Per<BR>
Ordinary Share &pound;</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Price Per<BR>
Ordinary Share $</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>High</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Low</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ended March 31, 2023</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">0.063</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">0.028</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"> <FONT STYLE="font-size: 10pt">0.077</FONT> </TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"> <FONT STYLE="font-size: 10pt">0.034</FONT> </TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.043</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.024</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.052</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.029</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter (to December 7, 2022)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.037</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.045</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.032</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ended March 31, 2022</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.078</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.060</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.095</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.073</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.065</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.040</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.080</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.049</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.085</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.041</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.105</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.051</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.083</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.048</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.101</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.058</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ended March 31, 2021</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.055</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.068</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.180</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.053</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.221</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.065</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.121</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.071</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.149</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.088</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.120</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.076</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.148</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.094</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Year Ended March 31, 2020</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">First Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.026</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.014</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Second Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.059</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.073</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Third Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.043</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.052</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.021</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Fourth Quarter</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.023</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">0.028</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.015</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 7, 2022, the
last reported sale price of our ordinary shares on LSE was &pound;0.0275 per ordinary share ($0.034 per ordinary share based on
the exchange rate set forth above).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
American Depositary Shares, or ADSs, have been trading on the Nasdaq Capital Market under the symbol &ldquo;OKYO&rdquo; since May 17,
2022. The following table sets forth, for the periods indicated, the reported high and low closing sale prices of our ADSs on the Nasdaq
Capital Market in U.S. dollars.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price Per ADS $</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Monthly:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: justify">May 2022 (from May 17, 2022)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">3.62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">June 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">July 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.96</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">September 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">October 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">November 2022 </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">December 2022 (to December 7, 2022)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1.90 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2022, the last reported sale price of our ADSs on the Nasdaq Capital Market was $1.90 per ADS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We estimate that the net proceeds
from this offering will be approximately $10.7 million, or approximately $12.3 million if the underwriters exercise their
over-allotment option in full), assuming a public offering price of $1.90 per ADS, which reflects the closing trade price on Nasdaq
on December 7, 2022 after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
$1.00 increase (decrease) in the public offering price per ADS would increase (decrease) our net proceeds, after deducting estimated
underwriting discounts and commissions and offering expenses, by approximately $5.9 million (assuming no exercise of the over-allotment
option by the underwriters).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    $8 million to fund the initial Phase 2 clinical trial of OK-101 in DED patients; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    remainder to fund working capital and other general corporate purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. We
may also use a portion of the net proceeds to in-license, acquire, or invest in additional products or assets, businesses, or technologies,
although currently we have no specific agreements, commitments, or understandings in this regard. As of the date of this prospectus,
we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or
the amounts that we will actually spend on the uses set forth above. Predicting the costs necessary to develop product candidates can
be difficult. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending
on numerous factors, including the progress of our development efforts, the status of and results from ongoing clinical trials or clinical
trials we may commence in the future, as well as any collaborations that we may enter into with third parties and any unforeseen cash
needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our existing cash resources, together with the net proceeds from the offering, will enable us to fund our operating expenses
and capital expenditure requirements for at least the 12 months after the date of this prospectus. We have based this estimate on assumptions
that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
their use, we plan to invest the net proceeds from the offering in short- and intermediate-term interest-bearing obligations and certificates
of deposit. The goal with respect to the investment of these net proceeds is capital preservation and liquidity so that such funds are
readily available to fund our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary
shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion
of our business. Pursuant to the Guernsey Companies Law, we may only pay a dividend if the directors who authorize the dividend make
a prior solvency statement in statutory form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the information in this &ldquo;Capitalization&rdquo; section together with &ldquo;Selected Consolidated Financial Data,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and our consolidated financial
statements and the related notes appearing elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth our cash and short-term deposits and short-term investments and capitalization as of March 31, 2022 derived from
our audited consolidated financial statements included elsewhere in this prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis; and</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an adjusted basis to give effect to the sale by us of 6,315,789 ADSs (representing 410,526,285 ordinary shares), assuming
    a public offering price of $1.90 per ADS, which reflects the closing trade price on Nasdaq on December 7, 2022, after
    deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us in connection with this
    offering</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of March 31, 2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Actual</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As Adjusted (1)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 60%; padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,700,724</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; width: 16%; text-align: right"> <FONT STYLE="font-size: 10pt">13,364,424</FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><U>Equity:</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Share premium</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">123,976,510</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">134,640,210</FONT> </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Other reserves</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,603,074</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,603,074</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Accumulated loss</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(112,426,034</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(112,426,034</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt"><B>Total shareholders&rsquo; equity</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2,947,402</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"> <FONT STYLE="font-size: 10pt">13,611,102</FONT> </TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total capitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">2,947,402</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"> <FONT STYLE="font-size: 10pt">13,611,102</FONT> </TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Each $1.00 increase or decrease in the assumed
public offering price of $1.90 per ADS in this offering, would increase or decrease the as adjusted total equity and total capitalization
by approximately $5.9 million after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An increase (decrease) of 1,000,000 in the number
of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, would increase (decrease) the as adjusted
total equity and total capitalization by $1.8 million, assuming no change in the public offering price per ADS and after deducting
the estimated underwriting discounts and commissions payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">81,820,000 ordinary shares issuable upon the exercise of share options
    at exercise prices of between $0.055 and $0.191 per ordinary share of which 24,375,000 ordinary shares are currently
    exercisable and 57,445,000 are exercisable between January 6, 2023 and January 31, 2032; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">35,909,090 ordinary shares that currently may be issued upon the exercise
    of warrants to purchase ordinary shares at exercise prices of between $0.034 and $0.055 per ordinary share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our ADSs in this offering, your interest will be diluted to the extent of the difference between the public offering price
per ADS paid by purchasers in this offering and our pro forma as adjusted net tangible book value per ADS after completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022, we had a historical net tangible book value of $0.002 per ordinary share (equal to $0.13 per ADS). Net
tangible book value per ordinary share represents the amount of our total assets less our total liabilities, excluding goodwill and other
intangible assets, divided by the total number of our ordinary shares outstanding as of March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">After giving effect to the sale
by us of 6,315,789 ADSs (representing 410,526,285 ordinary shares) at an assumed public offering price of $1.90
per ADS in this offering, which reflects the last reported sale price on Nasdaq on December 7, 2022, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering, our as adjusted
net tangible book value as of March 31, 2022 would have been $13.6 million, (equal to $0.48 per ADS). This represents
an immediate increase in net tangible book value of $0.005 per ordinary share (equal to $0.35 ADS) to existing shareholders and
an immediate dilution of $0.02 per ordinary share (equal to $1.42 per ADS) to new investors purchasing ADSs in this offering.
Dilution per ADS or ordinary share to new investors is determined by subtracting the as adjusted net tangible book value per ADS or ordinary
share after this offering from the assumed public offering price per ADS paid by new investors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution to new investors purchasing ADSs in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
                                            of</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
                                            31, 2022</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: justify">Assumed public offering price per ADS</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 18%; text-align: right"> 1.90 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Historical net tangible book value per ADS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Increase in historical net tangible book value per ADS attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: right"> 0.35 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">As adjusted net tangible book value per ADS after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="text-align: right"> 0.48 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dilution per ADS to new investors in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"> 1.42 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If the underwriters exercise
in full their over-allotment option to purchase an additional 947,369 ADSs, our as adjusted net tangible book value after this
offering would be $0.008 per ordinary share (equal to $0.53 per ADS), representing an immediate increase in as adjusted net tangible
book value of $0.006 per ordinary share (equal to $0.39 per ADS) to existing shareholders and immediate dilution of $0.02
per ordinary share (equal to $1.37 per ADS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Each $1.00 increase (decrease)
in the assumed public offering price of $1.90 per ADS in this offering, which reflects the last reported sale price on Nasdaq
on December, 7, 2022 would increase (decrease) the as adjusted net tangible book value after this offering by $0.21 per
ADS and the dilution to new investors in this offering by $0.79 per ADS, assuming that the number of ADSs offered by us in this
offering, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">An increase of 1,000,000 in
the number of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, would increase the as adjusted
net tangible book value after this offering by $0.04 per ADS and decrease the dilution to new investors participating in this
offering by $0.04 per ADS, assuming no change in the assumed public offering price per ADS and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">A decrease of 1,000,000 in the
number of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, would decrease the as adjusted net
tangible book value after this offering by $0.05 per ADS, and increase the dilution to new investors participating in this offering
by $0.05 per ADS, assuming no change in the assumed public offering price per ADS and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">81,820,000 ordinary shares issuable upon the exercise of share options
    at exercise prices of between $0.055 and $0.191 per ordinary share of which 24,375,000 ordinary shares are currently
    exercisable and 57,445,000 are exercisable between January 6, 2023 and January 31, 2032; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">35,909,090 ordinary shares that currently may be issued upon the exercise
    of warrants to purchase ordinary shares at exercise prices of between $0.034 and $0.055 per ordinary share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that share options or warrants are exercised, or we issue additional ADSs or ordinary shares in the future, there will be
further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market
conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If
we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result
in further dilution to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>SELECTED
CONSOLIDATED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables set forth our selected consolidated financial data for the periods indicated. We have derived the consolidated statement
of comprehensive income for the years ended March 31, 2022, 2021 and 2020 and the consolidated balance sheet data as of
March 31, 2022 and 2021 from our audited consolidated financial statements included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB.
We report our financial results in U.S. dollars.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statement of Operations and Comprehensive Loss Data: </B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in thousands except share and per share data)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: justify">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,301</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(174</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(518</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,916</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,192</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,017</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,535</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,535</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other income (expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net loss attributable to ordinary shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,007</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,457</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Basic and diluted net loss per ordinary share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheet Data:</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended March 31,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands except share and per share data)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2,701</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">6,889</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,280</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,091</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,319</TD><TD STYLE="text-align: left">&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="ba_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>AND
RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion of our financial condition and results of operations should be read in conjunction with the audited consolidated
historical financial statements as of March 31, 2022, 2021 and 2020.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion includes forward-looking statements that reflect our plans, estimates and beliefs and involves risks and uncertainties.
Our actual results could differ materially from those discussed in these statements. Factors that could cause or contribute to these
differences include, but are not limited to, those discussed below and elsewhere in this registration statement, particularly in &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We are a preclinical biopharmaceutical
company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular
pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology
of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting inflammatory and pain
modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product candidate, for the
treatment of dry-eye disease (DED). On November 18, 2022, we filed a new drug application (IND) with the Food and Drug Administration
(FDA) on OK-101 to treat DED, and plan to open a Phase 2 clinical trial of OK-101 in DED patients in the first quarter of 2023.
We also plan to evaluate OK-101&rsquo;s potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical analogue candidate for the treatment
of neuropathic ocular pain, and plan on maintaining this drug candidate at the exploratory level while we focus our primary energies
on the OK-101 program.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license
from OTT to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our
ophthalmic disease drug programs. These licenses gave us the right to exploit the IP estate which is directed to compositions-of-matter
and methodologies for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We also have a license from
TMC to a separate IP estate for treating symptoms of ocular neuropathic pain and uveitis associated pain. On August 6, 2019, we signed
a collaborative agreement with TMC on a research program focused on ocular neuropathic pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
currency translations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements are measured using the currency of the primary economic environment in which the entity operates
(the functional currency). The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into U.S. dollars on the following basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Our Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the
near future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate
revenue in the future from product sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with the research and development of our product candidates
and are expensed as incurred. These expenses consist of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our preclinical studies and
    other scientific development services;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in research and
    development functions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with regulatory requirements;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
    costs, depreciation and other expenses, which include rent and utilities; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    for maintaining our third-party licensing agreements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided
to us by our service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
direct research and development expenses are tracked on a program-by-program basis for our product candidates and consist primarily of
external costs, such as fees paid to outside consultants, CROs and CMOs in connection with our preclinical development, manufacturing
and clinical development activities. Our direct research and development expenses by program also include fees incurred under our license
agreements. We do not allocate employee costs or facility expenses, including depreciation or other indirect costs, to specific programs
because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily
to oversee the research and development as well as for managing our preclinical development, process development, manufacturing and clinical
development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our research and development expenses incurred by program: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Direct research and development expense by program:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: justify">OK-101</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,300,664</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">170,417</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">449,580</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">OK-201</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,404</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">68,518</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total direct research and development expense</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,301,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">518,098</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total research and development expense</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,301,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">173,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">518,098</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have
higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials and related product manufacturing expenses. As a result, we expect that our research and development expenses will increase
substantially over the next several years as we increase personnel costs and prepare for regulatory filings related to our product candidates.
We also expect to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with
whom we have entered into license agreements to acquire the rights related to our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate
or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any
of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty
is due to the numerous risks and uncertainties associated with development and commercialization, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development
    activities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile with IND- and CTA-enabling studies;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    patient enrollment in, and the initiation and completion of, clinical trials;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
    maintaining, defending and enforcing patent claims and other intellectual property rights;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulation;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the product candidates following approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical
trials. We may elect to discontinue, delay or modify clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel
in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting,
accounting and audit services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal,
regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being
a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Realization
Bonus Expenses</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is an extraordinary expense item for this year and includes the expenses for a realization bonus which became payable, triggered by a
fundraising event during the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of an asset</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is an extraordinary expense item for this year and includes the expenses for the impairment of a non-current asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disposal
of Intellectual Property</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is an extraordinary expense item for this year and includes the expenses related to the disposal of intellectual property during the
year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Income (Expense)</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense consists of interest on a convertible loan note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Taxation</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are
based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income
statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability
for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
UK tax legislation, small and medium entity research and development relief allows us to claim back up to 14.5% of our surrenderable
losses as a tax cash credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of operations that follow reflect the historic periods under review and should not be taken as indicative of future performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of Years Ended March 31, 2022 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarizes our results of operations for the years ended March 31, 2022 and 2021:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended March 31,</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: justify">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(1,301,178</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(1,127,357</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,916,388</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,192,385</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,724,003</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,217,566</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,366,206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,851,360</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other Income/ (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,295</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Tax credit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">786,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">761,527</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,431,045</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,077,538</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(837,152</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,183,517</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total Comprehensive (Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,268,197</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,007,142</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,261,055</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities were $1,301,178 for the year ended March 31, 2022 compared to $173,821 for the year ended March 31,
2021 an increase of $1,127,357. The increase is due to an increase in research and development activity after the temporary pause
in research and development activity in 2020 while the Scientific Advisory Board and management team were established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> expenses were $4,916,388 for
the year ended March 31, 2022 as compared to $3,192,385 for the year ended March 31, 2021, an increase of $1,724,003. The increase is
predominantly due to the establishment of a management team and an increase in activity in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Income
Tax Credit</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credits of $786,521 and $24,994 are recognized for the years ended March 31, 2022 and 2021, respectively. The credits are obtained
at a rate of 14.5% of 230% of our qualifying research and development expenditure, respectively. The increase in the provision is due
primarily to an increase in qualifying research and development expenditure incurred in the year ending March 31, 2022, plus more qualifying
research and development expenditure identified for the year ending March 31, 2021 than was provided for.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of Years Ended March 31, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarizes our results of operations for the years ended March 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: justify">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">344,277</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,175,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Total Operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,366,206</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,831,560</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other Income/ (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(85,701</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,407</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Tax credit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,295</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,809,448</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">259,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total Comprehensive (Loss)/Profit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,007,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,549,737</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities were $173,821 for the year ended March 31, 2021 compared to $518,098 for the year ended March 31, 2020. The
decrease of $344,277 is due to the temporary pause in research and development activity in 2020 while the Scientific Advisory Board and
team were established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $3,192,385 and $1,016,548 for the year ended March 31, 2021 and 2020. The increase of $2,175,837 is
predominantly due to bonuses accrued of approximately $1,200,000, additional share-based payment charges of approximately $485,000, additional
legal and audit costs of approximately $142,000 and realized foreign exchange approximately $466,000 offset by savings of approximately
$103,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Income
Tax Credit</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credits of $24,994 and $76,289 are recognized for the years ended March 31, 2021 and 2020, respectively. The credits are obtained
at a rate of 14.5% of 230% of our qualifying research and development expenditure, respectively. The decrease in the provision is due
primarily to the decrease in qualifying research and development expenditure incurred in the year ending March 31, 2021.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have
funded our operations to date primarily with proceeds from the sale of ordinary shares, ADSs, and convertible loan notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, we had cash and cash equivalents of $2,700,723.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 31, 2022, we had received net cash proceeds of $1,378,387 from exercise of warrants.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
Flows</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for each of the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: justify">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(5,468,065</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(1,600,198</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(1,202,066</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,669</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,153,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,826,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Effect of exchange rate changes on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(872,141</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,708</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net (decrease)/increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,316,464</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,208,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(371,423</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Cash Used in Operating Activities</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of cash in each of the years ended March 31, 2022, 2021 and 2020, resulted primarily from our net losses, adjusted
for non-cash charges and changes in components of working capital. Net cash used in operating activities of $5,468,065 during the year
ended March 31, 2022 increased by $3,867,867 compared to the year ended March 31, 2021. The increase in net cash used in operating activities
was primarily due to increased activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of cash in each of the years ended March 31, 2021 and 2020 resulted primarily from our net losses, adjusted for non-cash charges
and changes in components of working capital. Net cash used in operating activities of $1,600,198 during the year ended March 31, 2021
increased by $398,132 compared to the year ended March 31, 2020. The increase in net cash used in operating activities was primarily
due an increase in accruals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Cash Used in Investing Activities</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2022, we used $1,669 of cash in investing activities for the purchases of property and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2021 we used $18,114 of cash in investing activities for the purchases of property and equipment and a loan
to West African Minerals Ltd. During the year ended March 31, 2020, $132,668 was used for the same reason.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Cash Provided by Financing Activities</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended March 31, 2022 and 2021, net cash provided by financing activities was $2,153,270 and $7,826,938, respectively,
consisting of net cash proceeds from our sale and issuance of ordinary shares, entering into fixed term convertible loan agreements and
the exercise of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
March 31, 2021, and 2020, net cash provided by financing activities was $7,826,939 and $963,310, respectively, consisting of net cash
proceeds from our sale and issuance of ordinary shares and entering into fixed term convertible loan agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Funding
Requirements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities,
manufacturing and clinical trials of our product candidates and as we:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure in anticipation of commercializing any product candidates for which we may obtain
    marketing approval and intend to commercialize on our own or jointly;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, medical and development personnel;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our infrastructure and facilities to accommodate our growing employee base; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources
sooner than we expect. If we receive regulatory approval for our other product candidates, we expect to incur significant commercialization
expenses related to product manufacturing, sales, marketing and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates,
we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could
increase significantly as a result of many factors, including:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development
    activities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates
    for which we receive marketing approval;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of hiring new employees to support our continued growth;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
    intellectual property-related claims; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire technologies.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through
equity offerings. To the extent that we raise additional capital through the sale of equity, your ownership interest will be diluted.
If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements
or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research
programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds
through equity financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization
efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Borrowings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 29, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $606,980 at an interest rate of 20%
per annum to be repaid no later than 48 months after the date of the agreement. On May 4, 2021, $167,434 of the fixed term loan agreement
plus the associated interest accrued, was converted and 62,920,000 shares were issued accordingly at a price of $0.006 per share. On
February 24, 2022, all remaining fixed term loan agreements plus the associated interest accrued were converted and 165,176,000 shares
were issued accordingly at a price of $0.006 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $4,828,250 at an interest rate of
2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021, the fixed term loan agreement plus
the associated interest accrued, was converted and 43,889,863 shares were issued accordingly at a price of $0.117 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $1,982,485 at an interest rate
of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 18,021,226 shares were issued accordingly at a price of $0.117 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $689,750 at an interest rate
of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 6,269,980 shares were issued accordingly at a price of $0.117 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loans were converted into ordinary shares in May 2021 and February 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">In
August 2022, we secured a short-term credit facility from Tiziana Life Sciences Ltd., a related party, for $2,000,000 in order to support
short term liquidity. The loan is available for a period of 6 months upon first draw-down and carries an interest rate of 16% per annum,
with additional default interest of 4% if the loan is not repaid after the 6-month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual commitments and obligations as of March 31, 2022 and 2021.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As at March 31, 2022</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Less
                                            than </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
                                            Year</B></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
                                            1 and 5 Years</FONT></P></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>More
                                            than</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5
                                            Years</B></FONT></P></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease obligations</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">As at March 31, 2021</TD><TD>&nbsp;</TD>
    <TD COLSPAN="14">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Less than </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>1 Year</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between 1 and 5 Years</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>More than</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5 Years</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt">Borrowings</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">8,371</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">8,371</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,371</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,371</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign
currency exchange rate fluctuations. We maintain significant amounts of cash and cash equivalents that are in excess of federally insured
limits in various currencies, placed with one or more financial institutions for varying periods according to expected liquidity requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
Rate Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to interest rate sensitivity is impacted by changes in the underlying U.S. and U.K. bank interest rates. Our surplus cash and
cash equivalents have been invested in interest-bearing savings and money market accounts from time to time. We have not entered into
investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital
preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates
would have a material effect on the fair market value of our portfolio, and therefore we do not expect our operating results or cash
flows to be significantly affected by changes in market interest rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Currency Exchange Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our consolidated financial statements in the functional currency pounds Sterling. Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance
sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the
exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included
in the determination of net income (loss) for the respective periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial reporting purposes, our consolidated financial statements are prepared using the functional currency, and translated into the
U.S. dollar. Assets and liabilities are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated
at the average exchange rates and shareholders&rsquo; equity is translated based on historical exchange rates. Translation adjustments
are not included in determining net income (loss) but are included in foreign exchange adjustment to accumulate other comprehensive loss,
a component of shareholders&rsquo; equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future.
Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be
used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Significant Judgments and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared in accordance with IFRS as issued by the IASB. The preparation of our consolidated financial
statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are described in more detail in our consolidated financial statements, we believe that the following
accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
Research and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that
have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when
we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet
date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the
accuracy of these estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and
development expenses include fees paid to:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vendors
    in connection with preclinical development activities;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CROs
    and investigative sites in connection with preclinical studies and clinical trials; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMOs
    in connection with drug substance and drug product formulation of preclinical study and clinical trial materials.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our expenses related to preclinical studies on our estimates of the services received and efforts expended pursuant to quotes and
contracts with multiple research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf.
The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of
the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion
of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level
of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate,
we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different
from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there
have not been any material adjustments to our prior estimates of accrued research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Valuation
of Share-Based Compensation and Tranche Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation expense for equity option awards based on the grant date fair value of the option award. For equity option awards
that vest based on a service condition, the share-based compensation expense is recognized on a straight-line basis over the requisite
service period. For equity option awards that contain both performance and service conditions, we recognize share-based compensation
expense ratably over the requisite service period when the achievement of a performance-based milestone is probable based on the relative
satisfaction of the performance condition as of the reporting date. We use the fair value of our ordinary shares to determine the fair
value of the equity option awards.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share-based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&rsquo;s ordinary share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair
value of the awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, directors or advisers are rewarded using share-based payments, the fair value of the employees&rsquo;, directors&rsquo; or
advisers&rsquo; services are determined by reference to the fair value of the share options / warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).
Warrants issued in association with the issue of convertible loan notes are also considered as share based payments and a share-based
payment charge is calculated for these too.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used. A corresponding credit is made to a reserve, or Share Based Payment Reserve, in the
case of options / warrants awarded to employees, directors or advisers, and ordinary shares to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserve
in the case of warrants issued in association with the issue of convertible loan notes, net of deferred tax where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate
of the number of share options / warrants expected to vest. Non-market vesting conditions are included in assumptions about the number
of options / warrants that are expected to become exercisable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
are subsequently revised, if there is any indication that the number of share options / warrants expected to vest differs from previous
estimates. No adjustment is made to the expense or share issue cost recognized in prior periods if fewer share options ultimately are
exercised than originally estimated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
exercise of share options / warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would
have been recognized for services received over the vesting period is recognized immediately within the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the impact of our share-based compensation expense for share option awards granted to employees, directors and other service providers
to grow in future periods due to the potential increases in the value of our ordinary shares and headcount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conducting the valuations, we considered all objective and subjective factors that we believed to be relevant for each valuation conducted,
including our best estimate of our business condition, prospects and operating performance at each valuation date. Within the valuations
performed, a range of factors, assumptions and methodologies were used. The significant factors included:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of an active public market for our ordinary shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    results of operations, financial position and the status of our research and preclinical development efforts;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    material risks related to our business;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    business strategy;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market performance of publicly traded companies in the life sciences and biotechnology sectors;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prices paid in recent transactions involving our ordinary shares;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    likelihood of achieving a liquidity event for the holders of our ordinary shares, such as an IPO, given prevailing market conditions;
    and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    recent contemporaneous valuations of our ordinary shares prepared in accordance with methodologies outlined in the practice aid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dates of our valuations have not always coincided with the dates of our share grants. In determining the value of our ordinary shares
set forth in the table above, our board of directors considered, among other things, the most recent sale and issuance of our ordinary
shares, our stage of research and development, our operating and financial performance and current business conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimates of fair value of our ordinary shares are highly complex and subjective. There are significant judgments and estimates inherent
in the determination of the fair value of our ordinary shares. These judgments and estimates include assumptions regarding our future
operating performance, and the determinations of the appropriate valuation methods. The assumptions underlying these valuations represent
management&rsquo;s best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different
assumptions, our stock-based compensation expense, net loss and net loss per share could have been materially different. If we had made
different assumptions, our net loss and net loss per ordinary share could have been materially different.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are
based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income
statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability
for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method on temporary differences arising between the tax base of assets and liabilities and
their carrying values in the financial statements. The deferred tax is not accounted for if it arises from initial recognition of an
asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting
nor taxable profit or loss. Deferred tax is determined using tax rates which have been enacted or substantively enacted at the balance
sheet date and are expected to apply when the related deferred tax asset is realized, or the deferred income tax liability is settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are recognized to the extent that it is probable that future taxable profits will be available against which the temporary
differences can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal
of the temporary difference is controlled by the group and it is probable that the temporary difference will not reverse in the foreseeable
future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_001"></A>Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory
eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays
a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting
inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product
candidate, for the treatment of dry eye disease (&ldquo;DED&rdquo;). We also plan to evaluate its potential in benefiting patients with
ocular neuropathic pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM,
lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain, and plan on maintaining this drug candidate
at the exploratory level while we focus our primary energy on the OK-101 program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">On November 18, 2022 we filed
with FDA an IND on OK-101 to treat DED, and plan to open a Phase 2 trial in DED patients in the first quarter of 2023
(see Figure 1).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1. OKYO Pipeline</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
evidence from over 40 years of scientific literature suggests inflammation as the most common underlying characteristic of DED. An increase
in the levels of inflammatory cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED.
Consequently, development of new therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients.
Moreover, a number of DED patients suffer from ocular neuropathic pain, making their condition more resistant to topical anti-inflammatory
therapy, and a drug capable of targeting both of these aspects of DED would be a significant addition to the ocular-care practitioner&rsquo;s
arsenal for the treatment of DED. On February 21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners
Limited, a related party) a license from OTT to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed
by OTT from TMC to support our ophthalmic disease drug programs. These licenses gave us the right to exploit the IP estate which is directed
to compositions-of-matter and methodologies for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We
also have a license from TMC to a separate IP estate for treating symptoms of ocular neuropathic pain, uveitis and associated pain. The
scope of our use of the TMC IP granted to us through the sublicense with OTT is commensurate with the scope of use of the IP granted
to OTT from TMC. This intellectual property forms the basis of our OK-101 program, which is discussed in greater detail below</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OK-101</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101,
our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one
of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation
accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. There are presently
approximately 20 million people suffering from DED in the U.S. alone (Farrand et al. AJO 2017; 182:90), with the disease affecting approximately
up to 34% of the population aged 50+ (Dana et al. AJO 2019; 202:47), and with women representing approximately two-thirds of those affected
(Matossian et al. J Womens Health (Larchmt) 2019; 28:502&ndash;514). Prevalence of DED is anticipated to increase substantially in the
next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We
believe this increase in prevalence of DED represents a major expanding economic burden to public healthcare. According to Market Research
Report, Dry Eye Disease, December 2020, the global DED market in 2019 was approximately $5.22 billion, with the market size expected
to reach $6.54 billion by 2027. In addition, DED causes approximately $3.8 billion annually in healthcare costs and represents a major
economic burden to public healthcare, accounting for more than $50 billion to the U.S. economy annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, there are five major prescription drugs available to treat DED: 1) Restasis (0.05% cyclosporine), 2) Cequa (0.09% cyclosporine),
3) Xiidra (5% lifitegrast), 4) Tyrvaya (0.03mg varenicline), and 5) Eysuvis (0.25% loteprednol &ndash; a corticosteroid for short term
use only). However, DED continues to be a major unmet medical need due to the large number of patients not well served by the treatments
available to them through the medical community.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient population suffering
from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical
trials. OK-101 is designed to target a chemokine-like receptor 1, or CMKLR1, or CHEMR23, which is a G protein-coupled receptor (See Figure
2) expressed on macrophages, neutrophils, monocytes, plasmacytoid/myeloid dendritic cells, natural killer cells and nonhemopoietic cell
types, such as endothelial and epithelial cells as well as neurons and glial cells in the dorsal root ganglion, spinal cord, and retina.
Activation of CMKLR1 by its endogenous peptide ligand chemerin is known to modulate inflammation and pain, but natural ligands for CMKLR1
have short half-lives due to rapid inactivation. Discovery of OK-101, a stable, high potency CMKLR1 agonist by On Target Therapeutics
(technology licensed exclusively to OKYO Pharma) provided an important step toward the development of a new class of anti-inflammatory
therapeutics that can be applied to the treatment of ophthalmic diseases including DED, uveitis and ocular pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_005.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2</B>. OK-101 binds to CHEMR23 receptor producing an anti-inflammatory response</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key driver in the development of OK-101 to treat DED, uveitis and other ocular conditions was an analysis of the inherent advantages
and difficulties associated with the treatment of ocular conditions. One of the major issues with topical administration of any drug
designed for treating DED is the requirement that the drug have adequate drug &lsquo;residence&rsquo; time at the ocular site to afford
a pharmacologic benefit before being washed out through natural processes of tear enhancement and lacrimal tear drainage. The drug candidates
we have developed are designed to combat washout by including a lipid &lsquo;anchor&rsquo; within the candidate drug molecule to enhance
the residence time of the drug in the eye. We refer to our candidates for DED as &ldquo;lipidated-chemerin&rdquo; analogues to highlight
this pharmacologic characteristic. Figure 3 shows the significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule
on drug potency and wash resistance conducted in a series of <I>in vitro</I> studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 64 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_006.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
3</B> shows the significance of including a lipid anchor in the &ldquo;chemerin&rdquo; molecule on drug potency and wash resistance conducted
in a series of <I>in vitro</I> studies. HEK293 cells were transiently transfected with cDNAs encoding human chemerin receptor CMKLR1.
Twenty-four hours after transfection, cells were stimulated with increasing concentrations of OK-101 for 15 min and luciferase activity
was determined as described (<I>Doyle J et al, J. Biol. Chem. 2014). </I>Data points represent the mean S.E. from at least three independent
experiments, each performed in triplicate. A lipidated stable chemerin analog showed higher potency against human chemerin receptor than
the corresponding non-lapidated peptide (Figure 3 top panel). Signaling of lipidated stable chemerin analog persisted despite serial
washes, whereas activity of the non-lipidated peptide was markedly diminished (Figure 3 bottom panel).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potency of OK-101 was first determined in a cell-based PathHunter&reg; &beta;-Arrestin assay. This assay monitors the activation of a
GPCR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC)
with &beta;-galactosidase (&beta;-Gal) as the functional reporter. The enzyme is split into two inactive complementary portions (EA for
Enzyme Acceptor and PK for ProLink) expressed as fusion proteins in the cells. EA is fused to &beta;-Arrestin and PK is fused to human
Chemokine-like receptor 1, CMKLR1. Activation of CMKLR1-PK induces &beta;-Arrestin-EA recruitment, forcing complementation of the two
&beta;-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent
signal, which is measured using chemiluminescent PathHunter&reg; Detection Reagents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assay
Design: PathHunter cell lines co-expressing the ProLink&trade; (PK) tagged GPCR (human Chemokine-like receptor 1, CMKLR1) and the Enzyme
Acceptor (EA) tagged &beta;-Arrestin were expanded from freezer stocks according to standard procedures. Cells were seeded in a total
volume of 20 &mu;L into white walled, 384-well microplates and incubated at 37&deg;C for the appropriate time prior to testing. For agonist
potency determination, cells were treated with various concentrations of peptide to induce response and incubated at 37&deg;C for 90
minutes. Assay signal was generated through a single addition of 12.5 or 15 &mu;L (50% v/v) of PathHunter Detection reagent cocktail,
followed by a one-hour incubation at room temperature. Microplates were read following signal generation with a PerkinElmer EnvisionTM
instrument for chemiluminescent signal detection. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).
Figure 4 below shows the agonist activity of OK-101 against human chemerin receptor CMKLR1 determined using PathHunter&reg; &beta;-Arrestin
assay. OK-101 was shown to have a sub-nanomolar EC50 potency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 65 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_007.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4.</B> Agonist activity of OK-101 using PathHunter&reg; &beta;-Arrestin assay</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further characterize the potential efficacy of OK-101 to treat DED, OK-101 was tested in a mouse model of acute DED. Animals were divided
into five separate cohorts that included: 1) non-stressed control animals untreated throughout the study, 2) animals treated with scopolamine
to induce acute DED, 3) animals treated with scopolamine to induce acute DED and treated with 0.1% cyclosporine as a positive control,
4) animals treated with scopolamine to induce acute DED and treated with phosphate buffer solution (the vehicle used for OK-101 delivery),
and 5) animals treated with scopolamine to induce acute DED and treated with OK-101 in phosphate buffered solution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Animals
in cohorts 1) and 2) were left untreated with test agents throughout the 5-day period, whereas animals in cohorts 3), 4) and 5) were
treated with either cyclosporine, or CS, vehicle or OK-101, respectively, twice a day during the 5-day period <I>via </I>bilateral topical
administration of the respective agents. On the fifth day, all of the animals were assessed for efficacy by evaluating corneal permeability,
a measure of dry-eye effectiveness, in live animals, as well as by exploring the impact of respective treatments on immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5 shows the results from this animal study. Animals induced with scopolamine to generate acute DED showed a dramatic, statistically significant
increase in corneal permeability relative to na&iuml;ve non-stressed animals. The addition of cyclosporine to scopolamine-induced DED
animals showed a statistically significant reduction of permeability (p &#8804; 0.001). Notably, OK-101 demonstrated a dramatic reduction
of DED-induced corneal permeability as well (p &#8804; 0.001). OK-101&rsquo;s effect in reducing DED-induced corneal permeability was
virtually identical to that of the cyclosporine positive control and close to the baseline corneal permeability observed in non-stressed
control animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 66 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_008.jpg" ALT="" STYLE="height: 409px; width: 670px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5</B>. Effect of various treatments on mouse corneal permeability. Corneal permeability was measured using Oregon Green Dextran (OGD)
staining followed by imaging. CS was positive control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the in-life portion of the study, immunohistochemistry was performed on frozen sections of enucleated mouse eyes to measure CD4+ T-cell
infiltration into the conjunctival epithelium of the eye (Figure 6). Animals induced to develop acute DED and not treated with drug (Vehicle
animals) showed significant infiltration of CD4+ T cells within the conjunctival epithelium, whereas OK-101 demonstrated a statistically
significant (p &#8804; 0.01) reduction in dry-eye-induced enhancement of CD4+ T-cells. In fact, the level of CD4+ T cells observed in
OK-101 treated animals was equivalent to the CD4+ T cell level observed in na&iuml;ve untreated animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 67 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_009.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6</B>. CD4+ T cells in the conjunctival epithelium after acute DED induction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunohistochemistry
was also performed on enucleated intact conjunctiva of mouse eyes fixed in 10% formalin, embedded in paraffin, and sectioned and stained.
DED typically leads to a loss of goblet cell density as was observed following induction of DED in the mice administered Vehicle (Figure
7). Whereas administration of OK-101 significantly rescued the DED-induced loss of Goblet Cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><IMG SRC="formf-1a_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7</B>. Goblet Cell density following acute DED induction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DED
is a multifactorial disease for which the exact pathophysiological mechanism remains unknown. The combination of a compromised tear film,
ocular surface inflammation, and neurosensory abnormalities is considered the main causes of DED. Nerves of the ocular surface have both
a sensory function and a physiological function. Sensory function involves the nociceptive system that provides awareness of surrounding
environment as well as internal stimuli to the central nervous system so that appropriate action can be initiated, if needed, to prevent
tissue damage. In addition, ocular surface nerves have a large impact on the tear film health and can impact both the progression and
treatment of DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
ocular pain in DED has remained a challenging condition to treat since there are no approved topical drugs available. Current treatments
for neuropathic ocular pain are limited to short term NSAIDs, steroids, gabapentin, and opioids in severe cases. Neuropathic pain occurs
through changes in both peripheral and central neurons leading to allodynia and hyperalgesia. Peripheral sensitization from the inflammatory
cytokines during and after ocular surface injury alters responsiveness of peripheral sensory neurons, which initiates complex neuroinflammatory
and electrophysiological signaling in the central nervous system that amplify the pain signaling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
a separate set of animal model experiments, we evaluated the pain-reducing activity of OK-101 in a ciliary nerve ligation mouse model
of corneal neuropathic pain. In collaboration with Pedram Hamrah, MD, Professor of Ophthalmology, an internationally recognized cornea
specialist, and clinician-scientist at Tufts Medical Center, Boston, we demonstrated that OK-101 suppresses corneal neuropathic pain
in a mouse model of ciliary nerve ligation developed in Dr. Hamrah&rsquo;s laboratory. OK-101 was topically administered to mice in comparison
to the positive control gabapentin which was administered via intraperitoneal injection. Pain relief was evaluated by an eye-wipe count,
and OK-101 was shown to reduce corneal pain similar to that of gabapentin (Figure 8), a commonly used anticonvulsant oral drug typically
used to treat neuropathic pain for conditions such as shingles and other systemic nerve pain disorders. Notably, the drug concentration
of OK-101 used in this study was identical to that used in mouse models of DED that demonstrated ocular anti-inflammatory activity. OK-101
had no neurotoxic effect and did not affect the corneal epithelial integrity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_011.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8.</B> <I>OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corneal
neuropathic pain when observed in DED patients typically makes their condition even more resistant to topical anti-inflammatory therapy.
Such patients would benefit from a drug with the potential to treat both the ocular surface through its anti-inflammatory activity and
the ocular sensory dysfunction with neuropathic pain-reducing activity. The chemerin receptor (ChemR23), that OK-101 targets is expressed
on select populations of immune cells, as well as on neurons and glial cells in the dorsal root ganglion, spinal cord, and retina. We
believe OK-101 has the potential to address both the increased inflammatory cytokines resulting from tear film imbalance as well as heightened
neuro sensory abnormalities through peripheral corneal nerve damage as pictorially shown in Figure 9. We believe that OK-101 is a promising
target for the treatment of both inflammatory and neuroinflammatory pain in DED patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 69 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formf-1a_012.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9. <I>OK-101 Addresses Inflammation and Pain Components of Dry Eye</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
evaluate the anticipated tolerance of humans to topical administration of OK-101, a separate series of experiments was also performed
to evaluate ocular tolerance of OK-101 in rabbits <I>via</I> repeated ocular instillation followed by clinical ophthalmic observations.
Rabbit ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis or hyperemia and no signs of local irritation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the overall results from the DED animal model, the neuropathic corneal pain model, and the rabbit ocular tolerance studies, we moved
forward over the past 18 months with plans to file an IND  on OK-101 to treat DED to enable us
to begin clinical trials soon thereafter. During the fourth quarter of 2021 we successfully manufactured a 200-gram batch of OK-101 drug
substance needed for initiating the IND-enabling studies that were begun during the first quarter of 2022. In support of this work, we
also had previously signed an agreement on April 13, 2021, with Ora, Inc., or Ora, a major CRO, specializing in ophthalmic drug development
who have provided us with the following services over the past 18 months:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
                                            of the OK-101 pre-IND briefing document used in the successful pre-IND meeting with FDA in
                                            February of this year;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            with the OK-101 pre-IND meeting OKYO accomplished with FDA earlier this year;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            for the planned regulatory publishing and submission of the OK-101 IND in electronic common
                                            technical document, or eCTD, format;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
                                            oversight for the recent successful development of the topical OK-101 formulation for future
                                            human studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
                                            oversight of the successful development and qualification of the drug stability analysis
                                            method for OK-101 along with successfully conducting stability studies to establish formulated
                                            drug product is stable for at least 90 days; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
                                            for the recently completed animal toxicology studies in rabbits and dogs</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outlook
and Strategy for Development of OK-101 to Treat DED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient population suffering
from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical
trials. The evidence from over 40 years of scientific literature, however, suggests inflammation as the most common underlying element
of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is looking to be an attractive approach
in improving symptoms in DED patients. Moreover, large number of dry eye patients suffer from ocular neuropathic pain, making their condition
more resistant to topical anti-inflammatory therapy, and a drug capable of targeting both of these aspects of DED would be a significant
addition to the ocular-care practitioner&rsquo;s arsenal for the treatment of DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the past nine months we accomplished the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            topical formulation of the OK-101 drug product as well as initial stability studies</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalized
                                            the bioanalytical method development to support the OK-101 clinical program</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            batch manufacture of cGMP OK-101 for clinical trials</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            toxicokinetic method development</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            toxicology studies in rabbits and dogs</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completed
                                            stability studies of formulated OK-101</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">We recently completed all
final stages of this concerted effort to complete all IND enabling activities and filed with FDA the IND on OK-101 to treat DED on November
18, 2022.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on recent consultations with our clinical CRO, Ora Inc., we are planning to commence the first human study with OK-101 in the first quarter
of 2023, and because the drug is designed to be administered topically, we plan to skip the standard Phase 1 studies typically expected
with orally delivered or injectable drug candidates in non-life-threatening conditions. This first trial is planned to be a Phase 2 efficacy
clinical trial in DED patients and is anticipated to be conducted in approximately 200 to 250 DED patients. The study is being designed
in conjunction with, and will be managed and monitored by Ora Inc. The Phase 2 trial is expected to be completed in 6-9 months
from enrollment of the first patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, we announced the successful completion of the pre-IND meeting facilitated by Ora with the FDA regarding development
plans for OK-101 to treat DED. Both nonclinical and clinical development milestones were covered in the pre-IND meeting, with the FDA
agreeing that our first human trial would be a Phase 2 safety and efficacy trial in DED patients. The FDA also provided guidance on the
planned protocol for this trial in DED patients, concurring with one particular option OKYO has considered for the final protocol which
is to designate co-primary efficacy endpoints covering both a sign and a symptom of DED in the clinical trial. Notably, the final decision
to designate any efficacy endpoints as primary endpoints in this trial would be highly significant as should this phase 2 trial then
meet any prespecified primary endpoints, the trial should considerably affect the timeline to an NDA filing with the FDA for OK-101 to
treat DED.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Applicable Disease Indications for OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ophthalmic
diseases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second related ophthalmic disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading
cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis
can damage vital eye tissue, leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections
that reduce inflammation, however, the long-term use of corticosteroids causes increased risk of cataracts and glaucoma, requiring close
monitoring for the drug&rsquo;s potential side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
we are in the clinic evaluating OK-101 to treat dry eye, we will also undertake the clinical plan to explore the drug candidate&rsquo;s
potential to suppress the inflammation associated with uveitis. In support of this plan, we will also be exploring preclinical development
of OK-101 for the uveitis indication by first establishing &lsquo;proof-of-concept&rsquo; for this indication utilizing animal model
studies of anterior uveitis to evaluate the potential of OK-101 to suppress the inflammation associated with uveitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third related ophthalmic disease indication that is the target of our chemerin-based technology is allergic conjunctivitis. Allergic
conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction that affects about 20% of the global population and
is typically treated with antihistamines, mast cell stabilizers and corticosteroids. Although there are effective drugs for the treatment
of ocular allergies, about one third patients do not respond adequately to the currently marketed drugs. Further, patients who display
poor response to antihistamines appear to suffer from chronic and seasonal allergies. There is a lack of an optimal treatment for the
perennial and severe forms of ocular allergies. We plan on conducting &lsquo;proof-of-concept&rsquo; studies using OK-101 for the treatment
of chronic and seasonal allergic conjunctivitis using a conjunctival allergen challenge animal model to investigate the potential of
OK-101 to suppress the inflammation associated with allergic conjunctivitis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 71 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>OK-201</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2018, we obtained a license agreement from Tufts Medical Center for the right to exploit all the intellectual property claimed
in patent application PCT/US2016/0611101 &lsquo;Lipidated BAM8-22 and methods of using same&rsquo; including claims covering composition-of-matter
and methodology for treating symptoms of neuropathic chronic pain, ocular pain and uveitis-associated pain. OKYO began an effort to explore
BAM8-22 analogs that have potential to ameliorate inflammation and neuropathic pain. OK-201 is the lead compound from the license agreement
with Tufts Medical Center and was the focus of the Company&rsquo;s initial efforts to develop a lipidated BAM8-22 analogue to treat neuropathic
pain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2019, we signed a collaborative agreement with Tufts Medical Center, Boston and Pedram Hamrah, MD, Professor of Ophthalmology
at Tufts University School of Medicine, Boston, MA to evaluate OKYO&rsquo;s BAM8-22 analogues, including OK-201, as non-opioid analgesics
to suppress corneal neuropathic pain using a mouse ocular pain model developed in Dr. Hamrah&rsquo;s laboratory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, we announced positive results of OK-201, a non-opioid analgesic drug candidate delivered topically in Dr. Hamrah&rsquo;s
mouse neuropathic corneal pain model, as a potential drug to treat acute and chronic ocular pain. Importantly, OK-201 demonstrated a
reduced corneal pain response equivalent to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations demonstrated
preclinical &lsquo;proof-of-concept&rsquo; for the topical administration of OK-201 as a potential non-opioid analgesic for ocular pain.
Current treatments for corneal pain are limited to short term NSAIDs, steroids, and oral gabapentin and opioids in severe cases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results with OK-201 were encouraging, due to subsequent success obtained with OK-101 (see section on OK-101) in follow-on animal
model studies utilizing the same mouse neuropathic corneal pain model as for OK-201, we have decided to maintain this drug candidate
at the exploratory level while we focus our primary energy on the OK-101 program to treat DED, based on OK-101&rsquo;s combination of
anti-inflammatory and ocular pain-reducing activities in animal models of these conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers
the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical
element in the success of our business. As of December 7, 2022, our owned and licensed intellectual property included 8 issued
patents and 15 pending patent applications in the U.S. and abroad.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
United States patent directed to lipidated chemerin fragments or analogs has a statutory expiration date of March 13, 2034, with potential
patent term extension available until 2039, following the grant of marketing authorization. Issued United States patent directed to methods
of using lipidated chemerin fragments or analogs for treating neuropathic pain has a statutory expiration date of March 13, 2034 (plus
187 days of patent term adjustment, or PTA), with potential patent term extension available until 2039, following the grant of marketing
authorization. Issued United States patent directed to methods of using lipidated chemerin fragments or analogs for treating DED has
a statutory expiration date of January 23, 2037, with potential patent term extension available until 2041, following the grant of marketing
authorization. We have pending patent applications for lipidated chemerin fragments or analogs and methods of use thereof that, if issued,
would be expected to expire in the United States and in countries outside of the United States between 2034 and 2043, excluding any patent
term adjustment that might be available following the grant of the patent and any patent term extensions that might be available following
the grant of marketing authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
United States patent directed to lipidated BAM8-22 peptides or analogs and methods of use thereof has a statutory expiration date of
November 9, 2036 (plus 70 days of PTA), with potential patent term extension available until 2042, following the grant of marketing authorization.
We have pending patent applications for lipidated BAM8-22 peptides or analogs and methods of use thereof that, if issued, would be expected
to expire in the United States and in countries outside of the United States between 2036 and 2040, excluding any patent term adjustment
that might be available following the grant of the patent and any patent term extensions that might be available following the grant
of marketing authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to protect our intellectual property position by, among other things, licensing or filing our own U.S. and foreign patent applications
related to our proprietary technologies and products, and any inventions or improvements that are important to the development and implementation
of our business. We also may seek patent protection, if available, with respect to biomarkers and diagnostic methods that may be used
to determine optimal patient populations for use of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, we seek to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select
countries. Because patent applications in the U.S. are maintained in secrecy for at least 18 months after the applications are filed,
and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain
that we were the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first
to file for protection of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party
patents or other intellectual property rights, in which case continued development and marketing of our products would require a license.
Required licenses may not be available to us on commercially acceptable terms, if at all. If we do not obtain these licenses, we could
encounter delays in product introductions while we attempt to design around the patents, or we could find that the development, manufacture
or sale of products requiring such licenses are not possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of
which can be difficult to protect. We seek to protect some of our proprietary technologies and processes by entering into confidentiality
agreements with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for
any breach and our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees
or our consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights
in related or resulting know-how and inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License
Agreement for OK-101</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTT
and TMC entered into a license agreement on April 3, 2017, or the Master License, pursuant to which OTT licensed exclusive rights to
certain patent applications that describe and claim lipidated chemerin peptides and their uses in DED, or Chemerin. The Master License
remains in effect until they royalty term has expired with respect to all licensed products in all countries. The Master License may
be terminated by either party in the event of a material breach and in addition, OTT may terminate the Master License at any time upon
90 days&rsquo; notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2017, OTT entered into a license and sublicense agreement with Panetta Partners Limited, one of our principal stockholders, relating
to Chemerin, or the Chemerin License Agreement, which was licensed from OTT and sublicensed from TMC. On May 1, 2018, we entered into
an assignment of the Sublicense with Panetta Partners Limited. Under the terms of the Chemerin License Agreement, we have exclusive rights
to Chemerin. Specifically, we have the benefit of the exclusive worldwide rights to a U.S. patent application (which if issued would
expire in 2036). In addition, we have exclusive worldwide rights to a Patent Cooperation Treaty, or PCT, patent which has been nationalized
in the U.S., Europe, Japan, Australia and Canada and if issued it would expire in 2037. The Chemerin License Agreement provides for the
payment by us of up to $4.9 million in development milestone payments and up to $37 million in sales milestones as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
milestone payments being:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$300,000
    upon first patient enrolled in a Phase I clinical trial;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$600,000
    upon first patient enrolled on a Phase II clinical trial;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500,000
    upon first patient enrolled in a Phase III clinical trial; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500,000
    upon first commercial sale of a licensed product.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 73 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
milestones payments as follows:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,000,000
    on first achievement of annual net sales of $50,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4,000,000
    on first achievement of annual net sales of $100,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,000,000
    on first achievement of annual net sales of $250,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000
    on first achievement of annual net sales of $500,000,000; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,000,000
    on first achievement of annual net sales of $1,000,000,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above payments equate to low and declining single digit percentage royalties on net sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have novel composition-of-matter coverage on the lipidated chemerin peptide lead analogues and novel method-of-use claims
in treating DED and other ophthalmic diseases. Each patent office has different patentability requirements, but we believe that the license
patent applications 16/070,467 (U.S. patent application entitled &ldquo;Compounds and methods for treating inflammation&rdquo;; applicant:
Tufts Medical Center / Trustees of Tufts College) and PCT/US2017/014605 (U.S. patent application entitled &ldquo;Compounds and methods
for treating inflammation&rdquo;; applicant Tufts Medical Center / Trustees of Tufts College) contain patentable subject matter. The
process for issuance of a patent involves a correspondence with each local patent office in the jurisdictions in which the patent application
is filed. That process, patent prosecution, involves a discussion of any relevant prior art and typically a discussion of the scope of
the claims. The patent prosecution process can take several years depending on the jurisdiction and is not in the control of the patent
owner, but in the control of the local patent office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subject matter of the licensed IP may have been developed with government financial assistance and are subject to certain federal regulations
under the Bayh-Dole Act of 1980. In particular, the federal government retains a &ldquo;nonexclusive, nontransferable, irrevocable, paid-up
license&rdquo; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also provides federal agencies
with &ldquo;march-in rights&rdquo; and allows the government certain rights to require products to be manufactured in the United States.
March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant
a &ldquo;nonexclusive, partially exclusive, or exclusive license&rdquo; to a &ldquo;responsible applicant or applicants.&rdquo; If the
patent owner refuses to do so, the government may grant the license itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>OK-201</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a license agreement with TMC on May 1, 2018 relating to intellectual property and proprietary technology for the use of
certain lipidated BAM peptides in the treatment of neuropathic pain. Under the terms of the license agreement, we have acquired an exclusive
license to certain patents (pending and issued), inventions (including future patent filings on lipidated BAM molecules related to the
licensed patents. The license agreement requires an upfront license fee of $15,000 (&pound;11,000), which has been paid by us and annual
maintenance fees of $15,000 (&pound;11,000) commencing on the first anniversary of the license agreement. The maintenance fees decrease
to $10,000 after the three year anniversary until the first commercial sale. The license agreement also provides for further development
and sales milestone payments and royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 23, 2021, we announced that patent No. 10,899,796 entitled &ldquo;Compounds and Methods for Treating Pain&rdquo; was issued
by the United States Patent and Trademark Office. The patent is directed to a class of BAM peptides linked to specific lipids that demonstrate
potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or DED. The work recited in this patent lays
out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects
and potential abuse associated with opioid medications and is the foundation of our OK-201 program. In addition to the license from TMC
we have a collaboration agreement with TMC pursuant to which TMC has agreed to make available the services of Dr Pedram Hamrah M.D. as
principal investigator and nominated reach associate to carry out investigative and research studies in furtherance of our OK-201 corneal
neuropathic pain program. The patent will expire in early 2036.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in most jurisdictions extensively regulate the research, development, clinical testing, manufacture, distribution and marketing
of pharmaceutical products such as those that the company is developing. Obtaining regulatory approvals and ensuring subsequent compliance
with applicable laws and regulations requires the expenditure of substantial time and financial and managerial resources. Regulatory
requirements in different jurisdictions vary, and the timing and success of efforts to obtain regulatory approvals can be highly uncertain.
Development of a successful drug candidate, from identification of a candidate drug compound, through preclinical and clinical testing,
to filing of a marketing approval application, to registration, typically takes more than ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development is a highly structured process divided into two major stages, preclinical and clinical. In the preclinical stage, the toxicology
and mode of action of an active compound is evaluated. The clinical stage is designed to prove the safety of any new pharmaceutical,
determine dosage requirements and, predominantly in the later phases, prove its therapeutic utility. This stage is carried out in three
phases, which, as a developer moves through the phases, require increasingly large, complex, expensive and time-consuming clinical studies.
During Phase 1, the product candidate is initially given to a small number of healthy human subjects or patients and tested for safety,
tolerance, absorption, metabolism, distribution and excretion. During Phase 2, additional trials are conducted in a larger, but still
relatively limited, patient population to verify that the product candidate has the desired effect and to identify optimal dosage levels.
Furthermore, possible adverse effects and safety risks are identified. The therapeutic utility of the product candidate for specific
targeted diseases is also studied in more depth. During Phase 3, trials are undertaken to further evaluate dosage, to provide statistically
significant evidence of clinical effectiveness and to further study the safety in an expanded patient population at multiple clinical
trial sites. Phase 3 trials may require several hundreds or thousands of patients and are therefore the most expensive and time-consuming
to conduct. At any time during one of the phases, a trial may produce a negative result, in which case the developer may choose to end
the development project or a regulator could force clinical trials to terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of the Phase 3 trials, the developer submits all the preclinical and clinical trial documentation as well as extensive data
characterizing the manufacturing process to the regulator to seek regulatory approval to market the formulation as a pharmaceutical product.
The regulator reviews all the information related to the safety of the active compound, and whether the pharmacological effect claimed
by the developer on the proposed label can be substantiated by the results of the clinical trials. The regulator has the option to decide
to approve the application as requested, ask for changes to the claims made by the developer, ask for more information, require that
further clinical trials are undertaken, or refuse to approve the formulation for sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after initial regulatory approval has been obtained, further studies, including Phase 4 post-approval safety studies, may be required
to provide additional data on safety and will be required to gain approval for the use of a product as a treatment for clinical indications
other than those for which the product was initially tested. There are also continuing annual user fee requirements for any marketed
products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data. In addition, regulatory authorities require post-marketing reporting to monitor the adverse effects of the product.
Results of post-approval programs may limit or expand the further marketing of the products. Further, if there are any modifications
to the product, including changes in indication, manufacturing process or labeling, or a change in the manufacturing facility, an application
seeking approval of such changes or, as the case may be, notification, must be submitted to the relevant regulatory authorities before
the modified product can be commercialized. Moreover, an approved drug product may be subject to a REMS, which could impose a number
of post-approval obligations, including (among other things) a communication plan for physicians regarding safe use of the drug, distribution
and use restrictions, and/or periodic assessments of the effectiveness of the REMS. Finally, studies may be required as a contingency
of regulatory approval (post-approval commitments), and completion of these studies within a regulator mandated time frame may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development, marketing and sale of medicinal products in the EU is subject to extensive pre- and post- marketing regulation by regulatory
authorities at both the EU and national levels. The requirements, regulatory approvals and processes governing the conduct of clinical
trials, product licensing, pricing and reimbursement vary from country to country, although there is some degree of EU wide harmonization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the EU must be conducted in accordance with EU and national regulations, focusing, in particular on traceability,
apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU,
it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy
and, in most EU countries, the sponsor is liable to provide &lsquo;no fault&rsquo; compensation to any study subject injured in the clinical
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the relevant regulatory authority, and a
positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things,
a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality
of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the regulatory
authority in each Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which took effect
on January 31, 2022, there is a centralized application procedure where one national authority takes the lead in reviewing
the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or
other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities
and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Marketing
Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU medicinal products can only be commercialized after obtaining marketing authorization, or MA. There are three procedures for obtaining
marketing approvals: the centralized procedure, the decentralized procedure and the mutual recognition procedure/national procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Community marketing authorization, which is issued by the European Commission through the centralized procedure, based on the opinion
of the CHMP of the EMA, is valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types
of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance
indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure
is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant
therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the decentralized procedure are available for products not falling within the mandatory scope of the Centralized
Procedure. An identical dossier is submitted to the regulatory authorities of each of the Member States in which the marketing approval
is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares
a draft assessment report, a draft summary of the product characteristics and a draft of the labeling and package leaflet, which are
sent to the other the concerned Member States, or CMSs, for their approval. A CMS can raise an objection, based on the assessment report,
the summary of product characteristics, the labeling and the package leaflet on the grounds of potential serious risk to public health.
If no such objections are raised the product will be granted a national marketing authorization in the RMS and all of the selected CMSs.
Where a product has already been authorized for marketing in a Member State, this decentralized procedure approval can be recognized
in other Member States through the mutual recognition procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the national procedure are issued by a single regulatory authority of one of the Member States and only apply
to the territory covered by the relevant regulatory authority. They are available for products not falling within the mandatory scope
of the centralized procedure. Once a product has been authorized for marketing in a Member State through the national procedure, any
application in another Member State must be by the mutual recognition procedure whereby the marketing approval can also be recognized
in other Member States through the mutual recognition procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the procedures described above, before granting the MA, the EMA or the relevant regulatory authority of the Member States of the EU makes
an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and therapeutic
utility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of a marketing authorization in any Member State of the EU is subject to various obligations under applicable EU regulations,
such as pharmacovigilance obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions,
and to submit periodic safety update reports to the regulatory authorities. The holder must also ensure that the manufacturing and batch
release of its product is in compliance with the applicable requirements. The marketing approval holder is further obligated to ensure
that the advertising and promotion of its products complies with applicable laws, which can differ from Member State to Member State
of the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Data
Exclusivity</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAAs
for generic medicinal products in the EU do not need to include the results of preclinical and clinical trials, but instead can refer
to the data included in the marketing approval of a reference product for which regulatory data exclusivity has expired. If a marketing
approval is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity,
during which generic MAAs referring to the data of that product may not be accepted by the regulatory authorities, and a further two
years of market exclusivity, during which such generic products may not be placed on the market. The two-year period may be extended
to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies
is approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not
meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes.
For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the
type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex
biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently
be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge
and regulatory experience gained at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Medicinal Products</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&rsquo;s Committee for Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting
not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention
or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely
that sales of the product in the EU would be sufficient to justify the necessary investment in developing the medicinal product. The
COMP may only recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over
existing approved products for the relevant indication. Following a positive opinion by the COMP, the European Commission should adopt
a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application
and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a
new product was approved for the indication and no convincing data are available to demonstrate a significant benefit over that product).
Orphan medicinal product designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years
of market exclusivity is granted following marketing authorization. During this period, the competent authorities may not accept or approve
any similar medicinal product, unless it offers a significant clinical benefit. This period may be redacted to six years if the orphan
medicinal product designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not
to justify maintenance of market exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 17pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Standard
Procedure</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&rsquo;s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition of a clinical
hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory studies, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice
    regulations;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which the FDA must approve before human clinical trials may begin;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of the human clinical trial by the institutional review board, or IRB, at each clinical site before each trial may be initiated;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations,
    sometimes referred to as GCPs to establish the safety and clinical utility of the proposed product candidate for its proposed indication;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a BLA or NDA;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the production facility or facilities where the product is produced to assess compliance
    with the FDA&rsquo;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s
    identity, strength, quality, purity and potency;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the BLA or NDA prior to any commercial marketing or sale of the product in the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Other potential consequences include, among other things:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 78 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Clinical
Trials</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the IND to human patients under the supervision of qualified investigators in accordance with GCP
requirements, which include the requirement that all research patients provide their informed consent in writing for their participation
in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating
in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about
certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on
their website. Regulatory authorities, IRBs or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research patients are being exposed to an unacceptable health risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Marketing
Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed
information relating to the product&rsquo;s chemistry, manufacture, controls, or CMC, and proposed labeling, among other things, are
submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the
submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that
are currently in effect, the FDA has a goal of 10 months from the date of filing of a standard NDA for a new molecular entity to review
and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because the FDA has approximately
two months to make a filing decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act of 2003<B><I>, </I></B>certain NDAs or supplements to an NDA must contain data that
are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on
its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine
whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an
NDA for filing. In this event, the application must be resubmitted with the additional information included. The resubmitted application
is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth
substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility
in which it is manufactured, processed, packaged or held meets standards designed to assure the product&rsquo;s continued safety, quality
and purity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a BLA or NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the
FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 79 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports
regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete
response letter (which generally contains a statement of specific conditions that must be met in order to secure final approval of the
NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application). Even with submission
of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA will typically issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings
or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted
to further assess a drug&rsquo;s safety after approval, require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially
affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Orphan
Drug Designation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act of 1983, the FDA may designate a biologic product as an &ldquo;orphan drug&rdquo; if it is intended to treat a rare
disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which
there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment
of the disease or condition will be recovered from sales of the product).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product
is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug
to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval
of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but
for a different indication for which the orphan product has exclusivity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval
Requirements for the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and the relevant regulatory authorities in the EU strictly regulate marketing, labeling, advertising and promotion of products that
are placed on the market in their respective territories. Drugs may be promoted only for the approved indications and in accordance with
the provisions of the approved label. The regulatory authorities actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the relevant regulatory authorities and are subject to periodic unannounced inspections by them to confirm
compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior approval of the
relevant regulatory authorities before being implemented. Regulations laid down by the FDA and the regulatory authorities in the EU also
require investigation and correction of any deviations from the requirements of cGMP and impose reporting and documentation requirements
upon the marketing approval holder and any third-party manufacturers that the marketing approval holder may decide to use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Laws in the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company will also be subject to healthcare regulation and enforcement by the U.S. federal government and the states and governments in
the EU and any other countries in which the company conducts its business, including its research, and the marketing and distribution
of its product candidates and products once they have obtained marketing approval. Failure to comply with these laws, where applicable,
can result in the imposition of significant civil penalties, criminal penalties, exclusion from participating in health care programs,
additional reporting requirements and oversight if the company becomes subject to a corporate integrity agreement or similar agreement
to resolve allegations of non-compliance with these laws and other sanctions. The healthcare laws and regulations that may affect the
Company&rsquo;s ability to operate in the United States include: the federal fraud and abuse laws, including the federal anti-kickback
and false claims laws; federal data privacy and security laws; and federal transparency laws related to payments and/or other transfers
of value made to physicians and other healthcare professionals and teaching hospitals. Many US states have similar laws and regulations
that may differ from each other and federal law in significant ways. Moreover, several US states have enacted legislation requiring pharmaceutical
manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic
public disclosures on sales and marketing activities, and prohibiting certain other sales and marketing practices. Rules and legislation
covering more or less the same subject matter as those in the United States apply to in countries in the EU and to other countries. These
can differ between jurisdictions and can sometimes result in lower or higher exposure in those countries than in the United States. Where
a product is sold in a number of countries compliance efforts can therefore be complicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement in the EU and United States</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of products developed from the Company&rsquo;s product candidates, if approved, will depend, in part, on the extent to which such products
will be covered by third party payors, such as government health care authorities, government health care programs, commercial insurance
and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical
products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third party payors.
Therefore, coverage and reimbursement for products can differ significantly from payor to payor. In addition, the U.S. government, state
legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
influence the price of medicinal products in the EU through their pricing and reimbursement rules and control of national healthcare
systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate
to currently available therapies. Other Member States allow companies to fix their own prices for medicines but monitor and control company
profits. The downward pressure on healthcare costs in general in the EU governments influence the price of medicinal products through
their pricing and reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adoption of price controls and cost-containment measures, and the adoption of more restrictive policies in jurisdictions with existing
controls and measures, could further limit the Company&rsquo;s net revenue and results. Decreases in third party reimbursement for the
Company&rsquo;s product candidates or a decision by a third-party payor to not cover the Company&rsquo;s product candidates could reduce
physician usage of the Company&rsquo;s product candidates, once approved, and have a material adverse effect on the Company&rsquo;s sales,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Privacy
and Data Protection Laws in Europe</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to European laws relating to our and our suppliers&rsquo;, partners&rsquo; and subcontractors&rsquo; collection, control,
processing and other use of personal data (i.e., any data relating to an identifiable living individual, whether that individual can
be identified directly or indirectly). We are subject to the supervision of local data protection authorities in those jurisdictions
where we are established, where we offer goods or services to EU residents and where we monitor the behavior of individuals in the EU
(i.e., undertaking clinical trials). We and our suppliers, partners and subcontractors process personal data including in relation to
our employees, employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health
and medical information. The data privacy regime in the EU includes the General Data Protection Regulation, or GDPR, the e-Privacy Directive
(2002/58/EC) and the e-Privacy Regulation (once in force) and the national laws and regulations implementing or supplementing each of
them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 81 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and
the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate,
relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred
outside of the EEA, (unless certain steps are taken to ensure an adequate level of protection) and must not be retained for longer than
necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain
organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure
the protection of data subject rights, including as required to respond to complaints and requests from data subjects. For example, the
GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal
data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where
sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the
EU and imposes additional obligations on us when we are contracting with service providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to the extent a company processes, controls or otherwise uses &ldquo;special category&rdquo; personal data (including patients&rsquo;
health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances
and the manner in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right for Member State
to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating
model or standard operating procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which
could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial
condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on a number of third parties in relation to the provision of our services, a number of which process personal data on our behalf.
With each such provider, we enter into contractual arrangements to ensure that they only process personal data according to our instructions,
and that they have sufficient technical and organizational security measures in place. In the case where we transfer personal data outside
the EU, we do so in compliance with the relevant data export requirements from time to time. We take our data protection obligations
seriously, as any improper, unlawful or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal
data (i.e., special category), could negatively impact our business and/or our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not
considered by the European Commission to offer adequate protection of personal data. Such transfers need to be legitimized by a valid
transfer mechanism under the GDPR. There is currently ongoing litigation challenging the commonly used transfer mechanisms, the EU Commission
approved model clauses. In addition, the U.S. Privacy Shield is currently under review by the European Commission. As such, it is uncertain
whether the Privacy Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find
alternative bases for the compliant transfer of personal data from the EU to the United States and we are monitoring developments in
this area. Invalidation of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental
enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU is in the process of replacing the e-Privacy Directive with a new set of rules taking the form of a regulation, which will be directly
implemented in the laws of each Member State, without the need for further enactment. The draft e-Privacy Regulation imposes strict opt-in
marketing rules with limited exceptions for business-to-business communications and alters rules on third-party cookies, web beacons
and similar technology. Regulation of cookies and web beacons may lead to broader restrictions on online research activities, including
efforts to understand users&rsquo; internet usage. The current draft also significantly increases fining powers to the same levels as
GDPR (i.e., the greater of 20 million Euros or 4% of total global annual revenue). While this <B>e</B>-Privacy Regulation was originally
intended to be adopted on May 25, 2018, it is still going through the European legislative process and the timing of its adoption remains
unclear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 82 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&rsquo;
national laws and the introduction of the e-Privacy Regulation once it takes effect. Any failure or perceived failure to comply with
global privacy laws carries with it the risk of significant penalties and sanctions of up to &euro;20 million or 4% of global turnover.
These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional
operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase
our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organizational
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out details of our significant subsidiaries:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Principal activity</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Registered address</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>shareholding</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation</B></FONT></P></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 19%; text-align: left">OKYO Pharma US Inc.</TD><TD STYLE="text-align: left; width: 2%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: left">Clinical stage biotechnology company</TD><TD STYLE="text-align: left; width: 3%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: left">420 Lexington Avenue <BR>Suite 1402 <BR>New York, NY 10170</TD><TD STYLE="text-align: left; width: 2%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; width: 16%; text-align: right">100</TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">%</TD><TD STYLE="text-align: left; width: 2%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="vertical-align: top; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD><TD STYLE="vertical-align: top; width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property,
Plant and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table contains information regarding existing or planned material tangible fixed assets owned or leased by us and our subsidiary.
We believe that suitable additional or substitute space will be available as needed to accommodate any future expansion of our operations.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tenure</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    use</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">420
    Lexington Ave</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NY
    10170</FONT></P></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monthly</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    Office</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_002"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our directors and senior management as of the date of this prospectus. The business
address of all persons identified below is Martello Court, Admiral Park, St. Peter Port, Guernsey GY1.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Chairman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Gary S. Jacob</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    and Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Raj Patil</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon (1)(2)(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio (1)(2)(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer (1)(2)(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
    Committee member</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
    Committee member</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    Committee member</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 83 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gabriele
Cerrone</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
Cerrone has been the Non-Executive Chairman of our company since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences Limited
and has been its Executive Chairman since April 2014. Mr. Cerrone has founded 10 biotechnology companies in oncology, infectious diseases
and molecular diagnostics, and has listed seven of these companies on Nasdaq, two to the Main Market and AIM Market in London. Mr. Cerrone
co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both
Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies,
Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007
with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.
Mr. Cerrone is the Executive Chairman and Founder of Nasdaq-listed Tiziana Life Sciences Limited, an oncology focused therapeutics company;
Co-Founder of Rasna Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals,
Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA
technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated
from New York University&rsquo;s Stern School of Business with a master&rsquo;s degree in business administration (MBA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Gary S. Jacob</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dr.
Gary S. Jacob has served as Chief Executive Officer and a director of our company since January 2021. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
<FONT STYLE="background-color: white">November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian
microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy
Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018</FONT> and served
as its Chairman from September 2013 to November 2018. Dr. Jacob is the co-inventor of the FDA-approved drug Trulance<SUP>&reg;</SUP>
which is currently marketed in the U.S. by Bausch Health Companies, Inc. to treat functional GI disorders. On December 12, 2018,
Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. <FONT STYLE="background-color: white">Since
March 19, 2014, Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served
as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals,
Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna
Therapeutics, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical
and biotechnology industries across multiple disciplines including research &amp; development, operations and business development. Prior
to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was
Director of Functional Genomics, Corporate Science &amp; Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as
Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology
Group at Oxford University, England</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Raj Patil</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dr.
Raj Patil has served as Chief Scientific Officer of our company since March 2021. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Patil has over 15 years of ophthalmic drug development experience, <FONT STYLE="background-color: white">including research &amp; development,
operations and business development. Dr. Patil </FONT>previously worked with Ora, as Vice President of Research &amp; Development, where
he was responsible for driving all anterior and posterior segment ocular research of Ora&rsquo;s R&amp;D Institute. From 2013 until 2018,
Dr. Patil worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil&rsquo;s tenure at iVeena
included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School, and
Principal Investigator at Singapore Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles at
Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma
and retina research. Prior to 2004, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology &amp; Genetics at the University
of Nebraska Medical Centre in Omaha from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology &amp; Pharmacology
at Washington University in St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University
of Pune, India, and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor,
MI. He is the recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director&rsquo;s
New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for
numerous journals, and is frequently invited to lecture at academic and industry events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 84 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Keeren
Shah</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
Shah has served as our Chief Financial Officer since August 2020. Ms. Shah currently also serves as the Finance Director of Tiziana Life
Sciences Limited, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for
all businesses from June 2016 to July 2020. Prior to joining us, Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance
team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as
leading and participating in key transformation programmes and Visa Inc.&rsquo;s initial public offering. Before joining Visa, Ms. Shah
also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor
of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Willy
Simon</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
Jules Simon has been a director of our company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London
before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment
Management from 1999 to 2002. He acted as chairman of Bank Oyens &amp; van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3
plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed
company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime
since 2015. He is also a non-executive director of Tiziana Life Sciences Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>John
Brancaccio</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">John
Brancaccio, a retired CPA, has served as a director of our company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was
the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a
director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and has
been a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004, as well as a director of Hepion Pharmaceuticals,
Inc. since December 2013, Rasna Therapeutics, Inc. since September 2016, and Tiziana Life Sciences Limited since July 2020. Mr. Brancaccio
served as a director of Synergy from July 2008 until April 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bernard
Denoyer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Bernard
F. Denoyer has served as a director of our company since December 2021. Mr. Denoyer served as Senior Vice President, Finance and Secretary
of Synergy Pharmaceuticals, Inc, from July 2008 until his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently
served as Principal Financial Officer of Synergy&rsquo;s former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December
2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President
of META Group, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Scientific
Advisory Board</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is assisted in its approach to its scientific strategy. Members of the Scientific Advisory Board are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Professor
Napoleone Ferrara, MD - University of California&rsquo;s Moores Cancer Center in San Diego</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr
Ferrara is Senior Deputy Director for Basic Sciences at University of California&rsquo;s Moores Cancer Center in San Diego; and Distinguished
Professor of Pathology at the University of California&rsquo;s School of Medicine, also in San Diego. Dr Ferrara&rsquo;s research led
to the development of the anti-VEGF monoclonal antibody bevacizumab (Avastin&reg;) which was initially approved for the treatment of
colorectal cancer and is now one of the top ten selling global pharmaceutical products. Dr. Ferrara won the 2010 Lasker Award for his
work on VEGF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Professor
Pedram Hamrah, MD, FRCS, FARVO &ndash; Tufts University School of Medicine, Boston, and Clinician-Scientist at Tufts Medical Center</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hamrah is an ophthalmologist and cornea specialist, with a focus on corneal immunology and neuroscience, ocular imaging (immuno-imaging),
ocular surface diseases, and corneal neuropathic pain. He is currently on faculty at the departments of Ophthalmology and Bioengineering
at Tufts University, where he is the director of clinical research and director of the Center for Translational Ocular Immunology. In
addition, he is a faculty member at the immunology, neuroscience, and cell, molecular and developmental biology graduate programs at
the Sackler School of Graduate Biomedical Sciences at Tufts. Throughout his career, he has focused on discovery, patient care and teaching.
Dr. Hamrah currently serves on over a dozen editorial boards, is the associate editor for The Ocular Surface and TVST, section editor
for Eye, and assistant editor at Ocular Immunology and Inflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Private Issuer Exemption</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FPI as defined by the SEC. As a result, in accordance with Nasdaq listing requirements, we may rely on home country governance
requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we voluntarily
follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from filing quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form
    8-K upon the occurrence of specified significant events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from Section 16 rules requiring insiders to file public reports of their stock ownership and trading activities and liability for
    insiders who profit from trades in a short period of time, which will provide less data in this regard than shareholders of U.S.
    companies that are subject to the Exchange Act.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the Nasdaq requirement requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement that our board of directors have a remuneration committee that is composed entirely of independent directors
    with a written charter addressing the committee&rsquo;s purpose and responsibilities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement to have independent director oversight of director nominations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to follow the laws of Guernsey and rules applicable to companies admitted to listing on the standard segment of the Official List
of the FCA and to trading on the Main Market of the London Stock Exchange in lieu of Nasdaq corporate governance requirements as follows:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to follow Nasdaq Rule 5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements
    are not required under the laws of Guernsey. In accordance with generally accepted business practice, our Articles provide alternative
    quorum requirements that are generally applicable to meetings of shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not intend to follow Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where
    only independent directors are present. Our independent directors may choose to meet in executive sessions at their discretion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may rely on certain home country corporate governance practices, we must comply with Nasdaq&rsquo;s Notification of Noncompliance
requirement (Nasdaq Rule 5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies
Nasdaq Rule 5605(c)(3), which addresses audit committee responsibilities and authority and requires that the audit committee consist
of members who meet the independence requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take all actions necessary for us to maintain compliance as an FPI under the applicable corporate governance requirements of
the Sarbanes-Oxley Act, the rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not have the same protections
afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. For an overview of
our corporate governance principles, see the section titled &ldquo;Description of Share Capital and Memorandum and Articles of Incorporation&mdash;Differences
in Corporate Law.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Code of Business Conduct and Ethics is applicable to all of our employees, officers and directors and is available on our website at
https://www.okyopharma.com. Our Code of Business Conduct and Ethics provides that our directors and officers are expected to avoid any
action, position or interest that conflicts with the interests of our company or gives the appearance of a conflict. Our directors and
officers have an obligation under our Code of Business Conduct and Ethics to advance our company&rsquo;s interests when the opportunity
to do so arises. We expect that any amendment to this code, or any waivers of its requirements, will be disclosed on our website. Information
contained on, or that can be accessed through, our website is not incorporated by reference into this registration statement, and you
should not consider information on our website to be part of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is currently composed of five members. Our board of directors has determined that, of our five directors, three of
the directors, Mr. John Brancaccio, Mr. Bernard Denoyer and Mr. Simon, each do not have a relationship that would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &ldquo;independent&rdquo;
as that term is defined under Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Articles, each of our directors for whom it is the third annual general meeting following the annual general meeting
at which they were elected or last re-elected, or who was appointed by the board since the previous annual general meeting, shall retire
from office but shall be eligible to stand for re-election. See &ldquo;Description of Share Capital and Articles of Association&mdash;Articles
of Association&mdash;Board of Directors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expiration of the current terms of the members of the Board of Directors and the period each member has served in that term are as follows:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 14%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                            Current</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    Began</B></FONT></P></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 14%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                            Current</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term
    Expires</B></FONT></P></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Gary S. Jacob</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted best practice for corporate governance in its country of incorporation so all directors will retire and stand for
re-election at each annual general meeting (as opposed to reliance upon rotational reappointment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of Our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has three standing committees: an audit committee, a remuneration committee and a nominating committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit,
Risk and Disclosure Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit, risk and disclosure committee, which consists of John Brancaccio, Bernard Denoyer and Willy Simon, assists the board of directors
in overseeing our accounting and financial reporting processes. Mr. Brancaccio serves as chairman of the audit committee. The audit committee
consists exclusively of members of our board who are financially literate, and Mr. Brancaccio is considered an &ldquo;audit committee
financial expert&rdquo; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable
Nasdaq rules and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board has determined that all of the members of the audit committee satisfy the &ldquo;independence&rdquo; requirements set forth in
Rule 10A-3 under the Exchange Act. The audit committee will be governed by a charter that complies with Nasdaq rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee&rsquo;s responsibilities include:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    the appointment of the independent auditor to the general meeting of shareholders;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit
    report or performing other audit services;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such
    services;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the independent auditor&rsquo;s qualifications, performance and independence, and presenting its conclusions to the full board of
    directors on at least an annual basis;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting
    process;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving or ratifying any related party transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remuneration
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee consists of Mr. Brancaccio, Mr. Denoyer and Mr. Simon. Mr. Simon serves as chairman of the remuneration committee.
Under SEC and Nasdaq rules, there are heightened independence standards for members of the remuneration committee, including a prohibition
against the receipt of any compensation from us other than standard board member fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee&rsquo;s responsibilities include:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing and proposing policies relevant to the compensation and benefits of our directors and executive officers;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    each executive officer&rsquo;s performance in light of such policies and reporting to the board; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering our employee share option scheme or equity incentive plans in operation from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nominating
Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating committee consists of Mr. Denoyer and Mr. Simon. Mr. Denoyer serves as chairman of the nominating committee. The nominating
committee&rsquo;s responsibilities include:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drawing
    up selection criteria and appointment procedures for directors;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    nominees for election to our board of directors and its corresponding committees;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
    the functioning of individual members of our board of directors and executive officers and reporting the results of such assessment
    to the board of directors; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    corporate governance guidelines.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our non-employee directors have any service contracts with Tiziana Life Sciences PLC or any of our subsidiaries that provide for benefits
upon termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 88 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
of Executive Officers and Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets the remuneration of the CEO and other Executive Directors for the financial year ended March 31, 2022.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>earned or </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>paid in </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>cash </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>earned or</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>paid in</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>cash </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>awarded </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000) (1)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: center"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Dr. Gary S.
                                            Jacob</P></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">517</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">942</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Dr. Kunwar Shailubhai (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Director</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">18</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">-</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">18</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the fair value of incentive stock options granted during the year to March 31, 2022 using an appropriate valuation model for computing
    stock-based compensation expense as of the date of grant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kunwar Shailubhai resigned as Director on 17 June 2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Narrative
Disclosure to the Compensation table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Dr. Gary S. Jacob, our Chief Executive Officer, on December 21, 2020 and amended the agreement
on January 19, 2021. Pursuant to the agreement, Dr. Jacob has an annual salary of $350,000 and a cash bonus of up to 50% of his annual
salary based on annual performance goals. In addition, Dr. Jacob was granted options to purchase 40,000,000 ordinary shares. The options
will vest over 4 years in 4 equal tranches.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jacob is also entitled to the same fringe benefits as we provide to our other executives from time to time and is eligible to receive
employee share incentives. If Dr. Jacob&rsquo;s employment with the company is terminated without cause, or if he resigns for good reason,
Dr. Jacob will also be entitled to receive severance equal to continuation of his base salary as then currently in effect for 12 months
following his date of termination and will be eligible for a pro-rated bonus and for reimbursement for medical coverage premiums for
6 months following his date of termination. Dr. Jacob&rsquo;s severance benefits are conditioned on, amongst other things, his execution
of our standard separation agreement and a general release of claims in our favor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had four full time employees. Two of our employees were engaged in research and development and two
employees were engaged in management, administration and finance. One is located in England and three are located in the United States.
None of our employees are members of labor unions. None of our employees are covered by a collective bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance
and Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by the Guernsey Companies Law, we are empowered to indemnify our directors against any liability they
incur by reason of their directorship. We maintain directors&rsquo; and officers&rsquo; insurance to insure such persons against certain
liabilities. We expect to enter into a deed of indemnity with each of our directors and executive officers prior to, or as soon as practicable,
following the filing of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to such indemnification, we provide our directors and executive officers with directors&rsquo; and officers&rsquo; liability
insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or
persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 89 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Total
Compensation for the Non-Executive Chairman and Non-Executive Directors for the year ending March 31, 2022:</I></FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Position</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>earned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>or paid</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>in cash</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>earned</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>or paid</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>in cash</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000) (2)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>awarded</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000) (1)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($000)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: left">Gabriele Cerrone</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center">Non-Executive Chairman</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Willy Simon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">John Brancaccio</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Bernard Denoyer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Non-Executive Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts have been translated
    into U.S. dollars from Pounds Sterling based upon the exchange rate as certified by the Federal Reserve Bank of New York for customs
    purposes as of March 31, 2022. These translations are merely for the convenience of the reader and should not be construed
    as representations that the Pounds Sterling amounts actually represent such U.S. dollar amounts or could be converted into U.S. dollars
    at the rate indicated.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the fair value of incentive stock options granted during the year to March 31, 2022 using the Black-Scholes model for computing stock-based
    compensation expense as of the date of grant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Narrative
Disclosure to the Compensation table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gabriele
Cerrone</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an appointment agreement with Mr. Gabriele Cerrone on January 6, 2021 to serve as our Non-Executive Chairman. This
agreement entitles Mr. Cerrone to receive a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement
with the Mr. Cerrone pursuant to which Mr. Cerrone was awarded a retrospective bonus of $687,273 for the financial year ended March 31,
2020 and a further bonus of $554,400 for the financial year ended March 31, 2021, in each case for services prior to his agreeing to
become a director of the Company, on condition that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise
a total of 147,969,396 warrants at exercise prices between $0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his
associated entities). Mr. Cerrone also agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through
to March 31, 2022, in the sum of $210,000 be waived and offset against the costs of the exercise of certain of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Non
-Executive Director remuneration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration of our non-executive directors is determined by our board as a whole, based on a review of current practices in other companies.
We intend to enter into service contracts with our directors for their services or amend and restate any prior service contracts in place
prior to, or as soon as practicable, following the filing of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employee
Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main features of the Employee Share Option Plan are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
executive directors and employees of the Company and any of its subsidiaries are eligible to participate in the Employee Share Option
Plan. The Remuneration Committee selects the individuals to whom share options are to be granted from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Grant
of options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may be granted at such time or times as the Remuneration Committee (or the Board, excluding any interested Director, until a Remuneration
Committee is formally established) determines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exercise
price and adjustments to options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Ordinary Shares are admitted to trading on the LSE, the exercise price per Ordinary Share may not be less than the average of the
middle market quotations for an Ordinary Share for the five dealing days immediately prior to the date of grant. While the Ordinary Shares
are not admitted to trading on the LSE, the exercise price will be the amount specified by the Remuneration Committee. If the Ordinary
Shares are newly issued the exercise price may not, in any event, be less than the nominal value of an Ordinary Share. In the event of
any variation in the share capital of the Company the exercise price and/or the number of Ordinary Shares comprised in each option may
be adjusted as the Remuneration Committee determines. No adjustment may be made which will reduce the exercise price below the nominal
value of an Ordinary Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
and restrictions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option granted under the Employee Share Option Plan is not transferable. The option certificate will specify when the option will lapse,
and such date may not be later than the tenth anniversary of its date of grant. Except in the circumstances referred to below, an option
will only be exercisable on or after the date which is three years after the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the participant ceases to be employed by the Company by reason of injury, disability, ill-health or redundancy; or because the business
or company that employs them is transferred out of the ultimate ownership of the Company, his option may be exercised within six months
after such cessation or transfer provided that this limit may be further extended by the Remuneration Committee in the event that any
exercise of the options would trigger any requirement upon the holder to make a general offer to shareholders under Rule 9 of the Takeover
Code. In the event of the death of a participant, the personal representatives of a participant may exercise his option within six months
after the date of death. The extent to which an option may be exercised in these circumstances will be determined by reference to any
exercise conditions and time vesting provisions set out in the option certificate unless the Remuneration Committee decides otherwise
and is satisfied that any waiver of such provisions does not constitute a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
cessation of employment for any other reason (or when a participant serves or has been served with, notice of termination of such employment),
the option will lapse unless the Remuneration Committee exercises its discretion to allow the exercise of the option for a period not
exceeding 6 months from the date of such cessation or notice. In such circumstances and where exercise is permitted, the extent to which
an option may be exercised will be determined by reference to any exercise conditions and time vesting provisions set out in the option
certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions does not constitute
a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate
events</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options,
to the extent not already exercisable, will become exercisable immediately prior to a change in control of the Company, in the event
of a takeover of the Company, in the event that an officer becomes entitled or bound to acquire Ordinary Shares or in the event that
the court sanctions a compromise or arrangement for the reconstruction of the Company or its amalgamation with any other company. In
such event, all share options may be exercised for a limited period and will lapse to the extent not exercised. Options, to the extent
not already exercisable, will become exercisable in the event that the Company is proposed to be voluntarily wound up and all share options
may be exercised within a limited period in connection with the winding up, failing which they will lapse. In such circumstances and
where exercise is permitted, the extent to which an option may be exercised will be determined by reference to any exercise conditions
set out in the option certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions
does not constitute a reward for failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
conditions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of share options may be subject to the satisfaction of such performance conditions, if any, as may be specified and subsequently
varied and/or waived by the Remuneration Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance
of Ordinary Shares</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Shares issued upon the exercise of share options granted under the Employee Share Option Plan will rank pari passu with the
Company&rsquo;s issued Ordinary Shares on the date of exercise, save as regards any rights arising by reference to a record date prior
to the date of such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Plan
limit</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may not be granted under the Employee Share Option Plan if such grant would result in the total number of &ldquo;Dilutive Shares&rdquo;
exceeding 15% of the Company&rsquo;s issued share capital from time to time. &ldquo;Dilutive Shares&rdquo; means, on any date, all shares
of the Company which (a) have been issued, or transferred out of treasury, on the exercise of share options granted, or in satisfaction
of any other awards made, under any share incentive scheme (including the Employee Share Option Plan) in the shorter of the five years
ending on (and including) that date and the period since Admission; and (b) remain capable of issue, or transfer out of treasury, under
any subsisting share options granted by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alternative
settlement on exercise</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instead
of delivering the number of Ordinary Shares specified in the exercise notice, the Remuneration Committee may make a cash payment with
the option holder&rsquo;s consent or deliver Ordinary Shares equal to the value of the Ordinary Shares over which the option is exercised,
less the relevant exercise price, or may deliver a combination of the above two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alteration</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may alter the Employee Share Option Plan except that (apart from minor amendments to benefit the administration
of the Employee Share Option Plan, to correct typographical or other errors, to take account of a change in legislation or to obtain
or maintain favorable tax, exchange control or regulatory treatment for participants or the Company) no alteration to the advantage of
participants or to the Employee Share Option Plan limit described above can be made without the prior approval of Shareholders in general
meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
amendment may have a materially adverse effect on share options granted before the amendment without the relevant option holder&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Termination
and Plan period</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may terminate or suspend the operation of the Employee Share Option Plan at any time, whereupon no further share
options shall be granted but in all other respects the provisions of the Employee Share Option Plan shall remain in force. In any event,
no share options may be granted after the date which is five years after the date the Employee Share Option Plan is adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_003"></A>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of related party transactions we have entered into with the beneficial owners of 3% or more of our ordinary
shares, which are our only voting securities, and senior management and members of our board of directors, for the two-year period ended
March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. On January
1, 2018, we entered into a Shared Services Agreement with Tiziana Life Sciences Limited, or Tiziana, pursuant to which we share premises
and other resources. The agreement is renewed for successive three (3) month periods. As of March 31, 2022, we had incurred $107,132
(2021: $90,371) worth of costs in relation to this agreement and $47,041 was due to Tiziana Life Sciences Ltd. At March 31, 2021, $27,376
was receivable from Tiziana Life Sciences Ltd. We share common officers and directors with Tiziana, namely Gabriele Cerrone, Willy Simon
and John Brancaccio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 92 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Letter
of Appointment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an appointment agreement with Mr. Gabriele Cerrone on January 6, 2021 to serve as our Non-Executive Chairman. This
agreement entitles Mr. Cerrone to receive a consultancy fee of &pound;120,000 per year. On April 28, 2021 we entered into an agreement
with the Mr. Cerrone pursuant to which Mr. Cerrone was awarded a retrospective bonus of $687,273 for the financial year ended March 31,
2020 and a further bonus of $554,400 for the financial year ended March 31, 2021, in each case for services prior to his agreeing to
become a director of the Company, on condition that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise
a total of 147,969,396 warrants at exercise prices between $0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his
associated entities). Mr. Cerrone also agreed that his accrued but unpaid compensation from January 1, 2021 to May 4, 2021 and through
to March 31, 2022, in the sum of $210,000 be waived and offset against the costs of the exercise of certain of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into deeds of indemnity with each of our directors and officers. See &ldquo;Management&mdash;Insurance and Indemnification.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
Person Transaction Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a written related person transaction policy, to be effective immediately upon the effectiveness of the
registration statement of which this prospectus forms a part, setting forth the policies and procedures for the review and approval or
ratification of related person transactions. This policy will cover, any transaction or proposed transactions between us and a related
person that are material to us or the related person, including without limitation, purchases of goods or services by or from the related
person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us
of a related person. In reviewing and approving any such transactions, our audit and risk committee is tasked to consider all relevant
facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained
in an arm&rsquo;s length transaction and the extent of the related person&rsquo;s interest in the transaction. All of the transactions
described in this section occurred prior to the adoption of this policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_004"></A>PRINCIPAL
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information relating to the beneficial ownership of our ordinary shares as of December 7, 2022 by:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    member of our board of directors and each of our executive officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of ordinary shares beneficially owned by each entity, person, board member, or executive officer is determined in accordance with
the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules,
beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well
as any ordinary shares that the individual has the right to acquire within 60 days of November 10, 2022 through the exercise of
any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named
in the table have sole voting and investment power with respect to all ordinary shares held by that person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Ordinary</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares Beneficially</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name and address of beneficial owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">5% or Greater Shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">553,043,715</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">39.08</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Executive Officers and Directors:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">553,043,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy Simon<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,307,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary S. Jacob <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Brancaccio<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bernard Denoyer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and executive officers as a group (5 persons)<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">569,050,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    beneficial ownership of less than 1% of the total outstanding ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gabriele Cerrone is the ultimate beneficial owner of ordinary shares through Planwise Group Limited and Panetta Partners Limited.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 2,000,000 stock
    options which are currently exercisable or exercisable within 60 days of December 7, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 13,250,000
    stock options which are currently exercisable or exercisable within 60 days of December 7, 2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 450,000 stock
    options which are currently exercisable or exercisable within 60 days of December 7, 2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_005"></A>DESCRIPTION
OF SHARE CAPITAL AND MEMORANDUM AND ARTICLES OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on 4 July 2007 under the BVI
Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc. Our legal and commercial name was changed
to Minor Metals &amp; Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation
on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of
the Company&rsquo;s AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry,
the Company was registered under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability,
an indefinite life and company number 65220. The Company is domiciled in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey, GY1 3HB and our telephone number is +44 (0) 20
7495 2379. Our website address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information
contained in, or that can be accessed through, our website is not a part of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
authorized share capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
issued share capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 7, 2022, our issued share capital was 1,415,040,468 ordinary shares, no par value. Each issued ordinary share is fully
paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 94 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">As of December 7, 2022,
there were vested options to purchase 24,375,000 ordinary shares outstanding with a weighted average exercise price of $0.069 per ordinary
share. The remaining options to purchase 57,445,000 ordinary shares vest between January 31, 2023 and August 31, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 7, 2022, there were warrants to purchase 35,909,090 ordinary shares outstanding as follows:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">No. outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Final Exercise Date</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 21%; text-align: right">35,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right"> 0.055 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&pound;</TD><TD STYLE="width: 22%; text-align: right">0.045</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/17/2023</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">909,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 0.034 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&pound;</TD><TD STYLE="text-align: right">0.0275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/21/2023</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
to purchase 909,090 ordinary shares are exercisable immediately until the final exercise date. Warrants to purchase the remaining
35,000,000 ordinary shares are exercisable based on the achievement of milestones, with a final exercise date of July 17, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
about the Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Articles, the following summarizes the rights of holders of our ordinary shares:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
    of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Articles</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in Guernsey as a non-cellular company limited by shares under company number 65220. We are governed by our Articles
and the Guernsey Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles were adopted by a special resolution of our shareholders at our annual general meeting held on September 25, 2020. The summary
below is not a complete copy of the terms of the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles contain no specific restrictions on our purpose and therefore our purpose is unrestricted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Articles contain, among other things, provisions to the following effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share
Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
share capital currently consists of ordinary shares. Subject to the Guernsey Companies Law and to any rights attached to existing shares,
we may issue shares with such rights or restrictions as may be determined by the board. In addition, shares which are to be redeemed,
or are liable to be redeemed at our option or the holder of such shares may be issued with the board determining the terms and conditions
of such redemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our issued and outstanding ordinary shares are fully paid. Holders of ordinary shares do not have conversion or redemption rights.
There are no provisions in our Articles discriminating against a shareholder as a result of such shareholder&rsquo;s ownership of a particular
number of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 95 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may provide for other classes of shares, including series of preferred shares. If any preferred shares are issued,
the rights, preferences and privileges of our ordinary shares will be subject to, and may be adversely affected by, the rights of holders
of such preferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Voting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any rights or restrictions attached to any shares, on a show of hands every shareholder who is present in person or by proxy at a
general meeting shall have one vote. On a poll, every shareholder present in person or by proxy at a general meeting shall have one vote
for every ordinary share held by such shareholder. A proxy need not be a shareholder of ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder shall not be entitled, in respect of any shares held by such shareholder, to vote (either personally or by proxy) at any
general meeting of ours unless all amounts payable by such shareholder in respect of that share in our capital have been paid or credited
as having been paid, or where such shareholder is in default of the provisions in the Articles requiring disclosure of ownership of shares
and we have served a direction notice on such shareholder advising such shareholder that such shares may not be voted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Variation
of Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
or any of the rights, privileges or conditions attached to any class of shares in issue may only be varied with the consent in writing
of the holders of 75% in value of the issued shares of that class (excluding treasury shares) or with the sanction of a special resolution
passed at a separate general meeting of the holders of the shares of that class. A quorum for the separate class meeting is two persons
(in person or by proxy) holding one-third of the voting rights of the shares of that class or group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alteration
of capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may by ordinary resolution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
sub-divide all or any of our shares into shares of a smaller amount than is fixed by our Articles or by ordinary resolution;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
cancel any shares which, at the date of passing the resolution have not been taken up or agreed to be taken up;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
convert the whole, or any particular class, of our shares into redeemable shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
redesignate the whole, or any particular class, of our shares into shares of another class;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
covert all or any of our shares into shares of a nominal amount of a different currency, at the exchange rate; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
where our shares were expressed in a particular currency, denominate or redenominate it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the Guernsey Companies Law, our directors may authorize dividends and distributions to be paid to Shareholders. If any share
is issued on terms providing that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend
or distribution accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Our directors may direct that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in
particular of paid-up shares, debentures, or other securities of any other company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No dividend or distribution payable shall bear interest against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 96 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
A transfer of shares shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
All dividends or distribution unclaimed for a period of one year from the date on which such dividend or distribution was declared may
be invested or otherwise made use of by our directors for the benefit of until claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
All dividends or distribution unclaimed for a period of six years from the date on which such dividend or distribution was declared shall,
if our directors so resolve, be forfeited and shall revert to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the Guernsey Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution
or paying any dividend, our directors may determine that those persons who are entered on the register of members at the close of business
on a day determined by our directors shall be the persons who are entitled to receive such dividends or distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Payments of dividends or distributions may be made by electronic transfer in such manner as agreed between the member and us or by cheque
or warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Transfer
of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may transfer all or any of their shares (i) in the case of certificated shares by transfer in writing in any usual or common
form or in any other form acceptable to our directors; and (ii) in the case of uncertificated shares, in the manner provided for in the
rules and procedures of the operator of the &ldquo;relevant system&rdquo; (i.e., the CREST System) and in accordance with and subject
to the CREST Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
instrument of transfer of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by
or on behalf of the transferee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may, in its absolute discretion and without assigning any reason, decline to register any transfer of certificated
share or uncertified shares unless it is:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share in which we have no lien;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    favor of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    relation to a certificated share, delivered for registration to our registered office (or such other place as our board of directors
    may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as our board of directors
    may reasonably require, to show the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors shall not refuse to register any transfer or renunciation of partly paid shares which are listed on the Main Market
of the London Stock Exchange on the grounds that they are partly paid shares in circumstances where that refusal would prevent dealings
in any such shares from taking place on an open and proper basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Disclosure
of Ownership</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may by notice in writing require a shareholder to disclose to us the identity of any person other than such shareholder who
has, or has had, at any time during the three years immediately preceding the date on which the notice is issued, any interest (whether
direct or indirect) in the shares held by such shareholder.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder, or any other person appearing to be interested in shares held by that shareholder, has been issued with such a notice
and has failed in relation to any shares, or the Default Interests, to give the Company the information thereby required within the prescribed
period from the service of the notice, our directors may in their discretion serve a direction notice on such shareholder which may direct
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the shareholder shall not be entitled in respect of the Default Interests to be present or to vote (either in person or by proxy) at
any general meeting or at any separate meeting of the holders of any class of shares or on any poll or to exercise any other right conferred
by membership in relation to any such meeting or poll; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
where the Default Interests represent at least 0.25%. of the number of shares in issue of the class concerned:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any dividend, distribution or other money payable in respect of the shares shall be withheld by us, which shall not have any obligation
to pay interest on it; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
no transfer of the Default Interests held by us shall be registered unless: (I) the shareholder is not themself in default as regards
supplying the information requested; and (II) the shareholder proves to the satisfaction of our directors that no person in default as
regards supplying such information is interested in any of the shares the subject of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Requirement
to disclose interests</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
shareholder shall be under an obligation to comply with the disclosure and notification requirements set out in Chapter 5 of the DTRs.
If the Company determines that a shareholder, or the Defaulting Member, has not complied with the provisions of Chapter 5 of the DTRs
with respect to some or all of such shares held by such Shareholder, or the Default Shares, we shall have the right by delivery of notice
to the Defaulting Member, or a Default Notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
suspend the right of such Defaulting Member to vote on the Default Shares in person or by proxy at any meeting of ours; and/or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) withhold, without any obligation to pay interest thereon, any dividend or other amount payable with respect to the Default Shares,
(ii) render ineffective any election to receive our shares instead of cash in respect of any dividend or part thereof, and/or (iii) prohibit
the transfer of any of our shares held by the Defaulting Member except with the consent of ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pre-emptive
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the laws of Guernsey nor the Articles provide shareholders with pre-emptive rights when new shares are issued by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Board
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise determined by the company by ordinary resolution, the number of directors (other than any alternate directors) shall not be
less than one, but there shall be no maximum number of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business and affairs of the Company shall be managed by, or under the direction or supervision of the our directors who may pay all expenses
incurred in promoting and registering the Company, and may exercise all such powers necessary for managing, and for directing and supervising
the management of, the our business and affairs as are not, by the Guernsey Companies Law or by the Articles, required to be exercised
by us in a general meeting, subject to the Articles, to the provisions of the Guernsey Companies Law and to such regulations as may be
prescribed by us by special resolution provided that such regulations are not inconsistent with the Articles or the provisions of the
Guernsey Companies Law.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Articles, our directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings as they
think fit. The quorum necessary for the transaction of the business is two unless otherwise resolved by our directors. A meeting of our
directors at which a quorum is present shall be competent to exercise all powers and discretions for the time being exercisable by our
directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director who is in any way, directly or indirectly, interested in a proposed transaction or arrangement with us, or in a transaction
or arrangement that has been entered into by us, must declare the nature and extent of such director&rsquo;s interest to our directors.
The declaration must be made at a meeting of our board of directors, or by written notice, or by general notice, in accordance with the
Guernsey Companies Law and the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors shall have power at any time and from time to time to appoint any person to be a director, either to fill a casual vacancy
or as an addition to our existing directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law and provided the director has disclosed their interest to our other directors, such director
notwithstanding their office may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
be a party to, or otherwise interested in, any transaction or arrangement with us, or in which we are otherwise interested;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
act by themself or through their firm in a professional capacity for us be entitled to remuneration as if they were not a director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
be a director or officer of, or employed by, or a party to any transaction or arrangement with, a shareholder of or otherwise directly
or indirectly interested in, any corporate entity promoted by us, or with which we have entered into any transaction with or are interested
in; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
not by reason of his office, be accountable to us for any benefit which such director derives from any such office or employment or from
any such transaction or arrangement or from any interest in any such body corporate and no such transaction or arrangement shall be liable
to be avoided on the ground of any such interest or benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director shall be counted in the quorum at any meeting in relation to any resolution in respect of which such director has declared an
interest and may vote thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person must not be appointed as a director unless such person has consented in writing and submitted their declaration that they are
not ineligible to act as a director under the Guernsey Companies Law. A director need not be a shareholder but shall be entitled to receive
notice of and attend all of our general meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
person shall, unless recommended by our directors, be eligible for election to the office of director at any general meeting unless not
less than three nor more than 21 days before the date appointed for the meeting there shall have been left at our registered office a
notice in writing signed by a shareholder, their intention to propose such a person for election (this must be accompanied by that persons
willingness to be elected and their signed declaration).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors shall be paid such remuneration (by way of fee) for their services as may be determined by our directors in their absolute
discretion. Our directors shall also be entitled to be repaid all travelling, hotel and other expenses of travelling to and from board
meetings, committee meetings, general meetings, or otherwise incurred while engaged on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law, every director shall have the power to purchase and maintain insurance for or for the
benefit of any persons who are or were at any time our directors, officers or employees (including any other company which is its holding
company or in which we have any direct or indirect interest in) against any liability incurred by such persons in respect of any act
or omission in the actual or purported execution and /or discharge of their duties or exercise or purported exercise of their powers
in relation to or in connection with their duties, powers or offices in relation to us or any other such company or subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 99 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
director may at any time by writing appoint any person to be their alternate director and may in like manner at any time terminate such
appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
office of director shall, ipso facto, be vacated if such director:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
resigns his office by writing under his hand and it is deposited at our registered office and we may agree to accept this at a later
date than specified;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
shall have absented themselves from meetings of the directors for six months in succession and all our other directors have resolved
that such director should vacate their office;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
becomes bankrupt, suspends payment or compounds with such director&rsquo;s creditors, or is adjudged insolvent or has his affairs declared
en d&eacute;sastre;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
dies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
becomes ineligible to act as a director under the Guernsey Companies Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
is removed by resolution of our directors in writing signed by all of our other directors (being not less than two in number); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
if we shall by ordinary resolution declare that such person shall cease to be a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors (including any alternate director), secretary and other officer or employee for the time being shall be indemnified out of
the our assets to the fullest extent permitted by the Guernsey Companies Law from and against all actions, costs, charges, losses, damages
and expenses in respect of which they may lawfully be indemnified which they or any of them shall or may incur or sustain by reason of
any contract entered into or any act done, concurred in, or omitted, in or about the execution of their duty or supposed duty or in relation
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations
on the Rights to Own Our Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any limitations on the rights to own our securities, including rights of non-resident or foreign shareholders to hold
or exercise voting rights on our securities, imposed by foreign law or by our Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual general meeting of ours shall be held in each calendar year (provided that no more than fifteen months may elapse between one
annual general meeting and the next) at such time and place as may be determined by our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may convene a general meeting whenever they think fit. General meetings shall also be convened by the directors within 21 days
of a requisition by our shareholders as provided for by the Guernsey Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
special notice is required in accordance with the Guernsey Companies Law, not less than fourteen days&rsquo; notice in respect of all
general meeting shall be given to all Shareholders (other than those who, under the provisions of the Articles or otherwise, are not
entitled to receive notices from the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
notice shall specify the place, the date and the time of the meeting and the general nature of the business of the meeting. Any general
meeting may be held in Guernsey, or elsewhere, as our directors may from time to time determine. There is no age limit at which a director
is required to retire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of determining which persons are entitled to attend and vote at any general meeting and how many votes such persons may cast,
the Company may specify in the relevant notice of general meeting a time, not more than forty eight hours (excluding any days which are
not business days) before the time fixed for the meeting, by which a person must be entered on the register of members in order to have
the right to attend and vote at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 100 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
business shall be transacted unless the requisite quorum is present when the meeting proceeds to business. Two shareholders present in
person or by proxy and entitled to vote shall be a quorum, save where we only have one shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
within half an hour from the time appointed for the general meeting a quorum is not present, if convened on the requisition of the shareholders
the meeting shall be dissolved. In any other case the meeting shall be adjourned to the same day in the next week at the same time and
place and no notice of such adjournment need be given. At any such adjourned meeting, those shareholders present in person or by proxy
shall be a quorum. If no shareholders are present at the adjourned meeting, the meeting shall be dissolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
question submitted to a general meeting shall be determined in the first instance by a show of hands of the shareholders present in person
or by proxy or by attorney and entitled to vote, but a poll may be demanded by no fewer than five shareholders having the right to vote
on the resolution, or one or more of the shareholders present in person or by proxy representing at least 10%. of the total voting rights
of all of the shareholders having the right to vote on the resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Corporate
representatives</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
corporation which is a shareholder may by resolution of its directors or other governing body authorize such person as it thinks fit
to act as its representative at any meeting of ours or of any class of shareholders, and the person so authorized shall be entitled to
exercise the same powers on behalf of the corporation which he represents as that corporation could exercise if it were an individual
shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Borrowing
Powers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Articles and the Guernsey Companies Law, our board of directors may exercise all of the powers of the company to:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">borrow
    money;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indemnify
    and guarantee;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mortgage
    or charge;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    and issue debentures and other securities; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">give
    security either outright or as collateral security for any debt, liability or obligation of the company or of any third party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Uncertificated
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Guernsey Companies Law, our board of directors may permit title to shares of any class to be issued or held otherwise than by
a certificate and to be transferred by means of a &ldquo;relevant system&rdquo; (i.e., the CREST System) without a certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may take such steps as it sees fit in relation to the evidencing of and transfer of title to uncertificated shares,
any records relating to the holding of uncertificated shares and the conversion of uncertificated shares to certificated shares, or vice-versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may by notice to the holder of an uncertificated share, require that share to be converted into certificated form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors may take such other action that the board considers appropriate to achieve the sale, transfer, disposal, forfeiture,
re-allotment or surrender of an uncertified share or otherwise to enforce a lien in respect of it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 101 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Winding
up</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any preferred, deferred or other special rights, or subject to such conditions or restrictions to which any shares in our capital
may be issued, on a winding-up or other return of capital, the holders of our ordinary shares are entitled to share in any surplus assets
<I>pro rata</I> to their holdings of such ordinary shares. A liquidator may, with the sanction of a special resolution of ours and any
other sanction required by the Guernsey Companies Law, divide amongst our shareholders in specie or in kind the whole or any part of
our assets (whether or not the assets shall consist of property of one kind or shall consist of property of different kinds), those assets
to be set at such value as such liquidator deems fair. A liquidator may also vest the whole or any part of our assets in trustees on
trusts for the benefit of the shareholders as the liquidator shall think fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
the Company is proposed to be or is in the course of being wound up and the whole or part of its business or property is proposed to
be transferred or sold to another company the liquidator may, with the sanction of an ordinary resolution, receive in compensation for
the transfer or sale, shares, policies or other like interests in such other company for distribution among our shareholders or may enter
into any other arrangement whereby our shareholders may, in lieu of receiving cash, shares, policies or other like interests, or in addition
thereto, participate in the profits of or receive any other benefits from such company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Issue
of shares and share rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may exercise the power of the company for an unlimited duration to issue an unlimited number of shares or grant rights to subscribe
for, or to convert any security into shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue shares which: (i) are redeemable shares; (ii) confer preferential rights to distribution of capital or income; (iii) do not
entitle the holder to voting rights; and (iv) entitle the holder to restricted voting rights. Our directors may issue shares which have
a nominal or par value, no par value, in any number they see fit and in fractions of a share. Subject to &ldquo;Variation of Rights&rdquo;
above, we may convert all or any classes of our shares into redeemable shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors may make arrangements on the issue of shares to distinguish between shareholders as to the amounts and the times of payments
of calls on their shares and issue shares that provide for the payment of dividends and distributions in differing proportions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquisition
of own shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the provisions of the Guernsey Companies Law and the rights of holders of any class of shares, we may purchase our own shares, including
redeemable shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liens,
Calls on Shares and Forfeiture</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
respect of any shares we issue that are not fully paid, we will have a first and paramount lien on every share (not being a fully paid
share) for all moneys payable at a fixed time or called in respect of such share. Our board of directors may make calls upon shareholders
for any amounts unpaid in respect of their shares, subject to the terms of allotment (whether in respect of nominal value or premium).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a call remains unpaid after it has become due and payable, then, following notice by our board of directors requiring payment of the
unpaid amount together with any accrued interest and expenses incurred, such share may be forfeited by a resolution of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder whose shares have been forfeited will cease to be a shareholder in respect of such share, but will, notwithstanding the forfeiture,
remain liable to us for all moneys which at the date of forfeiture were presently payable together with interest. A forfeited share may
be sold, re-allotted or otherwise disposed of as our board of directors sees fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 102 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
that Would Delay, Defer or Prevent a Change of Control</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no provisions in our Articles that would have the effect of delaying, deferring or preventing a change in control of us and that
would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Relevant Laws and Regulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mandatory
Bid</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.K. City Code on Takeovers and Mergers, or Takeover Code, applies to the company. Under the Takeover Code, where:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    person, together with persons acting in concert with them, acquires, whether by a series of transactions over a period of time or
    not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert
    with them are interested) carry 30% or more of the voting rights of a company; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    person who, together with persons acting in concert with them, is interested in shares which in the aggregate carry not less than
    30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any
    person acting in concert with them, acquires an interest in any other shares which increases the percentage of shares carrying voting
    rights in which he is interested, such person shall, except in limited circumstances, be obliged to extend offers, on the basis set
    out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non-voting,
    and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity
    share capital must be comparable; the U.K. Panel on Takeovers and Mergers, or Takeover Panel, should be consulted in advance in such
    cases.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
offer under Rule 9 of the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required
to make an offer or any person acting in concert with them during the 12 months prior to the announcement of the offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Takeover Code, a &ldquo;concert party&rdquo; arises where persons acting together pursuant to an agreement or understanding (whether
formal or informal and whether or not in writing) cooperate, through the acquisition by them of an interest in shares in a company, to
obtain or consolidate control of the company. &ldquo;Control&rdquo; means holding, or aggregate holdings, of an interest in shares carrying
30% or more of the voting rights of the company, irrespective of whether the holding or holdings give <I>de facto</I> control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Notification and Disclosure Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are obliged to comply with the shareholding notification and disclosure requirements set out in Chapter 5 of the DTRs. As the company
is classified as a &ldquo;non-UK issuer&rdquo; for the purposes of the DTRs, a shareholder is required pursuant to Rule 5 of the DTRs
to notify the company if, as a result of an acquisition or disposal of shares or financial instruments, the shareholder&rsquo;s percentage
of voting rights of the company reaches, exceeds or falls below 5%, 10%, 15%, 20%, 25%, 30%, 50% and 75%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DTRs can be accessed and downloaded from the FCA&rsquo;s website at <U>https://www.handbook.fca.org.uk/handbook/DTR/</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are urged to consider their notification and disclosure obligations carefully as a failure to make a required disclosure to the company
may result in disenfranchisement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 103 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shareholder
rights under Guernsey Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the rights of shareholders under the Guernsey Companies Law and other applicable laws in Guernsey. Prospective
shareholders are advised that this is not a complete statement of the rights of Shareholders under applicable law in Guernsey or under
the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
Company alterations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, it is possible for a Guernsey company to merge with another Guernsey company or an overseas company with
the approval by a special resolution of members, provided that there is a short form amalgamation process for amalgamations between a
company and its wholly-owned subsidiary or between two or more wholly- owned subsidiaries of the same company which does not require
a special resolution of the members of each company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, a compromise or arrangement is permitted between the company and its creditors or shareholders, or any class
thereof, whether for the purpose of facilitating the company&rsquo;s reconstruction or its merger with another company, or otherwise.
An application must be made to court which court will then order a meeting of the company&rsquo;s creditors or shareholders. It is necessary
for 75%. in value of the creditors or 75% of the voting rights of the shareholders, or class thereof, as the case may be, to agree to
the compromise or arrangement and if such compromise or arrangement is sanctioned by the court, it will be binding on the creditors or
shareholders, or class thereof, as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Guernsey Companies Law also requires the approval of the shareholders by special resolution for the removal of a company from the Guernsey
Register of Companies for the purpose of becoming registered as a company under the law of a district, territory or place outside Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Guernsey Companies Law, amendments to a company&rsquo;s articles of incorporation so permitted may be authorized by way of a special
resolution of the company&rsquo;s shareholders (provided that certain provisions within a company&rsquo;s articles of incorporation can
be embedded with a higher voting threshold required for change).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
Rights of dissent and appraisal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Guernsey Companies Law contains rights of dissent (the granting of which is discretionary on the part of the court), which are applicable
where the company resolves to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
amalgamate with another corporation (other than vertical or horizontal short form amalgamations);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
transfer of its registration into another jurisdiction; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
carry out a takeover transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)
Shareholder derivative actions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws of Guernsey permit derivative actions to be brought by a shareholder, or such person as the court directs who, in the discretion
of the court, is a proper person to make an application to court to bring a derivative action. Under the laws of Guernsey, the complainant
must obtain permission of the court to commence a derivative action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)
Sale of undertaking</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law does not contain provisions in relation to shareholder authority for the sale of a company&rsquo;s undertaking and, accordingly,
the sale, lease or exchange of all or substantially all the property of the company will be governed by the articles of incorporation
of a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(e)
Unfair prejudice</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
member of a company may apply to the court on the ground that the affairs of the company are conducted in a manner that is unfairly prejudicial
to the interests of members generally or of some part of its members (including at least themselves), or an actual or proposed act or
omission of the company is or would be so prejudicial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the court is satisfied that an application is well founded it may make such orders as it sees fit, which may include without limitation:
(a) requiring the company to refrain from doing or continuing to do an act, or require it to do any act which the applicant has complained
it has omitted to do; or (b) providing for the purchase of shares of any member of the company by other members of the company or by
the company itself (and the reduction of the company&rsquo;s capital accordingly).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Differences
in Corporate Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a non-cellular company limited by shares incorporated in Guernsey, we are governed by the Guernsey Companies Law. The applicable provisions
of the Guernsey Companies Law differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of
certain differences between the provisions of the Guernsey Companies Law applicable to us and the Delaware General Corporation Law relating
to shareholders&rsquo; rights and protections. This summary is not intended to be a complete discussion of the respective rights and
it is qualified in its entirety by reference to the laws of Guernsey and Delaware law.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
    Meetings</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
                                            a company&rsquo;s memorandum or articles of incorporation state otherwise, the directors
                                            are required to call a general meeting once the company receives requests to do so from shareholders
                                            who hold more than 10% of the capital of the company that carries the right of voting at
                                            general meetings (excluding any capital held as treasury shares).</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
                                            generally do not have the right to call meetings of shareholders unless that right is granted
                                            in the certificate of incorporation or bylaws.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    be held at such time or place as designated in the certificate of incorporation or the bylaws, or if not so designated, as determined
    by the board of directors</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the shareholders pass a resolution exempting the company from holding an annual general meeting, a company must hold a general meeting
    of its members within a period of 18 months beginning on the date on which it was incorporated and thereafter at least once every
    calendar year (with no more than 15 months elapsing between one annual general meeting and the next).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
                                            be held inside or outside Delaware</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, a meeting may be held at any place in Guernsey or elsewhere.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    Whenever shareholders are required to take any action at a meeting, a written notice of the meeting shall be given which shall state
    the place, if any, date and hour of the meeting, and the means of remote communication, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    A meeting must be called by at least 10 days&rsquo; notice or such longer period as provided by the articles of incorporation. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    A meeting may be called by shorter notice if all shareholders entitled to attend and vote so agree.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The notice shall specify the date, time and place of the meeting, the information of any resolutions to be passed at the meeting
    and such other information as is required by the articles of incorporation.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;
    Voting Rights</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the memorandum or articles of incorporation provide otherwise, directors are appointed by ordinary resolution of the shareholders.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    limited exceptions, and unless the certificate of incorporation provides otherwise, shareholders may act by written consent to elect
    directors.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    shareholder may appoint another person or persons to be their proxy to exercise all or any of their rights to attend, speak and vote
    at a meeting.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    stockholder entitled to vote may authorize another person or persons to act for such shareholder by proxy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the quorum shall be two shareholders holding 5% of the total voting rights of the company between
    them.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    certificate of incorporation or bylaws may specify the number to constitute a quorum, but in no event shall a quorum consist of less
    than one-third of shares entitled to vote at a meeting. In the absence of such specifications, a majority of shares entitled to vote,
    present in person or represented by proxy, shall constitute a quorum.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain limited exceptions, a provision of the articles of incorporation is void to the extent that it would have the effect of
    excluding or making ineffective a demand for a poll at general meeting.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    certificate of incorporation may provide for cumulative voting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the board of directors must consist of at least one director and is not subject to a maximum number
    of directors.</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors must consist of at least one director and is not subject to a maximum number of directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, the board of directors may determine the remuneration or other benefits given to a director.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    number of directors shall be fixed by the bylaws, unless the certificate of incorporation fixes such number, in which case a change
    in the number shall be made only by amendment of the certificate of incorporation.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    person will cease to be a director if such person:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    classified board is permitted.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    provides written notice of their resignation to the company; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation
    or bylaws.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    is removed in accordance with the memorandum and articles of incorporation; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    becomes ineligible to be a director under the laws of Guernsey; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    dies; or </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
    Any or all of the directors may be removed, with or without cause, by the holders of a majority of the shares entitled to vote unless
    the certificate of incorporation provides otherwise. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    otherwise vacates office in accordance with the memorandum and articles of incorporation.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ndash;
    In the case of a classified board, shareholders may affect removal only for cause.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interested
    Shareholders&rsquo; Transactions</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Guernsey Companies Law does not contain any specific prohibition on interested shareholder transactions.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Delaware General Corporation Law contains a business combination statute applicable to corporations whereby, unless the corporation
    has specifically elected not to be governed by such statute, it is prohibited from engaging in certain business combinations with
    an &ldquo;interested shareholder&rdquo; for three years following the date that such shareholder becomes an interested shareholder.
    An interested shareholder generally is a person or a group that owns at least 15% of the corporation&rsquo;s outstanding voting stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interested
    Director Transactions</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    director must, immediately after becoming aware of the fact that such director is interested in a transaction or proposed transaction
    with the company, disclose to the board the nature and extent of such director&rsquo;s interest.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested
    director transactions are permissible and may not be legally voided if:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the memorandum and articles of incorporation, a director who is interested in a transaction may vote, attend board meetings, sign
    documents and do any other thing in such director&rsquo;s capacity as a director in relation to a transaction in which such director
    is interested as if such director was not interested in the transaction provided that such director has made the necessary declarations.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the material facts of the director&rsquo;s interest are disclosed and a majority of the disinterested directors approve the transaction;
    </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    transaction in which a director is interested is voidable by the company at any time within 3 months of the date after which the
    transaction is disclosed to the board unless:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the material facts of the director&rsquo;s interest are disclosed and a majority of the shareholders entitled to vote approve the
    transaction; or </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the director&rsquo;s interest was disclosed at the time the transaction was entered into or a disclosure was not required (for example,
    if the transaction is entered into in the ordinary course of business and on usual terms and conditions);</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the transaction is determined to have been fair to the corporation at the time it is authorized, approved or ratified by the board
    of directors, a committee thereof or the shareholders.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the transaction is ratified by the shareholders; or</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the company received fair value for the transaction.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 106 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may pay a dividend if the board of directors is satisfied on reasonable grounds that the company will, immediately after
    payment of the dividend, satisfy the statutory solvency test contained in the Guernsey Companies Law as well as any other requirement
    of the memorandum or articles of incorporation.</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    board of directors may declare and pay dividends, subject to any restrictions contained in the certificate of incorporation, upon
    the shares of the corporation&rsquo;s capital stock either: out of its surplus or, in case there is no surplus, out of its net profits
    for the fiscal year in which the dividend is declared or the preceding fiscal year.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    dividend may be of such amount, be paid at such time and be paid to such members as the board of directors thinks fit; <I>provided
    </I>that the directors must not authorize a dividend in respect of some but not all of the shares in a class or that is of a greater
    value per share in respect of some shares of a class than in respect of other shares of that class.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, there is no requirement for dividends to be paid out of a particular account or source.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Variation
    of Rights of Class of Shares</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may only vary the rights of a class of shareholders in accordance with the provisions of the articles of incorporation or,
    in the absence of such provisions, with the consent in writing from the holders of at least 75% in value of the issued shares of
    that class or by means of a special resolution passed by at least 75% in value of the issued shares of that class at a separate meeting
    of shareholders of that class.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless
    the certificate of incorporation provides otherwise.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mergers
    and Similar Arrangements</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the articles of incorporation, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a
    company may be negotiated and approved by the board of directors. Depending on the structure of such a transaction, a separate shareholder
    approval may be required.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
                                            the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale,
                                            lease or transfer of all or substantially all of the assets of a corporation must be approved
                                            by the board of directors and a majority of the outstanding shares entitled to vote thereon.</FONT></P>
    <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
    within a period of four months after the date of an offer being made in respect of a transfer of shares, the offer is approved or
    accepted by the shareholders comprising not less than 90% in value of the shares affected, the offeree may, within two months immediately
    after the last day on which the offer can be approved or accepted, give notice to any dissenting shareholders of its desire to acquire
    the remaining shares. On the expiration of one month from the date of the notice to acquire, the offeror will be entitled to acquire
    the shares of the dissenting shareholder(s) by sending them a copy of the notice to acquire and by paying or transferring to them
    the consideration that such shareholder(s) are entitled to in respect of those shares, at which point the offeror shall be registered
    as the holder of those shares.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Delaware General Corporation Law also provides that a parent corporation may, by resolution of its board of directors, merge with
    any subsidiary of which it owns at least 90% of each class of capital stock without a vote by the shareholders of such subsidiary.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appraisal
    Rights</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Guernsey Companies Law does not specifically provide for any appraisal rights of shareholders. The Guernsey Companies Law does, however,
    give the courts of Guernsey broad authority in respect of orders made pursuant to successful unfair prejudice claims under the Guernsey
    Companies Law.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    shareholder of a corporation participating in certain major transactions may, under certain circumstances, be entitled to appraisal
    rights under which the shareholder may receive cash in the amount of the fair value of the shares held by such shareholder in lieu
    of the transaction consideration.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 107 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
    Suits</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    shareholder may commence or continue a claim as a representative of those with the same interests in the claim. Unless the court
    directs otherwise, any judgment in which a party is acting as a representative will be binding on all persons represented.</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    actions and derivative actions generally are available to shareholders for, among other things, breach of fiduciary duty, corporate
    waste, and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party
    to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    actions are also available to shareholders in respect of a cause of action arising from an actual or proposed act or omission involving:
    negligence, default, breach of duty and/or breach of trust by a director of the company.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
    are awarded by the court at its discretion. The normal order is for the winning party to recover its costs incurred in connection
    the action.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
    on Directors&rsquo; Liability and Indemnification of Directors and Officers</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may include in its articles of incorporation provisions limiting the liability of its directors (and officers or other persons);
    however, any provision that purports to exempt a director from any liability in connection with any negligence, default, breach of
    duty or breach of trust in relation to the company is void.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may include in its certificate of incorporation provisions limiting the personal liability of its directors to the corporation
    or its shareholders for monetary damages for certain breaches of fiduciary duty. However, such provisions may not limit liability
    for any breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation
    of law, the authorization of unlawful dividends, stock purchases, or redemptions, or any transaction from which a director derived
    an improper personal benefit.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    provision by which a company directly or indirectly provides an indemnity for a director of the company, or any associated company,
    against any liability in connection with any negligence, default, breach of duty or breach of trust is void, except that:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    corporation may indemnify a director or officer of the corporation against expenses, judgments, fines and amounts paid in settlement
    actually and reasonably incurred in defense of any action, suit or proceeding by reason of such person&rsquo;s position if (i) the
    person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation
    and (ii) with respect to any criminal action or proceeding, the person had no reasonable cause to believe the conduct was unlawful.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a company is not prevented from purchasing and maintaining for a director of the company, or any associated company, insurance against
    any such liability; and </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    such restriction does not apply to a qualifying third-party indemnity provision, which is a provision for indemnity against liability
    incurred by a director to a person other than the company or an associated company that does not provide any indemnity against a
    prescribed list of liabilities, including certain fines and penalties and liabilities incurred in defending certain proceedings.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 108 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors&rsquo;
    Fiduciary Duties</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    duties of directors in Guernsey are generally owed to the company and its shareholders as a whole rather than to any other person
    or particular shareholders (subject to certain exceptions) and arise from customary laws, statutory laws and contractual obligations.</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    of a Delaware corporation have a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of
    care and the duty of loyalty.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customary
    law duties of directors include:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under
    similar circumstances. Under this duty, a director must inform themselves of, and disclose to shareholders, all material information
    reasonably available regarding a significant transaction. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to act in good faith, in the best interests of the company, and not for any collateral purpose; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation.
    He or she must not use their corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and
    mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director,
    officer or controlling shareholder and not shared by the shareholders generally.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to exercise powers for a proper purpose. Even if a director is acting in good faith and in the best interests of the company,
    such director must nevertheless use their powers for the proper purpose for which they were conferred; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to avoid and mitigate conflicts of interest; and </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a duty to account for profits. As a fiduciary, a director may not take a personal profit from opportunities arising from such director&rsquo;s
    office, even if the director is acting honestly and in the best interests of the company. Any such profit must be paid to the company.
    A director&rsquo;s entitlement to remuneration and payment of expenses will be governed by the company&rsquo;s articles of incorporation.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the
    action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one
    of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, such director must prove the procedural
    fairness of the transaction, and that the transaction was of fair value to the corporation.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory
    duties of directors include:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    a general duty to manage the business and affairs of the company; and </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    the directors are responsible for considering a solvency test in various circumstances, including in authorizing distributions by
    the company to its shareholders.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 109 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspection
    of Books and Records</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 42%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    register and index of members, register of directors, register of secretaries and copies of all resolutions of shareholders passed
    other than at general meetings and minutes of the proceedings of general meetings, in each case, in the last six years, must be open
    for the inspection by any shareholder of the company without charge during ordinary business hours. They must also be open to inspection
    by any other person upon payment of such fee as may be prescribed by the Guernsey Committee for Economic Development or such lesser
    fee as the company may request.</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    shareholders have the right, upon written demand, to inspect or obtain copies of the corporation&rsquo;s shares ledger and its other
    books and records for any purpose reasonably related to such person&rsquo;s interest as a shareholder.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
    a company receives a request to inspect its records, the company must comply with that request or apply to the Guernsey courts for
    a direction not to comply.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendments
    of Governing Documents</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to certain exceptions, such as the alteration of the statement of the company&rsquo;s name, a company may only make or alter a provision
    of its memorandum of incorporation in accordance with the terms of the memorandum of incorporation or by unanimous resolution of
    all of its shareholders.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
    to the certificate of incorporation require the affirmative vote of the holders of a majority of the outstanding shares entitled
    to vote thereon, unless the certificate of incorporation provides otherwise. Bylaws may be amended with the approval of a majority
    of the outstanding shares entitled to vote and may, if provided in the certificate of incorporation, also be amended by the board
    of directors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may alter its articles of incorporation by means of a special resolution passed by at least 75% of the shareholders.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dissolution
    and Winding Up</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    company may be dissolved by means of a compulsory or voluntary winding up or a compulsory or voluntary striking off.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    the board of directors approves the proposal to dissolve, dissolution must be approved by all of the shareholders. Only if the dissolution
    is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    application for voluntary winding up requires a special resolution of the members passed by a majority of at least 75%.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    application for the voluntary striking off of a company must be made by the board of directors and be accompanied by a declaration
    of compliance confirming that all requirements of Guernsey law with respect to the striking off have been complied with.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Guernsey Law Considerations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required by the Guernsey Companies Law to keep a register of our shareholders. Under the laws of Guernsey, the ordinary shares are
deemed to be issued when the name of the shareholder is entered in our share register. The share register therefore is prima facie evidence
of the identity of our shareholders, and the shares that they hold. The share register generally provides limited, or no, information
regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Computershare Investor
Services (Guernsey) Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 110 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
future holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share
register. The depositary, the custodian or their nominees will be the holder of the shares underlying our ADSs. Potential future holders
of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see
&ldquo;Description of the American Depositary Shares&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will perform all procedures necessary to update the share register to reflect any ordinary shares being sold in any potential offering,
including updating the share register with the number of ordinary shares to be issued to the depositary upon the closing of any such
offering in the future. We also are required by the Guernsey Companies Law to register a transfer of shares (or give the transferee notice
of and reasons for refusal as the transferee may reasonably request) as soon as practicable and in any event within two months of receiving
notice of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
any of our shareholders, or any other affected person may apply to the court for rectification of the share register if:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    name of any person, without sufficient cause, is entered in or omitted from our register of members; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">default
    is made or unnecessary delay takes place in entering on the register the fact of any person having ceased to be a member or on which
    we have a lien, provided that such delay does not prevent dealings in the shares taking place on an open and proper basis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may transfer all or any of his shares (i) in the case of certificated shares by transfer in writing in any usual or common
form or in any other form acceptable to the Directors; and (ii) in the case of uncertificated shares, in the manner provided for in the
rules and procedures of the operator of the relevant system and in accordance with and subject to the CREST Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
instrument of transfer of a certified share shall be signed by or on behalf of the transferor and, if the share is not fully paid, by
or on behalf of the transferee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may, in its absolute discretion and without assigning any reason, decline to register any transfer of certificated share or uncertified
shares unless it is:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share which is fully paid up;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of a share in which the Company has no lien;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    respect of only one class of share;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    favor of a single transferee or not more than four joint transferees; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    relation to a certificated share, delivered for registration to the registered office of the Company (or such other place as the
    Board may from time to time determine) accompanied by the relevant share certificate(s) and such other evidence as the Board may
    reasonably require to prove the right of the transferor to make the transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board shall not refuse to register any transfer or renunciation of partly paid shares which are listed on the Main Market of the London
Stock Exchange on the grounds that they are partly paid shares in circumstances where that refusal would prevent dealings in any such
shares from taking place on an open and proper basis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 111 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Distributions
and Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the Guernsey Companies Law, our directors may authorize dividends and distributions to be paid to shareholders. If any share
is issued on terms providing that it shall rank for dividend or distribution as from a particular date, such share shall rank for dividend
or distribution accordingly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Our directors may direct that any dividend or distribution shall be satisfied wholly or partly by the distribution of assets, and in
particular of paid-up shares, debentures, or other securities of any other company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
No dividend or distribution payable shall bear interest against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
A transfer of shares shall not pass the right to any dividend or distribution declared thereon before the registration of the transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Unless otherwise directed, any dividend or distribution may be paid by way of electronic transfer in such manner as agreed between the
shareholder and us or by cheque or warrant sent through the post to the registered address of such shareholder entitled thereto, or in
the case of joint holders to that one whose name stands first on our register of members in respect of the joint holding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
All dividends or distribution unclaimed for a period of one year from the date on which such dividend or distribution was declared may
be invested or otherwise made use of by our directors for our benefit until claimed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
All dividends or distribution unclaimed for a period of six years from the date on which such dividend or distribution was declared shall,
if our directors so resolve, be forfeited and shall revert to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Subject to the Guernsey Companies Law or in the terms of issue of any share in our capital, for the purposes of making any distribution
or paying any dividend, our directors may determine that those persons who are entered on the register of members at the close of business
on a day determined by our directors shall be the persons who are entitled to receive such dividends or distributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
on Owning Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles do not restrict in any way the ownership or voting of our shares by non-residents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purchase
of Own Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles, a summary of which is provided above, do not prohibit us from purchasing our own shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Articles do not have conditions governing changes to our capital which are more stringent that those required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholder
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
rights granted under the Guernsey Companies Law, including the right to requisition a general meeting or require a resolution to be put
to shareholders at the annual general meeting, are only available to our members. For Guernsey law purposes, our members are the persons
who are registered as the owners of the legal title to the shares and whose names are recorded in our register of members. In the case
of shares held in a settlement system operated by the Depository Trust Company, or DTC, the registered member will be DTC&rsquo;s nominee,
Cede &amp; Co. If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Guernsey Companies
Law, they may be required to first take steps to withdraw their ADSs from the settlement system operated by DTC and become the registered
holder of the shares in our register of members. A withdrawal of shares from DTC may have tax implications, for additional information
on the potential tax implications of withdrawing your shares from the settlement system operated by DTC, see &ldquo;Material Tax Considerations&mdash;Guernsey
Taxation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 112 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exchange
Controls and Other Limitations Affecting Security Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Guernsey law, there are currently no restrictions on the export or import of capital, including foreign exchange controls or restrictions
that affect the remittance of dividends, interest or other payments to nonresidents holders of our ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enforcement
of Civil Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
laws do not necessarily extend either to us or our officers or directors. We are incorporated under the laws of Guernsey. Some of our
directors and officers reside outside of the United States. Substantially all of the assets of both us and our directors and officers
are located outside the United States. As a result, it may not be possible for investors to effect service of process on either us or
our officers and directors within the United States, or to enforce against these persons or us, either inside or outside the United States,
a judgment obtained in a U.S. court predicated upon the civil liability provisions of the federal securities or other laws of the United
States or any State in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have appointed OKYO Pharma US, Inc., as our agent to receive service of process with respect to any action brought against us in the
United States under the federal securities laws of the United States or of the laws of any state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
judgment of a U.S. court is not directly enforceable in Guernsey, but constitutes a cause of action which may be enforced by Guernsey
courts provided that:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    applicable U.S. courts had jurisdiction over the case, as recognized under Guernsey law;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment is given on the merits and is final, conclusive and non-appealable;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment relates to the payment of a sum of money, not being taxes, fines or similar governmental penalties;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    defendant is not immune under the principles of public international law;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    same matters at issue in the case were not previously the subject of a judgment or disposition in a separate court;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    judgment was not obtained by fraud; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recognition and enforcement of the judgment is not contrary to public policy in Guernsey.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
courts award compensation for the loss or damage actually sustained by the plaintiff. Although punitive damages are generally unknown
to the Guernsey legal system, there is no prohibition on them either by statute or customary law. Whether a particular judgment may be
deemed contrary to Guernsey public policy depends on the facts of each case, though judgments found to be exorbitant, unconscionable,
or excessive will generally be deemed as contrary to public policy. Moreover, certain defendants may qualify for protection under Protection
of Trading Interests Act 1980, an act of the UK extended to Guernsey by the Protection of Trading Interests Act 1980 (Guernsey) Order,
1983. This Act provides that a qualifying defendant is not liable for multiple damages, in excess of that required for actual compensation.
A &ldquo;qualifying defendant&rdquo; for these purposes is a citizen of the UK and its Colonies (as defined in the Act), a corporation
or other limited liability entity organized under the laws of the UK, Guernsey or other territory for whose international relations the
UK is responsible or a person conducting business in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
courts cannot enter into the merits of the foreign judgment and cannot act as a court of appeal or review over the foreign courts. It
is doubtful that an original action based on U.S. federal or state securities laws could be brought before Guernsey courts. In addition,
a plaintiff who is not resident in Guernsey may be required to provide a security bond in advance to cover the potential of the expected
costs of any case initiated in Guernsey. In addition, Clarivate has been further advised by our legal counsel in Guernsey that it is
uncertain as to whether the courts of Guernsey would entertain original actions or enforce judgments from U.S. courts against us or our
officers and directors which originated from actions alleging civil liability under U.S. federal or state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 113 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="ak_006"></A>DESCRIPTION
OF THE AMERICAN DEPOSITARY SHARES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JPMorgan
Chase Bank, N.A., or JPMorgan, as depositary, will issue the ADSs. Each ADS will represent an ownership interest a designated number
of ordinary shares which we will deposit with the custodian, as agent of the depositary, under the deposit agreement among ourselves,
the depositary and yourself as an ADR holder. In the future, each ADS will also represent any securities, cash or other property deposited
with the depositary but which they have not distributed directly to you. Unless certificated ADRs are specifically requested by you,
all ADSs will be issued on the books of our depositary in book-entry form and periodic statements will be mailed to you which reflect
your ownership interest in such ADSs. In our description, references to American depositary receipts, or ADRs, shall include the statements
you will receive which reflect your ownership of ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary&rsquo;s office is located at 383 Madison Avenue, Floor 11, New York, NY 10179.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may hold ADSs either directly or indirectly through your broker or other financial institution. If you hold ADSs directly, by having
an ADS registered in your name on the books of the depositary, you are an ADR holder. This description assumes you hold your ADSs directly.
If you hold the ADSs through your broker or financial institution nominee, you must rely on the procedures of such broker or financial
institution to assert the rights of an ADR holder described in this section. You should consult with your broker or financial institution
to find out what those procedures are.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an ADR holder, we will not treat you as a shareholder of ours and you will not have any shareholder rights. The laws of Guernsey governs
shareholder rights. Because the depositary or its nominee will be the shareholder of record for the ordinary shares represented by all
outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder. Such rights derive from the
terms of the deposit agreement to be entered into among us, the depositary and all registered holders from time to time of ADRs issued
under the deposit agreement. The obligations of our company, the depositary and its agents are also set out in the deposit agreement.
Because the depositary or its nominee will actually be the registered owner of the ordinary shares, you must rely on it to exercise the
rights of a shareholder on your behalf. The deposit agreement and the ADSs are governed by New York law. Under the deposit agreement,
as an ADR holder, you agree that any legal suit, action or proceeding against or involving us or the depositary, arising out of or based
upon the deposit agreement, the ADSs or the transactions contemplated thereby, may only be instituted in a state or federal court in
New York, New York, and you irrevocably waive any objection which you may have to the laying of venue of any such proceeding and irrevocably
submit to the exclusive jurisdiction of such courts in any such suit, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary,
it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire
deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which is filed
as an exhibit to the registration statement of which this prospectus forms a part. You may also obtain a copy of the deposit agreement
at the SEC&rsquo;s Public Reference Room which is located at 100 F Street, NE, Washington, DC 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-732-0330. You may also find the registration statement and the attached
deposit agreement on the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
Dividends and Other Distributions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
will I receive dividends and other distributions on the ordinary shares underlying my ADSs?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it
will pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities,
after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all
cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate
of JPMorgan to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division,
branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary.
You will receive these distributions in proportion to the number of underlying securities that your ADSs represent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 114 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner:</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash.
    </I>The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or
    the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable
    basis, subject to (i) appropriate adjustments for taxes withheld, (ii) such distribution being impermissible or impracticable with
    respect to certain registered ADR holders, and (iii) deduction of the depositary&rsquo;s and/or its agents&rsquo; expenses in (1)
    converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable
    basis, (2) transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the
    extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental
    authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4)
    making any sale by public or private means in any commercially reasonable manner. <I>If exchange rates fluctuate during a time when
    the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares. In the case of a distribution in ordinary shares, the depositary will issue additional ADRs to evidence the number of ADSs
    representing such ordinary shares. Only whole ADSs will be issued. Any ordinary shares which would result in fractional ADSs will
    be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
    to receive additional ordinary shares.</I> In the case of a distribution of rights to subscribe for additional ordinary shares or
    other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary
    will distribute warrants or other instruments in the discretion of the depositary representing rights to acquire additional ADRs.
    However, if we do not timely furnish such evidence, the depositary may:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
if it is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short
duration or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
    Distributions.</I> In the case of a distribution of securities or property other than those described above, the depositary may either
    (i) distribute such securities or property in any manner it deems equitable and practicable or (ii) to the extent the depositary
    deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute
    any net proceeds in the same way it distributes cash.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Elective
    Distributions. </I>In the case of a dividend payable at the election of our shareholders in cash or in additional ordinary shares,
    we will notify the depositary at least 30 days prior to the proposed distribution stating whether or not we wish such elective distribution
    to be made available to ADR holders. The depositary shall make such elective distribution available to ADR holders only if (i) we
    shall have timely requested that the elective distribution is available to ADR holders, (ii) the depositary shall have determined
    that such distribution is reasonably practicable and (iii) the depositary shall have received satisfactory documentation within the
    terms of the deposit agreement including any legal opinions of counsel that the depositary in its reasonable discretion may request.
    If the above conditions are not satisfied, the depositary shall, to the extent permitted by law, distribute to the ADR holders, on
    the basis of the same determination as is made in the local market in respect of the ordinary shares for which no election is made,
    either (x) cash or (y) additional ADSs representing such additional ordinary shares. If the above conditions are satisfied, the depositary
    shall establish procedures to enable ADR holders to elect the receipt of the proposed dividend in cash or in additional ADSs. There
    can be no assurance that ADR holders generally, or any ADR holder in particular, will be given the opportunity to receive elective
    distributions on the same terms and conditions as the holders of ordinary shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered
ADR holder, the depoasitary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution
of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of
the ADR holder as deposited securities, in which case the ADSs will also represent the retained items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be
withheld without liability and dealt with by the depositary in accordance with its then current practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>There
can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights,
shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All
purchases and sales of securities will be handled by the Depositary in accordance with its then current policies, which are currently
set forth in the &ldquo;Depositary Receipt Sale and Purchase of Security&rdquo; section of www.adr.com/Investors/FindOutAboutDRs, the
location and contents of which the Depositary shall be solely responsible for.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deposit,
withdrawal and Cancellation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
does the depositary issue ADSs?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will issue ADSs if you or your broker deposit ordinary shares or evidence of rights to receive ordinary shares with the custodian
and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this
prospectus, we will arrange with the Selling Shareholders named herein to deposit such ordinary shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such
deposit, be registered in the name of the depositary, the custodian or a nominee of either.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
custodian will hold all deposited ordinary shares (including those being deposited by or on our behalf in connection with this offering
to which this prospectus relates) for the account and to the order of the depositary for the benefit of registered holders of ADRs, to
the extent not prohibited by law. ADR holders thus have no direct ownership interest in the ordinary shares and only have such rights
as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in
substitution for the deposited ordinary shares. The deposited ordinary shares and any such additional items are referred to as &ldquo;deposited
securities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
each deposit of ordinary shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement,
including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue
an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled.
All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&rsquo;s direct registration system,
and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&rsquo;s
name. An ADR holder can request that the ADSs not be held through the depositary&rsquo;s direct registration system and that a certificated
ADR be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
do ADR holders cancel an ADS and obtain deposited securities?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
you turn in your ADR certificate at the depositary&rsquo;s office, or when you provide proper instructions and documentation in the case
of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying
ordinary shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&rsquo;s
office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may only restrict the withdrawal of deposited securities in connection with:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">temporary delays caused
    by closing our transfer books or those of the depositary or the deposit of ordinary shares in connection with voting at a shareholders
    meeting, or the payment of dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the payment of fees, taxes
    and similar charges; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with any U.S.
    or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
right of withdrawal may not be limited by any other provision of the deposit agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Record
Dates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable
to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated,
as the case may be):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to receive any distribution
    on or in respect of deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to give instructions for
    the exercise of voting rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to pay the fee assessed
    by the depositary for administration of the ADR program and for any expenses as provided for in the ADR;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to receive any notice or
    to act in respect of other matters; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all subject to the provisions
    of the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
do I vote?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise
the voting rights for the ordinary shares which underlie your ADSs. Subject to the next sentence, as soon as practicable after receipt
from us of notice of any meeting at which the holders of ordinary shares are entitled to vote, or of our solicitation of consents or
proxies from holders of ordinary shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit
agreement in respect of such meeting or solicitation of consent or proxy. The depositary shall, if we request in writing in a timely
manner (the depositary having no obligation to take any further action if our request shall not have been received by the depositary
at least 30 days prior to the date of such vote or meeting) and at our expense and provided no legal prohibitions exist, distribute to
the registered ADR holders a notice stating such information as is contained in the voting materials received by the depositary, stating
that that each registered holder of ADRs on the ADS record date will, subject to any applicable provisions of the laws of Guernsey, be
entitled to instruct the depositary as to the exercise of any voting rights pertaining to ordinary shares underlying such holder&rsquo;s
ADSs, and describing how you may instruct the depositary to exercise the voting rights for the ordinary shares which underlie your ADSs,
including instructions for giving a discretionary proxy to a person designated by us. For instructions to be valid, the depositary must
receive them in the manner and on or before the date specified. The depositary will try, as far as is practical, subject to the provisions
of or governing the underlying ordinary shares or other deposited securities, to vote or cause to be voted the ordinary shares or other
deposited securities as you instruct. The depositary will only vote or attempt to vote as you instruct. Holders are strongly encouraged
to forward their voting instructions to the depositary as soon as possible. Voting instructions will not be deemed to be received until
such time as the ADR department responsible for proxies and voting has received such instructions notwithstanding that such instructions
may have been physically received by the depositary prior to such time. The depositary will not itself exercise any voting discretion.
Furthermore, neither the depositary nor its agents are responsible for any failure to carry out any voting instructions, for the manner
in which any vote is cast or for the effect of any vote. Notwithstanding anything contained in the deposit agreement or any ADR, the
depositary may, to the extent not prohibited by law or regulations, or by the requirements of the stock exchange on which the ADSs are
listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of, or solicitation of consents
or proxies from, holders of deposited securities, distribute to the registered holders of ADRs a notice that provides such holders with,
or otherwise publicizes to such holders, instructions on how to retrieve such materials or receive such materials upon request (<I>i.e.</I>,
by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons
who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reports
and Other Communications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Will
ADR holders be able to view our reports?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement,
the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian
or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if we make any written communications generally available to holders of our ordinary shares, and we furnish copies thereof (or English
translations or summaries) to the depositary, it will distribute the same to registered ADR holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees
and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.7pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>What
fees and expenses will I be responsible for paying?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares,
issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared
by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities,
and each person surrendering ADSs for withdrawal of deposited securities or whose ADSs are cancelled or reduced for any other reason,
$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary
may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other
distribution prior to such deposit to pay such charge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing ordinary shares or by any party
surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split
declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fee of U.S.$1.50 per
    ADR or ADRs for transfers of certificated or direct registration ADRs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fee of up to U.S.$0.05
    per ADS for any cash distribution made pursuant to the deposit agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an aggregate fee of up
    to U.S.$0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which
    fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date
    or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding
    provision);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fee for the reimbursement
    of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the
    custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange control regulations or any
    law or regulation relating to foreign investment) in connection with the servicing of the ordinary shares or other deposited securities,
    the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in
    connection with the depositary&rsquo;s or its custodian&rsquo;s compliance with applicable law, rule or regulation (which fees and
    charges shall be assessed on a proportionate basis against holders as of the record date or dates set by the depositary and shall
    be payable at the sole discretion of the depositary by billing such holders or by deducting such charge from one or more cash dividends
    or other cash distributions);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fee for the distribution
    of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the $0.05 per ADS
    issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating
    all such securities as if they were ordinary shares) but which securities or the net cash proceeds from the sale thereof are instead
    distributed by the depositary to those holders entitled thereto;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock transfer or other
    taxes and other governmental charges;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT, cable, telex and
    facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of ordinary shares,
    ADRs or deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer or registration
    fees for the registration or transfer of deposited securities on any applicable register in connection with the deposit or withdrawal
    of deposited securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in connection with the
    conversion of foreign currency into U.S. dollars, JPMorgan shall deduct out of such foreign currency the fees, expenses and other
    charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection with such conversion;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees of any division, branch
    or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities
    under the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions
and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A., or the Bank, and/or
its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars. For certain currencies,
foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For
other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third
party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such foreign exchange transactions. For
further details see <U>www.adr.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements
from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us
and the depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the
termination of the deposit agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise
upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and
cancellation of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from intermediaries
acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed
or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services
by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants
acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no
distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services
to holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary,
all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment
of Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian
or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon,
such tax or other governmental charge shall be paid by the holder thereof to the depositary and by holding or having held an ADR the
holder and all prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and
its agents in respect thereof. If an ADR holder owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof
from any cash distributions, or (ii) sell deposited securities by public or private sale (after attempting by reasonable means to notify
the ADR holder hereof prior to such sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder
remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to affect any registration,
registration of transfer, split-up or combination of deposited securities or withdrawal of deposited securities until such payment is
made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may deduct the amount required
to be withheld from any cash distribution or, in the case of a non-cash distribution, sell the distributed property or securities (by
public or private sale) in such amounts and in such manner as the depositary deems necessary and practicable to pay such taxes and distribute
any remaining net proceeds or the balance of any such property after deduction of such taxes to the ADR holders entitled thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective
officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority
with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source
or other tax benefit obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reclassifications,
Recapitalizations and Mergers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we take certain actions that affect the deposited securities, including (i) any change in nominal value, split-up, consolidation, cancellation
or other reclassification of deposited securities or (ii) any distributions of ordinary shares or other property not made to holders
of ADRs or (iii) any recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or
substantially all of our assets, then the depositary may choose to, and shall if reasonably requested by us:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend the form of ADR;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribute additional or amended ADRs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribute cash, securities or other property it has
    received in connection with such actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell any securities or property received and distribute
    the proceeds as cash; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">none of the above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part
of the deposited securities and each ADS will then represent a proportionate interest in such property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amendment
and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
may the deposit agreement be amended?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given
at least 30 days&rsquo; notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes
and other governmental charges, transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or
other such expenses), or otherwise prejudices any substantial existing right of ADR holders. Such notice need not describe in detail
the specific amendments effectuated thereby, however, it must identify to ADR holders a means to access the text of such amendment. If
an ADR holder continues to hold an ADR or ADRs after being so notified, such ADR holder is deemed to agree to such amendment and to be
bound by the deposit agreement as so amended. Any amendments or supplements which (i) are reasonably necessary (as agreed by us and the
depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs or ordinary shares to be
traded solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by
ADR holders, shall be deemed not to prejudice any substantial rights of ADR holders. Notwithstanding the foregoing, if any governmental
body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement
or the form of ADR to ensure compliance therewith, we and the depositary may amend or supplement the deposit agreement and the ADR at
any time in accordance with such changed laws, rules or regulations, which amendment or supplement may take effect before a notice is
given or within any other period of time as required for compliance. No amendment, however, will impair your right to surrender your
ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>How
may the deposit agreement be terminated?</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination
to the registered holders of ADRs at least 30 days prior to the date fixed in such notice for such termination; provided, however, if
the depositary shall have (i) resigned as depositary under the deposit agreement, notice of such termination by the depositary shall
not be provided to registered holders unless a successor depositary shall not be operating under the deposit agreement within 60 days
of the date of such resignation, and (ii) been removed as depositary under the deposit agreement, notice of such termination by the depositary
shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement
on the 120<SUP>th</SUP> day after our notice of removal was first provided to the depositary. After termination, the depositary&rsquo;s
only responsibility will be (i) to deliver deposited securities to ADR holders who surrender their ADRs, and (ii) to hold or sell distributions
received on deposited securities. As soon as practicable after the expiration of six months from the termination date, the depositary
will sell the deposited securities which remain and hold the net proceeds of such sales (as long as it may lawfully do so), without liability
for interest, in trust for the ADR holders who have not yet surrendered their ADRs. After making such sale, the depositary shall have
no obligations except to account for such proceeds and other cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
on Obligations and Liability to ADR holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limits
on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the issue, registration, registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any distribution
in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian
may require:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment with respect thereto
    of (i) any stock transfer or other tax or other governmental charge, (ii) any stock transfer or registration fees in effect for the
    registration of transfers of ordinary shares or other deposited securities upon any applicable register and (iii) any applicable
    fees and expenses described in the deposit agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the production of proof
    satisfactory to it of (i) the identity of any signatory and genuineness of any signature and (ii) such other information, including
    without limitation, information as to citizenship, residence, exchange control approval, beneficial ownership of any securities,
    compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and
    the ADRs, as it may deem necessary or proper; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with such regulations
    as the depositary may establish consistent with the deposit agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of ADRs, the acceptance of deposits of ordinary shares, the registration, registration of transfer, split-up or combination
of ADRs or the withdrawal of ordinary shares, may be suspended, generally or in particular instances, when the ADR register or any register
for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw
ordinary shares may only be limited under the following circumstances: (i) temporary delays caused by closing transfer books of the depositary
or our transfer books or the deposit of ordinary shares in connection with voting at a shareholders meeting, or the payment of dividends,
(ii) the payment of fees, taxes, and similar charges, and (iii) compliance with any laws or governmental regulations relating to ADRs
or to the withdrawal of deposited securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement expressly limits the obligations and liability of the depositary, ourselves and each of our and the depositary&rsquo;s
respective agents, provided, however, that no disclaimer of liability under the Securities Act or the Exchange Act, to the extent applicable,
is intended by any provision of the deposit agreement. In the deposit agreement it provides that neither we nor the depositary nor any
such agent will be liable to registered holders or beneficial owners of ADSs if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any present or future law,
    rule, regulation, fiat, order or decree of the United States, Guernsey, England and Wales or any other country or jurisdiction, or
    of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or
    governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism, nationalization,
    expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure
    or circumstance beyond our, the depositary&rsquo;s or our respective agents&rsquo; direct and immediate control shall prevent or
    delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement
    or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it exercises or fails to
    exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution
    or action may be lawful or reasonably practicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it performs its obligations
    under the deposit agreement and ADRs without gross negligence or willful misconduct; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it takes any action or
    refrains from taking any action in reliance upon the advice of or information from legal counsel, accountants, any person presenting
    ordinary shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice
    or information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the depositary and its agents may rely and shall be protected in acting upon any written notice, request, direction, instruction or document
believed by them to be genuine and to have been signed, presented or given by the proper party or parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of
any deposited securities or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or
other proceeding in respect of any deposited securities or the ADRs, which in our opinion may involve us in expense or liability, if
indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as
may be required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or
on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the
deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including without
limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary shall
not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system.
Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency
of any custodian that is not a branch or affiliate of JPMorgan Chase Bank, N.A. Notwithstanding anything to the contrary contained in
the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising
from, any act or omission to act on the part of the custodian except to the extent that any registered holder of ADRs has incurred liability
directly as a result of the custodian having (i) committed fraud or willful misconduct in the provision of custodial services to the
depositary or (ii) failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance
with the standards prevailing in the jurisdiction in which the custodian is located. The depositary shall not have any liability for
the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall
it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection
with any such sale or proposed sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary has no obligation to inform ADR holders or other holders of an interest in any ADSs about the requirements of the laws of
Guernsey, rules or regulations or any changes therein or thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities,
for the manner in which any such vote is cast or for the effect of any such vote. The depositary may rely upon instructions from us or
our counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall
not incur any liability for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or
for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities,
for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse
upon the terms of the deposit agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for
any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection
with any matter arising wholly after the removal or resignation of the depositary. Neither the depositary nor any of its agents shall
be liable to registered holders or beneficial owners of interests in ADSs for any indirect, special, punitive or consequential damages
(including, without limitation, legal fees and expenses) or lost profits, in each case of any form incurred by any person or entity,
whether or not foreseeable and regardless of the type of action in which such a claim may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the deposit agreement each party thereto (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests
in ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit,
action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the ordinary shares or other
deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether
based on contract, tort, common law or any other theory).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Disclosure
of Interest in ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other
ownership of deposited securities, other ordinary shares and other securities and may provide for blocking transfer, voting or other
rights to enforce such disclosure or limits, you agree to comply with all such disclosure requirements and ownership limitations and
to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you to deliver your ADSs
for cancellation and withdrawal of the deposited securities so as to permit us to deal with you directly as a holder of ordinary shares
and, by holding an ADS or an interest therein, you will be agreeing to comply with such instructions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Books
of Depositary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary or its agent will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which
register shall include the depositary&rsquo;s direct registration system. Registered holders of ADRs may inspect such records at the
depositary&rsquo;s office at all reasonable times, but solely for the purpose of communicating with other holders in the interest of
the business of our company or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time,
when deemed expedient by the depositary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary will maintain facilities for the delivery and receipt of ADRs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-release
of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
its capacity as depositary, the depositary shall not lend ordinary shares or ADSs; provided, however, that the depositary may (i) issue
ADSs prior to the receipt of ordinary shares and (ii) deliver ordinary shares prior to the receipt of ADSs for withdrawal of deposited
securities, including ADSs which were issued under (i) above but for which ordinary shares may not have been received, each such transaction
a &ldquo;pre-release.&rdquo; The depositary may receive ADSs in lieu of ordinary shares under (i) above (which ADSs will promptly be
canceled by the depositary upon receipt by the depositary) and receive ordinary shares in lieu of ADSs under (ii) above. Each such pre-release
will be subject to a written agreement whereby the person/entity, or applicant to whom ADSs or ordinary shares are to be delivered (a)
represents that at the time of the pre-release the applicant or its customer owns the ordinary shares or ADSs that are to be delivered
by the applicant under such pre-release, (b) agrees to indicate the depositary as owner of such ordinary shares or ADSs in its records
and to hold such ordinary shares or ADSs in trust for the depositary until such ordinary shares or ADSs are delivered to the depositary
or the custodian, (c) unconditionally guarantees to deliver to the depositary or the custodian, as applicable, such ordinary shares or
ADSs, and (d) agrees to any additional restrictions or requirements that the depositary deems appropriate. Each such pre-release will
be at all times fully collateralized with cash, U.S. government securities or such other collateral as the depositary deems appropriate,
terminable by the depositary on not more than five (5) business days&rsquo; notice and subject to such further indemnities and credit
regulations as the depositary deems appropriate. The depositary will normally limit the number of ADSs and ordinary shares involved in
such pre-release at any one time to 30% of the ADSs outstanding (without giving effect to ADSs outstanding under (i) above), provided,
however, that the depositary reserves the right to change or disregard such limit from time to time as it deems appropriate. The depositary
may also set limits with respect to the number of ADSs and ordinary shares involved in pre-release with any one person on a case-by-case
basis as it deems appropriate. The depositary may retain for its own account any compensation received by it in conjunction with the
foregoing. Collateral provided in connection with pre-release transactions, but not the earnings thereon, shall be held for the benefit
of the ADR holders (other than the applicant).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the deposit agreement, each registered holder of ADRs and each person holding an interest in ADSs, upon acceptance of any ADSs (or any
interest therein) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be a party to and bound
    by the terms of the deposit agreement and the applicable ADR or ADRs; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoint the depositary
    its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit
    agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such
    action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement
    and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness
    thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -36.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement and the ADRs shall be governed by and construed in accordance with the laws of the State of New York. In the deposit
agreement, we have submitted to the jurisdiction of the courts of the State of New York and appointed OKYO Pharma US, Inc. as an agent
for service of process on our behalf. Notwithstanding the foregoing, any action based on the deposit agreement or the transactions contemplated
thereby may be instituted by the depositary in any competent court in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
holding an ADS or an interest therein, registered holders of ADRs and owners of ADSs each irrevocably agree that any legal suit, action
or proceeding against or involving us or the depositary, arising out of or based upon the deposit agreement, the ADSs or the transactions
contemplated thereby, may only be instituted in a state or federal court in New York, New York, and each irrevocably waives any objection
which it may have to the laying of venue of any such proceeding, and irrevocably submits to the exclusive jurisdiction of such courts
in any such suit, action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="s_001"></A>ORDINARY
SHARES AND ads</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">s <FONT STYLE="text-transform: uppercase">ELIGIBLE
FOR FUTURE SALE</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our initial public offering offering, no public market existed for our ADSs. Future sales of substantial amounts of ADSs in the public
market, the availability of ADSs for future sale or the perception that such sales may occur, however, could adversely affect the market
price of our ADSs and/or ordinary shares and also could adversely affect our future ability to raise capital through the sale of our
ADSs and/or ordinary shares or other equity-related securities at times and prices we believe appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the number of our ordinary shares outstanding as of November __, 2022, upon the closing of the offering, we will have __ ADSs
outstanding, representing __ ordinary shares, and __ ordinary shares outstanding (including ordinary shares in the form of
ADSs).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the ADSs sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except
for any shares sold to our &ldquo;affiliates,&rdquo; as that term is defined under Rule 144 under the Securities Act. The outstanding
ordinary shares held by existing shareholders are &ldquo;restricted securities,&rdquo; as that term is defined in Rule 144 under the
Securities Act. Restricted securities may be sold in the public market only if the offer and sale is registered under the Securities
Act or if the offer and sale of those securities qualifies for exemption from registration, including exemptions provided by Rules 144
or 701 promulgated under the Securities Act. Restricted securities may also be sold outside of the United States to non-U.S. persons
in accordance with Rule 904 of Regulation S under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the lock-up agreements described below and the provisions of Rule 144 or Regulation S under the Securities Act, as well as our insider
trading policy, these restricted securities will be available for sale in the public market at various times beginning at least 135 days
after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days,
a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding
a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates, is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice
provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates,
then such person is entitled to sell such shares without complying with any of the requirements of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to
sell upon expiration of the lock-up agreements described below, within any three-month period beginning 90 days after the date of this
prospectus, a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of ADSs
    then outstanding, which will equal approximately shares immediately after this offering&#894; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading
    volume of our ADSs during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a shareholder who was issued shares pursuant to a written compensatory plan or contract and who is not deemed to
have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without
being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also
permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements
of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus
before selling those shares pursuant to Rule 701.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements
of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="s_002"></A>certain
U.S. AND GUERNSEY TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
U.S. Federal Income Tax Considerations for U.S. Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs
by U.S. Holders. This discussion applies to U.S. Holders that purchase our ADSs pursuant to this offering and hold such ADSs as capital
assets for U.S. federal income tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated
thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject
to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may
be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under
U.S. federal income tax law (such as certain financial institutions, insurance companies, dealers or traders in securities or other persons
that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities or governmental organizations,
retirement plans, regulated investment companies, real estate investment trusts, grantor trusts, brokers, dealers or traders in securities,
commodities, currencies or notional principal contracts, certain former citizens or long-term residents of the United States, persons
who hold our ADSs as part of a &ldquo;straddle,&rdquo; &ldquo;hedge,&rdquo; &ldquo;conversion transaction,&rdquo; &ldquo;synthetic security&rdquo;
or integrated investment, persons that have a &ldquo;functional currency&rdquo; other than the U.S. dollar, persons who are subject to
the tax accounting rules of Section 451(b) of the Internal Revenue Code, persons that own directly, indirectly or through attribution
10% or more (by vote or value) of our equity, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and
other pass-through entities, and investors in such pass-through entities). This discussion does not address any U.S. state or local or
non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences. Except as discussed below, this discussion
does not address U.S. federal income tax reporting obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this discussion, the term &ldquo;U.S. Holder&rdquo; means a beneficial owner of our ADSs that is, for U.S. federal income tax
purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation
for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District
of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with
respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United
States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury
regulations to be treated as a domestic trust for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our ADSs, the U.S. federal income tax consequences relating
to an investment in such ADSs will generally depend upon the status and activities of such entity and the particular partner. Any such
entity and a partner in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable
to it (and, as applicable, its partners) of the purchase, ownership and disposition of our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not sought, nor will we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that
the IRS will not take a different position concerning the tax consequences of the purchase, ownership or disposition of the ADSs or that
any such position would not be sustained. Persons considering an investment in our ADSs should consult their own tax advisors as to the
particular tax consequences applicable to them relating to the purchase, ownership and disposition of our ADSs, including the applicability
of U.S. federal, state and local tax laws and non-U.S. tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Passive
Foreign Investment Company Rules</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a corporation organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least
75% of its gross income is &ldquo;passive income,&rdquo; referred to as the PFIC income test, or (2) on average at least 50% of its assets,
determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income, referred to
as the PFIC asset test. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents,
and gains from the sale or exchange of property that give rise to passive income. Assets that produce or are held for the production
of passive income generally include cash, even if held as working capital or raised in a public offering, marketable securities, and
other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share
of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into
account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature
of our current and expected income and the current and expected value and composition of our assets, and while not free from doubt, we
do not believe we were a PFIC for our 2020 tax year and we do not expect to be a PFIC for our current taxable year. Nevertheless, there
can be no assurance that we will not be a PFIC in future taxable years. Furthermore, even if we determine that we are not a PFIC for
a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge
our position. Because of the uncertainties involved in establishing our PFIC status, our U.S. counsel expresses no opinion regarding
our PFIC status, and also expresses no opinion with respect to our predictions or past determinations regarding our PFIC status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC in any taxable year during which a U.S. Holder owns our ADSs, the U.S. Holder would be liable for additional taxes and
interest charges under the &ldquo;PFIC excess distribution regime&rdquo; upon (1) a distribution paid during a taxable year that is greater
than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&rsquo;s holding
period for our ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a
pledge, of our ADSs, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution
or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&rsquo;s holding period for our ADSs.
The amount allocated to the current taxable year (<I>i.e</I>., the year in which the distribution occurs, or the gain is recognized)
and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year.
The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as
applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will
be added to the tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs and one of our non-United States subsidiaries is also a
PFIC (<I>i.e</I>., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of
the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain
from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions
or dispositions. Any of our non-United States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships
for U.S. federal income tax purposes would not be corporations under U.S. federal income tax law and accordingly, cannot be classified
as lower-tier PFICs. However, a non-United States subsidiary that has not made the election may be classified as a lower-tier PFIC if
we are a PFIC during your holding period and the subsidiary meets the PFIC income test or PFIC asset test.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized
on our ADSs if a valid &ldquo;mark-to-market&rdquo; election is made by the U.S. Holder for our ADSs. An electing U.S. Holder generally
would take into account as ordinary income each year, the excess of the fair market value of our ADSs held at the end of such taxable
year over the adjusted tax basis of such ADSs. The U.S. Holder would also take into account, as an ordinary loss each year, the excess
of the adjusted tax basis of such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess
of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&rsquo;s
tax basis in our ADSs would be adjusted annually to reflect any income or loss recognized as a result of the mark-to-market election.
Any gain from a sale, exchange or other disposition of our ADSs in any taxable year in which we are a PFIC would be treated as ordinary
income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market
gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be
classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would not be required to take into
account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ADSs would
be classified as a capital gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
mark-to-market election is available to a U.S. Holder only for &ldquo;marketable stock.&rdquo; Generally, stock will be considered marketable
stock if it is &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange&rdquo; within the meaning of applicable U.S. Treasury regulations.
A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ADSs will be marketable stock as long as they remain listed on Nasdaq and are regularly traded. A mark-to-market election will not apply
to the ADSs for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year
in which we become a PFIC. Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S. Holder may continue
to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the U.S. Holder&rsquo;s
mark-to-market election for our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences that would apply if we were a PFIC would also be different from those described above if a U.S. Holder were able to
make a valid QEF election. As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to make a QEF
election, prospective investors should assume that a QEF election will not be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own
tax advisors with respect to the impact of our possible PFIC status on the purchase, ownership and disposition of our ADSs, the consequences
to them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with
respect to the purchase, ownership and disposition of ADSs of a PFIC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Distributions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder that receives a distribution
with respect to our ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when
actually or constructively received by the U.S. Holder to the extent of the U.S. Holder&rsquo;s pro rata share of our current and/or
accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a
U.S. Holder is not a dividend because it exceeds the U.S. Holder&rsquo;s pro rata share of our current and accumulated earnings and profits,
it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&rsquo;s
ADSs. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&rsquo;s ADSs, the remainder will be taxed as capital
gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should
expect all distributions to be reported to them as dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
on our ADSs that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit
purposes and generally will constitute passive category income. The amount of any dividend income paid in a currency other than the U.S.
dollar will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt,
regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars
on the date of receipt, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend amount.
A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
paid on our ADSs will not be eligible for the &ldquo;dividends received&rdquo; deduction generally allowed to corporate shareholders
with respect to dividends received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &ldquo;qualified foreign
corporation&rsquo;&rsquo; to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather than the marginal
tax rates generally applicable to ordinary income provided that a holding period requirement (more than 60 days of ownership, without
protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements
are met. Each U.S. Holder is advised to consult their tax advisors regarding the availability of the reduced tax rate on dividends to
their particular circumstances. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable
year (see discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules&rsquo;&rsquo;), we will not be treated as a
qualified foreign corporation, and therefore the reduced capital gains tax rate described above will not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 128 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid
or the preceding taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays
on ADSs that are readily tradable on an established securities market in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of any dividend income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange
rate in effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted
into U.S. dollars on the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency
gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into
U.S. dollars after the date of receipt (actual or constructive).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sale,
Exchange or Other Taxable Disposition of Our ADSs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &ldquo;&mdash; Passive Foreign Investment Company Rules,&rdquo; a U.S. Holder generally will recognize
capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ADSs in an amount equal
to the difference, if any, between the amount realized (<I>i.e</I>., the amount of cash plus the fair market value of any property received)
on the sale, exchange or other disposition and such U.S. Holder&rsquo;s adjusted tax basis in the ADSs. Such capital gain or loss generally
will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of
sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate
U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations.
Any gain or loss recognized from the sale or other disposition of our ADSs will generally be gain or loss from sources within the United
States for U.S. foreign tax credit purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Medicare
Tax</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax
on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition
of our ADSs. If you are a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding
the applicability of this Medicare tax to your income and gains in respect of your investment in our ADSs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Information
Reporting and Backup Withholding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ADSs, including,
among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of
a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for our ADSs may be required
to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties
and other adverse circumstances may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
on and proceeds from the sale or other disposition of our ADSs generally have to be reported to the IRS unless the U.S. Holder establishes
a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S.
taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons.
However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or
a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder
on a timely basis to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EACH
PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ADSs IN LIGHT OF
THE INVESTOR&rsquo;S OWN CIRCUMSTANCES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guernsey
Tax Considerations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary below is based on current Guernsey law and published practice in Guernsey as of the date hereof, both of which are subject to
change, possibly with retrospective effect. This summary is intended as a general guide of certain Guernsey tax matters related to the
holders of ordinary shares of the Company (&ldquo;<B>Shareholders</B>&rdquo;) only and is not, is not intended to be nor should it be
construed to be, legal or tax advice or a summary of all tax matters in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders,
whether corporations or individuals, that are not residents of Guernsey for tax purposes and who do not conduct business in Guernsey
through a permanent establishment situated in Guernsey, will not be subject to Guernsey income or Guernsey withholding tax. Any distributions
made by the Company to non-Guernsey tax resident Shareholders will not be subject to Guernsey income or Guernsey withholding tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
Shareholders who are residents of Guernsey for tax purposes will generally be subject to Guernsey income tax at the individual standard
rate of 20% on distributions received from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
Shareholders that are residents of Guernsey for tax purposes (and which do not have exempt company status under the Income Tax (Exempt
Bodies) (Guernsey) Ordinance, 1989, as amended) will generally be subject to Guernsey income tax at the company standard rate, which
is currently 0%, on distributions received from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
does not currently levy capital gains tax (with the exception of a dwellings profit tax) and, therefore, Shareholders will not suffer
capital gains tax in Guernsey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
stamp duty is chargeable in Guernsey on the issue, acquisition, transfer, conversion or redemption or other disposition of ordinary shares
of the Company (provided that it does not hold Guernsey real property).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guernsey
has implemented through domestic legislation matters related to (i) the Foreign Account Tax Compliance Act, or FATCA, contained in the
United States Internal Revenue Code of 1986 and the Treasury Regulations promulgated thereunder and (ii) the Organization for Economic
Co-operation and Development&rsquo;s regime known as the Common Reporting Standard, or CRS. Pursuant to FATCA and CRS, disclosure and
reporting of information may be required, including disclosure of certain information about Shareholders, their ultimate beneficial owners
and/or controllers and their investment in the Company. You should consult your tax advisers regarding the possible implications of FATCA,
CRS and other similar regimes that may be relevant to your ownership and disposition of ordinary shares of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="s_003"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
is acting as the representative of the underwriters of this offering, or the &ldquo;Representative.&rdquo; We have entered into an underwriting
agreement dated________, 2022 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed
to sell to each underwriter named below and each underwriter named below has severally and not jointly agreed to purchase from us, at
the public offering price per ADS less the underwriting discounts set forth on the cover page of this prospectus, the number of ADSs
listed next to its name in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Underwriters</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of ADSs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%">ThinkEquity</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are committed to purchase all ADSs offered by us other than those covered by the over-allotment option described below,
if any are purchased. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting
agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&rsquo; obligations are subject to customary conditions,
representations and warranties contained in the underwriting agreement, such as receipt by the underwriters of officers&rsquo; certificates
and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering the ADSs subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, and other conditions. The underwriters reserve the right to withdraw, cancel or modify offers to the public
and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the ADSs offered by us to the public at the public offering price set forth on the cover of the prospectus.
After the ADSs are released for sale to the public, the underwriters may change the offering price and other selling terms at various
times.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option, exercisable for 45 days from the closing date of this offering, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ADSs (15% of the ADSs sold in this offering) from us
to cover over-allotments, if any, at a price per ADS equal to the public offering price, less the underwriting discounts and
commissions. The underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with
this offering. To the extent the option is exercised, each underwriter must purchase a number of additional ADSs approximately
proportionate to that underwriter&rsquo;s initial purchase commitment set forth in the table above. Any ADSs issued or sold under
the option will be issued and sold on the same terms and conditions as the other ADSs that are the subject of this offering. If this
option is exercised in full, the total offering price to the public will be $ and the total net proceeds, before expenses, to us
will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised us that the underwriters propose to offer the ADSs to the public at the public offering price per ADS set
forth on the cover page of this prospectus. The underwriters may offer ADSs to securities dealers at that price less a concession of
not more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, of which up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS may be re-allowed to other dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting discounts and commissions and proceeds before expenses to us assuming
both no exercise and full exercise by the underwriters of their over-allotment option:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    ADS</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Without Over-allotment Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    With Over-allotment Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discounts and commissions (7.0%)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to reimburse the Representative for the fees and expenses of its legal counsel in connection with the offering in an amount
not to exceed $75,000, the fees and expenses related to the use of book building, prospectus tracking and compliance software for the
offering in the amount of $29,500, out-of-pocket fees and expenses of the Representative for marketing and roadshows for the offering
not to exceed $10,000, data services and communications expenses in the amount of $10,000, up to $3,000 of the costs associated with
preparing bound volumes of the public offering materials and any commemorative mementos or lucite tombstones for the offering, and up
to $30,000 in market making and trading, and clearing firm settlement expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to certain &ldquo;lock-up&rdquo; agreements, we and our executive officers, directors and certain shareholders, have agreed, subject
to limited exceptions, without the prior written consent of the Representative, not to directly or indirectly, offer, pledge, sell, contract
to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, our common stock or any securities convertible into
or exercisable or exchangeable for our common stock, or the Lock-Up Securities, enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, make any demand for or exercise
any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any Lock-Up
Securities, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities, subject to customary
exceptions, or publicly disclose the intention to do any of the foregoing, for a period of twelve months from the date of this prospectus,
with respect to our executive officers and directors, and six months from the date of this prospectus with respect to the shareholders
signing such agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against liabilities relating to this offering arising under the Securities Act and the Exchange
Act, liabilities arising from breaches of some or all of the representations and warranties contained in the underwriting agreement,
and to contribute to payments that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of ADSs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by one or more underwriters or selling group members,
if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses
electronically. The representative may agree to allocate a number of ADSs to underwriters and selling group members for sale to their
online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make
internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on the
underwriters&rsquo; websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which
this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not
be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a period of twelve months after the closing of this offering, the representative of the underwriters will have, subject to certain
exceptions, an irrevocable right of first refusal to act as sole and exclusive book-runner, sole and exclusive underwriter and/or sole
and exclusive or lead placement agent, at the representative&rsquo;s sole discretion, for each and every future public and private equity
and debt offering, including all equity linked financings, during such twelve month period, for us, or any successor to or any
subsidiary of us, on terms and conditions customary for the representative for such transaction, except for any financings done in the
United Kingdom; provided the representative has agreed to allow such other qualified investment banks or brokerage firms suggested by
us, and subject to the representative&rsquo;s approval, to assist with such transaction, including being part of the selling group, as
applicable. The banking fees payable to any other bank or brokerage firm will be determined by the representative in its reasonable discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales which involves making bids for, purchasing and selling
ADSs in the open market for the purpose of preventing or retarding a decline in the market price of the ADSs and, indirectly, our ordinary
shares while the offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
transactions permit bids to purchase ADSs so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the
purpose of preventing or retarding a decline in the market price of the ADSs and, indirectly, our ordinary shares while the offering
is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Over-allotment
transactions involve sales by the underwriters of ADSs in excess of the number of ADSs the underwriters are obligated to purchase. This
creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position,
the number of ADSs over-allotted by the underwriters is not greater than the number of ADSs that they may purchase in the over-allotment
option. In a naked short position, the number of ADSs involved is greater than the number of ADSs that they purchase in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment option and/or purchasing ADSs in the open
market. The underwriters will not purchase ordinary shares in the open market to close out any such short position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
covering transactions involve purchases of ADSs in the open market after the distribution has been completed in order to cover syndicate
short positions. In determining the source of ADSs to close out the short position, the underwriters will consider, among other things,
the price of ADSs available for purchase in the open market as compared with the price at which they may purchase ADSs through exercise
of the over-allotment option. If the underwriters sell more ADSs than could be covered by exercise of the over-allotment option and,
therefore, have a naked short position, the position can be closed out only by buying ADSs in the open market. A naked short position
is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the
ADSs in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the representative to reclaim a selling concession from a syndicate member when the ADSs originally sold by that syndicate
member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price
of our ADSs and, indirectly, our ordinary shares or preventing or retarding a decline in the market price of our ADSs and, indirectly,
our ordinary shares. As a result, the prices of our ADSs and ordinary shares in the open market may be higher than they would otherwise
be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that
the transactions described above may have on the price of our ADSs or ordinary shares. These transactions may be affected in the over-the-counter
market or otherwise and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, underwriters and selling group members may engage in passive market making transactions in our ADSs on
the Nasdaq Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the securities and extending through the completion of the distribution. This means that if the representatives
of the underwriters&rsquo; purchase ADSs in the open market in stabilizing transactions or to cover short sales, the representatives
can require the underwriters that sold those ADSs as part of the offering to repay the underwriting discount received by them. A passive
market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent
bids are lowered below the passive market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.
Furthermore, stabilization transactions will also need to comply with UK and EU laws, in particular the Market Abuse Regulation (Regulation
(EU) 596/2014), which is part of UK domestic law pursuant to the Market Abuse (Amendment) (EU Exit) Regulations (<I>SI 2019/310</I>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their affiliates may in the future provide various advisory, investment and commercial banking and other services for
us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have
no present arrangements with any of the underwriters for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of the ADSs we are offering was negotiated between us and the underwriters based on the trading of our ordinary
shares prior to the offering, among other things. Other factors considered in determining the public offering price of the ADSs include
our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have
been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such
other factors as were deemed relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor our underwriters can assure investors that the ADSs will trade in the public market at or above the public offering price after
this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase ADSs or ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws
and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering
material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into
whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering
and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any
securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not constitute a disclosure
    document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (the &ldquo;<B>Corporations Act</B>&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has not been, and will
    not be, lodged with the Australian Securities and Investments Commission (&ldquo;<B>ASIC</B>&rdquo;), as a disclosure document for
    the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes
    of the Corporations Act; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may only be provided in
    Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, available
    under section 708 of the Corporations Act (&ldquo;<B>Exempt Investors</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for
or buy the ordinary shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating
to any ordinary shares may be distributed in Australia, except where disclosure to investors is not required under Chapter 6D of the
Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for
the ordinary shares, you represent and warrant to us that you are an Exempt Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
any offer of ordinary shares under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure
to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By applying for the ordinary shares,
you undertake to us that you will not, for a period of 12 months from the date of issue of the ordinary shares, offer, transfer, assign
or otherwise alienate those ordinary shares to investors in Australia except in circumstances where disclosure to investors is not required
under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the ordinary shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in the EEA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to each member state of the EEA (each, a &ldquo;<B>Relevant State</B>&rdquo;), no securities have been offered or will be offered
pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the securities
which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and
notified to the competent authority in that Relevant State, all in accordance with the EU Prospectus Regulation, except that offers of
securities may be made to the public in that Relevant State at any time under the following exemptions under the EU Prospectus Regulation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which
    is a qualified investor as defined under Article 2(e) of the EU Prospectus Regulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 150 natural
    or legal persons (other than qualified investors as defined under the EU Prospectus Regulation), subject to obtaining the prior consent
    of the representatives for any such offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances
    falling within Article 1(4) of the EU Prospectus Regulation,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of securities shall require us or any representative to publish a prospectus pursuant to Article 3 of the EU Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the EU Prospectus Regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this provision, the expression an &ldquo;offer to the public&rdquo; in relation to securities in any Relevant State means
the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so
as to enable an investor to decide to purchase or subscribe for any securities, and the expression &ldquo;EU Prospectus Regulation&rdquo;
means Regulation (EU) 2017/1129, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in the UK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
securities have been offered or will be offered pursuant to the offering to the public in the UK prior to the publication of a prospectus
in relation to the securities which has been approved by the FCA, all in accordance with the UK Prospectus Regulation, except that offers
of securities may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity which
    is a qualified investor as defined under Article 2(e) of the UK Prospectus Regulation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 150 natural
    or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent
    of the representatives for any such offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances
    falling within Section 86 of the FSMA,</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided
that no such offer of securities shall require us or any representative to publish a prospectus pursuant to Section 85 of the FSMA or
supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an
&ldquo;offer to the public&rdquo; in relation to the securities in the UK means the communication in any form and by any means of sufficient
information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe
for any securities, the expression &ldquo;UK Prospectus Regulation&rdquo; means Regulation (EU) 2017/1129 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018, as amended, and the expression &ldquo;FSMA&rdquo; means the UK Financial Services
and Markets Act 2000, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the UK, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be
directed at persons who are &ldquo;qualified investors&rdquo; (as defined in the Prospectus Regulation) (i) who have professional experience
in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, as amended, or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as &ldquo;relevant persons&rdquo;) or
otherwise in circumstances which have not resulted and will not result in an offer to the public of securities in the UK within the meaning
of FSMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
person in the UK that is not a relevant person should not act or rely on the information included in this document or use it as a basis
for taking any action. In the UK, any investment or investment activity that this document relates to may be made or taken exclusively
by relevant persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
to prospective investors in Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ordinary shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange
Act. Accordingly, none of the ordinary shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to,
or for the benefit of, any &ldquo;resident&rdquo; of Japan (which term as used herein means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan
or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise
in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines
of Japan in effect at the relevant time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="s_004"></A>Expenses
of This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that our expenses in connection with this offering will be as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"> 1,521 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA Filing Fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2,570 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing and engraving expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">153,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer agent and registrar fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,800</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous costs</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"> 6,109 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right">225,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
amounts in the table are estimates except the SEC registration fee, the listing fee, and the FINRA filing fee. We will pay all of the
expenses of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="s_005"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters with respect to English law and Guernsey law in connection with the validity of our ordinary shares registered hereby will
be passed upon for us by Orrick, Herrington &amp; Sutcliffe (UK) LLP, United Kingdom and Carey Olsen (Guernsey) LLP, Bailiwick of Guernsey,
respectively. Certain matters of U.S. federal law will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York,
New York. Certain legal matters respect will be passed upon for the underwriters by Dorsey &amp; Whitney LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_006"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of OKYO Pharma Limited as of March 31, 2022, 2021, and 2020 and for each of the years then ended, included
in our Form 20-F annual report for the year ended March 31, 2022 and incorporated by reference in this prospectus have been audited by
Mazars LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
The registered business address of Mazars LLP is 30 Old Bailey, London EC4M 7AU, United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_007"></A>SERVICE
OF PROCESS AND ENFORCEMENT OF LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated and currently existing under the laws of Guernsey. In addition, certain of our directors and officers reside outside
the United States, and most of the assets of our non-U.S. subsidiaries are located outside the United States. As a result, it may not
be possible for investors to effect service of process within the United States upon OKYO or those persons or to enforce against OKYO
or them, either inside or outside the United States, judgments obtained in U.S. courts, or to enforce in U.S. courts, judgments obtained
against them in courts in jurisdictions outside the U.S., in any action predicated upon civil liability provisions of the federal securities
laws of the United States. Both in original actions and in actions for the enforcement of judgments of U.S. courts, there is doubt as
to whether civil liabilities predicated solely upon the U.S. federal securities laws are enforceable in Guernsey. See &ldquo;Description
of Share Capital and Memorandum and Articles of Incorporation&mdash;Enforcement of Civil Liabilities.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 137 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_008"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under
the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information in the registration
statement and its exhibits. For further information with respect to us and the ADSs offered by this prospectus, we refer you to the registration
statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents of
any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract
or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by the filed
exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may review a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials
at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of
the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet website (www.sec.gov) that contains reports,
proxy and information statements and other information regarding issuers, like us, that file electronically with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> subject to the information reporting
requirements of the Exchange Act applicable to FPIs. Accordingly, we will be required to file reports and other information with the
SEC, including annual reports on Form 20-F and reports on Form 6-K. Those reports may be inspected without charge at the locations described
above. As an FPI, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements,
and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained
in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also maintain a website at www.okyopharma.com contained in, or accessible through, our website is not a part of this prospectus, and
the inclusion of our website address in this prospectus is an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_009"></A>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
PHARMA LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm<FONT STYLE="background-color: #CCEEFF"> PCAOB ID: 1401</FONT></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Income</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo; Equity</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statement of Cash Flows</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#s_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><A NAME="s_010"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shareholders and Board of Directors of OKYO Pharma Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opinion
on the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of OKYO Pharma Limited and its subsidiary (the Group) as of March 31, 2022
and 2021, together with the related consolidated statements of operations and comprehensive loss, consolidated statements of
shareholders&rsquo; equity, and consolidated statements of cash flows for each of the three years in the period ended
March 31, 2022 and the related notes (collectively referred to as the &ldquo;consolidated financial statements&rdquo;). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Group as of March
31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended March
31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Going
Concern Uncertainty</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
accompanying consolidated financial statements have been prepared assuming that the Group will continue as a going concern. As discussed
in Note 2 to the consolidated financial statements, the Group are pre-revenue, and its business model requires significant ongoing expenditure
on research and development. The forecast prepared by management indicates that the current cash held will be exhausted by October 2022
without additional financing facilities in place. The Group is in the final stages of its Investigational New Drug (IND) application
for OK101, due to be filed with the U.S. Food and Drug Administration (FDA) in mid-November 2022 after which there is a 30 day period
for the FDA to raise questions or issue a clinical hold. On completion of the IND application process, management intends to raise sufficient
funds to enable the Group to complete Phase II clinical trials for OK101. As management&rsquo;s forecasts indicate current cash held
is not sufficient to complete the IND application process and cover working capital requirements until further funds are raised for the
Phase II clinical trials, to meet the short-term need, the Group has secured a $2 million short-term credit facility with a related party,
Tiziana Life Sciences Limited, which must be repaid six months after the initial draw-down. After taking this facility into consideration
the available cash position will be extended to approximately April 2023. If further funds for the Phase II clinical trials are not raised
before then, to continue operating, the Group will need to raise additional funds sufficient to meet its ongoing working capital requirements
as well as to repay the $2 million short-term credit facility. These conditions raise substantial doubt about the Group&rsquo;s ability
to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Basis
for Opinion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Group&rsquo;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. The Group is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Group&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Group&rsquo;s auditor since 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London,
England</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
15, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><A NAME="s_011"></A>OKYO
Pharma Limited</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2,700,724</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">6,889,329</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,664</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Current taxation
                                            receivable</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">781,688</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other receivables</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,956</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,295,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,986,686</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and Equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,057</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Right of use asset</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">98,579</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total non-current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,225</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">104,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,300,593</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">Trade and other
                                            payables</P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,306,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,673,154</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Related party payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities - current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,148</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,353,191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,707,302</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Lease liabilities - non current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,353,191</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,771,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders&rsquo; Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,976,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,629,173</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share options reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,355,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">636,313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,413</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">861,214</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Loan Note reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370,836</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign currency translation reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,011,527</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,174,375</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Retained deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(112,426,034</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(106,003,753</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,947,402</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,319,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,300,593</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,091,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><A NAME="s_012"></A>OKYO
Pharma Limited</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations and Comprehensive Loss</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(1,301,178</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(173,821</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(518,098</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,916,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,192,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,016,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,217,566</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,366,206</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,534,646</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income/(expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Impairment of loan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,172</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(132,668</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss from operations before income taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,217,566</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income tax provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">786,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Loss for the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,431,045</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
                                            difference on translating foreign operations</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(837,152</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,268,197</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(3,007,142</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Basic and diluted loss per share attributable to common shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.01</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><A NAME="s_013"></A>OKYO
Pharma Limited</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Shareholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Warrant reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Convertible Loan Note reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Translation Reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; font-weight: bold; padding-bottom: 1.5pt">Balance at 31 March 2019</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; text-align: right">524,108,283</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">111,741,860</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57,101</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">30,242</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(100,888,643</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,607,394</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">333,166</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Issue of share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,188,766</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,171</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Warrants charge</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(627,047</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">609,661</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,386</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">609,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">984,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,544,059</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86,654</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,544,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">86,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,457,405</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Balance at 31 March 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">636,297,049</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">112,079,984</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">93,441</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">639,903</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(102,432,702</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,520,740</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(140,114</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issue of share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,269,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,515</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,305</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,006</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible loan note issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,395</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,151,777</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Convertible loan note interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">219,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(450,811</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,370,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(217,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,466,664</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353,507</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,353,507</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Currency translation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,353,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">346,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,007,142</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Balance at 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">672,816,302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">111,629,173</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">636,313</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">861,214</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,370,836</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(106,003,753</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(10,174,375</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,319,408</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,737,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,737,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options forfeiture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,149</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,149</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrants Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">386,512,756</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,470,940</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,010,030</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,460,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible loan note conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,086,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,876,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,876,397</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible loan note and warrant interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,918</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(991,236</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Currency translation on Convertible Loan note conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">654,833</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">654,833</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer between equity reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">594,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(594,190</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total transactions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">701,599,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,347,337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,718,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(807,801</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,370,836</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(991,236</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,896,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431,045</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431,045</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Currency translation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837,152</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837,152</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,431,045</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837,152</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,268,197</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at 31 March 2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,374,415,468</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">123,976,510</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,355,040</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">53,413</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(112,426,034</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(11,011,527</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,947,402</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><A NAME="s_014"></A>OKYO
Pharma Limited</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left">Loss from operations before income taxes</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(6,217,566</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(3,378,501</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(1,620,347</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share option charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,737,876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">550,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant charge</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Forfeiture of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(19,149</P></TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,751</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Depreciation of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain/Loss on foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,230</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,915</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Impairment of loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,668</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain on disposal of right of use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(818</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net decrease/ (increase) in related party receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,862</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(543</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase/(decrease) in related party payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,311</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (increase) / decrease in operating assets/other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(802,154</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(122,190</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (decrease)/increase in trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(297,991</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash inflow from taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,468,065</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,600,198</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,202,066</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
        of property, plant and equipment</FONT></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,669</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,943</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan to West African Minerals Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,669</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,668</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of ordinary shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">990,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of convertible loan notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,593,380</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Processed from options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Processed from warrants exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,153,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loan to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(518,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loan repayment from related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Repayment of leasing liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,331</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,139</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,153,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,826,938</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">963,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease)/increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,316,464</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,208,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(371,423</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalent, beginning of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,889,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627,616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exchange difference</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(872,141</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,708</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalent, end of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,700,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,889,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_015"></A>1.
Reporting Entity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (the &ldquo;Company&rdquo; or &ldquo;OKYO&rdquo;) is a company domiciled in Guernsey and listed with a standard listing
on the main market of the London Stock Exchange (LSE) and on the NASDAQ Capital Market (LSE: OKYO, NASDAQ: OKYO).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate parent of the group is Panetta Partners, incorporated in the British Virgin Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years presented unless otherwise stated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of preparation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Basis of measurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &pound;76.8m (&pound;64m of this accumulated loss relates to a discontinued business prior
to the reorganization in 2018), a net loss for the year ended March 31, 2022, of &pound;4.0m and net cash used in operating activities
of &pound;4.0m.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &pound;1.5m, with current liabilities of &pound;978k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &pound;2.4m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&rsquo;s ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took strategic
advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential liquidity in the
US, which is generally a more favorable environment for life sciences companies to raise money and where there are more specialist investors
focused on early-stage opportunities. The Directors are also confident that the nature of the OK101 clinical program is such that various
inflection points arise over a relatively short period of time which should provide financing opportunities, for example the FDA approval
of the IND in December 2022 for OK101 in dry-eye and the return of headline data from the Phase II registration trial to be held between
July and December 2023; these pivotal events in the primary clinical program for OK101 have the benefit of being near term events (which
is unusual in the context of the normal timeframes for Phase II clinical programs to deliver meaningful data points. The Directors have
also consulted the Company&rsquo;s investment bankers with a view to planning a number of alternative financing strategies to ensure
the Company has access to sufficient capital to finance its planned research and development activity in the coming 18 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
meet the Company&rsquo;s short-term liquidity needs, the Company has secured a $2m short-term credit facility with a related party in
order to bridge any delays in the occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for
a period of 6 months upon first draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the
loan is not repaid after the 6-month period. The loan will extend the Company&rsquo;s fixed cost cash burn to April 2023 without the
need to raise additional funds. The Directors believe that this facility together with additional working capital management measures
will be sufficient to complete the IND application. The Directors also considered any risks to the short-term cash position of the company
such as delay in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash
resources and the additional financing strategies already disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
completion of the IND application the company will be in a position to raise funds on the market, via the financing strategies being
discussed with the Company&rsquo;s investment bankers. The necessary steps are being taken to affect such a fundraise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a significant doubt on the Group
and Company&rsquo;s ability to continue as a going concern, and therefore, that it may be unable to realize its assets and discharge
its liabilities in the normal course of business. Despite this significant doubt, the Directors conclude that it is appropriate to continue
to adopt the going concern basis of accounting as the Directors are confident, based on the previous fund-raising history as well as
additional measures already put in place and being planned, that sufficient funds will be forthcoming and accordingly they have prepared
these financial statements on a going concern basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>New
and Revised Standards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Standards
in effect in 2022</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&rsquo;s return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealized gains on transactions between group companies are eliminated upon consolidation. Unrealized losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment
reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
currency translation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&rsquo;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&rsquo;s presentation currency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets and liabilities at the rate of exchange ruling
    at the year-end date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit and loss account items at the average rate of
    exchange for the year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalized as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. License fees expenses are recognized as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&rsquo;s products, the criteria for development costs to be recognized as an asset, as set out
in IAS 38 &lsquo;Intangible Assets&rsquo;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Financial assets, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Financial liabilities, initial recognition and measurement and subsequent measurement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s financial liabilities include trade and other payables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and cash equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents comprise cash on hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of financial assets measured at amortized cost</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognizes a loss allowance for expected credit losses on financial assets measured at amortized cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognized, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
approach</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognizes a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognized at an amount equal to the lifetime expected credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Simplified
approach</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognizes a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of non-financial assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are impaired when their carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher
    of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0.75in; text-indent: 0pt"></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the Company are classified as equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(i)
Recognition and measurement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalized as part of that equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Depreciation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognized in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures and
    fittings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5 years</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT and equipment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3 years</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognizing a right-of-use asset and a lease liability except for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases of low value assets; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    with a duration of 12 months or less</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognizes a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&rsquo;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
term leases exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognized in profit and
loss on a straight-line basis over the term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
have assessed the categorization of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy
has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - valued using quoted prices in active markets for identical assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - valued by reference to valuation techniques using inputs that are not based on observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
based payments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&rsquo;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&rsquo;, Directors&rsquo; or
advisers&rsquo; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &ndash; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &ndash; warrants, in the case of warrants issued in return for services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued in return for services.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrants
issued as part of a financing transaction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognized within equity and is not remeasured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &lsquo;fixed&rsquo; test for non-derivatives, and the &lsquo;fixed for fixed&rsquo;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
loan notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Where
the fixed for fixed condition is met</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve as it is convertible into equity.. The accrued interest on the principal
amount is also recorded in the Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount
is reclassified from the convertible loan note reserve to share capital and share premium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being IFRS as
issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income
and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based
on historical experience and other factors, including expectations of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be the key sources of estimation uncertainty<B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share-based
payments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes estimates as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest
rate for the term of the award and correlations and volatilities of the shares of peer group companies. The Group also makes estimates
as to the vesting period for awards that have performance-based criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resulting cost of an equity incentive award is recognized as expense over the requisite service period of the award, which is usually
the vesting period. Compensation expense is recognized over the vesting period using the straight-line method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 27 to our consolidated financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OPERATING EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Operating expenses are stated
after charging:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended March 31,</B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-style: italic"><U>Group</U></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">2022</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">$</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">2021</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">$</P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P>

</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Director fees including bonus (excluding Chairman&rsquo;s bonus)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">707,385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">278,224</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chairman&rsquo;s bonus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160,347</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Auditor&rsquo;s Remuneration (refer to Note 20)*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,511</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,402</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal and Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,143,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">343,422</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,433</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(Gain)/Loss on disposal of leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(179</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FX Gains and losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,577</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,061</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Depreciation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,423</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,512</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">* <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the company&rsquo;s
auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements. Refer to note 20 where
details of auditor&rsquo;s remuneration has been disclosed. This has no impact on the primary financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEGMENTAL REPORTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year under review management identified the Group&rsquo;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYEES INCLUDING OFFICERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P>

</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><U>Group</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Staff costs comprised:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left">Directors&rsquo; salaries</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">707,385</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,438,571</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Wages and salaries</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">229,347</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Social security costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,449</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,740</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Recruitment Costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,259</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,922</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,129,279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,582,739</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">420,188</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">The average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March 31, 2020 were:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Corporate and administration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company made $2,622 of payments to a defined contribution pension schemes on behalf of Directors or employees during the year
ending March 31, 2022 (March 31, 2021: $2,904, March 31, 2020 $2,774)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
REMUNERATION OF KEY MANAGEMENT PERSONNEL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the years ending March 31 2022, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="30" STYLE="font-weight: bold; text-align: center">Year ended March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors&rsquo;</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>fees</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors&rsquo;</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>fees</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share based payment expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">G. Cerrone (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">1,160</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">G Jacob (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,579</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">W Simon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">K. Shailubhai (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">J Brancaccio (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">G Macrae (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">B Denoyer (5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">283</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">75</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">350</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,589</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">158</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,201</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">85</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">503</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&rsquo;000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors<BR>
    fees</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based<BR> payment<BR> expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">W
    Simon</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
    Shailubhai (6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Macrae (4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">L
    Zambeletti (7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone&rsquo;s bonus awarded for $1,160k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19
    indication when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring,
    backing and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory
    appointments to the Board with the result that the Company now has a clear and accelerated path to the clinic.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary Jacob became an employee
    and Director of the Company on 7 January 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Brancaccio was appointed
    as Director on 10 June 2020</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor Macrae was appointed
    as Director on 18 December 2019 and resigned on 10 June 2020</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Bernard Denoyer was
    appointed as Director on 24 November 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K Shailubhai resigned as
    Director on 17 June 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Leopoldo Zambeletti resigned as Director on 18 December
    2019</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2022</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2021</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <BR> options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">J Brancaccio</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">325,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">450,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">G Jacob</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">B Denoyer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,575,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">40,450,000</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director has yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Key Management Personnel of the Group are members of the leadership team who have the authority and responsibility for planning, directing
and controlling the activities of the Group either directly or indirectly. They include all Directors of the Board (executive and non-executive).
Key Management Personnel compensation is set out below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&rsquo;000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&rsquo;000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&rsquo;000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: justify">Short-term employee benefits</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1,026</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">351</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Share based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">515</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,841</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,970</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">392</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><U>Group</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left">Current year tax (credit)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(509,282</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(24,952</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments in respect of prior periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(277,239</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Origination and reversal of timing differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(786,521</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">The tax charge for the year is different from the standard rate of corporation tax in the United
    Kingdom of 19%. The difference can be reconciled as follows:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loss before taxation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,045,372</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,378,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,620,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss charged at standard rate of corporation tax 19%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,181,337</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(641,915</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(307,866</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tax losses arising in the year not recognized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524,870</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">660,594</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,114</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax losses surrendered for Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">667,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expenses not deductible for taxation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Tax increase from effect of capital allowances and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development tax claim</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(509,282</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and Development enhanced expenditure</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(377,187</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development tax credits claimed in respect of previous periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(277,240</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,289</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consolidation adjustment in relation to foreign exchange movements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,983</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,504</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Loans written off</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(786,521</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(76,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will
be recoverable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Group has tax losses of $15,870,525
(2021: $9,411,521, 2020: $4,421,886) to carry forward for use against future profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
FINANCE INCOME AND COSTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Finance Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; text-align: left">Interest income</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">48,125</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total finance income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,125</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Finance Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,158</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,123</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,158</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
PROPERTY, PLANT AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&rsquo;s property, plant and equipment are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">IT equipment</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%">At 1 April 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">8,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">8,343</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,669</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,669</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Disposals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(233</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(233</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 31 March 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,779</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>At 1 April 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Charge in year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,331</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 31 March 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,554</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,554</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net Book Value as at 31 March 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,225</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">IT equipment</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%">At 1 April 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Disposals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>At 1 April 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Charge in year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,593</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">At 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Net Book Value as at 31 March 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,057</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,057</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s property, plant and equipment is located in the following operating segments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid">Group</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; border-bottom: Black 1.5pt solid">Net Book Value March 31 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">$</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-decoration: underline; text-align: justify">UK</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">2,937</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">US</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,225</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
OTHER RECEIVABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Other receivables</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">19,130</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">4,499</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">VAT receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,617</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Prepayments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">711,209</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,956</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">43,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
include $639,635 of prepaid invoices relating to the OK-101 project.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
TRADE AND OTHER PAYABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended March 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">$000</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">Trade payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">741,807</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">210,992</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,773</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Bonus accrual</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,391,069</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,306,150</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,673,154</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
CAPITAL AND RESERVES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
Management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Company&rsquo;s capital management, capital includes called up share capital, share premium, share based payments
for options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s objectives when managing capital are to safeguard the Group&rsquo;s ability to continue as a going concern and
to maximize shareholder value through the optimization of the debt and equity balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital to maximize the return to the shareholders through the optimization of equity. The capital structure
of the Company as at 31 March 2022 consists of equity attributable to equity holders of the Company, comprising issued capital,
reserves and retained deficit as disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by
shareholders. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital
to shareholders or issue new shares and release the Company&rsquo;s share premium account. No changes were made in the objectives, policies
or processes during the year ended 31 March 2022 and 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
capital and premium</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares
and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class
or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share in the Company confers upon the shareholder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to one vote at
    a meeting of the shareholders or on any resolution of shareholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to an equal share
    in any dividend paid by the Company; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the right to an equal share
    in the distribution of the surplus assets of the Company on its liquidation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&rsquo;s Articles of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authorized</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Share capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issued ordinary shares of US$0.00 each</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">At 31 March 2020 </TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 16%">636,297,049</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 16%">112,079,984</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares issued - private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,269,253</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,019</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Relative Fair value charge for warrants issued in conjunction with private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(138,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">CLNs issued in lieu of fundraising commission</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(558,395</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">At 31 March 2021</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">672,816,302</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">111,629,173</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">386,512,756</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,470,940</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Conversion of CLN</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,086,410</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,876,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer between equity reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">At 31 March 2022</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,374,415,468</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">123,976,510</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance
of ordinary shares</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, 36,363,636 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, 75,825,130 ordinary shares were issued at an issue price of 1.1p per ordinary share by way of a further placing of ordinary
shares to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, 36,269,253 ordinary shares were issued at an issue price of 0.005p per ordinary share by way of a placing of ordinary shares
to raise finance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, 250,000 ordinary shares were issued in relation to an exercise of options at an issue price of 0. 045p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, 36,363,636 ordinary shares were issued in relation to an exercise of warrants at an issue price of 0.0135p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, 72,000,000 ordinary shares were issued in relation to an exercise of warrants at an issue price of 0.0055p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, 76,605,760 ordinary shares were issued in relation to a conversion of loan notes at an issue price of 0.004p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, 73,304,650 ordinary shares were issued in relation to a conversion of loan notes at an issue price of 0.085p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, 39,605,760 ordinary shares were issued in relation to an exercise of warrants at an issue price of 0.004p per ordinary share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, 165,176,000 ordinary shares were issued in relation to a conversion of loan notes at an issue price of 0.004p per ordinary
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, 238,543,360 ordinary shares were issued in relation to a cashless exercise of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
options reserve</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for options represents the cost to issue share-based compensation, primarily share options, based on their
grant date fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
warrants reserve</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for warrants represent the cost to issue warrants based on their grant date fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Loan Note reserve</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible loan note reserve represents the proceeds received on issuance of convertible loan notes classified as equity instruments,
accrued interest and any relative fair value adjustments. .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Retained
Deficit reserve</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
deficit represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Translation
reserve</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors paid no dividend during the year to 31 March 2022 and 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transfer between equity reserves</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company affected a transfer between reserves in equity in order to align the values of the equity reserves on a relative fair value basis.
The total amount recorded in equity remains unaltered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
SHARE OPTIONS AND WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Options</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>exercise
                                            price </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cents)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
                                            </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>exercise
                                            price </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(cents)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Outstanding at 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">60,750,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">19,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.91</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,500,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(750,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.49</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,400,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.90</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,750,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,437,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR> Average <BR> exercise
    price <BR> (cents)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%">Outstanding at 1 April</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">5.58</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">23,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.58</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,500,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Outstanding at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercisable at 31 March</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,875,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending 31 March 2022, no options were exercised. During the year ending 31 March 2021, 250,000 options were exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The total outstanding fair value charge
of the share option instruments is deemed to be approximately $2,072,515 (2021: $2,682,050). A share-based payment charge for the year
of $1,718,727 (2021: $545,582) has been expensed in the statement of comprehensive income. The share based payment charge in the year
to March 31, 2022 includes a forfeiture of $19,149.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average contractual life of options outstanding at March 31, 2022 is 7.77 years. (2021: 8.07 years).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options outstanding at the end of the year have the following expiry dates and exercise prices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Grant Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Expiry Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; border-bottom: Black 1.5pt solid">Share Options as at 31 March 2022 <BR>(&lsquo;000)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%">6 July 2018</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center">6 July 2025</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: center">4.5p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">2,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>20 August 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19 August 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15.5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>6 January 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 January 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>12 January 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11 January 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.9p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>15 April 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15 April 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.88p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>31 August 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">31 August 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4.9p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">31 January 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">30 January 2032</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">8.0p</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
value of options granted</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Grant Date</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">15 April 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">31 August 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">31 January 2022</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Grant date share price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">7.7</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">4.9</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">4.8</TD><TD STYLE="width: 1%; text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise share price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.9</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.9</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.0</TD><TD STYLE="text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% each year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25% each year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25m
                                            options vest 33% each year and 7.5m options have developmental milestone performance conditions</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.35</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80.20</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Option life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20 August</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6 January</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12 January </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Grant date share price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">15.5</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">0.8</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">0.79</TD><TD STYLE="width: 1%; text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise share price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.5</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.79</TD><TD STYLE="text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25% each year</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25% each year</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33% in 6 months and 67% in 1 year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-0.01</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.4%, 0.6</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66.7%, 83.7</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Expected option life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5 years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 months to 1 year</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Warrants</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the acquisition of the OK-101 project, the underlying scientific founders of the OK-101 Project (inukshuk Holdings),
who will continue to be involved in the development of the Project, received 35,000,000 warrants as consideration. The warrants are exercisable
at a price of 4.5 pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until 17 July 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, warrants were granted over 36,363,636 shares at an exercise price of 1.35p per share in connection with a private placement.
These warrants were exercised in May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 40,000,000 shares at an exercise price of 0.55p per share in connection with a private placement.
These warrants were exercised on a cashless basis in February 2022 (post a price reduction offer to 0.012p), resulting in the issuance
of 39,400,000 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over 35,825,130 shares at an exercise price of 0.55p per share in connection with a private placement.
These warrants were exercised in May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, warrants were granted over 36,174,870 shares at an exercise price of 0.55p per share in connection with a private placement.
These warrants were exercised in May 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, warrants were granted over 909,090 shares at an exercise price of 2.75p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, warrants were granted over 750,000 shares at an exercise price of 14p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, warrants were granted over 76,605,760 shares at an exercise price of 0.4p per share in connection with the conversion of convertible
loan notes. 39,605,760 were exercised immediately and the remaining 37,000,000 were exercised on a cashless basis in February 2022, (post
a price reduction offer to 0.012p), resulting in the issuance of 36,445,000 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, warrants were granted over 165,176,000 shares at an exercise price of 0.4p per share in connection with the conversion
of convertible loan notes. 165,176,000 were exercised on a cashless basis in February 2022 (post a price reduction offer to
0.012p), resulting in the issuance of 162,698,360 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, during the year, 147,969,396 warrants were exercised for proceeds of &pound;1,045,332, resulting in the issuance of
147,969,396 shares. 242,716,000 warrants were also exercised on a cashless basis resulting in the issuance
of 238,543,360 shares.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cent)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cent)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: justify">Outstanding at 1 April</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">185,022,726</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">147,188,766</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">2.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">241,781,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.
                                            5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37,833,960</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">Exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(390,145,396</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(0.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at 31 March</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">36,659,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6.11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">185,022,726</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable at 31 March</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1,659,090</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">10.30</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">149,568,181</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">1.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for warrants granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">29
    May 2020</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 76%">Grant date share price</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right">1.75</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">p</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercise share price</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">p</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk free rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">July 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">May 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>April 2020</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%">Grant date share price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">8.3</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">2.8</TD><TD STYLE="width: 1%; text-align: left">p</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1.8</TD><TD STYLE="width: 1%; text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise share price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">p</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vesting periods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
                                            vested</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50%
                                            of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium
                                            to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company
                                            exceeds a 200% premium to the Exercise Price (conditions have been met)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fully
                                            vested </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.68</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.22</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
                                            years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                            years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
                                            years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining fair value of the warrant instruments is deemed to be approximately $43,348 (2021: $108,873). For the consideration warrants,
the charge has been expensed over the vesting period. For all other warrants, the charge has been expensed over the service period. A
share-based payment charge for the year of $61,721 (2021: $81,914) has been expensed in the statement of comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has raised convertible equity finance via the issuance of convertible loan notes as per the table below. All notes are not convertible
into cash and are convertible on the fourth anniversary of the date of issue of the Notes, or at the election of the noteholder on completion
of the next non-qualifying equity financing or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers
and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming,
unconditional.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Terms</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
                                            $</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 38%; vertical-align: top">29 May 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: left">&#9679; 20% coupon per annum <BR> &#9679; Conversion price of 0.4p <BR> &#9679; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of 0.4p with a maximum life of 5 years from the
    date of the conversion of the loan note</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">541,239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Fees relating to equity fundraise 29 May 2020 issued as CLN</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679; 20% coupon per annum <BR> &#9679; Conversion price of 0.4p <BR> &#9679; Upon conversion the
    shares will be issued with a warrant attached at an exercise price of 0.4p with a maximum life of 5 years from the date of the conversion
    of the loan note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,474</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">27 July 2020</TD><TD>&nbsp;</TD>
    <TD>&#9679; 2.15% coupon per annum <BR> Conversion price of 8.5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,506,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">17 August 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679; 2.15% coupon per annum <BR> &#9679; Conversion price of 8.5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,882,641</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">3 September 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&#9679; 2.15% coupon per annum <BR> &#9679; Conversion price of 8.5p</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663,055</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Fees relating to all other equity fundraise issued as CLN</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&#9679; 2.15% coupon per annum <BR> &#9679; Conversion price of 8.5p</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">525,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,151,777</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
noteholders were offered the option to convert during the year and any conversions took place on May 7, 2021 and February 21, 2022. Loan
note holders were offered conversions including the full interest that would have been accrued had the note reached its full term</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
FINANCIAL INSTRUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main risks arising from the Group&rsquo;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarized below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the maturity profile of the Group&rsquo;s financial liabilities based on contractual undiscounted
payments:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Group</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Less than 3</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>months</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3 to 12</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>months</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Trade and other payables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">649,624</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">92,186</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">741,810</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Related party payables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">47,041</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">47,041</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">696,665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">92,186</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">788,851</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Group</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Less than 3</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>months</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3 to 12</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>months</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify">Trade and other payables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">110,179</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">100,813</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">210,992</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Related party payables</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">110,179</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">100,813</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">210,992</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Credit
risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and currently
has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their
internal reporting and assess outstanding receivables for ability to be repaid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest
rate risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has limited exposure to interest-rate risk arising from its bank deposits and convertible loan note instruments. These deposit
accounts are held at variable interest rates based on Barclays bank &amp; Penn base rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2022 or 31 March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions occurred in the normal course of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>West
African Minerals Limited (&ldquo;WAML&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, the Group disposed of its Cameroon operations by way of an in-specie distribution of all of its shares in
West African Minerals Limited (formerly Ferrum Resources Limited) to shareholders. As part of this transaction, the Group had agreed
to a deed of release with WAML whereby it agreed to write off $17,056,070 of loans in exchange for shares in WAML to be distributed as
part of the in-specie distribution. A remaining amount of $3,400,000 was outstanding from WAML, however, after careful consideration
of the operations of WAML and its subsidiaries, the Group decided to impair this receivable down to $nil in 2018 as it did not
expect to recover any of this outstanding debt. In addition to the $3,400,000 outstanding was a working capital loan advance of $600,000
which was also impaired as the Group does not expect to recover any of this outstanding debt. During the year ended March 31, 2022, the
Group had funded $0 (2021: $11,172) towards this $600,000 loan facility and as at the year-end no further amounts were payable
under this facility. The amounts funded in the year have been immediately written off as the Group has no reasonable expectation of recovering
the contractual cash flows of the loan in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. The Company
shares premises and other resources with Tiziana Life Sciences Ltd and there is a shared services agreement in place between the
Company and Tiziana Life Sciences PLC. As at 31<SUP>st</SUP> March 2022, the Company had incurred $107,132 (2021: $86,567)
worth of costs in relation to this agreement and at 31 March 2022 $47,041 was due to Tiziana Life Sciences Ltd. At 31 March 2021, $27,664
was receivable from Tiziana Life Sciences Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
BASIC AND DILUTED LOSS PER SHARE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March 31,</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">(Loss) attributable to equity holders of the company ($)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(6,268,197</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">(3,353,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">979,212,888</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">672,767,629</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(0.01</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year ended<BR> March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left">(Loss) attributable to equity holders of the company ($)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">(1,544,059</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">595,474,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered
dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented
on the face of the Statement of comprehensive income are therefore identical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is a lessee and does not have any leases as a lessor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognizing a right-of-use asset and a lease liability except for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Leases of low value assets; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Leases with a duration of 12 months or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Group has leases for its offices.
Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have leases of low value
assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales)
are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent
manner to its property, plant and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties
in their original condition at the end of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year to March 31, 2022, the Group entered into new lease agreements on its existing office. The new leases all have a term
shorter than 12 months, so the Group has applied the exemption allowed by paragraph 5a in IFRS 16 in respect of short-term leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the year to March 31, 2021,
the group terminated from its lease early resulting in the right of use asset of $27,069 and lease liability of $27,887 being written
off to the profit and loss. A new lease was subsequently entered into in January 2021. The initial recognition resulted in a right of
use asset and a lease liability of $104,377 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Right-of-use assets</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Property</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify">At 1 April 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">98,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derecognition
                                            of right of use asset</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(97,553</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Impact of Foreign exchange</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(1,026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">At 31 March 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify">At 1 April 2020</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">30,099</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Impact of Foreign exchange</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,030</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Depreciation of early terminated lease</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,060</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Early Termination write off</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,069</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additions</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">104,377</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">Depreciation of new lease</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right">(5,799</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">At 31 March 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid">Lease Liabilities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">31 March 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">31 March 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-size: 10pt">At 1 April</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">98,760</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">31,689</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">740</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Lease payments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,542</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Impact of foreign exchange</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,207</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Derecognition of lease liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(97,553</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Early Termination write off</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(27,887</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Additions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">104,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">382</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Lease payments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,000</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">98,760</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">31 March 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">31 March 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">$</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">$</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 54%; font-size: 10pt">Current</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; font-size: 10pt; text-align: right">34,148</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">Non-current</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">64,612</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">98,760</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Operating
leases</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><U>Operating leases which expire:</U></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">31 March 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">31 March 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 60%; text-align: justify">Within one year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right">18,713</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">18,713</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
Auditor&rsquo;s Remuneration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period, the group obtained the following services from the company&rsquo;s auditors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">31 March</P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2022</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">31 March</P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2021</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Fees payable to the company&rsquo;s auditors for the audit of the parent company and consolidated financial statements</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">200,773</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">58,874</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fees payable to the company&rsquo;s auditors for other services:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify">Audit-related assurance services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">148,892</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">72,637</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">349,665</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">131,511</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
Cash and Cash Equivalents </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">31 March</P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2022</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">31 March</P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">2021</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash at bank and in hand:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">GBP</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,400,817</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,344,740</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: justify">USD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">299,907</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,544,589</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">2,700,724</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right">6,889,329</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
Comments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&rsquo;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialization of the products of this research
and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that
the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101 &ndash;
    We are obligated to pay to On Target Therapeutics the following additional amounts in respect of the first licensed product or service
    which achieves the stated development milestones:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a) </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">First Patient Enrolled in a Phase I Human Clinical trial</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b) </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">First Patient Enrolled in a Phase II Human Clinical trial</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">600,000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c) </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">First Patient Enrolled in a Phase III Human Clinical trial</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAM8 &ndash;
    The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
    fee is $15,000 until May 2021, and $10,000 thereafter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post Balance Sheet Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022 OKYO announced the closing of its underwritten public offering of 625,000 American Depository Shares (the &ldquo;ADSs&rdquo;)
at a public offering price of $4.00 per ADS, for gross proceeds of $2.5 million, before deducting underwriting discounts and offering
expenses. As a result, the Company is now listed on the NASDAQ stock exchange and is therefore a dual listed Company with its existing
listing on the London Stock Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022, the Remuneration committee awarded the Non-Executive Chairman a bonus of $150,000. The committee noted that in order to
support the offering the Non-Executive Chairman  participated in the offering. It was noted that the offering may have failed
without this subscription, so it was agreed to compensate Mr. Cerrone for this transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2022, the Group secured a short-term
credit facility from Tiziana Life Sciences, a related party, for $2m in order to support short term liquidity. The loan is available
for a period of 6 months upon first draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if
the loan is not repaid after the 6-month period.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>6,315,789
</B></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>American Depositary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Representing
410,526,285 Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><IMG SRC="formf-1a_013.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all references to &ldquo;OKYO&rdquo; or the &ldquo;company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo;
or similar terms refer to OKYO Pharma Limited and its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. Indemnification of Directors and Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the company&rsquo;s memorandum and articles of incorporation, the directors (including any alternate director), secretary and other
officer or employee for the time being of the company shall be indemnified out of the assets of the company to the fullest extent permitted
by the Companies (Guernsey) Law, 2008 from and against all actions, costs, charges, losses, damages and expenses in respect of which
they may lawfully be indemnified which they or any of them shall or may incur or sustain by reason of any contract entered into or any
act done, concurred in, or omitted, in or about the execution of their duty or supposed duty or in relation thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7. Recent Sales of Unregistered Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following list sets forth information regarding all unregistered securities issued by us since January 1, 2019 through the date of the
prospectus that is a part of this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2019, we issued
    36,363,636 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise &pound;400,000, at a price of
    &pound;0.011 per ordinary share, following which we had 560,471,919 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 24, 2020, we issued
    40,000,000 ordinary shares to Veneto Seed Ventures Ltd. and 35,825,130 to Panetta Partners Ltd. by way of a placing of ordinary shares
    to raise &pound;379,126, at a price of &pound;0.005 per ordinary share, following which we had 636,297,049 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 29, 2020, we raised
    &pound;440,000 through the issue of convertible loan notes which carry an interest rate of 20% compounding and have maximum term
    of 4 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.004 per share and, if converted, the shares
    will be issued with a warrant attached at an exercise price of &pound;0.004, with a maximum life of 5 years from the date of issue
    of the convertible loan notes, regardless of the conversion date).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 5, 2020, we issued
    36,269,253 ordinary shares to Panetta Partners Ltd. by way of a placing of ordinary shares to raise &pound;181,346 at a price of
    &pound;0.005 per ordinary share, following which we had 672,566,302 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2020, we raised
    &pound;3,500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum term
    of 3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2020, we
    raised &pound;1,437,104 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and have maximum
    term of 3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September
    3, 2020, we raised &pound;500,000 through the issue of convertible loan notes which carry an interest rate of 2.15% compounding and
    have maximum term of 3 years. The convertible loan notes convert into ordinary shares at a price of &pound;0.085 per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    36,363,636 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise &pound;490,909 at a price of &pound;0.0135
    per ordinary share, following which we had 709,179,938 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    72,000,000 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise &pound;396,000 at a price of &pound;0.0055
    per ordinary share, following which we had 781,179,938 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    25,920,000 ordinary shares to Panetta Partners Ltd. through the conversion of convertible loan notes, following which we had 807,099,938
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    22,000,000 ordinary shares to Mayflower Medical Ventures. through the conversion of convertible loan notes, following which we had
    829,099,938 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    15,000,000 ordinary shares to Babington Microcap. through the conversion of convertible loan notes, following which we had 844,099,938
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    18,329,093 ordinary shares to Planwise Ltd. through the conversion of convertible loan notes, following which we had 862,049,031
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    25,079,922 ordinary shares to Laura Fonda. through the conversion of convertible loan notes, following which we had 887,508,953 ordinary
    shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    17,122,557 ordinary shares to Morris Silverman. through the conversion of convertible loan notes, following which we had 904,631,510
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    16,144,722 ordinary shares to Howard Freedberg. through the conversion of convertible loan notes, following which we had 920,776,232
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    3,573,888 ordinary shares to Carmine Rotandaro. through the conversion of convertible loan notes, following which we had 924,350,120
    ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    6,269,980 ordinary shares to John Storey. through the conversion of convertible loan notes, following which we had 930,620,100 ordinary
    shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    470,248 ordinary shares to Optiva. through the conversion of convertible loan notes, following which we had 931,090,348 ordinary
    shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    25,920,000 ordinary shares to Panetta Partners Ltd. through the exercise of warrants to raise &pound;103,680 at a price of &pound;0.004
    per ordinary share, following which we had 957,010,348 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 7, 2021, we issued
    13,685,760 ordinary shares to Planwise Ltd through the exercise of warrants to raise &pound;54,743 at a price of &pound;0.004 per
    ordinary share, following which we had 970,696,108 ordinary shares in issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 46,500,000 ordinary shares to Mayflower Medical Ventures. through the conversion of convertible loan notes and the cashless
    exercise of warrants, following which we had 1,017,196,108 ordinary shares in issue</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February
    24, 2022, we issued 68,500,000 ordinary shares to Saviese Generation Limited. through the conversion of convertible loan notes and
    the cashless exercise of warrants, following which we had 1,085,696,108 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 48,224,320 ordinary shares to Toro Chimica Ventures Limited. through the conversion of convertible loan notes and the cashless
    exercise of warrants, following which we had 1,133,920,428 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 39,982,880 ordinary shares to Babington Microcap. through the conversion of convertible loan notes and the cashless exercise
    of warrants, following which we had 1,173,903,308 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 68,500,000 ordinary shares to Garcer Ventures Limited. through the conversion of convertible loan notes and the cashless exercise
    of warrants, following which we had 1,242,3403,308 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 24,112,160 ordinary shares to High Octane. through the conversion of convertible loan notes and the cashless exercise of warrants,
    following which we had 1,266,515,468 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 68,500,000 ordinary shares to PPIH Ltd. through the conversion of convertible loan notes and the cashless exercise of warrants,
    following which we had 1,335,015,468 ordinary shares in issue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2022, we
    issued 39,400,000 ordinary shares to Scion Sciences Limited. through the conversion of convertible loan notes and the cashless exercise
    of warrants, following which we had 1,374,415,468 ordinary shares in issue</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. Unless otherwise
specified above, we believe these transactions were exempt from registration under the Securities Act in reliance upon Section 4(a)(2)
of the Securities Act (and Regulation S promulgated thereunder), or Rule 701 promulgated under Section 3(b) of the Securities Act as
transactions by an issuer not involving any public offering or pursuant to benefit plans and contracts relating to compensation as provided
under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities
for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed
upon the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to
information about us. The sales of these securities were made without any general solicitation or advertising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8. Exhibits and Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
19: EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222034473/ex1-1.htm" STYLE="-sec-extract: exhibit">Form of Underwriting Agreement</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Incorporation of OKYO Pharma Limited (incorporated by reference to Exhibit 3.1 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222007784/ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Deposit Agreement (incorporated by reference to Exhibit 2.1 filed with Amendment No. 1 to Form F-1 on March 25, 2022).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222007784/ex2-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of American Depositary Receipt (included in Exhibit 2.1) </FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222034473/ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion of Carey Olsen (Guernsey) LLP</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO Pharma Limited Share Option Plan With Non-Employee Sub-Plan And US Sub-Plan (incorporated by reference to Exhibit 10.1 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-2.htm" STYLE="-sec-extract: exhibit">Executive Employment Agreement dated December 21, 2020 between Gary S. Jacob and OKYO Pharma Limited, as amended on January 19, 2021 (incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated June 4, 2018 (incorporated by reference to Exhibit 10.3 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated October 22, 2018 (incorporated by reference to Exhibit 10.4 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement dated as of May 1, 2018 by and between Tufts Medical Center, Inc. and OKYO Pharma Limited (incorporated by reference to Exhibit 10.5 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shared Services Agreement dated as of January 1, 2018 by and between OKYO Pharma Limited and Tiziana Life Sciences plc (incorporated by reference to Exhibit 10.6 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License and Sublicense Agreement dated May 22, 2017 by and between On Target Therapeutics, LLC and OKYO Pharma Limited (incorporated by reference to Exhibit 10.7 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the License and Sublicense Agreement dated March 25, 2021 by and between On Target Therapeutics, LLC and OKYO Pharma Limited (incorporated by reference to Exhibit 10.8 filed with Form F-1 on March 4, 2022).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration Agreement dated August 6, 2019 between Tufts Medical Center, Inc. and OKYO Pharma Limited (incorporated by reference to Exhibit 10.9 filed with Form F-1 on March 4, 2022).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Collaboration Agreement dated November 10, 2020 between Tufts Medical Center, Inc. and OKYO Pharma Limited(incorporated by reference to Exhibit 10.10 filed with Form F-1 on March 4, 2022).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Appointment between OKYO Pharma Limited and Gabriele Cerrone dated January 6, 2021(incorporated by reference to Exhibit 10.11 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement between OKYO Pharma Limited and Gabriele Cerrone dated April 28, 2021 (incorporated by reference to Exhibit 10.12 filed with Form F-1 on March 4, 2022)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> 10.13* </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222034473/ex10-13.htm" STYLE="-sec-extract: exhibit">Loan Agreement between OKYO Pharma Limited and Tiziana Life Sciences Ltd. dated August 2, 2022.</A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries (incorporated by reference to Exhibit 21.1 filed with Form F-1 on March 4, 2022).</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Mazars LLP, independent registered public accountants regarding the financial statements of OKYO Pharma Limited as of March 31, 2021 and 2020 and for each of the years then ended.</A> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222034473/ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Carey Olsen (Guernsey) LLP (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1849296/000149315222034473/formf-1.htm#s_017" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex107.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"> * Previously filed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the
consolidated financial statements or the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. Undertakings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned
    registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates
    in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification
    for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
    pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and
    Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
    In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
    is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
    unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
    the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
    by the final adjudication of such issue.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant
    hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining
    any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
    in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h)
    under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of determining
    any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a
    new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
    deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom, on the 9th day of December,
2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO PHARMA LIMITED</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary S. Jacob</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary S. Jacob, Ph.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_017"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below does hereby constitute and appoint Gary S. Jacob and Gabriele Cerrone and each of them singly (with
full power to act alone), as his true and lawful attorneys-in-fact and agents, each with full power of substitution and re-substitution,
for him and in his name, place and stead, in any and all capacities, in connection with this registration statement, including to sign
and file in the name and on behalf of the undersigned as director or officer of the registrant, any and all amendments and supplements
(and any and all prospectus supplements, stickers and post-effective amendments) to this registration statement with all exhibits thereto,
and sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing
pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and any applicable
securities exchange, securities self-regulatory body or other regulatory entity, granting unto said attorneys-in-fact and agents, and
each of them (with full power to act alone) full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith and in and about the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes may lawfully
do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in
the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <I>*</I> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">December 9, 2022</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele Cerrone</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary S. Jacob</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary S. Jacob, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren Shah</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy Simon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Brancaccio</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard Denoyer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO Pharma US, Inc.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary S. Jacob</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized U.S. Representative</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    9, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary S. Jacob, Ph.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
  By:</FONT> </TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
  Gary Jacob</I></FONT> </TD>
    <TD STYLE="width: 50%"> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
  Jacob</FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-Fact</FONT> </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


















































































































































































































































































































































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-1_001.jpg" ALT=""></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tower
    Bridge House</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St
    Katharine&rsquo;s Way</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E1W
    1DD</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +44 (0)20 7063 4000</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.mazars.co.uk</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors of OKYO Pharma Limited:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the reference to our firm under the caption &ldquo;Experts&rdquo; and to the use of our audit report dated August 15, 2022
on the consolidated balance sheets for the years ended March 31, 2022 and March 31, 2021 and the related consolidated statements of operations
and comprehensive loss, cash flows and shareholders&rsquo; equity for each of the years in the three-year period ended March 31, 2022,
and the related notes, in the Registration Statement (Form F-1) of OKYO Pharma Limited dated December 9, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex23-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London,
England</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
9, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP is the UK firm of Mazars, an integrated international advisory and accountancy organisation. Mazars LLP is a limited liability partnership
registered in England and Wales with registered number OC308299 and with its registered office at Tower Bridge House, St Katharine&rsquo;s
Way, London E1W 1DD. Registered to carry on audit work in the UK by the Institute of Chartered Accountants in England and Wales. Details
about our audit registration can be viewed at www.auditregister.org.uk under reference number C001139861. VAT number: GB 839 8356 73</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>3
<FILENAME>ex107.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculation
of Filing Fee Tables</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
F-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
PHARMA LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Title of each Class of Securities to be Registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount <BR> Registered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed <BR> Maximum <BR> Offering <BR> Price Per <BR> Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Maximum <BR> Aggregate <BR> Offering <BR> Price(1)(2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of <BR> Registration <BR> Fee(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: center">Ordinary Shares, no par value(4)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"> 13,800,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"> 1,521 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Registration Fee Previously Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,268 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">Registration Fee Paid Herewith</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 253 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registration fee for securities is based on an estimate of the Maximum Aggregate Offering Price of the securities, assuming the sale
    of the maximum number of shares at the highest expected offering price, and such estimate is solely for the purpose of calculating
    the registration fee pursuant to Rule 457(o).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    ordinary shares represented by American Depositary Shares, or ADSs, that are issuable upon exercise of the underwriters&rsquo; over-allotment
    option to purchase additional shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated
    pursuant to Rule 457(a) based on an estimate of the proposed maximum aggregate offering price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    ordinary shares are represented by ADSs, each of which represents ordinary shares of the registrant. ADSs issuable on deposit of
    the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form F-6 (File No. 333-264685).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>formf-1a_001.jpg
<TEXT>
begin 644 formf-1a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !J 1H# 2(  A$! Q$!_\0
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M5GI0DJD>9"T45\]_'']H7Q1X+U8>'?!OPW\1>)_$$_RP7CVCIIJ_[1E_B_\
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MDOC1\%?%GP+\:77ACQA8M9WOS2P7:?-;WD7_ #UB;^)?_'T_CK]&OV ?VLO
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MAAT?2UCC7RK>VBVJJ_PJJU\!ZIXUBTW0?&_Q*U>)KYK6"?59(=_^MV_<B_\
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M6<O_ #UB?^%O_0OXJ_';]HS]F?QC^R]XQAMM5$MQI4LN_1_$=KO2*?9\R?\
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>formf-1a_002.jpg
<TEXT>
begin 644 formf-1a_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (" G # 2(  A$! Q$!_\0
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M=6\4\$L<UO*N^*:%MZ,O]]7J)1E'X@C*,_A'TRBB2H+"FT44 %%%% !1110
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M_P#\77Y_7/\ P3'^):2OY6N>%+E/[_GW"?\ M*HO^'9/Q0_Z"OA3_P "I?\
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MY3V/_@H1\<O _B'X,P^$]!\2Z;KVMWFIP7#0Z9=)<>1%%O=W=U^5?X%KC/\
M@EGI\LGB[XBZAM_T=-/L[??_ +32N_\ [)6+HO\ P2[\>S72+JOBSPWI5O\
MQ/;K/</_ -\;$_\ 0Z^W?@/\!_#_ .SWX(_X1_06GN7N)?M%]J%Q_K;R79MW
MO_=7^ZE*K4I4J/LJ4N8F$:DZGM9'HU,I],KRST@IE%%!8^BBB@ H_BH\NGT$
M!3J;3J 'QU+'38Z='64@)HZ=3:=0 1T^F45 #Z*** "BBB@ HHHH *9]VC^&
MB@#"\RA'W4RBN@LFJ6HJ=0 V2JCI5UTJNZ59!5HJ7RZ9)0 VG4VG4 /\RCS*
MB\RCS*@!WG4WS*KN]%!9=1ZE1ZI1U8CH(+J/15='I_F58 [U7=ZE=ZK_ ,5
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M<1\,3U-/V1_C2WRQ?M*Z_P";_#OM9=F[_O[5W]A'XO\ B_XCZ+XXT3QGJO\
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MIUHQE'VD/^WAT9<LN61[S3*?3*XSJ#RZ**/+H+"BGT4$!113HZ ".GT4^.@
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M<_\ @#:__&J\2FFWU7FJS>,I'N#_ +=OQW_Z*#<_^ -K_P#&J/\ AO#X]?\
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MWY:?9V']E2O_ &G V^5?EWK6GK>@Q:5XF>QMI_[8N%;_ %T/S[J=<NWB'?\
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MS9X/O[?DKJKS[58+N;Y[?^__ ':I)#;7EN[-MW_WZ]*$91][[)G&/-'WS/\
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M;<OW&^[3D3?YJ_\ /5=]'*0-=-BIN^_$VQJE_B3_ #_G^"HIIM\3M_>7YO\
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MFBV_+_'7./K$O^JVKO\ []7G17M4W,U8[(R2OM_AH]A'E]XF-27-*,@>9O\
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M*5/FY>;^OD:7@#Q58Z#YO_"0Z9_;&F-*O^B+>/;_ #;_ +_R_P"QO7_@=/\
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MLWPR[-U>I@Z/LX\L9<O_ &Z>)7CRU/:4S0\)6T6B:I<7VJW,]A91++%%J%C
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MH]SJ_P ^F?89-DO^S1'XO=/6I4)P^+W8EK1->N8;B*"^\S[.S?,[KOK>MO\
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M-)@B\/ZM&FG?;O/>+Y;^WV?,R,_RNCJK;4>NGA_9 ^#.B?%;2/@5KGB7Q?\
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MUZVAV2[?GKG[9[:;^)JZ#3;.SF9%;[E<DN4^CPU;VLO=-.VU:SFN/-\W8_\
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M?ZE J.)F/\4?&#4O$GP+\._#.?1;2&UT;7)]>748FVO++*\KM%Y2IM5/WO\
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MXN4R_LN=+XI%RQ^)WC.S_8?\3V=CK5U]GM_%4&FM#Y";5LI;"=Y8F^7[C/\
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M+[2XMOA!;6&MW%_ITVG+%I]I9K:RRVMZK[/EE>7RG\W[S,[55\'^*D\$Z;\
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M$[;]SKL^79_=JB]_?3:7;Z9+>7+Z9:RM<06+ROY44K??=$^ZK/L3_OBB-#E
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MY=FSYI4?^*N;\220Q^&=8_:>AM(5?7/ ,6EP*L2(J^*)7_LZZV)_>2**6?\
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M:OUVWFH6FIRK<72_]-6W_-_P.CV!9]M7UC-\.-5^._B#5M4OU\:VS:)*-;\
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M\JQ\"K#+]QGFEKVCP?\ !SQCK&DI8RV/AO1T\WS?M'E>;+_N5M+,*$?BY?\
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MM_N;/X:Y7Q/I<$/BJXL;'=;1>;L6&[^^M8QG4C^ZJ1_[>/4Y:-./[N7O2_\
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M?WL3?/5'5='\FW^\U=!->2I\L2[$K'O[R7Y]U:QJ2/$E3E*1S%MIOS(S?/\
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MDDFV+5M:5VEE_CLX'=-W_CEPW_ *^Q5T=H;K5M0CE9[W4X/L%MO_ (-GF_\
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M*->:E3E_-'_R:([QM\/?%'ANWM]/T]9-5TK35:5K&&)'N+!6^=_-V_\ [/\
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M\3*EW9?Z/O\ ^!_)_P!\/_XZ]5_"OC#_ (6+\$TTJ>7?J%K9[(G_ (_-@?\
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MOR_[;UY)K?@/_A V_L^74Y-2M-S//<6+>;%MV?)\G]ZN/^'OQCU?P8SVTO\
MI.G_ /+>TF^Y_P#8UZ7<ZEIGC:R^V>'+Q8;C[\MC,VQ__LJY(?6\'+]Y+FIG
MT$:>"S&ES1]VI_Z4>1/<Q)O:VE\ZW;[UN]4?M/\ 9MQY^GLVQOO6[UWVO6VB
MPZ;=V=]9[-;9E>*^A^3;7GZ6R_;/(O)=B?PW"?Q5Z]/DK>Z?.XGFP[YOZ_X!
MU'C"V\/>)/#.F3Z+ MMJ<2_Z4G]ZN)MK.72;!]0\_9,O\%3([6UUN@;YE_\
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MW/1HSC2C&G+[7Q?X?^"=1XDFU7PK:I%!I\_]H7%JMQ:HD7^HMV^Y</\ [/\
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M5?G=?NUR^CV"WD?F,WR?PUT&E7GDM]F9OG6HE_,=$I<L>4S[K7FMGVQ*V_\
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M)HFL+I7[ION,V]:[J,O;KFD>;5IQPZY1\UU.DJ*Z_)_Z%69K%XTRI!\R(O\
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MBX^4?=]*)%$E_P#,-WROUYHHKKQ'\,NE\9ES?ZEO]^JL/^MHHJH_"7(NP_\
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6T85'VI.*KZPH^U/Q1173'X#@7Q'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>formf-1a_003.jpg
<TEXT>
begin 644 formf-1a_003.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 0@!\D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4E^Z*6D7
M[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!%^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!%^Z*6D7[HI: "BBB@ HHHH **** "H;R8VUI-*!
MDHA8#Z"IJJ:M_P @N[_ZY-_*IEI%LJ.K2/S/^)O_  4V\9^"_'FLZ+;Z)#)!
M9SM$KDCD URA_P""LWC0'!T2VS_O"OGCXK01W7[1.JP3+YD,FI%70]"-U?K5
MX$_9'^$&I>#=%NI_ FF2S2VL;N[H26) R3S7T?+AZ.'IU:D+W_R/%E*M4Q,Z
M<)6L?'7A#_@K/KJWV=9T"&2VSSL;G%?>WP$_:$\,_M >%TU70K@><HQ/:L?F
MC:ODS]N?]B_P3X=^%][XK\(Z9#HMW9%=T$(PC U\[_\ !-+QM?>'OCV-.CG<
M6-Y"4>#/R[L]:F%+#XVE-TH\LH_U^(JE2O@Y1=25XL^T_P!N/]KC7/V:&TG^
MR;**[^UGYO,.,5VG[&'[1&I_M%?#V77-4M8[6=)-FV,Y%8W[8?Q.^#/@#^S!
M\5/#7]O^8?W'[DR;?U%=7^R;XX^&OCKP/)>?#/1/[#T@/AH/+*<_3-<%&,?J
MDFX7=_BZ+4[ZS?UB"4K*RT[Z'NE%?.'QH_;L^'_P+\9CPSX@BU!M0R!FWBW+
MS[U#\4OV\OA[\-?!VG:S)-+=7&HP^;;6BCY_;<.U<BHU)14U'1[&[G&,G!O5
M:GTK17Y^>!O^"L'A[5->2VU_17L;&1]JS0Y)'N<U]R^"?&VD?$+P[:ZWHEVE
MY87"[DD0Y_ UK5PU6BN:<;(RIXBG5?+%ZF]17+?$?XE:%\*_#-SKOB"\2TLH
M1GD\M[ 5\/>-/^"LVAV.J20^'M">[M5./,N,@GWK.E1G7=J:N:5*D:2O-V/T
M*I&.U2?05\H? 7_@HAX"^,6J6^BW/F:+J\@'^OXC9O0$U]6[UDAWJ0RLN0PZ
M$8HK4:E%VFK"IU85?@=S\[_C]_P4.\6_"WXQ7OA6QT>&>TAF$:R,><$U]EV/
MQ'NYO@:/&3PK]L_LTWGE]MP&<5^1/[9G_)SVI_\ 7TO\Z_6+X<7VFZ;^S?I=
MUK$/VC2X=*WW$6,[T Y%=]6E!9=3JI>\^OR.>-27U^5/[*Z?<?'/P3_X*0>*
MOB3\;=&\'W6E6\-I>W9MVD5AD#-?I%7P/\(?CQ^S!K_Q>TG2_"_@4V'BB:Y*
M6]W]F*[9/7.:^ROBI\3-*^$/@?4/%.M+*VG62AI!"N6Y]!48Q1C&GRT^73[R
ML/S2J37-?7;L==17S7\)_P!OKX9_%RXODT^6[L$LXS))+>QA%P*\8^)/_!5K
MPUH>MS6'AG27U)('*/--D!L'J*YUA:SG[/EU-/;TN7GYM#[[HKYI_9Q_;G\%
M_'Z\CTF$2:;KFW+03<*Q]%KZ59@JEF.% R2:SJT9T7:HK%4ZL*JO!W%HKY3^
M/W_!0GP)\&-4FT6#?K.KID$0<QJWH2*\@\&?\%:-"O-42+Q#H3VEJS8\RWR2
M/>M:>%K5H\T(Z$5,13I/ED]3]"Z*Y/X:_$_P_P#%CPS!KGAV]6[LY1V/S*?0
MBNLKFE&4&XR5F;1DIKFB[H*^6_VW/VH-;_9NT73+S1[%+U[I]K!STKZDK\]?
M^"M'_(I:!_UU_K544I5J<7LVBI:4JDNR9Y-)_P %8O&\6-^A6Z_5A3/^'M'C
M/_H"VO\ WV*Z'_@FK\&?!/Q2T76Y/%?AVUUN6$_NVN1G;S7V_P#\,=?!O_H0
M=*_[]G_&O>Q#PN&J>SE3N>)0^L5X<\9GR+^SS_P4A\4_%CXK:5X9O=)MX;:[
M.&=6&1S7Z/CD UY=X:_9?^%W@_6(=5T;P;IUAJ$/,=Q$A#+^M>EWM[!IMG+<
MW,JP6\*EGD<X"@=S7E8JK0J<OL8\MMST:%.K%OVDKW)Z*^-/C)_P4R\!?#W4
MKO2='AEUK48<CS%'[DGTR*X#P3_P5GT&\U)8_$>A/:6K''F6V21[\TJ>#KU(
M\T8Z#J8BE3?+*6I^A5%<?\,?BMX=^+GAN'6O#E\EW:R#)7(W)[$5U5Y>0Z?:
MR7%Q*L,$:EGD<X  [URSBZ;<9JS1O&2J).+N345\8_&3_@IGX%^'^H7>E:+!
M+K.HV[E&<#]UD>XK@?!__!6G0[K4!'XAT%[6U8@![;)(]S753PE:I'FC'0QJ
M8BE3?+*6I^AE%<?\,/BMX>^+OAN+6O#MZMW:N!N /S(3V(KS;]H+]LCP1^S?
MK5CIGB>.]>XNX_-C^RQ[ACWKG]G/G]G;WNQK&<91YT]#WFBO-O@/\>/#W[0G
M@T^)?#:W"6 E,.+E-K;A[5/\;OC;H/P&\'2^)/$*SO81G:1;KN;\J)TY4Y^S
MFK/8<)1J1YHNZ/0J*\#_ &?_ -L[P-^T;K%SIWAB.^2>!=S?:HMHKM_C3\=O
M"WP(\-G6/$MWY41.$ACY=S["G4I3I249JS8J<XU4W!WL>BT5^=7B;_@K9I<.
MHNNB^'C/9Y^5KC(:NW^%7_!4;P1XNU"UT[7K*;2KNX<(LBC,8)/<FNE8'$-7
MY3G>+HIV<C[>HJMINHV^K6,%Y:2K/;S('213D$$5\Z_&W]O3X>? ?Q<WAWQ#
M%J#WP7=FWBW+7)&$IS]G%:]CI<DH\[>A])T5R?PQ^)&E_%?P?9>(]'$HL+I=
MR"9<-7643C*G)QDK-!&2FE*+NF%8?C'QIH_@+0KC6-<O8[&Q@&6DD./P'O6V
M3M!)Z5^0_P#P44_:2U+QY\1+OP9IUW)%HVER>7+'&V [U5&E+$5%2AU_!"J3
MC2@ZDMD>W_%;_@JUH^DWEW:>$M*^W)&2J7,QQN->6Z3_ ,%:/%:ZA&;S0[=K
M;/S .*[/]BW]@+2?$GANU\7>.[?[3#=*'M[)NC+ZFOK36/V)?@YJVFR6J>#+
M&S9EVB:%2&'O7L5/J>%?LW'F:W/+@\1BE[1/E1Y]\ _^"B7@?XM7L6E:J1H>
MK2$+&KGY'/UKZSCE2:-9(V#HPRK*<@BOQ4_;&_9<NOV9?&5I=Z3<R/I-VQEM
MIU.#&0>E?='_  3F_:&NOBO\/9=#UJY:?5]+.Q&<\M&.]9UL-2JT/K&&V6Z+
MA7JTJRHU^NS*_P"VU^V9XA_9P\3:?IVCZ9'>1W$0=F<],UZU^Q]\<-3^/WPH
M@\3:K:K:7,DA0QJ>.*^(_P#@K)_R4#1O^O=?Y5]&?\$U]1MM'_9ABOKR58+6
M&1WDD<X  Y-9TZ<'E\JK7O7W^9I5J36,C3B]&E^1]9>(_$6G^$]%NM5U2X2U
MLK9"\DCG  %?F]\5/^"J&KZ?XVO+'PEHT=[I44GEQ3,>9.<9KA?VZOVTKKXI
M:M<^#O"=Q)%H%N^R62,\SL..U=9^P;^P]+XAN+;QQXWL@=+QOM+.4<N>Q(K7
M"86$8/$8G2/1?U^!&*Q,N;V%#67?^OQ/LO\ 9;\??$7XE^&QKWC328](M;I
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MXJ:+\'?!]UXCUYW6QM_O",98_05Y%\#_ -NGP'\??%1T#PW:ZG]K"[B\T.$
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MM]XHT^W6YN8'50CG YKY]_8E_;@\0_M)?$74-!U73X;2"WM3.&C;))S7T?\
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M]Z?7$=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[MGJ0A&G'EBM#QC]K[_D@?B?_K@?Y&ORQ_X)_P#_ "<5IG^__4U^IW[7W_)
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M'NF\1*5)Z,]+!*<:*C/=!1117GG<%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 B_=%+2+]T4M !1110 4444 %%%% !535O^07=_P#7)OY5;IDL:S1M
M&XRK#!%3)730XNS3/P4^)UQ$/VDM1!=<_P!J>O\ MBOW(^&O_(@:!_UYQ_\
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MH+./4Y(&/^CNV >37[T^,O"&G>.O#]UHVJQ>=8W"[9$]17@X_P""??P?'_,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z*6D7[HI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\?VS/V(_'?QQ^*LNO:#-
MEDPP!(.:^M_V9/AOJ?PI^$>D>'M7=7O;9,.4Z5ZO175]8G[!8?[*,)48RK_6
M'\04445RFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z*6D7[HI: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z*6D7[HI:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!%^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!%^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!%^Z*6D7[HI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!%^Z*6D7[HI: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEFK,4*D:BYHNZ"BBBLRPHI"0H))P!6/I/B[2-<U*[L;"^BNKFU_UR1G.SZT
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MBBB@ HHHH **** "BBB@!%^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#\Z?\ @I0H;XW?"+(S_IB?^AU[C^U9^T[JG[.FD^$7L+!;
MV*]\M)0>N,#I7AO_  4H8+\;OA#DX_TQ/_0ZU_\ @HWL,?PT#\J;B'@_A7KT
M8J=#"P>SG)?B<F(ERSJ36ZIIG0?$7]K;XN>!]+TOQG<^#((? ]QM+3;_ -YM
M/<BO<?$7[4F@>'?@)#\2[A?]%GB#10=V<CI7G7[8BQK^QQC:H46<.!CIP*\#
M^)F@7NK_ /!/WPA?6D;S6]A(DLZ("?E'7BLW"G4A)6MRU%&_D^Y,)2]I3;=^
M:#E;S6QZ-<?M$?%WQM\+-<\47_@R"/P5>VT@AE5_WH0CAMM<Q^P'KBZ3\$_B
M+JZVZS"-I)?)<<-R>#7K?A7XZ^!3^R'$XU2UW+I9@-EN'F!]N,;:\5_8GN([
MK]GWXIS1C9&_FLJXZ#)K::5..*C&-DDE^)S1;J2PLI2O=M_@>^?L<?'"V\=?
M#OQ#K5WI-OH5KI\SF3R0 "!GGCZ5QT?[67Q0^+^J:M-\*?"=OJ&B:3(RS7-S
M)M,FWKM]37 ?L<:->>)/V8_B/8:<3]KE>8(!U/6NE_X)X_$[PSX0^'GB#0M<
MO[?2M4T^YD-Q'<L%9@#R>>M76HPC5K22^!1LO7=BHU9NC35_BE)-^FR/<O@!
M^T\?BIX9UV;6-$NM'U?0E;[7;O&0&*CG;ZUY#J7[5'Q@\9VNM^(_!7@V&+PG
MI#,)9M1?RG<*>2 >M=I%^U1X,\7>#_'E]X%T6::[TF*19KC[/MCE8 \Y[U\O
M?"O4I?BO\'?%GBCQ5\1VT:-?,6/0;=@H;D\8KEC3NYU7"UDM'MKY;N_0ZW*R
MC34KWDUYZ=+['T_\,OVGM9_:"^ 7B35/#>G1Q>++&)XVM6?"D@')S7SQ^P3K
MWQ3NOB1KS1:?#=:;)<$:K---EHFST7/6N@_X)I&W?X<>/EMFW'][L]2N#S6O
M_P $\_$VEZ;XT^(&G7=_%;WTMXVR"1L,WS=A76X1H5:RA'["?WVT]#DC.5:C
M!S>TVON_4[CX=?'(:U^V=X@\$CP]:VYM8F8ZBJCS&P.YK3^)W[76MWGQ,NOA
MW\,-%37_ !':Y\]I&PB8]Z\8^$?[W_@I!XT1&P[6\@4_@:K_ +-FOZ?\'_VQ
MOB!9>,95TVXU"1S;WEUPK@D\ FLHT83]E=?\NN;U9I*K.#K6_P"?G+Z*VY[-
M\.OVNO$7AWXAVW@7XMZ''X?UB[(%M/"VZ-R>@S1^T3^U_K'P9^,>B>&;32UU
M&SU!0%V]2QZ?K7D/[9'B/3?B]\?O .A>#GCU75+.Y22>YM/F"+D=2*B_:=@$
M/[77PSMIP&DCCB5P1GD8HH4H5IT93C;F<DUY):,UJ2E3C7C%WY8Q:?9MJZ.[
M\;?M??%+X.^,M$?QSX2M[+PUJ\JK#+#)N*JW<^AK[1T/5X->TBSU&V;=;W,:
MRH?8BOB;_@IKM'@GP>6 _P"/N/''O7UK\&_^27>&?^O*/^5<\HQGA?:I6:DU
M\K7&I2CB53O=.-_G>QV5%%%>>=H4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?G;_ ,%-#:K\4OA6]]M^Q+< S;^FS<<YKT7XQ>+/
MV>6^$&JQNVCRW!L2(E@"^9YFT8Z>]>:_\%/M-AUWXE?"_2KABL%[.()"O7:6
M(->L>&_^":OPLM9+"^F:\O0JK(T,KDH_&<'FO6IJ#P4/:2:5Y;>IRUW-8E."
M3]U;^K///V&?%6J?#?\ 9)\7^)H(7DM+.:2:QAE[CG_ZU=1\$OVIOBW\?M,L
M+KPUX8M?LT-QLU"XFD"[5SV]:]K^/7A'1_ O[,_BS2=#L8M.T^&Q;9#", 5Y
ME_P3)AB7]GU)40!WNGW-CD\TW5A6E6KN-[<MK_=J8>SG1ITJ:=G)RO;[]#H/
MC+^U1JN@>-;/X=^!]*37/'4L8:6!CA(SCG)K)^&O[57BS0_B1;>!?BSH,>@Z
MI>C-K/"VY')Z#-?+?Q:\+:U8?MWZF\_B:;P8NH#_ $76%. !SQFMK4O NFZA
M^T+X8TW6?B)JWCG7[>198IK<;T1?<BKP]"E*%/FUYTV][_+T\Q8FI.$ZBC]F
MUO\ @^I^G8.X CD5XG^TS^TMIW[/NCV&^W-]K.IOY5E:C^-CP/UKQSX^?!']
MI+Q1XV2Z^'WCR+1] 6)56WDE"MD8KQ/]J;PGXU^']Y\)]8^(5Y_;DME=J+R[
M3YE7GJ:XZ&'A4G34IJTG9KKU.FM5E3C-QC=I7\OZ_P CV:;]J+XR?#6^TK5/
M'O@=$\,ZDZA)+(^8\:MR"0.G!K!_X*.:O;^(O O@;4[8-]GNKJ.1 XP0"0>1
M7N_Q*_:B^%O@WP3I-[J]Y;ZW!=+&L5G:J)7W%1CCM7SW_P %!M<L_$7PU\ Z
ME8VTEG97%U&\4,J[6521@8K:G[U:D^2UII7_ $]1T]%/W[W@W;]?0]"_:&^*
MH^%'[/G@6^_L>#6?-2%/*G ('3GFM+XX?M/:E\'?@=X1\5Z=ID9^WI&9+9>
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M7Q#I-IJ5E();6YC$D;CN#7YB_&[PK;1^&_#\'BGXPZGXPM-0:/[-I]H0[*Q
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M])_9]\)Z-\4+KQ];VSC7[A=KR$\5Z914QDXN\7;H.45-6DKK<****DH****
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MQ\_Z;^PU\)=+\6C7XO#T;7"OO$#<Q _2O>+&PM]+M([6TA2WMXQM2.,851Z
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M;7!GF=I'<.<DDY-=Y\&/V/? _P #?$4FL^'HIDNG38?,<D5[K13^LUK<O,[
MZ%.3YG'7<****YC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 1?NBEI%^Z*6@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 1?NBEI%^Z*6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_0N:M^8_PH_X>;^"?^A<U;\Q_A7YS44>TD'^JN5?R/\ \"9^C/\ P\W\$_\
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M_H7-6_,?X5^<U%'M)!_JKE7\C_\  F?HS_P\W\$_]"YJWYC_  H_X>;^"?\
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M_M5_[M']JO\ W:H44 7_ .U7_NT?VJ_]VJ%% %_^U7_NT?VJ_P#=JA10!?\
M[5?^[1_:K_W:H44 7_[5?^[1_:K_ -VJ%% %_P#M5_[M']JO_=JA10!?_M5_
M[M']JO\ W:H44 7_ .U7_NT?VJ_]VJ%% %_^U7_NT?VJ_P#=JA10!?\ [5?^
M[1_:K_W:H44 7_[5?^[1_:K_ -VJ%% %_P#M5_[M']JO_=JA10!?_M5_[M']
MJO\ W:H44 7_ .U7_NT?VJ_]VJ%% %_^U7_NT?VJ_P#=JA10!?\ [5?^[1_:
MK_W:H44 7_[5?^[1_:K_ -VJ%% %_P#M5_[M']JO_=JA10!?_M5_[M']JO\
MW:H44 7_ .U7_NT?VJ_]VJ%% %_^U7_NT?VJ_P#=JA10!?\ [5?^[1_:K_W:
MH44 7_[5?^[1_:K_ -VJ%% %_P#M5_[M']JO_=JA10!?_M5_[M']JO\ W:H4
M4 7_ .U7_NT?VJ_]VJ%% %_^U7_NT?VJ_P#=JA10!?\ [5?^[1_:K_W:H44
M;5E=&Y5B1C!Q5FL_2?\ 5O\ 6M"@ HHHH **** /P?F_UAIE/F_UAIE<1_3Z
MV"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!R7CS[L/UKD:Z[QY]V'ZUR-?<Y;_NL3^8>
M,O\ D=UOE^04445ZA\4%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'^K'^\O\Q4E1W'^K'^
M\O\ ,4 ?O7\$?^2+>"/^P7#_ "KM*XOX(_\ )%O!'_8+A_E7:5\%/XWZGV,?
MA04445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 :>D_P"K?ZUH5GZ3_JW^
MM:% !1110 4444 ?@_-_K#3*?-_K#3*XC^GUL%%%% PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#DO'GW8?K7(UUWCS[L/UKD:^YRW_=8G\P\9?\ ([K?+\@HHHKU#XH****
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M?6)=CZ5_X3SP]_T%(J/^$\\/?]!2*OFKRU_NBCRU_NBC^SX?S,/K$NQ]*_\
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M (3SP]_T%(J^:O+7^Z*/+7^Z*/[/A_,P^L2['TK_ ,)YX>_Z"D5'_">>'O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3TG_ %;_ %K0K/TG_5O]
M:T* "BBB@ HHHH _!^;_ %AIE/F_UAIE<1_3ZV"BBB@84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!R7CS[L/UKD:Z[QY]V'ZUR-?<Y;_NL3^8>,O^1W6^7Y!1117J'Q04444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *]%^'/Q&?2I8]/U!RUJW"N?X:\ZHK*I3C
M5CRR*C)Q=T?5T,R7$*RQ-OC89#"G5XI\.?B,^DS)8:@Y:U;A6/\ #7M,4J7$
M22QL'C89#"OF:U&5&5F>E":FKH=1117.:!1110 4444 %%%% !1110 4444
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M^LB8JWU%>WZU\,_VA=+TFZN]0N]=%C$A:;=?,1M[Y%:&N?L_Z9J7[.]O\1M
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MU^$OA2U\#P>#VTN*[T"!-D=O<J'VCV]ZY?P/^RS\-/AWK4FJZ/H,9O6.0UP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** -/2?]6_UK0K/TG_ %;_ %K0H **** "BBB@#\'YO]8:93YO]8:97$?T
M^M@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <EX\^[#]:Y&NN\>?=A^M<C7W.6_[K$_F
M'C+_ )'=;Y?D%%%%>H?%!1110,^VOV)U9_V:_B\%4NVTX"CGI7QA8>'=6UB\
M%G9:9=7%S-,55$B))^:O:/V=?VL]8_9RT?6M+L/#]CKUGJS!IX[SI]*] M_^
M"@T^FLTVF?"SP[IM[SLN8E&Y#ZCBN&4:D,34JQC=24>O9'9&4)T8TY2LTW^-
MCN?B\S?"GX!_#KP-J!":O<W<=S);D_,@)'45RG_!1,M))X'A8DH+"/"GI]VO
MG3QY\8/$7Q*\=1^*M=N#=7L;AXXF/R* <@ >E;7QP_: U;X[2:3)JNGV]@=-
MA6%/(_B &,FL5AZG-"<M^9R?E=6-?;4XJ4([**BO/6Y] _LRQCX_?L^Z[\*9
MI0U]%,LEHK?>"CKBLG]MC5H_!G@OP7\+[9@/[,M@;E5XS(/6C_@G[X)\5^&?
MB@GCNZT^XT_PI;6DCM?3C;#+[ UX7^T5X^?XE?&;Q+K9D\R"2Y80X/ 7..**
MD.;&*,7I\3]5HATI<F%E*6^L5Z/5GGUC_P A*Q_Z^(__ $(5^AO[</Q8\;?#
MGP9\,H_"E_-9QS:?'YHB3=GY:_.^&0PSQ2CK&ZN/J#FOK>3_ (*,:MJ6AZ5I
MFL_#G0]:3385@ADN>3A1C-=&*IRJ*FXJ_+)MKY6.;#U(P<^9VNK?BCQK4_VD
M/BUK.GSV-[K%U+:3J4DC\H\J>M>R?L1^(H_$GAGQI\,;Z3']K6SO;I(>DI]/
M>J-U^WG;W%I/#_PJ+PU'YB%-X497/<<5A?LK^"/&'C#XZZ9XTTS1IK#08;L3
MW=W&,01)R2N:GD4X3A4@HQ:WT^0W-P<9PGS23T6I[?\ $"UM?V</ 7@3X;74
MBQ27&HK/><X)4L.OM7<?M9?&;P_\.M6T0WWPGC\:Z?-91"'5"<I]WI7R9^W-
M\4A\4?CYJ%Y;3A[6P_T>)HSQE>XK4^'O[=OB7P;X/MO#>L>&M-\7V%K_ *DZ
MD 66N&G1J5Z,*TM9-N36VZM^!W5*L*%:5)?"H\OH[W.]^.WQXUWQI^S:FE+\
M+H?!_A2>56@N&?YQ] :^*UX45Z]\<_VFO$OQX^S6^H6\&D:1;#$.FV@ B6O(
MJ]##4W34FXVN^]SAQ%3GY8IW27:P4445V'(%%%% !1110 4444 %%%% !111
M0 4444 %1W'^K'^\O\Q4E1W'^K'^\O\ ,4 ?O7\$?^2+>"/^P7#_ "KM*XOX
M(_\ )%O!'_8+A_E7:5\%/XWZGV,?A05PWQ?_ .19'^_7<UPWQ?\ ^19'^_6N
M'_BQ]2:GPL\'7I2TB]*6OJSRPHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH * "Q  R3T H +$ #)/0"O5OAO\-MVS4]23
MCK'$P_6L*M:-&/-(N,7-V0?#;X;;MFIZDG'6.-A7K*@*H X X%*JA5"J-JC@
M 45\S6K2K2YI'I1BH*R"BBBL2PI<TE% "YQ7!?'#XC:E\*?AWJ'B73-'_MR:
MT7<]IZKWKO*AO;.#4K.:TNHEGMIE*21N,@@U,KV]W<J+2DN;8\(TGP7\'_VG
MO!>G>(-1TW3%U"YA$D\5O(J/!(1R#CN*\6\$>%;3]GO]J71/#/P^UJ76=#U;
M<U_9>>95ML=.<\5W?BO_ ()[>']4U2>\\,^-M9\%K<2F66WTYCL8GJ,9KT[X
M)?LR^&?@A-->VD\VM:S, )-2O"3(WYUK3<5/VBT6NG>ZV]#*HI.#AN]->UGO
MZGQ%XX^!>J?'3]J/Q]8:;KDVD/:JTZPQ9_?.!PI]J^L_V1_B4_B;X8ZGX5U2
M".PU_P .A[.:W"A6D"@_/BNS\'?L]Z1X+^+FK_$&UU&XFU'4\^9;/]Q?I39/
MV>-)C^+4WCVPU.YTV[N(#!<6,/$4N>K'WJ8>[1C1Z..OE+6W^14O>JRJ]5+3
MTLKGR?\ #\@?L_\ QK)Z"]E)^F37T/\ L6>-/#C_ +-^D30:A9VT-N',\9<*
M1CKN%<_\4/@AI7P7_9\^)+Z=?37@U0M<2B;^$L3D"O)/V?\ ]BW1?BI\%]!U
MF'Q7JGAZ.X9OM-G9,1',/0\T1;DIQ7\L%Z.S$URN+?\ --_+W3OOV/;>;5/C
M=\5M?M!G0KF^_<2)_JWZ\BN__;FTR]U3]GS6%L4>0Q_/(J=2N17JOPU^&^B_
M"GPK:Z!H< BM85P7Q\TA]2:W]4TRUUK3;BPO85GM;A"DD;#((-%;WHQC#[*2
M7R+HRY9NI);MO[SSKX!^,O#]S\!?#DMOJMG'!;Z4L<Z>:!L8)R&'K7S_ /L=
MZ,OBSQC\:9[<B30-4WP6Y4?NV)X)%;NL?\$[_#]YKDUUI7CC6M#TF>0R2Z1:
ML?);/4=>E?0_PQ^&>A?"/PS;Z'X?M5M[6+EF_B=NY-:-QFYU'O)-6]6F_P M
M#-)PC&G'9-._I>WYZGYYI\1[SX;^"_%WP:?>NH76L"RM$SR89&Y('I7>?MA?
M"[4?!_P2^&?A[3KJ32K.UN(UNM0C7(@)P=Y_.OH'Q=^QSX3\8_&_3?B=<7MQ
M#J=ES]C0?NI&_O'WKU[QQX-TKXB>&[S0M:MEN+&ZC\ME(Z<=16,FY4HMZSNF
M_P#MW1:^:U]3:Z55\OPV=O66K^YGQ#J'[(_B.]^'_P#:&H?M)3-X=FMPS\ I
MM(Z 9K.^)7@#2OA_^R+X7T72]=E\4::NJQLM_<)M,A+\\>E>J6O_  3HT&WU
M96D\>:Y<^'U?<-"=SY& >!UZ5[%\1OV<_#OQ"\!Z7X16632-+TZ6.6$6XYRA
MXK3FV:ZRB[>2=S&SY>5ZV3^]JQWO@W]WX-T6->$6UCPO8?**UZK:78KI6EVM
ME&Q=+>-8U9NI &*LT3?-)M!37+!)A1114%A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 &,U@ZI\0?">AW0MM2\3Z387)X\FXNE1OR->2?M:?&#4
M_AWX=TW0?#RYU_7YUM(I!UB5N-X^E<5H?_!/3PAJVFPW?CK4KWQ%X@E'F2W4
MTK QL><#!HC>2<NB=O\ ABI6C9/=Z_(^I['4+35+<7%C=PWMNW26W<,I_$5.
M 3P!DU\4QZ?KG['?QH\.Z/;:Q/J?P_UZ7R1'=L3]G;VS7OWQZ^(WB[PII=C9
M^!=#;6-5U1?W4[+F*$'^)CVHDUR*<-4]/FNA,4^=PEIU^7<]0AU*RN+B2WAO
M()KF,XDA1P73ZCM5BOA[]@UO$Z_&#XDP^+[PW>MQW7[[#$HA/85]Q#KS6DH\
MJB[[I/[R%*\I+L[%34]8T_0[4W.IW]OIUL.LUS($7\S6?H_B/PMXJE\[2-3T
MG6;B/_EI:R)*Z_B.E> ?&;X(>)?C_P#%:+2]=O);#X?62!_+MV(-PW<-BO'/
MC)\&;/\ 9#\>>!]7^&M[<VR7UTL%SIAD9EF4M@G!-12]YQ4].9V7Y*_J74M%
M2Y=>57?YZ'WIJ&I66DVS7.H7D-C;+RTUPX51^)JCHOC'P]XFW?V-KVGZMMX(
ML[A9,?E7RC^T:M[\;_CMX3^&37\]AH4UBMUJ"V[$%S@$J<5S'Q1^ .D_LD>,
M/!GBCP+J-SI^E3WR07UBTC&.1>,DY-%/WN5ST4G9?E^>@2ZJ&K2N_NO^1]Q:
MEJEAHMJUUJ5[!I]LO6:Y<(H_$U2T7QEX=\3,5T;7].U9EZK9W"R$?E7SM\9/
MA'XG_:-^)6D6U[>R6/PV6W6XDCMV(-P2.5..U>5?&/X%Z5^R+XD\*^)?AS>W
M-J\]TD,VFF1F696;!.":(+WHQGIS.R];VU"7PMPULK_A?\C[LU#4K+1[5KG4
M+R"PMEZS7#A%'XFJ>B^+= \2[AHVN6&JE?O"SG60C\J\:^,GP.UOX_W&A)J6
MK/I?A,0)+=V\#E6D; .#CM7@GC3X8Z%^S7\3_!C?"G5)KJYOKU8-0TN*4N!'
MQEB,T07--0GI=V7_  ?(4G:#G'6RO_P/4^]**;"[26\3N-KLH++Z&G4;: M5
M<****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T])_U;_6M"L_
M2?\ 5O\ 6M"@ HHHH **** /P?F_UAIE/F_UAIE<1_3ZV"BBB@84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % !8@ 9)Z
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M1WVYZ5]^VTSR0Q22KLE9 SKZ,>HK6RC0Y8N]VW\]/TZF3;E53?1)+[[GQ_\
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M[!T[_GSC_*C^T%_*'U=]SYB^SS?\\9/^^:/L\W_/&3_OFOIW^P=._P"?./\
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M-_SQD_[YKZ=_L'3O^?./\J/[!T[_ )\X_P J/[07\H?5WW/F+[/-_P \9/\
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MSC_*C^P=._Y\X_RH_M!?RA]7?<^8OL\W_/&3_OFC[-.>!!)G_=KZ=_L'3O\
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M;_6M"L_2?]6_UK0H **** "BBB@#\'YO]8:93YO]8:97$?T^M@HHHH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <EX\^[#]:Y&NN\>?=A^M<C7W.6_[K$_F'C+_D=UOE^044
M45ZA\4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %1W'^K'^\O\Q4E1W'^K'^\O\Q0!^]?P1_Y
M(MX(_P"P7#_*NTKB_@C_ ,D6\$?]@N'^5=I7P4_C?J?8Q^%!1114%!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!IZ3_JW^M:%9^D_P"K?ZUH4 %%%% !1110
M!^#\W^L-,I\W^L-,KB/Z?6P4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M_?Q/_BJ/[0H=W]P?4JW],_,/-&:_3S_AU?\ "G_H?-0_[^)_\51_PZO^%/\
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M<?\ ST- &;16E_9<?_/0T?V7'_ST- &;16E_9<?_ #T-']EQ_P#/0T +I/\
MJW^M:%06MLMLI"MNR:GH **** "BBB@#\'YO]8:93YO]8:97$?T^M@HHHH&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 8OB3Q3K?AQ8_[(U:ZTW=][[.Y7-8?_"T/&G_0U:G_
M -_C5GQY]V'ZUR-?<9;%/"QNC^8^,I/^VZVO;\CI?^%H>-/^AJU/_O\ &C_A
M:'C3_H:M3_[_ !KFJ*]/ECV/BN9]SI?^%H>-/^AJU/\ [_&C_A:'C3_H:M3_
M ._QKFJ*.6/8.9]SI?\ A:'C3_H:M3_[_&C_ (6AXT_Z&K4_^_QKFJ*.6/8.
M9]SI?^%H>-/^AJU/_O\ &C_A:'C3_H:M3_[_ !KFJ*.6/8.9]SI?^%H>-/\
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M[S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\
M?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^
MWYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4
M .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_
M 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\
MOM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM
M% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC
M_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_
M +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z
M;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>
M8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q
M_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_
M.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^=
M'F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O
M,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]
MOSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?
MG1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10
M[S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\
M?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^
MWYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4
M .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_
M 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\
MOM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM
M% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC
M_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_
M +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z
M;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>
M8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_.FT4 .\Q
M_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^='F/_ 'V_
M.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O,?\ OM^=
M'F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]OSIM% #O
M,?\ OM^='F/_ 'V_.FT4 .\Q_P"^WYT>8_\ ?;\Z;10 [S'_ +[?G1YC_P!]
MOSIM% &II+%HWR<\U?K/TG_5O]:T* "BBB@ HHHH _!^;_6&F4^;_6&F5Q']
M/K8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% ')>//NP_6N1KKO'GW8?K7(U]SEO^ZQ/Y
MAXR_Y'=;Y?D%%%%>H?%!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q_JQ_O+_,5)4=Q_JQ_
MO+_,4 ?O7\$?^2+>"/\ L%P_RKM*XOX(_P#)%O!'_8+A_E7:5\%/XWZGV,?A
M0445@>-/$C^%]*^UH@D.<8-*,7-J*&W979OT5X^/CA<_\^JT?\+PN?\ GU6N
MOZG6[&7MH=SV"BO'_P#A>%S_ ,^JT?\ "\+G_GU6CZG6[![:'<]@HKQ__A>%
MS_SZK1_PO"Y_Y]5H^IUNP>VAW/8**\?_ .%X7/\ SZK1_P +PN?^?5:/J=;L
M'MH=SV"BO'_^%X7/_/JM'_"\+G_GU6CZG6[![:'<]@HKQ_\ X7A<_P#/JM'_
M  O"Y_Y]5H^IUNP>VAW/8**\?_X7A<_\^JT?\+PN?^?5:/J=;L'MH=SV"BO'
M_P#A>%S_ ,^JT?\ "\+G_GU6CZG6[![:'<]@HKQ__A>%S_SZK1_PO"Y_Y]5H
M^IUNP>VAW/8**\?_ .%X7/\ SZK1_P +PN?^?5:/J=;L'MH=SV"BO'_^%X7/
M_/JM'_"\+G_GU6CZG6[![:'<]@HKQ_\ X7A<_P#/JM'_  O"Y_Y]5H^IUNP>
MVAW/8**YGP7XXM?%EKP1%<KUC-=-7+*,H/EDM35-25T%%%%0,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#3TG_ %;_ %K0K/TG_5O]:T* "BBB@ HHHH _!^;_ %AIE/F_UAIE
M<1_3ZV"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R7CS[L/UKD:Z[QY]V'ZUR-?<Y;_N
ML3^8>,O^1W6^7Y!1117J'Q04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<?ZL?[R_P Q4E1W
M'^K'^\O\Q0!^]?P1_P"2+>"/^P7#_*NTKB_@C_R1;P1_V"X?Y5VE?!3^-^I]
MC'X4%<-\7_\ D61_OUW-<-\7_P#D61_OUKA_XL?4FI\+/!UZ4M(O2EKZL\L*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"WI
M>J7&CWL=U;2%)%.>#UKWWP/XWM_%5BH+".\489">M?.]6]+U2XT:]CNK9RDB
M'/'>N/$8=5UYFM.HX/R/J6BN7\$>-K?Q58J"P2\489">M=17S<H2@^62U/23
M4E=!1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#3TG_5O]:T*S])_P!6_P!:T* "BBB@ HHHH _!
M^;_6&F4^;_6&F5Q']/K8****!A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')>//NP_6N1KKO'
MGW8?K7(U]SEO^ZQ/YAXR_P"1W6^7Y!1117J'Q04444 %%>__  "_9QT;XO?"
M?QOXLU#4KBSO- &888?NR<=Z^?\ =\Q&/XROZXK-34JDJ2W5K_/8T<&H*H]G
M?\!:*^C_ (@_LHVN@_#KP;K7A^\NM1UOQ 0OV-Q\H)':O!_%7A/5?!.O2:-K
M-J]IJ,9 :%Q@\THU83DXIZIM?=N.5*48J;6C5_O,BBNKU[X6^)O#.F:9?ZAI
MLL5OJ0S:_+S)]*[*R_9-^*>H:&-7A\,7;693S ?+Y(INI"*NWH)0E)I);GD5
M%>A_"/X=67B[XB#PYXD@U*!%+++%8QYF4@>E>W?!7]AFY^,'B;Q*L<EY8^'M
M-WBVEE&)9&'0$>M14K0IJ\GI:_R*C2E/1;WL?)U%?07AO]F>WLW\96GC*TUJ
MVU'1_,-J+&+*$#."_H*\\^'?P%\<_%6&>?PWH=Q>V\;E?-5..#3C6A*]GHK/
M[QRHSAHUK>QP%%=A\0/A%XM^%MRD'B72)]/9_NM(N :X^KC*,U>+NC.490=I
M*P44459 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'^K'^\O\Q4E1
MW'^K'^\O\Q0!^]?P1_Y(MX(_[!</\J[2N+^"/_)%O!'_ &"X?Y5VE?!3^-^I
M]C'X4%<-\7_^19'^_7<UPWQ?_P"19'^_6N'_ (L?4FI\+/!UZ4M(O2EKZL\L
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH MZ7JEQHUXEU:N4D4YX/6O??!'C>V\562@L([Q1\Z$]:^=ZMZ7JEQH]XE
MU:N4D4]CUKCQ&'5>/F;4ZC@_(^I:*XCPC\4=/U_RK6?,-[C!)^Z37;U\Y.G*
MF[25CT(R4E=!1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR:VJ^;Q6(]M+39'HTZ?(@HHHKB-@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#3TG_ %;_ %K0K/TG_5O]:T*
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M-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]#ZY3[/[CXWZK/NOO/SPW#U%&X>HK]#_ /AEK]EG_H>!_P!]T?\ #+7[+/\
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M)_\ #+7[+/\ T/ _[[ILG[+/[+#+@^. !D?Q^]'UVGV?W!]5GW7WGVW\$/\
MDBO@C_L%P_RKM*I^!='T;2_ ^A66DW'GZ7;VJ1VTO]^,#@UN?9;7^_7R$M9-
MGTD=(I&?16A]EM?[]'V6U_OU)1GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_
MOT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9
M]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'
MV6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_
MOT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9
M;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_
M0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT
M5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9
M;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_
M1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM
M?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[]
M&?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16
MA]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM
M?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'
MV6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_
MOT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9
M]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'
MV6U_OT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_
MOT?9;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9
M;7^_0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_
M0!GT5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT
M5H?9;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9
M;7^_1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_
M1]EM?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM
M?[] &?16A]EM?[]'V6U_OT 9]%:'V6U_OT?9;7^_0!GT5H?9;7^_1]EM?[]
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M,R''0CM7RK1N8]7=AV#,2!14_:E+NV_O+P.%6"H1H)WM?7U=PHHHIG<%%%%
M!1110 4444 %%%% ')>/"P6':[)S_"<5R6Z3_GM+_P!]FNM\>?=A^M<C7W.6
M_P"ZQ/YAXR_Y'=;Y?D+ND_Y[2_\ ?9HW2?\ /:7_ +[-)17J'Q8NZ3_GM+_W
MV:-TG_/:7_OLTE% "[I/^>TO_?9HW2?\]I?^^S244 +ND_Y[2_\ ?9HW2?\
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M1_V"X?Y5VE?!3^-^I]A'X4%%%%04%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.CZI6_E#VL.YZE17EO\ PNZ'_GU/YT?\+NA_Y]3^='U2M_*'M8=SU*BO+?\
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ML3PIXJM?%6GI-"P$P'SQ]P:VZ^<E%Q=F>@G=704445(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T])
M_P!6_P!:T*S])_U;_6M"@ HHHH **** /P?F_P!8:93YO]8:97$?T^M@HHHH
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <EX\^[#]:Y&NN\>?=A^M<C7W.6_[K$_F'C+_D=U
MOE^04445ZA\4%%%% '4?"[PA/X\^(F@Z);J6-Q=(K\?PYYK]$_B[\#_B7;_%
MKX>S>&+5?^$=\-I&LBQRJ!)@#/&:^5OV,]:\+>![[Q'XO\0WL<-Y8VSI96[C
MEW(X(KR3Q-\;/''B+Q!J.HKXLUBU2XF9UACNV"J,\ #-<-93J5H1A]G5WVN]
M/R.RCR0I3E/[6B[VW9],?\%$/A/-X7^+N@^*X;<0VNJ"+SE3D"7(SR*].^*'
M_)0_@?\ [L7]*\X\-_%SP]\7OV59=$\9:SM\5Z+<+-:RW1W22J#TR:VOB'\5
MO"=YXV^#]Q#J\<L&FK&+MQ_RSQC.:XZ<)T_9T):\D]/1IV_R.F<HU%4KK[5-
MI^J:_P"'/:/"_P /;?6/VJ/B%XDE:UBNK&V5+>>[&4B8KPQ^E<_X'\-^,]!^
M)LFM^(OCKHFL:!-*PN-'DD!C$?/RA:X&Z_:B\+^&?VI/%*7-W]N\&:[ L,ES
M&>%)7&?PK)A^!/P6\-^*KGQAJ'Q1&JZ!DSIHD9P^3SMS7+"+C&$IZ1Y$MK^J
MMW.RM)2<HQ=Y73WMT5M3U/\ 9YMM"\'_ +27Q6O?#5Q;WNFR:8UP/('R;L$\
M5XG^SCXJU_X[?M)7]MXOU:XU?2=,GGFM]/N&W1)M)( %6OV8?B]X(T?XE_$Z
M_P#/_L31;O3WAL$F.2_!Q7A/P-^+$_PJ^.D_B&TMI;^QENY!+' A8M&QY.![
M5V4:4O:M/=4XV;[Z_B<N(JITVUUF[V[61ZEXM_:\\?V_[2$<%MJLD&A6^H+:
MKI:G$7EAL8V_2OISXL:G_:G[9'PVOE7RA-I:OLQTR,UY1J7P?^"OBSXK:7X]
M@\<QVPN;J.9] 9,2^;G./SKT3]H'Q9H?A;]KSX?ZC?7*V&EQ::H#-_"N.,US
M1Y/W$%&TDI7T_NO[S5\S=>=_==K?^!+[BG\-=!L=+^*7QA\>36T=UJ6E+(]M
MYBYV-SR*^8/#/[<WC[0O%6NW&M7CZ_I=ZTD?]G77SQH#P,"O3_!7[2?AGPO^
MT!XWTW4Y_M/A#Q$[PM=+T4'^*EMO@C\!OAMK&I^,-3\<0>)].??+;Z-$H# G
MH,U5.,8)2K1O%P26E]>J]6*HW-RC2E[W.WVTZ/T1\8^(M577M>O=12!;9;F0
MR"%1@+DYQBLZMKQIJ6GZQXJU&\TFV^QZ9)(3! ?X5SQ6+7MT_@6ECR:GQRN[
MZA1116AD%%%% !1110 4444 %%%% !1110 4444 %1W'^K'^\O\ ,5)4=Q_J
MQ_O+_,4 ?O7\$?\ DBW@C_L%P_RKM*XOX(_\D6\$?]@N'^5=I7P4_C?J?8Q^
M%!7#?%__ )%D?[]=S7#?%_\ Y%D?[]:X?^+'U)J?"SP=>E+2+TI:^K/+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-/P_X@NO#>H)<VSD 'YDSP:^@O"GBJU\4Z>DT+ 3 ?/'W%?-5:?A_P 077AN
M_2YMG(P?F3/!%<.)PRK*ZW-J=1P?D?3M%8GA7Q5:^*M/6:%@)@/GCSR#6W7S
MDHN+Y6>BG=704445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+'U)J?"SP=>E+2+TI:^K/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBG1Q//(L<2EW8X"BD!I^&M<O=#U2*6R+
M,Y8 QK_%7TEIEU)>:?!-+'Y4CJ"5]*X'X<?#E-+C34+]=UPPRJ,/NUZ/7SV,
MJPJ3M%;=3T*,7%:A1117G'0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYKVI3ZAJ%PUU>SMODE<Y)-5**(TX1?-&*3!U)RCRMZ!1116AF%%%% !1110
M5'<?ZL?[R_S%25'<?ZL?[R_S% '[U_!'_DBW@C_L%P_RKM*XOX(_\D6\$?\
M8+A_E7:5\%/XWZGV,?A05PWQ?_Y%D?[]=S7(_$W2[G5_#_DVL9DDW9P*TP[2
MJQ;%/X6?/B]*6N@'@#7/^?-_RI?^$!US_GS?\J^G]K3_ )D>;RR['/45T/\
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M6AXT_P"AJU/_ +_&N:HHY8]@YGW.E_X6AXT_Z&K4_P#O\:/^%H>-/^AJU/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** -/2?]6_UK0K/TG_ %;_ %K0H **** "BBB@#\'YO]8:93YO]8:9
M7$?T^M@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <EX\^[#]:Y&NN\>?=A^M<C7W.6_[
MK$_F'C+_ )'=;Y?D%%%%>H?%!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=Q_JQ_O+_,5)4=
MQ_JQ_O+_ #% '[U_!'_DBW@C_L%P_P J[2N+^"/_ "1;P1_V"X?Y5VE?!3^-
M^I]C'X4%<-\7_P#D61_OUW-<-\7_ /D61_OUKA_XL?4FI\+/!UZ4M(O2EKZL
M\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#9\+^*+KPOJ"3Q.QAS\\>>#7T%X=\16OB73TNK9AR/F3/(KYDK9\+>*+KPOJ
M"3Q,S19^://!K@Q6&59<T=S>G4Y-'L?2]%97AWQ%;>)-.2ZMV&2/F3/(K5KY
MR2<79GH)WU04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCV/I:BLOP[XBM?$E@EQ;R*7(^= >0:U*^<DG%V9Z"=]4%%%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWBW=>KT9Z%^S#?2>-OV0_B)X=U.7SK6QA,UNTO/EL?2M+P=8^'?V3OV9]/\
M&DFB6FN>+]58B'[:F^, =.*S?B#?>&_V4?V?;[X?:=JD6J>,M:_X_FA8,(US
MTR*W(="7]JS]D?0M&\/7D#^,=%^4Z?)($+C'O7'6DYNI5I_"Y13?=):OTON=
M5&*A&G2J_$E-I/I?9>N[2/./'_[0?@'X[?#G3UU?PW;:+X\CNDVR6"!(G7/3
M%6OV[M#TW1_"/P]DL+""SDET]#(T*X+G Y-8&L_LCV_P9^&Z>*OB%K%OIOB&
M*93!I,<@=B!]*]J_:"^#6L_M-?"/P#K/@.:UU$VMHD-S TRJT6,9)S53=*,H
M.D_=4]>RT%3522E&HM7%V[O5?TCAO%6@Z7#^PWX<OX]/@2_;45#7(7YR-P[U
MT?[8%OIUYX2^!L6KK))IS11>:D7WF&!P*V?V@/!=M\._V,?#.A#4+>\O8;Y/
MM"QR E'W#(XK0^-5[X?@NO@!)KLT$FG+''O^8,%; QD4E)5,1S1>GM/_ &QA
MRN%!*2L_9O\ ]*1NZ=JWCJ'4]+T[P#\)]+L/!B+&)+W6(5,DJXY(S7"?M=?"
M'0_"WQT^%^KV>FPVC:I-&;VVB4")F.,\5U'QT\ _&WQ9\3K6[T77XK+X=+Y;
MI<6]V$1(@.?E^E3?M=&U_P"$H^"RVNI1:E##/$CW2R [CQR:YZ4OWE&:>KEK
MWL[[FU2/+"K!ZI1^738P/VT/COI_P1\41^#?"_A+1V2^L5>YN)H 77(_A-?!
MWAF<W'CC3;@C:9;U'*CH,L.*^B?^"CCQR?'VU,<L<J_V<GS1L&'0>E?.7@_'
M_"7:-DX'VN/K_O"O3RR"]G"IU>_WGGYC-WE36R7Z'Z"_M9?LPZU\9H?!^HZ=
MJ]C81QV2 I<N ?NCWK ^ _PITG]CO3/$GC'Q7XJL;B_N+)[6WL;=P2Y(],UQ
M?[?WB#4;&^\%IIVLSV\?V%<K:SX'W1UQ7Q]J6KZEJL>V^U&ZO@.BSR%@/SKE
MH4JE6A*"E:+<D].EW<ZZTX4ZE.4HW:47^&A]H_L\ZU;2Z%XB\0^#OA^_B[QK
M?73NIN4#01*3UYKWRZ^&FM?%KX'^+&^)7A31]&U>RMFFM?[+C564A2<'%><?
M"&WUSQ!^R3:Z?\'[JWMO&"S$WJB01R,OUKT/]GGPCXH\#_"_X@0^/_$R7WB:
M]L9/] EN0YB^0]#FN7'>ZJR6CC:W?2VWD;81W=*;UYF[]M7]H\+\/^&=)_X9
M#L;A]-MWO%U58OM#+\Y4-C&:]+_:6^-&@?LW^&_ [Z'X/TF]UR[L$>1KF$,N
MT@9_&N'T62-/V0K=&FB$@UKE"XS]_P!*X_\ X*,2123?#HQRQRXTA ?+8-CI
MUK>HN?$.+V<__;#.E[L$^JIR_P#2C<_:RT7P]\1_@-X;^)UEI%OHVK73".XB
MM4VH3[5\1*VY0:^W/BK+$?V%O"J":,R?:.4#C=^5?$4?^K7Z5VX5<LJL%LI.
MQQXB3G"E-[N(ZBBBO0.$**** "BBB@ HHHH *CN/]6/]Y?YBI*CN/]6/]Y?Y
MB@#]Z_@C_P D6\$?]@N'^5=I7%_!'_DBW@C_ +!</\J[2O@I_&_4^QC\*"N&
M^+__ "+(_P!^NYKAOB__ ,BR/]^M</\ Q8^I-3X6>#KTI:1>E+7U9Y84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44JJTC!5&YF. !0!M>$_$UYX9U))+7+JY :/UKZ-TZZ:^L89V0QM(H)4UYM\
M-_AL+=4U'4X\R'F.,]O>O4>%  & . *^=QM2$Y^[NNIZ%&,HK4****\XZ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUCU+4D#,>4C;M7J/   & .@KQ,7BK_NZ9VTJ7VI!T  & .@HHHKQSK"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#3TG_ %;_ %K0K/TG_5O]:T* "BBB@ HHHH _!^;_ %AIE/F_UAIE
M<1_3ZV"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R7CS[L/UKD:Z[QY]V'ZUR-?<Y;_N
ML3^8>,O^1W6^7Y!1117J'Q04444 %%%% !1110 4444 %%%% !1110 4444
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MG/*1,.E+\./AK]EVZCJ:9E_@B8=*]0X   P!T KR,5B[_NZ9UTJ7VI!P. ,
M=!1117CG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &GI/^K?ZUH5GZ3_ *M_K6A0 4444 %%%% 'X/S?ZPTROKIO^";_ (R=
MB?[9A'X4G_#MSQE_T&8?RKDY)=C^@5GV6?\ /]?B?(U%?7/_  [<\9?]!F'\
MJ/\ AVYXR_Z#,/Y4<DNP_P"WLL_Y_K\3Y&HKZY_X=N>,O^@S#^5'_#MSQE_T
M&8?RHY)=@_M[+/\ G^OQ/D:BOKG_ (=N>,O^@S#^5'_#MSQE_P!!F'\J.278
M/[>RS_G^OQ/D:BOKG_AVYXR_Z#,/Y4?\.W/&7_09A_*CDEV#^WLL_P"?Z_$^
M1J*^N?\ AVYXR_Z#,/Y4?\.W/&7_ $&8?RHY)=@_M[+/^?Z_$^1J*^N?^';G
MC+_H,P_E1_P[<\9?]!F'\J.278/[>RS_ )_K\3Y&HKZY_P"';GC+_H,P_E1_
MP[<\9?\ 09A_*CDEV#^WLL_Y_K\3Y&HKZY_X=N>,O^@S#^5'_#MSQE_T&8?R
MHY)=@_M[+/\ G^OQ/D:BOKG_ (=N>,O^@S#^5'_#MSQE_P!!F'\J.278/[>R
MS_G^OQ/D:BOKG_AVYXR_Z#,/Y4?\.W/&7_09A_*CDEV#^WLL_P"?Z_$^1J*^
MN?\ AVYXR_Z#,/Y4?\.W/&7_ $&8?RHY)=@_M[+/^?Z_$^1J*^N?^';GC+_H
M,P_E1_P[<\9?]!F'\J.278/[>RS_ )_K\3Y&HKZY_P"';GC+_H,P_E1_P[<\
M9?\ 09A_*CDEV#^WLL_Y_K\3Y&HKZY_X=N>,O^@S#^5'_#MSQE_T&8?RHY)=
M@_M[+/\ G^OQ/D:BOKG_ (=N>,O^@S#^5'_#MSQE_P!!F'\J.278/[>RS_G^
MOQ/D:BOKG_AVYXR_Z#,/Y4?\.W/&7_09A_*CDEV#^WLL_P"?Z_$^&?'GW8?K
M7(U]@_M!?L'^-OA_X9BU>.;^U\/M-O F6_2OG!?@OXZ90?\ A&K[_OTW^%?:
MY;**PT4V?SUQ55ABLVJUJ+YHNUG\CC:*[/\ X4MXZ_Z%J]_[]-_A1_PI;QU_
MT+5[_P!^F_PKT^>/<^2Y)=CC**[/_A2WCK_H6KW_ +]-_A1_PI;QU_T+5[_W
MZ;_"CGCW#DEV.,HKL_\ A2WCK_H6KW_OTW^%'_"EO'7_ $+5[_WZ;_"CGCW#
MDEV.,HKL_P#A2WCK_H6KW_OTW^%'_"EO'7_0M7O_ 'Z;_"CGCW#DEV.,HKL_
M^%+>.O\ H6KW_OTW^%'_  I;QU_T+5[_ -^F_P *.>/<.278XRBNS_X4MXZ_
MZ%J]_P"_3?X4?\*6\=?]"U>_]^F_PHYX]PY)=CC**[/_ (4MXZ_Z%J]_[]-_
MA1_PI;QU_P!"U>_]^F_PHYX]PY)=CC**[/\ X4MXZ_Z%J]_[]-_A1_PI;QU_
MT+5[_P!^F_PHYX]PY)=CC**[/_A2WCK_ *%J]_[]-_A1_P *6\=?]"U>_P#?
MIO\ "CGCW#DEV.,HKL_^%+>.O^A:O?\ OTW^%'_"EO'7_0M7O_?IO\*.>/<.
M278XRBNS_P"%+>.O^A:O?^_3?X4?\*6\=?\ 0M7O_?IO\*.>/<.278XRBNS_
M .%+>.O^A:O?^_3?X4?\*6\=?]"U>_\ ?IO\*.>/<.278XRBNS_X4MXZ_P"A
M:O?^_3?X4?\ "EO'7_0M7O\ WZ;_  HYX]PY)=CC**[/_A2WCK_H6KW_ +]-
M_A1_PI;QU_T+5[_WZ;_"CGCW#DEV.,HKL_\ A2WCK_H6KW_OTW^%'_"EO'7_
M $+5[_WZ;_"CGCW#DEV.,HKL_P#A2WCK_H6KW_OTW^%'_"EO'7_0M7O_ 'Z;
M_"CGCW#DEV.,J.X_U8_WE_F*[?\ X4MXZ_Z%J]_[]-_A4<_P5\=L@ \-7Q.X
M?\LF]?I1SQ[AR2['[<?!'_DBW@C_ +!</\J[2N3^#>GW%C\'_!MM<1-%/%IL
M2O&PP5('2NO\E_[IKX6?Q/U/KH_"AE%/\E_[IH\E_P"Z:@H913_)?^Z:/)?^
MZ: &44_R7_NFCR7_ +IH 913_)?^Z:/)?^Z: &44_P E_P"Z:/)?^Z: &44_
MR7_NFCR7_NF@!E%/\E_[IH\E_P"Z: &44_R7_NFCR7_NF@!E%/\ )?\ NFCR
M7_NF@!E%/\E_[IH\E_[IH 913_)?^Z:/)?\ NF@!E%/\E_[IH\E_[IH 913_
M "7_ +IH\E_[IH 913_)?^Z:/)?^Z: &44_R7_NFCR7_ +IH 913_)?^Z:/)
M?^Z: &44_P E_P"Z:/)?^Z: &44_R7_NFCR7_NF@!E%/\E_[IH\E_P"Z: &4
M4_R7_NFCR7_NF@!E%/\ )?\ NFCR7_NF@!E%/\E_[IH\E_[IH 913_)?^Z:/
M)?\ NF@!E%/\E_[IH\E_[IH 913_ "7_ +IH\E_[IH 913_)?^Z:/)?^Z: &
M44_R7_NFCR7_ +IH 913_)?^Z:/)?^Z: &44_P E_P"Z:/)?^Z: &44_R7_N
MFCR7_NF@!E%/\E_[IH\E_P"Z: &44_R7_NFCR7_NF@!E%/\ )?\ NFCR7_NF
M@!E%/\E_[IH\E_[IH 913_)?^Z:/)?\ NF@!E%/\E_[IH\E_[IH 913_ "7_
M +IH\E_[IH 913_)?^Z:/)?^Z: &44_R7_NFCR7_ +IH 913_)?^Z:/)?^Z:
M &44_P E_P"Z:/)?^Z: &44_R7_NFCR7_NF@!E%/\E_[IH\E_P"Z: &44_R7
M_NFCR7_NF@!E%/\ )?\ NFCR7_NF@!E%/\E_[IH\E_[IH 913_)?^Z:/)?\
MNF@!E%/\E_[IH\E_[IH 913_ "7_ +IH\E_[IH 913_)?^Z:/)?^Z: &44_R
M7_NFCR7_ +IH 913_)?^Z:/)?^Z: &44_P E_P"Z:/)?^Z: &44_R7_NFCR7
M_NF@!E%/\E_[IH\E_P"Z: &44_R7_NFCR7_NF@!E%/\ )?\ NFCR7_NF@!E%
M/\E_[IH\E_[IH 913_)?^Z:/)?\ NF@!E%/\E_[IH\E_[IH 913_ "7_ +IH
M\E_[IH 913_)?^Z:/)?^Z: &44_R7_NFCR7_ +IH 913_)?^Z:/)?^Z: &44
M_P E_P"Z:/)?^Z: &44_R7_NFCR7_NF@!E%/\E_[IH\E_P"Z: &44_R7_NFC
MR7_NF@!E%/\ )?\ NFCR7_NF@!E%/\E_[IH\E_[IH 913_)?^Z:/)?\ NF@!
ME%/\E_[IH\E_[IH 913_ "7_ +IH\E_[IH 913_)?^Z:/)?^Z: &44_R7_NF
MCR7_ +IH 913_)?^Z:/)?^Z: &44_P E_P"Z:/)?^Z: &44_R7_NFCR7_NF@
M!E%/\E_[IH\E_P"Z: &44_R7_NFCR7_NF@!E%/\ )?\ NFCR7_NF@!E%/\E_
M[IH\E_[IH 913_)?^Z:/)?\ NF@!E%/\E_[IH\E_[IH 913_ "7_ +IH\E_[
MIH 913_)?^Z:/)?^Z: -#2?]6_UK0JAI2E8WR,<U?H **** "BBB@!!TI:1>
ME+0 4444 %%%% !1110 445STWCS1K?QA#X8DNU76)HO/2WSR4]:.M@\SH:*
MX3XC?&SPA\*;BP@\2:M%I\M\XC@60X+DTWXA?'#P?\+]'T_5/$>K1:?8WV/(
MED. V>E'2_2]OF/E=['>T5E^'?$NF^*]#MM7TJZ2\T^X3S(YHSE6%<IX3^.G
M@WQMXSU+PKI&KPW>MZ?G[1:H?F3'7-.SYN7J3=6YNAW]%>*^-/VP_A7\/]>N
M-&UOQ1:V>H0'$D3L,J:L> _VMOA9\2-4_L[1/%EC<7G\,9D +?2E'W_AU'+W
M?BT/8J*0,& (.0>AILTR6\3R2.L<:C+,QP /6@!]%>*^*_VQOA)X-UPZ3J7C
M"Q2\4X95D!P?2O3_  CXTT3QUI$6IZ#J4&IV4@RLL#AA0O>7,M@?NNS-NBBB
M@ HK@_$7QN\(>%O&EEX4U+58K?6[S'DVS'ELUW8.X CI1NKAUMU%HHHH ***
MR?%7BC3?!F@W>L:O<K::?:KOEF?HHI-J*NQI-NR-:BN7^'GQ(T#XI>'X]:\.
M7R:AISDJLT9R"172K,DC,JNK,O! /2J::=F2FGJA]%,\U/,\O>N_&=N>:?2&
M%%%% #)H8[A=LL:R+_==015?^R;'_GSM_P#OTO\ A7'?$+XW>#_A?J.GV/B+
M5H;"ZOW"6\<AP7)]*[>UN8[RVBGB;=%*H=6]01D4U=KF6P/1V9#_ &39?\^=
MO_WZ7_"C^R;+_GSM_P#OTO\ A5B25(5W.RHO3+'%.!SR.E %7^R;+_GSM_\
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M_"K=% #5154*J@*.  .!2[1Z4M%(!-H]*-H]*6F33);PO+*P2- 69F.  .]
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M1R:U/^"I.GG4O@#\-;6,9EDCA5/J5&*?_P %8 %\:?#, 8 OH\#_ ($*N_\
M!2=BOPB^$A'4/;?R6JBO:89)]:W^1T5&Z<H-=*3_ %)O^"9/QRU/18[OX,^+
MV>+4[*#S; S'[T9&<#-<Q^PS"L?_  4(^+9 P=TU:_[6'PEOO /@/P+\=O!R
M-%K.DVT(OHX!AI4*C.<?C7GG_!+OQL_Q(_:T\;>)Y(_)DU*V>5D]#BNNG+VF
M)E)_%&,XO\+/YH\B:Y,-&WPRE!KRUU7R9!H7P#\)_M _\%!/'6A>+8))[")6
MD5(VQELUW?[87_!/3PI\&?AG/X\^&US=:'JFCL)GQ(?G .:E_9_OK73_ /@I
M)X^DN[J"TC\IL-/($!]LFOH7_@H?\6_#'A_]G'7]/DU>TFOM13R;>WAF5W9C
M[ UY;_=X*C*&CMT[\QZD?>QE6,]5?\+(Z[]A?XO7GQD_9_T+5=1E\_48D\F:
M0G)8@8R:W/VQI]>MOV=_&,OAQI$U%;-R&B^\!CG%>8?\$R? ]]X-_9KTIKZ)
MX9+QC,J2#!VFO6OVH/C8/@+\,;OQ-+X<E\2V<9V7%I%S\AZDC'2NS,HQYYQO
M:]OO_P"'.7 2E:+2O:Y^5W[*OAC]FKXB>#?L_P 4=2N[/QR[LLTUXY'S<\\U
M]M?L0?LX:U\%_$FLZAH?C^S\4?#J]):SLX9-[P^@/I7-Z3\ _P!G#]LWP&GC
M:RM;+PUJ%]&?.2.X2)H'[Y&:\7_8PN+_ ."W[:VI_"_PSXCF\1^#=AW2"0R1
MH<=CTK6$I>VE3:Y9.+TZ:+^K&<[>Q]HGS137KJS[9\$_MH^&_''[1&K_  BM
M=(OH=8TT,7O)"/*; R<<9J3XK?ME>&_A/\9-"^'>H:3?7.HZN0(KB''EKGUX
MKX^^!!2S_P""J7CA)G6$E)=H<XSQVI_[8^I6EW^WE\.HH+B.:1)$#*C [>>]
M<]/WGA+_ /+S?\?\C65XO$_W-ON1#^VGX@T_PI^W1X%UG46V6T*(YZY/3BOH
MFT_X*0>$+'QI9Z!X@\,:QX<M;MQ%:ZI>KB"8DX!'%?.G[:$6DS?MU?#E=:\O
M[#B+=YV-O;KFO4/^"J.G^'8_V?=(FMH;)+V.XC^Q-"%W]L;<5$)>SPU.3U7,
MU;U=BHT_;8J44[-Q3O\ (]\_:2_;$\+?LU:?X=O]9L;K4K+6F40S69&%#=&/
M'2O-?%7_  4R\&>$=8TZ.]\+ZT-#O=NW6MN+=<^O%?*'[8[:CJ'[-_P(&MAF
MN9'@5Q+U*\8S^%>R?\%!/#^EZ=^Q1X72VT^W@&(?F2, ]!WK2<?9>TOKRU.7
MU6AG&:FZ<;6YH.7W,]2\:_\ !2GP7X5-I>6GAS6-;\.S$>9K5JO[B+/]XXKT
MSXF?%3P+\0/V9]5\7WL<VL>#[BU,DT5L?G9<<@>]?-WBKPWI6G_\$O[TV^G6
M\;-I(<L(QNW<<Y]:YKX"RO-_P2MU;>Q;:EP!GL.*G$Q4*6)CNZ=OG<O#S]I*
MA-:*?Z'HGA#X\^$OAS^Q'>>*_A=X6U2/2OWD4%H>98F/&\^PKSO]@G]L;Q#J
M7AGQ)!KOAC7O$%XK/>?V@IW)@9_=C(ZUT?['\4<G_!.W6A)&L@%M<'##/K71
M?\$K4M9/@GKN4A>7[>X.0"V,MQ]*Z))JKB%?:,?QL9Q=Z%-V^TT>%?LF_MI^
M*]6_:?\ %\6M:'KFNVNHW!M[>SA.1IZ[NK#M7VQ\=OVSO"OP1OK/2FT^\\1^
M(+I XTK3?FE7/8\&OE/_ ()XI;?\-;?&Y62$2+<2%%8#(^?M7D&D:E\1Y/V[
MO&;^%[2WU#6D8B*/4\%57/&W=67Q>PI+K"]_1;?\$UG[D\1-_9E;[WO_ , _
M0SX!_MF>%?CIK$VAC3[SPSX@BY.F:I\LI^G J#]H7]MKP?\  '7[/P_/97GB
M+Q#=?<TW3?FD_'@U\6+X7^)6K?M@>&-<\2R6.EZ[ P62ST\ >8N>K8K?^#-O
MIVI?\%&O%'_"5+'+=1H?L:WV,#C^'-$8^UE22TNI-]?A[>I$I>R51O6W+;I\
M7?T/.OVY?C7I?QJ^*7PPGATR[T:^AO(S)8WP(E4;AUZ5^M/@WCPEHW_7G%_Z
M *_-#_@IW8^'[?XY_#.6Q2VCU5KN,2^0%#%=PZXK],/!W_(IZ-_UYQ?^@"KI
M-/!NRM[\OR159-8B-W?W%^9^:O[<G[87BKPS^T1H7AK3-(U>WTK2KA6GB@)'
MV_G^'UK[KT7]H#18O@U!X_\ $EK/X5T_R!(]MJ!Q(O'3ZU\:?MYQV\?[6/PL
M+QQJ&F7<6 &[GO6S_P %:;B[A^$O@R&%FCT&348A=>1]S;D<'':N>G)_5(+K
M*;C?MJE?^MC:I%>WOT4;V^3T.V7_ (*>>%3?"9O!/B!?#A?:-=*?Z.1G&?N]
M*^L? ?CW1?B3X9M-=T&\CO=/N4#(Z'./8UXI<:'X#_X9"CBFM]+&B_V$I#83
M&[9USZYKPW_@DC<ZE)X \5Q2O.^D1W[BR\W.W;NXV^V*Z8QBY5:76"3OWUL<
MKD_9TZO\SM;Y7/J_]IS_ )(+XVXS_P 2V;_T$U^6_P"Q#\ OV>?B%\*[G4OB
M1J]M9ZZ+MD$<T^PA 3BOU(_:;;;\!O&I_P"H;-_Z":_,3]A7]@'P?^T=\*;O
MQ+KNH7EO=+=M$$MY"HQD]OPKEHI^TK.W2/RU9K5:Y:2;ZR^>A]S?L_\ [/7P
M8^'&EZ]K7PNNXKYI+62.66&;S /E/%?%'[(O[*?@/]HKXQ?$IO&%I+<FUO)#
M$J-@?>K[_P#@3^RWH'[,/@'7]+T&ZN+J&ZBD=C<.6(.TU\K_ /!-O5+'3OC!
M\5#>7UM:$WCX$\JH3\W;)K:GRRQ+N[VI_=J92YHT;VM>:^9P'[9O[).G?L9V
MFB_%'X8:A=:2EI=QQW%MYA^?)Z?2OT7^$?Q3B\5_ ?0_&]\X5)M-%U,Q/H.:
M^1?^"LOQ.T'5/@[8>"M.U"WU'7-1OHC';VL@D8 'V-)\;/&]U^SG_P $Y_#.
MEN[0ZM?6$=D(\X<%O;\16/M)+!U7O:=H_-;?>=/LXRQ-);7B[^B>Y\A^(/@W
MJW[5.M?%WXJF28PZ+.YL=N>=C$C^5?I9_P $_?C"?BU^S_H[7,PDU+35^R3K
MGD;0 ,U^=O[/_C[]I#X9?">;0/#OP^_M#1-61I6N)(N95<'D_G7H/_!+WQYK
M7PN^.'BGP-XOMI-)O-:;SX[.8[1&Y.3@5VT8I.6&CMRJW^*._P!YRUIN26(E
MOS._^%[?<?K37A'[0'[8'@[X 7MOI=^D^L:_<KNATJQ^:9_;O7NKYV-MZXXK
M\P?A!'9ZQ_P4:\3CQL(YKF+=_9Z7^-HZXV[JY(IU*T:2=KIO[NAM*2ITI56K
MVLOO/J'X/_M[>$?B5XHM_#>L:-J/@C7KDX@L]8PK2>F.!6]^T)^V7X4_9Q\5
M:%HOB*QNY?[6.([J#&Q/KQ7R]_P5'L]"L/$WP[O-'$,/BW[?&(S9@"8KN'7'
M.*X_]O.&75/&WP-CU9/-FD$'G)(,Y/&<U4/WWLN72\^1^?FC3DY7.+?V')>3
M/HS5O^"EW@_0/%=CIVI^%M:L='O65(-<E7%NQ/3M7UOH>M6GB+1[34[&436=
MU&)8I%Z%37PG_P %1/#NE:?^R'I;VNGV]N\,]KY;11A2G Z8KZ>_9*=I/V<?
M 3.Q=CIL>6;K5Q2E3F^L96]5:YS2DXSI]I1;^:=CQ?\ X*G1B7]F+44(SNDP
M/J<5\L_\$P?C)JWP9\41> /&#26^E:^BRZ7)*<(K'G S7U/_ ,%2_P#DV:]_
MZ[K_ #%>&>/O@#<_$/\ 8S^'OCCPX#!XG\+Q)=H\(P\BJ 2,BLL/-4?;59?#
M>*?HUO\ +1F]>+K.C16C:DUZIK\]C,MX4/\ P5)G<#.Y<@Y[<U]I_M ?M@>#
MOV?[ZWTJ_CN-9\07*[H=*L?FF?T'>OS0_9%^+%U\9?VU]+UZ[@:#4%M_)D5N
MI91BO:/A#'9ZQ_P4:\4?\)L(YKF$'^STU#!4>FW=6\:<N2AA[])._H^GJ<?.
ME4KUVNL5;U74^G_@]^WMX1^)GBBW\-:QHVH^"->N3B"SU@!6D],<"MWQ_P#M
MC>'?AQ\=]$^&6K:1?1W>K8\C4^!;\]NE?+W_  5(M-"T_P 4?#N]T80P>+OM
M\8C-G@3%=PZXYQ74_MX?#*_UK]GWP;\1;>-AXD\-QVT\CJ/WC+@%LFL8SBX1
MK25HJ?++T[K[]3L<'S.FGJXW7KV/I;]IC]I[P]^S'X+MO$.M6EQJ8N9EAAM+
M,CS'+="/:J7CK]K3PI\.?A1HOC;7(;BU_M:)7M=+/_'PQ/1<>OX5\"V_Q';]
MN;X[?"[P[ [3:5I%ND]^#RF]!R#5_P#X*$?\)#IO[4'P]TO1H8WM[9(UL[>Y
M_P"/<L, <'BFXN/+"6\YM+_"O\WL3&2DW);1BF_5]/EU/JWX9_\ !0KPIXV\
M46>AZ[X;U;P5-?-MLYM7&U)\],<"NF_:&_;6\)?LX>+/#NB>(-/O+G^VO]3=
M6^-B^F>*^&OVL/#GQ@\<6O@Z+QM%I6@&UO(Y+":S"B1CD<#':K_[?-C)=?$G
MX!6>J#SY MNDN_G?@CDU45SRI+:\^5^EOS[DRDH1G)ZVAS>CO^1]+ZI_P4T\
M%^&_%EEI6N^&=9T>PO2/L^JW  A<'N.*F\7?\%*O!G@_Q+96=QX:UB70[IE1
M->1<6P)]\5XG_P %7-#TZW\$_#2*&Q@A3SX5_=QA>/2MK]NC0=,TO]A/PS]D
ML+>!A'"0R1@-G YS4)KV;J/[,U'UN4O>JQI?S1<O2QZ%_P %(/$%AXQ_9!GU
MC3Y1<:?=[)HY%/!4X-<#\#/VY/#_ ,&?V>O"=M_PBVL:]96MNJW-]8+F*'@9
M)X-<_P#&J9YO^"8NAM*Q;]Q&"3Z9KW#]E72_!TW[$%D/)TY[1M,E,YD"?>V?
MQ9[U<HO#K%*+TC)?/W11E[989R6LE+\SWGX3_'SPE\8/AZOC'1;]1I2H7F\Q
M@##@<AJ\!\3?\%*O"FD:_>VFD^$=<\1:792>7<:M8IF"/!Y.<5\9? :^UVQ_
M9Q^-J:.9DTA;F40F#. N3]W%;?[)]Y\9S^SS<Q^&M(T>Y\.RK(+FXN@ADYSD
MMFE4^*<H[*,96_Q=WT0H/2,9;N3C?T[=V?I=X1^/7AGQU\+[CQQHDQO=.MX&
MFEA0_O$P,E3[U\\^'_\ @IMX7\91HOASP7KVMW@NS:3VUL 6APV-S<=*\G_8
M>\*ZUX5^$GQ92_OEO+2>*:4+%_JXW(.0*U/^"2'AW3_^$;\;ZBUK%)=RZBX,
MCH"<!NU:*"=::^RHQE][U1+DXTHM[\SC\DMS]!](OVU32[6\:![9IXUD,,GW
MDR,X/O7R-^VU=?&;Q=J'_"&?#Q!INA3V32W^L'@H,<J#7V)6'XZ^7P=K1'!^
MR2?^@FN2M;E<NBOH=-"ZDEU>A^<__!(?2YM%UOX@6-U.;J\M[AHYIR2=[!N3
M6=_P41TN;Q+^T]X)TCQE?W6F_#BX*B>96*Q>^:Z3_@E9_P CY\4O^OZ3_P!"
MK#_;@\2-\</VM/#?P5UZX@T7PJ0KR7\V%+$\\,>E==:\ZF%LKNT7;I\.IG&*
MA]:5[).6O5:H\TD\!^$OA;^V!X'L_@/K$FH6LX0WJVLA9-O?-?L+;[_(C\S[
M^T;OKCFOR(USX?Z+^PM^TMX*/@'5X/$0U=EAGAWB9T!..HZ5^M%GKUI-;VGG
MW,$%S/&KB!Y%#\C/ SFA-2PT+.]G+?O?;T70RE_'::M[J_X?U-.OBW]HC]AG
MQ'^TA\<K#6_$?B=?^$"M@!_8\9(8U]I5\U?MC_M:67[/>@VFEZ>L=[XKUDF"
MRM]X&QCP&/I7+*T91E:[Z+NSHBI24HIV3W?D?#?QG^"^C_LN_M>?#/2/A1?7
M5N=0E3[=9QR%@!NYW8]J](_;KDOOC9^UG\/OA++?36WA^:))K^&-B ^<$BO4
M?V1?V8XM!\4/\3/B5XFT_P 0>-=3/G6\#W*/]E#<A1SUYKRC]IJ]@\ _\%(/
MA_J^J/\ 9]/OH4C6XDX0'/<UU4X_O,/0JZV<F^U[72^1SSD^6O6HZ>ZDN^^L
MCEOBM\&],_8C_:K^&UYX$N+FTT/4ITBNK1I"0Y) .:^C/VB_V*O$W[4'QET+
M7M6\4K!\.HX4>71T)$C9&?I7DO[?VM6/CS]IWX3>'-'NHM1N_M4<C?99!)M&
M1U(KZ5_:K_:DM?V;? 6FZ78B.]\7ZA EO96C.!M;:!N/XUC&5\/"<]6IR4?/
MR^^YM*/^T.%/1."OY;Z_<?$WQO\ @=X=_9:_:@^'EG\*[ZXMKZ[F07=G')N.
MW/.0*^IOVF_V-?&'[3WQ \,WFI^*([/P5:QH;S25R&D.!FL']D;]F-;7QB?B
MW\3O$UAKGC75!YL%DURCBU#<A0,]>:]J_:Z_:HTS]FSP3%<1K'?:_J#>18V8
M< [CP&/M53_=4Z<)^])-OOJ_L^=B8?O*LW3TBTE\EN_(^!_VHOV??#7[*OQK
M^&P^%5[=6FK7MZB7-G'+N.W(Y(%?K1X?DFET'37N/]>UM&9,_P![:,_K7PM^
MRC^S5)K'C@_&#XK>)[#6/$.I?O['3)+I&%H#R!@GK7WNFW:NW&W'&.F*U]ZG
M1C2F[RNV_*_3Y&;Y95G4I_#9+UMU'4445@:!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (O2EI%Z4M !1110 44
M44 %%%% !1110!\V?M5_L:VG[3NL^&]0N/$$^C-HTZS*D4>X28(.#^53?M'?
ML>VG[0GA'PIH=QK\VE+H)C*S1IN,NS'7\J^C:*(^['D6U^;Y]RI2<M7VM\NQ
MQO\ PK'3KOX8KX+U'%]8?8_LCM(OWAMQNQZU\]?LM?\ !/\ TK]F#XHZSXMT
MSQ'/J$-^CQI8R1!5B#'L>]?6]%4I-5'56[T?S,^5>S5+[*LU\CX#^-?_  2K
MM_BW\4-6\90?$/4-#GOWWM#;Q#Y?;-0_#/\ X)'^&_#'B:WU3Q7XSU/QC!;N
MKQ6EWD("#G/6OT"HJ:?[E)0Z%S?M&W+J5-)TFUT/3;>PL85M[2W01QQH,!5
MP*J>*O"^G>-/#]]HNK6R76GWD1BEC<9!!K6HHE[]^;6XH^[;ETL?GAXT_P""
M0/A_5/$$]WX8\>:MX6TV9MQT^VR4'TYKZ'_9@_8I\&?LRQRW.F&35-;F&)=2
MNN9&KZ(HJH2=-6B*:51WD?)7QT_8%T_XG?%!/B%X9\47?@OQ0W^NN[1-WF#W
MK!_X=MZ;)\1_#OC:Y\87UUK6F.LD\LJY^T,/7GBOM.BE3?LK<G3;R'/]Y?FZ
MZ'RC^T)^P/HO[0?Q2TOQAJFOW-G]AB5%M85X)'0YKFH?^"<46N>,[#4O&?CS
M4?%.AZ=('LM'N%Q'%@\#KS7VG12A^[MR]-?F$O>O<^;_ -J/]C73OVD-.\*V
M0UJ7P_;:!*CPQV\8(8*>%K4_:"_94M?CQ\&=,\ SZW-ID5CLQ=QIN9MH Z?A
M7OE%*RY7'HW?Y]Q67,I=4K?+L>$:U^RY;:Q^S)-\(&UJ9+>2T%I_:(3YP/7%
M8O@/]C>T\$_LNWGP<7Q#-<V]P) =2,8#C?[5](T54W[134OM[^=@@E34%'[.
MWD>'_ 7]E_3_ (+_  1F^'$NIR:U8S+(CW$J[6(;VKS_ /9\_8<N?V?/B1?Z
MYI'CF]N/#MT[/_8+QXC4G/?\:^L**KF?.ZG5JWR)Y5R>SZ7O\SX_N/\ @G^N
MD_'>Y^)'A'QM>>&Y+Z;S;ZPACRD^3D@G-=%\<_V'=(^*GB*U\4:%KUUX/\6P
MH%;5+(?-(1W(%?3U%9VM&,%M';R-7)RE*3WEOYGS1^S[^Q=9?"'Q1/XJ\0>)
M+SQIXHD^[J%YD;/H,U!^T=^P[HWQP\76/B[2=;N/"'BJU&%U&R7EOJ.]?3U%
M5+WG%O[.WD3'W>:W7<^'?$W_  3+M/&6I:!K.M>.M0O_ !!IDZRO?2IGS@"#
MMQGCI7VMH^GC2=)L[(/Y@MX5BW'OM &:N457,^7DZ7O\Q65U)[I6/G+]J[]C
MC3OVF/[+O4UN?PWKNFMNM]0MUW,M=)#^S3IWB#X)1?#SQUJ#^+HUCVM?7"X<
MMCAOK7M-%9I)0=/H]2FVY*?5'PNW_!-.\?;I#_%#5F\%JW&AE3M"Y^[G/2OK
MOX8?"_0/A'X3L_#WAZS2TL;=0ORCECZFNMHJ^:2BXWW(Y5=/L<Q\3/!2?$;P
M)K7AN2Y:T34K9[<S*,E-PQFO-_V2_P!F>W_9;^'L_A>VUF76TEN#/Y\J;2,Y
MXQ^->WT5,?=YFOM6O\AR2ERWZ;?,K:E9C4-/N;4ML$T;1EO3(Q7YU^*O^"/\
M&O>+M6URT^)^J:6U_.TS1V\6,9.<9!K]':*CE7-S]=B^9VY>A\/_  )_X);^
M$OA7XMMO$/B'Q#>^-;ZV;=#]OY5#VX->E?M3?L9V_P"TWJGAMKSQ)/I&DZ/*
ML@T^&,%)<=C7TM16KDY<M_LNZ]2(KEYK?:5GZ&3X;\-VGAK0-/TJWB3R+.!8
M$^0#A1BOG'XL?L-V'Q$^/6B?%#3_ !%/H&HZ>RF2WMXQMFQZFOJ2BCF?M%5^
MTM0LN1T^C5AD,9BAC0MN*J 6]<#K7SI^T+^Q7X<^-^OV_B:SOYO#/BRW7$6J
M68PP/J0.M?1U%9RBI--[HI.R:Z'R1\)_V [#PSXTM/%OCSQ5=_$'7K-MUM-?
M+A8\=.*Z7]H_]C:S_:"\<^%/$<NOS:0V@RK(EO%&"LF#G'M7TE16G,[PE_*[
MKR8H^[S6^TK/T/#OVH?V9+?]I3X1P>![C69='CBDBD%U$@8G8!VKT/X3^ 4^
M%OPZT'PK'=->QZ7;+;BX<8+X[FNNHI)M*275W?J)I-Q;^RK+T/(/VH/V?;?]
MI+X:S^$KC59-'CD</]HB7<1C';\*W_A'\);;X7_"K3O!+71U.UM;<V[32K@R
M*1@Y%>@44E[L916TK7^0Y>\XR>\;V^9\;?#+_@G#H/PK_:"G^)6C^(IXXI)&
MD72O* 12QR>:[O\ :&_8K\.?'#Q!;^)K._F\,^++==L.J68PP/8D#K7T=12M
M[L8=([>0?;E/K+?S/DCX3_L!6'AGQI:>+?'GBJ[^(.O6;;K:>^7"QXZ<5],>
M-O!MCXY\(ZCX?OHU^QWD#0L,<*", @>U;]%.?[R')+8(^[+G6Y\N_LG?L)^'
M_P!EGQ!K>KV6J2:O=:@[%&FC"^2I/W17<?M(_LL^&OVCM'M8M4>33]4LVWVN
MHV_$D3#IS7M5%.?[Q14NFWE8(?NVW'KN?'7P_P#^"?3:;XPTW6O'?C[4O'46
MEL&L;2[RJ1$=._-=9^T=^Q99?M _$#P=XFD\03:/_P ([(KQVT4899 #G'M7
MTS13YG>+_E=UZ]R7%-23^TK/T['SI^U5^Q_:?M.:/X;L;G7Y]&&C2)(K1)N\
MS;V-7?CM^RE:_&WX&Z;\.I]<FTZ*S5%%Y&F6;;[5[]14_9<.C=_GW*6DU46Z
M5OD?-?B[]C2S\6?LSV7PBD\03PV]LBI_: CR[ >U>6O_ ,$T)=/\(6GA?0_B
M5JFDZ&J!+JUC4XG&.>_&:^YJ*J4G*4I/>3N_,(^[&,5M';R/)_A/^S;X0^$_
MPM;P-86:W&FS1E+EI "TQ/4FOGC6?^";,UMJ%_#X0^).J^%O#E](7N-(MP2C
M GD#GBOM^BE)\TW.6["/NQY%M_6IY+X#_9TT'X<_"2\\#Z,[Q17<#13WC<N[
M$8+&N=_9/_95MOV7=$UC3K;7)M:74+EK@O,FW9DYQ7OE%5S2YI3OK)6?HB>5
M<JAT3O\ ,*HZYI@UK1[RP9S&+B)HBX[9&,U>HK-I25F6FXNZ/G/]ES]C^T_9
MIU[Q1J5MK\VL'6YVF9)4V^7DYP*9^U-^Q#X0_:=6&\O9YM%U^ 8BU2UXD6OH
M^BG/]XHJ7V4DOD";4I2ZRU9\3_L\_P#!,7PO\&/&L'B?6O$5[XRU&V.;<WPX
MC]*L_M'?!J[U;]I;P+XIT?6[]KJ&9(YM)A9A"L0_B..*^SZIKI-FM\;T6T?V
MHC;YV/FQ5J<N>G-_8=T39*,U_,K%M>% [XKX<_::_P""9Z_M(?$R;Q;>?$&^
MTQF $5JD098O]W/2ON2BLG%.2D]T7&3C%Q6S/SL\%?\ !)2;PCXMT?6C\6M;
MNUT^YCG\AL@/M.=O7H:^G?VG/V1_"O[3?A>#3]99[+4[50+;4X1^]B([@U[M
M15S?/!0ELM?F3'W9<RW/C[]E_P#X)R^&OV>_%0\3:AKMUXOUR,_N+J^'^J^E
M87[4G_!-@?M,?%";Q?=^/[[2%**D-G'$&6+'<9Z5]O44I>^XN7V=@C[G-R_:
MW/SK\$_\$DYO"'BS2M9/Q:UN[6QG2;[.V0'VG.T\]*[S]J#_ ()P?\-+>+;'
M6;SQ_?:9'9P"&.V2(.HP!\PSWXK[8HHE[R2?35!'W6Y+JK?(_.'P[_P2%FT'
M7-/OQ\7=<E6TE6018(!P<XZ]*_1+2+#^R])L[+S&E^SPI%YC=6VJ!D_E5RBK
MYGR\O0CE7-S]=@HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $7I2TB]*6@ HHHH **** "BBB@"CK=_+I>
MD7EW#;M=RPQ-(L"?><@9P*_/S5_V^M1C_:+T_3CX?U2W06Y@?1RWWILX!K]#
M;B+SX9(R2H=2N1U&17SXW[$?@.36)M8=;B35Y+\7_P!L9\N&!^Z#Z40]VJI2
MV*E9TW%+5G ?M9?M<:Q\,? ,B/X7U+2Y[VT26&^4X$<A(ROUKJ_V?/VB-1^+
M_P ';W45T>\LEL]-++J4YXED"9./QKT7XJ?LY^&?C#?:++XB,]U!I?W+;?\
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M)( K/^/7Q^F\7?L@6_PW\2R[/%_AC55M9(I/O,BG /Y4XJ^'HP^VE"7K%O\
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M:W=3:?<+([V<K' &<KQ^-?KOJFL6.BVYGO[N&SA'\<SA1^M?D7\!?!Z>"/\
M@I58:2D?EI%9+Q_P!:V_CA^T%H7Q4_:ZU[P7\3?$U]H7PZT8-$(].+!Y) .A
MVUU2:E"C"&[4ON3,N5J=2<MDH_B?JMI.NZ=KUOY^G7L%[%_?@D##]*DU+5K+
M1K5KB_NH;2!>LDSA1^M?E'\&?C5H'P>_:CTC0OA3KVL>(OA_JP$<T5\DCB)N
M_P Q%7/VG/VAM(^)G[4@\$>._$=]X?\ AWIZ@RK8;A)(3Z[:AKFY.3[5]]+6
MW_X'<%]N_P!FVW6^Q^I>D:_INO0^=IM];WL7]Z"0,/TKYU^.O[:FA?"3XO\
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M :_'Z3QU^T/\=/VD_'_A+P'XMELH=)NY-L;N=JH#P!7[ S?ZF3_=/\J_,O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $7I2TB]*6@ HHHH **** "B
MBB@ HHHH *PO'5O)=^#=:AA4O+):2*JCN2IQ6[143CSQ<>Y49<LD^Q\(_P#!
M.'X5ZWX+OO'I\2Z']E%U?,\+7$/+#<>F:^ZH;>*U7;#$D2_W44*/TIZJ%Z #
MZ"EK:4N9179)?<91CRN3[MO[S\^/VE_A;XIU[]M[P/X@T_2I[C1[;9YURB$J
MN,=Z^DOVO/@')^T)\%;_ ,-VK!-2""2VW' +@=*]TV@G) S]*6L7!.BJ+V3;
M^]W-(MPKNO'=I+[C\I?#]C\0/!?PYC^&8^#=F_C2,F"#7OLX90.@<G%?;'P,
M_9ZN+7X#-X0^)*6^KW&IKF_@B0(G/\/%?0'EKNW;1N]<<TZMI2YE)25W+?Y>
M70S4>5QY=%&]OF?.7AW]AOX0?"<WVM^$O"4=AK*6\BQ3+(S,"5/ S7@__!/G
MX7^*O!7C[XIW6NZ5-8Q7\DIMWD0@/D]J_06FA57H /PJ(W4G*^\7'[]2W9Q4
M?-/[C\]_V(/A?XI\'_M1_$S5-8TF>ST^]G<P32(0K@D]#7D'_!3']B77;KQX
MGCCP/I,U]!J;_P"FVULI)\PG[V!7ZSA54Y"@'Z4K*&&" 1[BB6OLO^G:2];?
MYFOM'SU)_P [N?GK^U-\+O%.O?L&^!?#^G:3/=:U:00F2U1"64J!P17D/@3]
MJ[]IOP7X+TSPMI_PQN"EK MK#<-&>., U^LY52,%01Z8I/*3^XOY4VW*=2;V
MF[M&*2481_E5D? _[$W[)OCRU^)FK?%OXO!?^$EO3NM8 V2BGGGTK[[HHJY2
MNHQ2LEHD3&-FY/5O<_.S3_A!XGF_X*,7/B2;29AH#6Y476P[#D8QFO*[']D_
MQ-#_ ,%%DO?[%G/A,7OVMKHJ?*QG/7I7ZR[5W9P,^N*7:-V<#/KBLZ/[ETFO
M^7::];N_X%U?WJJ)_;M?Y*Q^=D/PA\46?_!3C_A*TTF<^'/(VB\V'8.,8S^%
M8_QN_9I\3?!G]IS4OBUI/A"W\<>&-4R;O3Y%#LK'OMK]*]HW9P,^N*&4,,$9
M'O2C>$::B]87_'>Y<Y<[G?:27_DNQ^?OP&\ _$'XI?&Z'Q8WA2S\!^ [5<I8
MBV422-^587[17[,?B7X:_M'+\5] \*6_C/P]< ?;M.E4,1]%K]'U4*,  #VH
M(##!&157LX.&G+?SWWN1_.I;2M?Y;'YX_"'P+\0/C1\;-/\ $MMX0L_A]X$L
M&#269ME#S,/PIW[?WPJ\=0_'_P"'OQ2\+Z&VN:?H>T3P1 EC@],5^ABJ%&%
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MIWPVFM95@6UBNFC/R\8!KW?]B7]E3Q-\%=/\6_$;QZ!=>.-8BDG$:_,8S@D
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M(=6SU %>Z_LP_ CQO\6OVE=2^.WC_2?[%AD0Q6-B^0P7&.17I_[!O[*OB_\
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M\G_V<_"_Q+^"/AGQ=\/9_A;%J_B34I)1'K%RF\ ,3@[C]:]'_P""=?PE\:^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!%Z4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNXYPHKZTKSJL/9U'#L=M.?M(*7<****R- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1>E+2+TI:
M"BBB@!#S7S]^TM\"+[Q=9CQ1X-F.F>,+$;TFB./- YP?6OH*D;..*WHUI4)J
MI QK4HUH.$CX+^&O_!02Y\)ZD/#OQ*TY[:[LSY,MT!\Q(XSBO:M0^+GP5^+<
M*7%QJL*S[<K*Q$;"KOQZ_8^\(_&B%[I;=-+U@Y;[5"N"Y]Z^+?$W_!.OXDZ/
M?2#3Y[>ZM-WR,LAW8]\&OIZ,<MQ?OJ;I3_#Y'SM2>887W.7VD>_4^I+CXA?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 (O2EI%Z4M !1110 4444 (>:3![&G44 )BEHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>formf-1a_004.jpg
<TEXT>
begin 644 formf-1a_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ EH# 2(  A$! Q$!_\0
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MG6J5357)<-['G>L> ]1TW3/"LVFPW=TVE0O'=0V=R()V:099T?UW9R.XKJ_
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M)'&H55'L!4U2]]!K8****0PHK@/^%P>&?[FH?]^!_P#%4?\ "X?#/]S4/^_
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M7UX>_P"@;J?_ 'PG_P 51_POKP]_T#=3_P"^$_\ BJKV,^Q'M(=SU6BO*O\
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M[O\ 6J-7M4_UT?\ N_UJC7KT/X:/@<T_WRIZ_H@HHR,XS16QYP44F1G&:6@
MHHHH **** "OJ;X?_P#)/- _Z\T_K7RS7U-\/_\ DGF@?]>:?UKEQ/PHZ*&[
M.A:6-3AI$!]"P%)Y\/\ SVC_ .^Q7(ZZ!_;$_'I_*L[ ]!64:%U>YNYV9W_G
MP_\ /:/_ +[%'GP_\]H_^^Q7 8'H*,#T%/ZNNXO:'?\ GP_\]H_^^Q1Y\/\
MSVC_ .^Q7 8'H*,#T%'U==P]H=_Y\/\ SVC_ .^Q1Y\/_/:/_OL5P&!Z"C ]
M!1]77</:'?\ GP_\]H_^^Q1Y\/\ SVC_ .^Q7 8'H*,#T%'U==P]H=_Y\/\
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MX44458@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "COQU]J,$G
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MOSH C\M/[B_]\BCRT_N+_P!\BI,I_=;\Z,I_=;\Z (_+3^XO_?(H\M/[B_\
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MZWYT -HIV4_NM^=&4_NM^= #:*=E/[K?G1E/[K?G0 VBG93^ZWYT93^ZWYT
M-HIV4_NM^=&4_NM^= #:*=E/[K?G1E/[K?G0 VBG93^ZWYT93^ZWYT -HIV4
M_NM^=&4_NM^= #:*=E/[K?G1E/[K?G0 VBG93^ZWYT93^ZWYT -HIV4_NM^=
M&4_NM^= #:*=E/[K?G1E/[K?G0 VBG93^ZWYT93^ZWYT -IT?^L7ZT93^ZWY
MTY"F]<*V<^M %FBBB@#Y*/6B@]:*R/O HHHH **** "BBB@ HHHH R]4_P!=
M'_N_UJC5[5/]='_N_P!:HUZ]#^&CX'-/]\J>OZ(**NQ:1?S20QQ6[.\\!N(U
M!&6C&<D?]\GCK38]*U&8,8K"Y<(&+;8B<;3AOR/%:W1Y]F5**U#X;U@6B77V
M"4P/]QP,[ON\#U/SK^=4+FUN+.=H+J&2&9>J2+@C\*+H+,BHHHIB"BBB@ KZ
MF^'_ /R3S0/^O-/ZU\LU]3?#_P#Y)YH'_7FG]:Y<3\*.BANR_>:[%973P- [
M%<<@BJ__  D\'_/M)_WT*R]<_P"0Q/\ A_*LZIC2BTF:N3N=+_PD\'_/M)_W
MT*/^$G@_Y]I/^^A7-457L8!SLZ7_ (2>#_GVD_[Z%'_"3P?\^TG_ 'T*YJBC
MV, YV=+_ ,)/!_S[2?\ ?0J6#Q';33+&\;Q!N-[$8%<K12]C .=GH5%<SH^M
M>1BVNF_=?P.?X?8^U=*"& (((/(([URS@XNS-4[BT445 PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCM5*@T@I+XF%%%%!8AT'4-7/FV:0,B?*WF7,<9SUZ,PS2?\ "%:Y_P \K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4Z/\ UB_6FTZ/_6+]: +=%%% 'R4>M%!ZT5D?>!1110 4444
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MYP5/,$BOCZ\\5E?\*Y\9?]"[>?DO^->I0DE32;/B,Q]_%3E'57_1',45T_\
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MM;M+2Q$B0(T#R?*T:1C:,JW3:!CD<8J[KMCX;E:TUK5;*WN7CDBC@GV;SEW
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MUBE662'=N$;@<$@GY>,_A3+[PUX0 U*^GTZVE:Z1C=!&),P(#XV@\DA0?H*
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M>')!,RR#Y@0<_)M.>.<XK7T#P='H>HK=K.CG[/+ X6+;O+S&7).><9Q7444
M<%!\.6ACM83J$7EQ)%$S+;8<+%*9%,9S\C'.&/.>M:>L>#CJ>NMJ*W@5)# [
MJ8LR*86+*(WS\@;/S<']:ZJB@#S'3/AK>2Z!:"[NTLKV.&W7R88L)F,NW[S:
MWSD[R,@CH*V+#X>Q6%W:SI>!WMY[:17:+YRL431E<YS@[L^W3FNVHIW%8Y'4
MO!"W^HWEXMVD37-QYY AY'^C-!C.>?O;JJM\/$_M/3+J*]2&.TMH[=T2#_6!
M49>F<8.XGID>O-=Q12&<PGA1UT7P_9&XMS+H\B,'\CY9 J,G3/!(;.<]166/
MATT6DV]G;:FL#Q:>]F9%MP=Y:17+$$]]N#]>M=W10!R/AKP6_A^]6Y-\LN$N
M5"K&0!YTBR<9)Z;<?C6&/A7*;*ZADU:.26<Q,)/(*X*!UW<-P2'[<<8QBO2J
M* .8U+P9;ZM'H4-]<R30Z8K*X!:-IR8]F<H1M]<#CM52X\ 0-?R7-G<1V@\Z
M%X0D )A2.!HM@.>GS9_"NRHH \T_X55(VG/;'5HQ(TXE$JP$;#Y2QG W?[.<
M'CG&*W]"\%_V+XDN]6;4)+CSO-*HP((,C!FR<X(!''%=910!S6A^']3L+G59
M]3U"VO);X\2I;E'4<[5R6(VJ#@  =SU-9FE_#Q=.EL)?MJ/+:2VK^9Y.&*PP
M&(KG/ ;.:[BB@#C[KP=>W6NW<SZI$NEW5[#?26RV_P"]+Q*@"[]V I,:D\9[
M5D6?PUO++3KRTAOM-1YBKI<+9OYA99A*-^9,,.,< 5Z/10!QE]X6OQX0\30M
M.E_J^KQNSE$$2%O+"*J@DX "CJ?6LV^^&EQJ-G(K:G#;O.[/)%%:XC0E(T!4
M!N"/+R><$L>.!7HM% '"7?PZ-W'<1?VDL*2&Y9#%#M8>=)')\QSS@H1VR#31
M\-E^SA6OT:40[ YA)V.;@3$KDD@<;>OO7>T47 X.3X=,UW9S1ZA%";6ZDF5H
M[?#%6F\W:?FVGD[>1TP1BN\HHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K#\1&SM[9KF^A)MBACDG +>0#W([#L2.GT
MK<I" RE6 ((P0>]-6OJ%VM5N>8-JMWIOBF[UF?Q#8OH#0XMX(IE8D_PJH!Y[
M#&.*Z#6[>SN_ 6J18DL[66'>9%C^4,<$E5)'&[UQUK7MO"?A^SOC>VVC645R
M3GS%A&0?4>GX5KR1I*A21%=#U5AD&M93CIRF<5/5-GC_ (B^V>)]+2+7-;M(
M885FEC^SV+Y9U79UWL"/G[?G6]I,EAX3U?4+:PU%?L%O;^?>6)CSB4 ;GA;/
M!Z;E/'/UKT!X(9,[XD;*E#E0<J>H^E1FQM",&UA(R3_JQU/7\Z7/I8.36YP=
MI-HDFO:QJDLX@BUV#[,CF( )Y:8<^8"0=V\8QU(QUK&C2[N]$T3PU=^(+)=.
MG\H1D6+),4C<;0V7PI8ICIUKU4V-H4V&U@*Y)VF,8R2"3^8!_"E-E:$,#;0D
M-]X;!SSG^='.'(3T445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formf-1a_005.jpg
<TEXT>
begin 644 formf-1a_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $- :@# 2(  A$! Q$!_\0
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M HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH
M**2H;J\CLX&FF;8B]: (=2O&L[?,:^=<-\L<6[;N:J>C:6VFQR37$OVB^N/F
MFFS_ ..K_=5:ATO2YC>-J6H%6O&7;'&I^6VC_NK_ +7]YJWZ!!1110,****
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M6M;37_>;:ZJ,I5*493^(YZD?B-:BBBMS@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!*6BB@ HHHH ;VJCJNHP:/IT][<OY4$"-(
M[&KW;FO"OB?XO/B35'TFU??I=FW[]E/^OE_N_P"ZM<>)K1P]-R./%8B.'I\\
MCDKS4[G7M2O-5N/]?>-N1'_Y9)_ E9=Y-+,J,JLB+\[(ZTR\N66Z>==SI%_
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M<2[5?RHM[(GWV_SLK)L+QOM#RM NQMJ;_P#T/97Z5&G%T?;3/H<#CZLJ=O\
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M-Z3=:GJR11?;H/M7^B??7^[\O][:U=EI?Q"DM_#JS7B[[Q63<EQ^Z=E;[O\
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M/-;RE_\ BWHE&$SLH8FK2^&1[[->:1JNL:;8Z#>>3<12P6^^X;<D\2_.^_\
MO?<KH'\S4/%T*7,<6M6FZ6Z1U5$V;4_BKYRTV:6P\J>V;[-+YO[IT^_M_P!B
MNK\/^,M2\/J[6TC/]J@9=Z_)M_W*XY4CZ2AF4?MQ/8K'6([BXN/M-S-IL5A
MTIM%^;]ZS_?_ -VNETO7+VZOO[662V>&)DMT^;YY_P"]_P"A5Y;HGQ.:SL;J
M">*-[V>6+<VW_EDM;<.M^'_^$?BB6/9+*TMPS?\ /)_X?]VN*5(]^ACH_9D>
MIZ+XLG5Y[F<21V4V[RGE;=]W^*M33?&C/I,LTY42*N]6E_=;T_O5YKJ4/F6&
MGZ?9ZKYM\L$46QV^1_-K=O\ [=-X@M8/W%_"TJHZ+\FS;\]<<J43W:>.J1/1
M%\30BQBN?+;#?>5?X:NR:O;QRQ1L_P#K?NM7G-M<3S:XZ7-GOB7=<?)]S_8J
MQ8ZEYWVAI(+G?:KL6%?X6KGE1B>K''2/15O(&F\D2+YO]WO3DN8I=P5E;;]Z
MN(MM8CDM_MCRR;MVQ?E^[6A#JB0Q)/YGS2[MR5G[([(XOF.I61&7<K K4G%<
M^EPL/[A95^;;5Y)E?]UN^[67*=,:W,:=%5X7W_Q58J#I"BBB@ HHHH ****
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MBB@#AM!\-Z5JFN>*YKO3;.[E&I[/,N+=';_CUM_:MW_A"O#W_0#TW_P#C_\
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M7?"%Y>:HLC?\?DZV]DRN_P#M!G?_ +[I>S%'%1_E/H(>"_#W_0#TW_P#C_\
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M5$W-]YI75=G^U6!I_P"RM>Z)<17-CKUJMQ:^;]EW6GRHVW9$_P![[R(]PO\
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MWU+_ , ;/_XU1_PB/B'_ *'?4O\ P!L__C5=?10!R'_"(^(?^AWU+_P!L_\
MXU1_PB/B'_H=]2_\ ;/_ .-5U]% '(?\(CXA_P"AWU+_ , ;/_XU1_PB/B'_
M *'?4O\ P!L__C5=?10!R'_"(^(?^AWU+_P!L_\ XU4%YX'UO4+.XMIO&NI&
M.:-XFVV=G]UN/^>5=M10!3T^QBTVQ@M8LB*"-8UW?W5XJY110 4444 )2T44
M %%%% !1110 4444 )M'I3=B_P!VGT4 ,VK1Y*T^B@!GDK1Y2?W:?10 S8O]
MVGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>formf-1a_006.jpg
<TEXT>
begin 644 formf-1a_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '@ :H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<RJZMM^7^+[]<58K"I\/7-I"7;[4TMMI+VDC1)YLJ;E5OX6B5-W]W[U>TT4
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MRN$^)5C;(OA^=8(UF;7K#]YM^;_6UW= !1110 4444 %%%% !1110 E%+24
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MW^SQ?):IN?C^]S]_=0!YWIWAO6-/_:"L/^$HEL+:6X\0?VDNIP^&[J/[5/\
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M[RHMC+MB3Y-J_<3YJ /0_'GQH@\)WD2VEC_:5NN@7GB.YE$OE%8(E7RE7/\
M%([JM<C;?M56NM6^J'1- EO+O3O"D'BF2*6;8H5SF:U^Y_K8E_\ 0A71>,/@
MFWB;7-$'VL_V1_8;Z#J81BDK1;XI8GB(_P!N+:W^R]9FL?LWV&EZ+XD_X0^1
MK/6M7CU2-6NI?W"?;GB\W[J_<BV?(GM0![-INH0ZII]I?0'=;W4:RQ-_LLNX
M5=JAI&FQ:/H]AI\/,-G D"?[J+M'\JOT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 445\N?MXWU[8^'OA ;2\GLVE^)6@Q2-;RNFY&E?<K[?X: /J
M.BOA>/\ :D^+%GJU[XBN+CPU/X,L/BL_@$Z2EE*E[/ UQY22^?YNU63>O\'S
M?-NKN?A[\;_B3\3)/B-XRL]0\/Z9X-\-ZIK&AV^@26#OJ#/9Q/LG>7S?E9I5
M7]UL^[0!]7T5^?T/[6'QJT_X)_#'7]2CT:_U_P")UY!'I<>@:)+=MIELL#/*
M_D-,GGSOM5E3<JKE_O;:ZK4OVG/BM;_#GPI9ZU8-X/\ B+K.J:A96NG1^%9[
M_4-4MK94=;N"R^T(L2['_>^;+\O.WM0!]KT5\"_\-D_$_7/@O\,/'[VVG>%?
M#>I6]X_B;Q+#HLVJPV$\%T]O$LMNDR2Q02[ [2_-L^[5_P 0_M=?%O7/C-XG
MTSP#X/F\0:%X8U>STN6PM=%:==1214>XN'O/.7R,*X:)=K;E7YJ /M;6-<T[
M0;,WFI7UOIUL'6/[1=2+&FYFVJNYN^ZM6OS8_:E^+7C?XN>!_B!,;W0;+P+X
M<^(^G^%8]%DM6.H2RP75NS7'F[]OS,_^KV?<#5]6_M.?%GQ1\/9OAUX7\&R:
M;8:_XUU]=&BU;5H6FM[&/RGE=_*#)O?Y=JIN[T >S:=K>G:M+=165_;7CV<W
MV>Y2WF5S!(,?(^W[K?[-:E?F=\._BM\2/AI8>-X/#%SX9N?&7BCXZ2^';RZG
M@E;3V:6U7?*J;]Z+O17^\W]VO:_&'[1WQ"^']Q\:M%U34-%N]5\"_#^RUNVN
MXK,Q13:BT4OFOM9_]6SHNU* /L:BOSW^(/[77Q=U;Q-I?AOP1-I\/B)M#\/W
ML&G6^@S:BVISWZ*UR[RH^VS2!?GVO]]37T3^TY\6O%7PG\)^ M.\.R:;_P )
M7XL\16/AF+6-3@;[):-*K[KAHE;YON-M3=_%[4 >UV&M:?JES>VUG>V]W<64
MOE7,-O*KM"_WMKJ#\K?6M2OS=\"_%?QC\'_$WQ7OC?:)?Z]J?QAT30-3O+:V
M86LD$\:QRLBL_P"[;;C^-MK;A7?_ !(_:U^)&BR?%Z'P]_8<MUX<\=:/X:T<
M7ENQA,5TB;UF=6Z[V^]_#0!]QUF6NLV-YJ%Y86UY!<7UD5%S;Q2JTL.Y=R[U
M_AW#UZU\/?M"?M5?%#X'VMYIT.OZ/XG\3^$])M]3\0VNE>%KB6T;S96V>?<-
M<(MJC+MV[=[]6Z5RGB#XH>.?AS\8/VG_ (B^#;_P[9P:39^'-<U#3-8@>6:_
M7^ST_<*RNGE+M9OG^;YMM 'Z"7_B;2M+6X-]JEC9I;O&LSW%PB")G/R!MQ^7
M=_#ZU>M]0MKJ6XCM[B.9X'V2JC[C&W]UO[M?FM^T9XJMO%?_  O]H_#^G:5+
M)-\/[^6Z@B87=QY\L3[;A]VUMGW5^5>]:'QF\:>)[#2_C-)X+O;+P)?6GQ6T
MFPN;_2[9_/U!95M_FE;S?[[_ #9^5T^2@#])JS]6U:RT&PEOM2O+>PLH5W27
M%W*L<48_VG8\5\8?%O\ :G^(WP3\6^,OA[JESI6M>--0M-&;P#-'8&W349[F
M7[+=;TWM_JI=S_>^[7;_ +;TT]YX<^#7A'4'6:Q\2_$'1M/U9E7:L\2L\KH5
M_NL\2T ?4RL'7(IU? OQD_;8^(7PM\0>/?",-II^H^*M!\51W$%NEK_S+'V3
M[5++LW_,RJC+OK=N_P!KSQ/XA\,^(M<T76["TT[5?&C>&_!:V6A2ZO=7\$$'
M[UXHDE3S6>7=\SNJJJ-0!]NUF6VM6%YJ-W807MO+?6>S[1;1RJTD.[[N]?X=
MU?"MO^V-\6=>^!7A?QC#IMKH]E#JNK6'B[Q%;Z#+?OI<5FP6*=K#[0CJC<^:
MV]O*VUS7B/XI^-_ WQ8_:1^)W@+5?#ES9:9H/A76K_[=8RRKJL7V)W5(#O7R
ME96=MS;V^Y0!^D5%?/7[4GQT\0_"[]F9OB%X3@M$UJ5]+-O;Z@IEA_TFXB1D
M;;_LR'YJ\;^*G[1WQT\$^.K7X:Z58VGB/QGI?AT^(-1OM"\-RWD-_+)<2I!;
MK#]H1H(MJ*K3;F;=_#0!]TU2L]1MM0C>2VFCN$1VB=HFW;77[RU\E^)/VC?B
M7H/Q.^'L?BBQ@^'7@W6;32S<7%WI+ZBDNHW.//T^>X29/L;K]V-F1M]>;:!\
M;?'/@+X,RZGX+\.:7X;\/IXV\1+XCUG2=%EU)]+@@N'V7#V7G(TNYO\ 6RJW
MR*GW: /T*HKX7\,?%;Q@/VCOB!XHG^*&F7'@"P\ :?XF2&6QE_L][>6&5DE1
M/-W)\R[V;;O9-BUS.G?MM_$RUTCXH"^-O>2:3X$_X3'1=2U#PY+I6\M*D2+Y
M#3OYL#;MRLVUJ /T.K+N-8L+75K?39;VWBU"Z1Y8;5Y5665$QN94^\VW<N:^
M(?%7QT^,#Z+\1?"FKZ[H=EJ=Y\+'\=Z9K&BV4L3Z;C*2VOSR_-\GW9ODVM\V
MVJ-Q<>)=*\!?L:>.->\0KXA\4W'B&PT]=02#RG>QU&RVS12_,WFO\J;G_B;Y
MJ /T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
MCQE\/?#OQ"@TN'Q#H]OJT6F:C!JMFMP/]1=19\N5?]I<FNGHH \\;X!^ )-/
MGLG\,6)M9]>_X2:6/YMK:IOW_:OO??W51/[.?PU;QY?^,AX-TY?$=^DJW.HH
MK(TWFQF*5F4';N=&96;&[%>HT4 >;ZS\ ?A]K_P^TOP-J/A2PN_"6EB,6.FR
M(Q6UV9V-&V=ZLO\ >#5DWW[*?PGU/PGI?ANY\#Z;/I&EW,MW9P,'+0RR_P"M
M??NW?/\ Q?-\U>O44 >,7G[(OP=U#2= TJY^'^DS:=H:R+I]KL;RHE>7S739
MN^9#*Q;:^Y:T?%7[,_PO\8>+D\4ZOX+T^ZU]?+)O%#1M(8O]5NV,JMMXV[J]
M6HH \D\1?LK_  H\7>*[WQ+K/@/2;_7;V2*:>^FB^>22/;LDX/WOD7Y_O5U/
MQ(^%_A7XM>'QHOB_0K77].65;A+>[3_5RK]UU93N1O\ :4^M=E10!Y=HG[-O
MPR\.VEC:Z7X,TRPM['68_$5M#!$42+4$B\I+A?\ :"<4SXB?LV_#/XL>($US
MQ9X*TK7=56U-F;J[@R[0_P!QN?FQN.W=]W->J44 ?$_Q:_X)\W'CSX@:_JFD
M^(M&TG2M6M-.LH&N-'>34M"ALT2-4L+A94V95?O.K5]1^,/A7X7^(G@J/PIX
MLTQ/$^D*D>Z/4?G9GCQMEW?>WY_B7GDTE]\6/#VF:Y<:3<7$BWD&HVVF,HC^
M433Q>;%_P';_ !5I7GCWPWI]NDUWK^EVT3E=KS7<2*VY=R]6_B7I0!Q4/[+_
M ,*H?".M>%8_ NDKX?UB:*>]L%B&R:6-55).OWUV_>^]2Z7^R[\*]%TBZTNQ
M\$Z7::?<WMKJ4T$*LJR7-L<P2M\WWDKLIOB%X8AL3?2>(M)2R\]K7[2U]$(O
M/4_ZK=N^_P#[/6K5EXLT74=5;3;36+"YU-8O-:SBN4>94_O%,[MOS+S[T <%
M\1/V8?A;\7-<?6?%O@K3-=U1X1:RW5PC!Y8U/RJ^UAOV_P .[[O:J_B;]D_X
M1>+M?EUO6_ .D:GJLCP/)=W,;,TGD(J0J_S?,BJB#8WR_*.*N7/[07AJWU75
M;1(-9N+33S<I-J]OILKV320([S1+/C:778P_N[OESFNJL/B7X5U32;'5(?$&
MFBROI%A@F>\C >4_\LOO??\ ]F@#&U_X"?#_ ,376OW&J^%[*]G\0/9MJDC[
M_P#2S9G=:E\-_P LOX:CU?X!?#[Q#I?BO3=3\)V%Y8^*;M+_ %F"56;[;<)M
MV2MS\K+L7[OI707'Q"\+6=_):W'B/28;N*5(I+=KV)71V;:JLN[[V[BIIO&_
MAV":^@GUW3H9K':MXDEY&K6^[[N_YOEW=LT >2^*_P!EW2?$WQD^$GBJ)[2U
MT'X=6]TMCI*P,TLLKJB0_O6;[D6S=M_O5TG[17P=D^-G@6RTJPU"/2-=TO6+
M+7-*U":+S4@NK:577<O=67>O_ ZZGP[\2?#WB6.UBM]1@@U&Y:7R=.NI42Z;
M8[JS^47W;?D9O]VLJQ^-7A6Z\?:KX/-Q<6NJ::K/+)<P-%;R;$2679+]UMB2
MHS?[U $^K_!?P5X@\97'BW4_#5A>>([G2WT:>_D7YY;-_OQ-_LG<U8EQ^S%\
M+;SX=Z5X'E\$Z8_A;29VNK'3MK@6TK,[,R-NWJV7?G=_%7:MX^\-PZ?87SZ_
MI<=E?MY=G<M>1>5<-_=C;=\Q^E22>,O#\4FI1R:YIR-INW[<KW<>;7=]WS?F
M^3_@5 'F]Y^R)\';_P -Z?H-Q\/]+&BV$\]Q;6*!U2)Y]OG?=;[K[$W+]WY>
ME=!J'P)^'VI6OBJ&X\*:?)#XGL[6PUA%5D6\MX$V6\3;3]U$^5=M:*_%SPDW
MB"/2UUZR=Y=-;64N%F0V_P!E5_*9_-W;?OFMJQ\5:-JD\%O9ZM8W<MS!]JBC
M@N4=I(C_ ,M%VG[O^U0!F^+OAGX6\=>#T\*Z]HUOJ7AU?(VZ=,&\K]TZM%_W
MRR+^58?Q*_9_^'GQ@O[*\\8>%+/6KRRB>*WNYB\4R1M]Y-Z,K;3_ '?NUZ51
M0!Y5??LV_#/4/%FC^)KGP9IL^M:/';Q6-PRL3$D"[8/DW;6V#.UF'RU6US]E
M?X5>)M(BTO5/!-C>:?%>W6H)"S2'$]RVZX;[W24_>7[M>O44 >::G^S[\.M8
M\16.MWG@W2[C4K'3&T:"8P85;+8R?9]@^5H]KLNUN*P]#_9 ^#GAFQUBTTSP
M#IMG!J]@VEWR(TG^D6K,K&%OF^[N1?\ OFO9Z* .(;X/^#/[<_M8^'K%K_\
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MUTB\T.'S86M/LFH:9YMJB/816LLJHK?ZW=%O5O\ ;?=FNM\$?L\CP?XUTSQ
M;ZSGNK>[GEDD2U"RRQ-906J)N_V6AW?\"KW"B@#PZ/X/^,;/2]<\*:?XETN+
MP3?)J+00RV#M?)]J64^2S[MNQ996?=MW?PUQ_B?]CL:M>1/8ZA86]KN\J73O
M(EBM_*>WMXI77RG3][OM]_\ P*OJ&B@#YSUO]E&TU:;4Y_/TLWEU_:^RXEL=
M\J_;'MVB9G^\SQ>5][_:JII?[))L?%=WJ5UJ5K?6YU:+48'N$E>:5/MJ74L4
MJL_E?P[5^6OI>B@#YY\,_LNOH/B6WUJ34[*YNK?5[74(I?L8\U8HGNG>)7_V
MOM7_ ([5;Q?^RF_B;QAX\UM-=CMG\6V[6LO^COOB14M_*VMN_OQ/O_O*_P#L
MU]'T4 ?..B_LVZIX?_L2]M)?#]QJ$)NH]1M-5M)[VR_?S)(\UNLC[DD_=(O]
MUJYSQ!^ROJNFV?B^YT][36KO4KI'L?M*RL^V6_BN)1<([^6RKM_A^]MKZQHH
M ^:U_95O)(;JZEU/2(]6N-\_DQZ6?L2S_;8KI(O*W_ZC]UM9?XM[-79_!?X(
MO\+M:U?5;NZL;N^U2!%9+&S\B*V/G3RO%%_=BW3?*O\ LU[#10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFN;J:QB>69Q\S,5&6KH[C_CWE_W&KE_A)_R3'PQ_V#X?_0: .OHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@
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M"K>>IN+C4%@;RU=EB?[C;MZU?^$.?^%7^%]R[&_L^+Y?^ T =E1110 4444
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MY=,M[YI_WX;S%,LBKL^[N3;][^"J/8RFM2H2K2K0YH\DNMM>G_#';^'?#_\
M8\<DMQ+]IU&YP]Q<_P!YO[J_W57/RK70-]VCBCK4GBRDY.[.*\/^'_$%CXNU
M74;R^T^33;M55+>&WD$R[<[<NS[?XO[M=J:7(I/O4%3FZCNQ:*6BD9A1110
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M/;<BGY]GR[O]V@#J:\@UZZME\4:BLTS3VLLB?V@=DL;6<"LJ[&)?:8F_V?\
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MO];^5 'M]]9P:C:RVUS$LT$J[9(WZ,M/AA2&)8XU6-%7:JK_  U-10 4444
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M(;ZTNTFM)ANCD.5W?]]5XGXB_9CO=5T\+;^(X6N%;>J26/E(W^^RLQK1T?\
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MO]H"ZTOXP1>&%L;9](\^*UDFWGSMSX^?^[M^85U*_#/Q%']WQ3IZ?]R]!_\
M%5S]QX-UY?B%86G]O::UVVGRW"WW]@0>:NUT7;][_;H ]4D\3Z3;CY]0M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>formf-1a_007.jpg
<TEXT>
begin 644 formf-1a_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $9 9(# 2(  A$! Q$!_\0
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MB+\(?"FO:)J']J6%UI\2K=8;YV1=C_>_VE:@#T&BBB@ HHHH **** "BBB@
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MN_%&K6GB_P ':C#X?^(6G6_V2VU*YC+P7,&[?]GN%7EHMQW?+_%5KX1_" ^
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M &:]"TC]GKX,W4J7>E^ _"<KP2;UFM+"!MC?\!%:'8>LT444 %%%% !1110
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MA];A7ED5L;I;ID^5_N_(/X:^@** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBO,/C GQ.O/[-LOA[J7AO0(;CS1J&M:[;RW<UM]W9]
MG@1D5V^]]]\?+]UJ /3Z*^76_9E^)^K;Y+G]J#Q=)J7WE_L_3+"WMU_[9*G_
M +-77_#+PC\<O!/BNWL/%/C?P_\ $;P9*C>;J=QIITW6('V_*-D6Z"1=W^[0
M![G1110 E%+10 F/:C'M2T4 ?,7[>.B67B3P'X T?4[9;S3+[QOI=O<VS_=E
M5G?Y:]H^&GPG\(?"/2[K3_!^AVV@V5U+]HEAMRV'?^]\QKQ3]O;0[/Q-\/?
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MKQ7]E?P'J/@WX;W.I:Y!+I_B'Q3J4_B'4]-=]R65Q/C="G^RNVO:J "BBB@
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MXHVK3J** "OFOXE,WQT^/&A> +9FF\)^&-NL>(I$Q-;W4_W8M/G7^%ONR_\
M :]A^*WQ$M/A7X#UCQ+>6[7HL8&>*RA<++=2_P $4?\ M-7R3\%_"_C'Q=J7
MBK0V\73> ?$UK*FNZUK,4217NMRRINMW96_Y=8HG6)O]M* /N=%6-0J\!:=7
MD_[._P 5M0^*W@FZO=4L5BO=.OI=,DO;?FUU%HO^7BW_ .F3?PUZQ0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P /RT ?5U9<FN:=#JT6E2WT$>HRQM/':M(OFO&IPS;?[OO7@_\ PSY\7_\
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MMWRU\I>/OV/?'WQ0\.-H/B3X^:[J&E2313M"NBVL?S1/O7YE_P!I5_*NB?\
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M8LJW%O)O3Y3\WS4L.N:?=:I<:9%>PR:E;(LL]HLB^;$K?=9EKYD\ _L>^/\
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M^(KG5_$<ECXY\%^.8/">K:]8/]E^U>1J$2-+\OW-\3KN_P"!5[=\&?%/B/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>formf-1a_008.jpg
<TEXT>
begin 644 formf-1a_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '; PH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ__ /"Y_P#M% 'U917RG_PP/_U<;\?_ /PN?_M%'_# _P#U<;\?_P#PN?\
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M?_M%'_# _P#U<;\?_P#PN?\ [10!]645\I_\,#_]7&_'_P#\+G_[11_PP/\
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M,#_]7&_'_P#\+G_[11_PP/\ ]7&_'_\ \+G_ .T4 ?5E%?*?_# __5QOQ_\
M_"Y_^T4?\,#_ /5QOQ__ /"Y_P#M% 'U917RG_PP/_U<;\?_ /PN?_M%'_#
M_P#U<;\?_P#PN?\ [10!]645\I_\,#_]7&_'_P#\+G_[11_PP/\ ]7&_'_\
M\+G_ .T4 ?5E%?*?_# __5QOQ_\ _"Y_^T4?\,#_ /5QOQ__ /"Y_P#M% 'U
M917RG_PP/_U<;\?_ /PN?_M%'_# _P#U<;\?_P#PN?\ [10!]645\I_\,#_]
M7&_'_P#\+G_[16[_ ,$_O'7B'XE?LA_#OQ#XGUFYU[79XKNWFU"Z;=)*D%[/
M!&7;'SL(XT!=OF;&YMS9- 'T?1110 4444 %%%% !1110 4444 %%%% !7RG
M^WSU_9R_[+-X<_\ ;BOJROE/]OGK^SE_V6;PY_[<4 ?5E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7(?%+P):_$[X>Z_X:N"%6_MFBCE_YY2_>B?_ ("X5OPH Z^BOF?6OB!K/C3]
MEFUT]8]GC+695\(W$6[YH[SS?L]P_P#WPDLM8_C'X\:EX'\53> / >I?#[P_
M8>$;6WM+F3QUK/V5KEO+79%;HK[OE0K\[_+N:@#ZPHKX_P#$_P 5]7^)>N?
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M?&,\%E"NFSSMJ%I)+%O267=\FUMOW5YH ^H:*^1?%W[7/B#_ (23Q!/X;O\
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M5]65\I_M\]?V<O\ LLWAS_VXH ^K**** "BBB@ HHHH **** "BBB@ HHHH
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M#&LEU<*'::3[J*JKO7YON5\[:GXO^!NFQZ@T_P "O$<(L$B>Z^T6GE+ LO\
MJGE_??)OKZS^.7P_G^*'POUWP[921Q7EU&K6[2_<$J.KKN_V<K7BOQ.^'GQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]N* /JRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;Z]WKS[X7?!CP_\ "2UO_P"RY-0U'4]1D66^UC6+MKJ]O&4?*996ZX_K7H-
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M10 4444 %%%% !7RG^WSU_9R_P"RS>'/_;BOJROE/]OGK^SE_P!EF\.?^W%
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MC4M-O] U'5(Y=$T6XL)HY;6XL(@K>9>3JR,MZW\*GY5KZ/KY4^%__)T_A?\
M[$S7O_2W1:^JZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#X5\8_P#)?_C-_P!C!9_^F/2ZCJ3QC_R7_P",W_8P6?\ Z8]+J.@
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M%?5E?*?[?/7]G+_LLWAS_P!N* /JRBBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@#X5\8_P#)?_C-_P!C!9_^F/2ZCJ3QC_R7_P",W_8P6?\ Z8]+J.@
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MIM]I/@OXNV&J:I)K.HVOCR_@NM1D^]=2HJ*TK9_O_>_&ON*@ HHHH *^5O\
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MO^Q-UG_TBEKRNO5/VL?^36_C%_V)NL_^D4M>5T %%%% !1110 4444 %%%%
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M*T;1/B)X4UC9KVC,W]G:Y:S[534K5W/RR=%7YF_V:Z>^_:A^#FEW#6]Y\6O
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M!(UC6==OW]J_*OTKHJY7X9-J/_"N_#!U>-HM5_LRW^U(Z[667REW;O?-=50
M4444 %%%% !7RG^WSU_9R_[+-X<_]N*^K*^4_P!OGK^SE_V6;PY_[<4 ?5E%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >4?M8_\FM_&+_L
M3=9_](I:\KKU3]K'_DUOXQ?]B;K/_I%+7E= !1110 4444 %%%% !1110 44
M44 'PO\ ^3I_"_\ V)FO?^ENBU]5U\J?"_\ Y.G\+_\ 8F:]_P"ENBU]5T %
M%%% !7Q?^WAK6LV?Q ^&>FZ9XC\0:%9W.F:W/<0Z%K=UIWGO'+IJQ,_D2IOV
M>=+][^\U?:%?%/[?'_)4OA1_V!_$'_I1I% 'S_\ ;O$/_0_^/_\ PM]7_P#D
MJC[=XA_Z'_Q__P"%OJ__ ,E444 'V[Q#_P!#_P"/_P#PM]7_ /DJC[=XA_Z'
M_P ?_P#A;ZO_ /)5%% !]N\0_P#0_P#C_P#\+?5__DJJ,-OKT-U]J'Q!\>"X
M;:DLH\7:BDLJK]U'E\W<ZKO?:N[Y=[[?OO5ZB@ ^W>(?^A_\?_\ A;ZO_P#)
M5'V[Q#_T/_C_ /\ "WU?_P"2J** #[=XA_Z'_P ?_P#A;ZO_ /)5'V[Q#_T/
M_C__ ,+?5_\ Y*HHH /MWB'_ *'_ ,?_ /A;ZO\ _)5?77[#'BK7?$GP_P#&
M%EK.M7^M)HOB1]/L9=3NGNYU@:PLKC:\\I:20^;/+]]F*[MOW555^1:^JO\
M@GO_ ,BC\3_^QR_]Q&F4 ?5E%%% !1110!\*^,?^2_\ QF_[&"S_ /3'I=1U
M)XQ_Y+_\9O\ L8+/_P!,>EU'0 4444 %%%% !1110 4444 %<5\<O^2)_$#_
M +%V_P#_ $G>NUKBOCE_R1/X@?\ 8NW_ /Z3O0!^D"?=6GTQ/NK3Z "BBB@#
MRO\ :N_Y-=^,/_8FZS_Z135_-77]*G[5W_)KOQA_[$W6?_2*:OYJZ "BBB@
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MBBB@ HHHH *XKXY?\D3^('_8NW__ *3O7:UQ7QR_Y(G\0/\ L7;_ /\ 2=Z
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MQ_R5+X4?]@?Q!_Z4:10!\_T444 %%%% !1110 4444 %%%% !7U5_P $]_\
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MQ?\ _P LJY7XY?\ )S'Q@_[#5A_Z9=-KE* /5?\ AL7XX?\ /WX _P#"8O\
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M?Q!_Z4:10!\_T444 %%%% !1110 4444 %%%% !7U5_P3W_Y%'XG_P#8Y?\
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M+>?^D[UU5<K\5O\ DEOC+_L"WG_I.] '[ 4444 %%%% 'E'[6/\ R:W\8O\
ML3=9_P#2*6O*Z]4_:Q_Y-;^,7_8FZS_Z12UY70 4444 %%%% !1110 4444
M%%%% !\+_P#DZ?PO_P!B9KW_ *6Z+7U77RI\+_\ DZ?PO_V)FO?^ENBU]5T
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MC'_DO_QF_P"Q@L__ $QZ74= !1110 4444 %%%% !1110 5Q7QR_Y(G\0/\
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MHH **** /A7QC_R7_P",W_8P6?\ Z8]+J.I/&/\ R7_XS?\ 8P6?_ICTNHZ
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M^UC_ ,FM_&+_ +$W6?\ TBEKRN@ HHHH **** "BBB@ HHHH **** #X7_\
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M 5\K?\$P/^3&?AK_ +VJ?^G6[KZIKY6_X)@?\F,_#7_>U3_TZW= 'U31110
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M9UB3^ZJ.RC_9W5R'P;_LK9X\;5_L7]D_V++_ &?YO^J_LO[7>_<W?\LON?\
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M /V HHHH **** /*/VL?^36_C%_V)NL_^D4M>5UZI^UC_P FM_&+_L3=9_\
M2*6O*Z "BBB@ HHHH **** "BBB@ HHHH /A?_R=/X7_ .Q,U[_TMT6OJNOE
M3X7_ /)T_A?_ +$S7O\ TMT6OJN@ HHHH *^*?V^/^2I?"C_ + _B#_THTBO
MM:OBG]OC_DJ7PH_[ _B#_P!*-(H ^?Z*** "BBB@ HHHH **** "BBB@ KZJ
M_P"">_\ R*/Q/_['+_W$:97RK7U5_P $]_\ D4?B?_V.7_N(TR@#ZLHHHH *
M*** /A7QC_R7_P",W_8P6?\ Z8]+J.I/&/\ R7_XS?\ 8P6?_ICTNHZ "BBB
M@ HHHH **** "BBB@ KBOCE_R1/X@?\ 8NW_ /Z3O7:UQ7QR_P"2)_$#_L7;
M_P#])WH _2!/NK3Z8GW5I] !1110!Y7^U=_R:[\8?^Q-UG_TBFK^:NOZ5/VK
MO^37?C#_ -B;K/\ Z135_-70 4444 %%%% !1110 4444 %%%% 'W]_P19_Y
M.F\2_P#8FW7_ *6V5?M57XJ_\$6?^3IO$O\ V)MU_P"EME7[54 %?*W_  3
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M);XR_P"P+>?^D[UU5<K\5O\ DEOC+_L"WG_I.] '[ 4444 %%%% 'E'[6/\
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M<?V7K6HVMO'Y=K!;(JHUE*WW;=6^_P#Q4O\ PQU\</\ GT\ ?^%/?_\ RMH
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MW?\ 0K^ ?_"POO\ Y4T +12?\*Q^-W_0K^ ?_"POO_E31_PK'XW?]"OX!_\
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M \JHKU7_ (8Z^.'_ #Z> /\ PI[_ /\ E;1_PQU\</\ GT\ ?^%/?_\ RMH
M\JHKU7_ACKXX?\^G@#_PI[__ .5M'_#'7QP_Y]/ '_A3W_\ \K: /*J*]5_X
M8Z^.'_/IX _\*>__ /E;1_PQU\</^?3P!_X4]_\ _*V@#RJBO5?^&.OCA_SZ
M> /_  I[_P#^5M'_  QU\</^?3P!_P"%/?\ _P K: /*J^JO^">__(H_$_\
M['+_ -Q&F5Y5_P ,=?'#_GT\ ?\ A3W_ /\ *VN@^&?P>_:P^#,/B"S\)/\
M!D:;K&I_VI)%K=YJUS+%+]EM[?8KQ0Q*5VVRM]W/S-0!]PT5\J?\9N_]6_\
M_E<H_P",W?\ JW__ ,KE 'U717RI_P 9N_\ 5O\ _P"5RC_C-W_JW_\ \KE
M' >,?^2__&;_ +&"S_\ 3'I=1U<TW]G_ /:(O/$?BO7_ !%8_#._UKQ!J$5_
M.^F:]J-G;QE+2WM51%:PE;[MJK??_BK6_P"%!_'#_H!^ /\ PKK_ /\ E70!
MSM%=%_PH/XX?] /P!_X5U_\ _*NC_A0?QP_Z ?@#_P *Z_\ _E70!SM%=%_P
MH/XX?] /P!_X5U__ /*NC_A0?QP_Z ?@#_PKK_\ ^5= '.T5T7_"@_CA_P!
M/P!_X5U__P#*NC_A0?QP_P"@'X _\*Z__P#E70!SM%=%_P *#^.'_0#\ ?\
MA77_ /\ *NC_ (4'\</^@'X _P#"NO\ _P"5= '.UQ7QR_Y(G\0/^Q=O_P#T
MG>O5_P#A0?QP_P"@'X _\*Z__P#E76'XV_9A^-OC+P7X@T!M*\!6BZKI\]@;
MA?%%\_E>;$R%]G]EC=][UH ^Y4^ZM/KY4_XS=_ZM_P#_ "N4?\9N_P#5O_\
MY7* /JNBOE3_ (S=_P"K?_\ RN4?\9N_]6__ /E<H ]7_:N_Y-=^,/\ V)NL
M_P#I%-7\U=?N[\0/!'[9?Q(\">)?"FJ2_ N+3=>TRYTNYELWUE9ECGB:)F4L
MC+NVL>JFOB'_ (<K_&__ *&KP#_X,+[_ .0Z /@"BOO_ /X<K_&__H:O /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>formf-1a_009.jpg
<TEXT>
begin 644 formf-1a_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 ;P# 2(  A$! Q$!_\0
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M]@#0?B;IWP3\"W7B?Q+H>I^#)O#5K_96F6>FO!=VWR)L\V4M\_R?+PO:N/\
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M7_Y%H_X9]_X*#_\ 17](_P#!@O\ \BU^FU% 'YD_\,^_\%!_^BOZ1_X,%_\
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M=OJU[++8::FBRZ:^EP*VS[/(DOSLZNC?,U>S5\#_ /#YCX(?] ?Q?_X 0?\
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M*7EY+J%Y--*TLMU<RX\V65F^9G;C_OE: /A/Q=\?-3^-7[87[-<.H_#'Q?\
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M^@)XO_\  &#_ ./4 ??5%? O_#YKX)?] 3Q?_P" ,'_QZC_A\U\$O^@)XO\
M_ &#_P"/4 ??5%? O_#YKX)?] 3Q?_X P?\ QZOJ?]GGX^^&OVE?AS#XS\*+
M>1:9)/):-'J$8CFCE3&]3AF_O+WH ]3HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\J_:4USQ)X;^!OC#5/!PN/^$EM;%FLWM;3[
M5<+\ZA_*B_CEV;M@Z;MNZO5:X'XV>!;WXE?"WQ%X8TW4FTB]U*V\J*YRX7.[
M=L?;\VQ]NQMOS;7:@#Y?^ ?QNN]!^+B:-%>?%SQ7X'U;3[=8;[QAX;N9GAU1
MI=K;9UA79%Y?WMWRHU?;U?)W[(OP!^(/PPUB[OO&4.BZ#IMG;WFGZ1H7AZ[E
MN(?+GOGNM[NX7Y$W)%$OWMN[=7UC0 4444 %%%% 'R-^U9_R>!^RE_V%M7_]
M)4KZYKY&_:L_Y/ _92_["VK_ /I*E?7- !1110 4444 %%%% !1110 4444
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M*** "OQ _:>_Y2-_$O\ W4_])+>OV_K\0/VGO^4C?Q+_ -U/_22WH 6BBB@
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MA7_P=6O_ ,71_P +T^&O_11/"O\ X.K7_P"+KY&_X<S? O\ Z"_C+_P8V_\
M\CU\Q?\ !03_ ()__#;]EWX)Z?XK\(WVOW.ISZS%8.NJ7D4L7EM%*WW5B3YO
MD6@#]5O^%Z?#7_HHGA7_ ,'5K_\ %T?\+T^&O_11/"O_ (.K7_XNOB+X:_\
M!(WX*^+_ (=^%->O-5\7I>ZII5K>S)#J,"INEA5VV_Z/_M5TG_#F;X%_]!?Q
ME_X,;?\ ^1Z /N'1=;T_Q%IL6H:9?VVI6$PW1W5I,LL3?[KJ>:TJ\5_9I_95
M\'_LK^'M3T?P?>:S>6NH7*W,O]L78G*LJ[?E5415_P"^:]JH **** "BBB@
MK\0/VGO^4C?Q+_W4_P#22WK]OZ_$#]I[_E(W\2_]U/\ TDMZ %HHHH ****
M"BBB@ HHHH Q?&W_ ")7B#_KQN/_ $"OOG_@C]_R:#%_V'[[_P!I5\#>-O\
MD2O$'_7C<?\ H%??/_!'[_DT&+_L/WW_ +2H ^WZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O*/CWXRO_#_ (-NM/TK2-:O=1U&
M"80WFEZ!_;,5JR8;][!O7?N_A7^*O5Z\M_:2\+Z[XT^!?C31/#5P;;6KW3GA
M@8WGV5/5E>7^!67>K-Z&@#YB^ WQ M/ _P 8)/$OCN3Q3%J&KVL'AN"[D\"+
MH.DP;I]T7VCRY9?WKRML5G^[OV_QU?\ VJ_$_AOX<_'C^W;?XB>%= \77^A0
M6UYHOC#PY/JD7V599O*FBEB7=$-S2[ESM;;6_P#L4>#?"%GJGB+4O#GPT\(^
M&+<P16MSJGAOQI_PD*7$JON\EUV_)MR&W5ZE\0OB7X,^&?Q._M?QAX3U32W3
M3ELH?&W]F-=:?Y#ON:W>6+>T7S?\]45?]J@#"_8KL_#TGP[U_5] \66GC"75
M]<GO=2NM+TI]+LH[K8B-'!:M]Q=JK\W\;9;O7T96%X2\4Z!XRT>+4_#>J:?J
M^FS?,ESILZ2Q-_P):W: "BBB@#Y&_:L_Y/ _92_["VK_ /I*E?7-?(W[5G_)
MX'[*7_86U?\ ])4KZYH \K_:@\;ZM\-?V=_B'XIT&9;?6M)T6XN[25X]^V54
M^5MM?CWX7_:^_:P\8:+%JFG_ !0D%I(S(OFV]FC_ "_]L*_6?]N'_DT/XN?]
MB]=?^@5^.'P$_P"29:?_ -=Y_P#T*@#OO^&F/VOO^BH#_OU9_P#QBC_AIC]K
M[_HJ _[]6?\ \8J2B@"/_AIC]K[_ **@/^_5G_\ &*XSXM>,OVB?CIX;C\/^
M.?&D/B'1X[E+I+2;R(4$JJZJ_P D2_WGKMZ* ,[2OV@/VK]!TFSTO3_B.MMI
M]C EM!"BVN(HT3:B_P"J_NXJ[_PTQ^U]_P!%0'_?JS_^,5)10!'_ ,-,?M??
M]%0'_?JS_P#C%'_#3'[7W_14!_WZL_\ XQ4E% '0?!G]M3]HOP[^T-\.M!\9
M^-(O$>DZ[JUOI\]A/!;^6T4LRQ.^Z*)65EW;EK]GJ_!"U_Y.P^!O_8?L/_2U
M*_>^@ HHHH *_$#]I[_E(W\2_P#=3_TDMZ_;^OQ _:>_Y2-_$O\ W4_])+>@
M!:*** "BBB@ HHHH **** ,7QM_R)7B#_KQN/_0*^^?^"/W_ ":#%_V'[[_V
ME7P-XV_Y$KQ!_P!>-Q_Z!7WS_P $?O\ DT&+_L/WW_M*@#[?HHHH ***^<_V
M\OC]KG[-?[/.I^,/#45M+K?VZVLK5KM-\47F/EF9?XOE5O\ OJ@#Z,HK\._^
M'O?[0;?Q^&/_  5?_;:/^'O/[0?]_P ,_P#@J_\ MM 'VK\=OV1_VF?B5\4]
M;U[PY\?/^$<\.S3M_9NE6]U=6XMH/X59(EVLW^U7!?\ # O[6?\ T<U=?^#.
M_KYG_P"'O/[0?]_PS_X*O_MM'_#WG]H/^_X9_P#!5_\ ;: -_P#:T\ _M*?L
MCZ#X>U77OC[K.MPZU>-9Q+I^K7J-&RIOW-OKW2W_ &#_ -K*\MHID_:9NMDJ
MJW_(3OZ^#?VBOVTOB9^U)HVBZ7XV.E/;Z3<M=VW]GVGV=M[+L^;YC7K5O_P5
MR_: MH8XT?PULC7:O_$J_P#LZ /IS_A@3]K/_HYJY_\ !G?U]F?LR_#_ .(7
MPS^%UOH7Q+\9)X[\16]Q)Y>JKN/[CY=BL[+N=E._YF]17Y.?\/>?V@_[_AG_
M ,%7_P!MH_X>\_M!_P!_PS_X*O\ [;0!^XE%?AW_ ,/>?V@_[_AG_P %7_VV
MO?/V%_\ @H=\7/V@OVD="\$>+6T4Z)>6UU+*MGI_E2[HH'=?FW?WEH _4BBB
MB@ HHHH **** "O&/VMH;&\_9Q\<6VJZE)I%G/:)"]U'#YN&:5%573Y=T;,5
M1O\ 99J]GKC/BQJOA31_AOXDO/'/V4^$5L9%U1;U-T3V[*5=67^+=G;MH ^?
M/V??#.I>$_VC-3B\4Z-X2\%^(9O"D26V@^!X'^RW5G'=!/M4\C;?G5OD1-GR
MJ[?,U:7[5O[1G_"O[VPTGPIX]\%:9XHLY'_M/0?$VK160>&6W=8I69E;Y49T
MEV_Q*M'[(Z_"*QUKQ'#\.?"GBO2+]X(FNM3\4Z?>QM) K;(88I;G^!?X8UKE
MOVW)=8^&\J>*-+\8^(8KW5BT5KH\$FG6FGP);6KRRL\\]I*V]DB;:G\;/M6@
M#N_V+=/@M_"/BNZL_$N@^-;:XUK">)M%CM4>_P!MO#O:X^S(J;E9G5?X]FW=
M7L'A?XH^&O&GBCQ/X>T?4X[[6/#<D46JV\:MFV>569%W$?,?D;[M>8_LC>+(
MO$G@WQ#:0:UJOB1-,U86SZMJ36S^:S6MO*RJUO%$OR&79]W=N4TSX1S1M^UU
M\?U616?[-X>^3=_TZRT >M>//'VB_#G03JNO7OV.V\V."+:C2RSS.P5(HHT&
MZ1V/\*@FCP+X^T3XC:"FK:#>K>6OFM!+N1HY89D8J\4D;C=&ZMGY&&:\4^/&
MK65Q\7O@+XADO;>[\'6'B2_LK^X25)8(+^6REBM-^T_*RR[UW_P,_P#M5R'A
MFX^(UUXI^/\ KWP9MM OUO?%5C#8?V])-%82RP6,46H.GE<L_F[%W_=;8W]V
M@"U^U9_R>!^RE_V%M7_])4KZYK\YO&%Y\<;K]L#]FS_A;^F^#;"%=5U+^SO^
M$7GN)69OLG[WS?-_X!MK]&: /#OVX?\ DT/XN?\ 8O77_H%?CA\!/^29:?\
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MO_)G=S_V';'_ -GK[<KXC_X*^_\ )G=S_P!AVQ_]GH _$6'_ %2_[M/ID/\
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M **** "BBB@ HHHH XZU_P"3L/@;_P!A^P_]+4K][Z_!"U_Y.P^!O_8?L/\
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M -)+>OV_K\0/VGO^4C?Q+_W4_P#22WH 6BBB@ HHHH **** "BBB@#%\;?\
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M_P""/W_)H,7_ &'[[_VE0!]OT444 %?$?_!7W_DSNY_[#MC_ .SU]N5\1_\
M!7W_ ),[N?\ L.V/_L] 'XBP_P"J7_=I],A_U2_[M/H **** "BBB@ HHHH
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M?-2_"?XI1?$F/7K:ZTUM!\3>'[]],U?2)91*8)=JNCHV%WQ2HZLC[5W?\!H
M\,_:L_Y/ _92_P"PMJ__ *2I7US7R-^U9_R>!^RE_P!A;5__ $E2OKF@#P[]
MN'_DT/XN?]B]=?\ H%?CA\!/^29:?_UWG_\ 0J_8_P#;A_Y-#^+G_8O77_H%
M?CA\!/\ DF6G_P#7>?\ ]"H ]"HHHH **** "BBB@ HHHH XZU_Y.P^!O_8?
ML/\ TM2OWOK\$+7_ ).P^!O_ &'[#_TM2OWOH **** "OQ _:>_Y2-_$O_=3
M_P!)+>OV_K\0/VGO^4C?Q+_W4_\ 22WH 6BBB@ HHHH **** "BBB@#%\;?\
MB5X@_P"O&X_] K[Y_P""/W_)H,7_ &'[[_VE7P-XV_Y$KQ!_UXW'_H%??/\
MP1^_Y-!B_P"P_??^TJ /M^BBB@ KXC_X*^_\F=W/_8=L?_9Z^W*^(_\ @K[_
M ,F=W/\ V';'_P!GH _$6'_5+_NT^F0_ZI?]VGT %%%% !1110 4444 %?6O
M_!*;_D][PQ_V#K__ -)7KY*KZU_X)3?\GO>&/^P=?_\ I*] '[O4444 %%%%
M !1110 4444 %%%% &;K>F#6-&O['?Y7VJ"2#?MW;=R[<U\>>"O!'BG5O"/P
M'^%-QX9U/3K_ .'NM6]_K.J7$+BR6#3UE2W>*7[DOVK<FU5;Y/GW?=K[5HH
M^;OBQ)?Z_P"+OA=\3],\/ZU<V7@O7-1L]3TZ73I8KXVT\+VKW44/WI41@C_*
MIWHVY>E8'A[X+^)/BY-\6O$Z>(O$WPK'C36[.XTV?2_]%U'['9VJ6Z/+N7<B
MRE';9\K*NS^]7UA10!\6:U_P3IU3Q+KVB:YJG[0GQ(O]7T5WETV]N+J)Y;-F
M7:[1/M^3<M;G_##GC;_HZ#XK_P#@Q6OK>B@#XY\0?\$__$'BW0;W1M9_:-^)
M^J:5?1-!=65W>1/#/$WWD9"O.:\_TW_@D#X9T:S%I9?%KQG:6JG<L4/D*O\
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MJ2_O=5>RMHK=K[4)?-N)RB[?-E?^)VQEC6W110 4444 %%%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>formf-1a_010.jpg
<TEXT>
begin 644 formf-1a_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $X ;D# 2(  A$! Q$!_\0
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M<9\?/">N^%?V!/ 6K^*]'L_A7\2_AEJ=J^A6]S?0-+?M%Y2L\6P_,[_?V?\
M3*@#]"_A[\:/!?Q8U3Q%I_A/7X=:NO#]U]BU/[-&^VWG^;Y-[+M8_*WW<]*[
MZOE__@GG\);SX6_LXZ5=:W#Y7BGQ9/+XDU5G38_FSG<BM](]G_CU?4% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<YX
MS\9:-\/]!NM<U^_ATW2[;:);BX.%W.X1%']YF9U55]6KC=>^.EGX1\$ZIXJ\
M0>'M;T+2[:>&"TCNX$^T:A)*^R)(HE?>KO(RIMEV<L* /5:*\_\ AG\5-/\
MB7-KU@-/OM$U[P_=):ZKHVI*GVBV=T$L1+(S(RNC*RLK&O0* "BBB@ HHHH
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M5SM\ZTNEW(^U@RY_X$!5.U^'7AFU\'S>%%T2S/AV:)H9=-DBWPR*WWMV[[U
M'@$.F^(O%7[2WQV?P'J]OH6H1>'-)TC^TY[;S88-4_>R[WBS^]98)8OF_P"
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M+H.EZQX[N[NSLM1N?L<#6EJT[&0(7QA?84 >1_\ #J_]FS_H1KG_ ,'-[_\
M':/^'5_[-G_0C7/_ (.;W_X[6/\ \/</V=O^@WK?_@GEH_X>X?L[?]!O6_\
MP3RT ?5G@7P3HOPY\(Z7X9\/62Z=H>F0+;VEJK,WEHO;YJZ*OC'_ (>X?L[?
M]!O6_P#P3RT?\/</V=O^@WK?_@GEH ^SJ*^,?^'N'[.W_0;UO_P3RU]5^!?&
M&F?$3P9H7BG1GDFTC6;.+4+.29"CM%*F]/E_A^5A0!T=%%% !1110 4444 %
M%%% !1110 4444 %?&?_  5M_P"3,=<_["EA_P"C:^S*^,?^"MO_ "9CKG_8
M5L/_ $;0!]8^!_\ D2] _P"P=;_^BEK=K"\#_P#(EZ!_V#K?_P!%+6[0 444
M4 %%%% !7G7QR\5>+/!?PI\0ZWX(\-+XQ\3V<'F6>CO+Y?VCGYO]XA=S;5Y;
M&VO1:* /S*_X>%?M6_\ 1LUW_P""?4J7_AX5^U;_ -&S7G_@GU*OTTHH _,O
M_AX5^U;_ -&S7G_@GU*C_AX5^U;_ -&S7G_@GU*OTTHH _,O_AX5^U;_ -&S
M7G_@GU*C_AX3^U;_ -&S7?\ X*=1K]-** /S+_X>$_M6_P#1LUW_ ."G4:/^
M'A/[5O\ T;-=_P#@IU&OTTHH _,O_AX3^U;_ -&S7?\ X*=1H_X>%?M6_P#1
MLUY_X)]2K]-** /S+_X>%?M6_P#1LUY_X)]2H_X>%?M6_P#1LUY_X)]2K]-*
M* /S+_X>%?M6_P#1LUY_X)]2J:S_ &^OVKM2OH+2+]FFZ$D[K$IETR_1-W^T
M[?*OXU^EU% '-> ]2UO7/!6B7WB328]!U^YLXIK[38YO/2UG9?GB#_Q;6R,U
MTM%% !1110 4444 %%%% !1110 45E^(KB2UT+4IX6V316TCJW]U@N17\[$O
M[8OQVNII)/\ A;?BY=S,S"/6)D7YO]E6H _H[KFO''P[\,?$O16TCQ7H.G>(
M]+9MQM-2MUG3=ZX:OYY_^&NOCM_T5[QA_P"#N?\ ^*H_X:]^/'_17?&'_@[N
M/_BJ /W._P"&)O@+_P!$B\(?^"J+_"C_ (8F^ O_ $2+PA_X*HO\*_#'_AKW
MX\?]%=\8?^#NX_\ BJ/^&O?CQ_T5WQA_X.[C_P"*H ^X_P!G+X"_#GQ)_P %
M&_C?X.U7P3HNH>%=,LY7L=)N+-7M[5O-M^43^'[S_P#?5?=?_#$WP%_Z)%X0
M_P#!5%_A7X&:1\:OB/X?\9:GXMTSQMK=AXGU--E[K-O?2I<72_+]]_O-]U:Z
M7_AK[X[_ /17/&'_ (.9_P#XJ@#]TH?V+/@1;R+)%\)?"*.K;E;^RHO\*]?L
M[.#3+6&VM8([>UB79'%$@157^ZJBOYSO^&O?CM_T5WQA_P"#N?\ ^+H_X:Z^
M.W_17O&'_@[G_P#BJ /Z/:*_G"_X:]^.W_17?&'_ (.Y_P#XNOIC_@G)^TQ\
M6/'7[6_A7P]XF^(/B#7=%O(+Q;FSU._>>)MMN[+\KGCYE2@#]I:*** "BBB@
M HHHH **** .%^*WQ,L_A/X-N-<O(/MTQEBM;33TGBMWO+J5ML4*/*RHK,?[
MS5R%Q^T%=>&?A5?^,O&/@77/!]Q!>16%MH=U+!<75Y-*Z10*C1.R_/)(J_,W
M:NK^*GA_X=^+M(LO#_Q$M=!U&PU*XV6>GZ]Y6V>XVO\ ZI7_ .6NUG^Y\W-?
M*FI^#_\ A7?@'P]*=2>;X;^#/BO#=V-Q=-+*+72=GE;'9MS/'%=3R_,WRJB!
MOX!0!]0_"WXMQ?$:^\3:1<Z5<>'?$WAJZ2VU72;F19?(:6(2Q,LB?*ZNC;LU
M\\_\%;?^3,=<_P"PK8?^C:Z?1=)U/XF_M%?'#4?!WB!_#\4>AZ7X<77+2%9_
M+OT\VX:6)6_=RLD5PB_-]UJ^9_\ @HA\#?B/X#_9CU?5?$WQTUWQWI27UFC:
M/?:3:V\4K-*-K[X_F^6@#](O _\ R)>@?]@ZW_\ 12UNUA>!_P#D2] _[!UO
M_P"BEK=H **_&S]I']JS]H&R_:R^)'@GP9\1[G2-*TN^E^RVCQ0;(HE1/E4^
M4S?Q5R7_  T1^UM_T5W_ ,=@_P#D>@#]B?C-_P )K_PK/7_^%<_8?^$V\C_B
M6?VA_P >_F[USO\ ^ [J^ /^%E_\%$_^A&TG_P !K+_X]7SG_P -%?M;?]%=
M_P#'8/\ Y'IW_#17[6W_ $5W_P A6_\ \CT ?17_  LS_@HG_P!"-I/_ ("V
M7_QZO.I/VS_VTXOC''\*FT31/^$[DC\Y=&^PV^_9Y7F[M_F[/N?-]ZO.O^&B
MOVMO^BN_^0K?_P"1ZX"34/CM)\7(OB>WCFU_X3Q8_(76]R^;M\KRMFWRMOW?
ME^[0!]D_\+,_X*)_]"-I/_@+9?\ QZC_ (69_P %$_\ H1M)_P# 6R_^/5\Z
M_P##17[6W_17?_';?_Y'H_X:*_:V_P"BN_\ CMO_ /(] 'ZR?LTW?Q4OOA+I
MEQ\88-.M?&LDLC26^F+M$<6<(LNT[/,QG.SY?NUZY7X?_P##17[6W_17?_';
M?_Y'IG_#1'[6W_17/_'8/_D>@#]PZ*_&;X#?M5?M#2?M1?#'PEXP^)-SJ^E:
MSJL"75I#%!LEB9MK(W[I37[,T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9'BK_D6=8_Z\Y?_0&K^7RS^Z_^]7]0?BK_ )%G6/\ KSE_
M] :OY?+/[K_[U $]%%% !1110 4444 %%%% !7U'_P $N_\ D]_P1_URO_\
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MV_\ Z-:OW0K\+_AC_P GS? S_L)V_P#Z-:OW0H **** "BBB@ HHHH ****
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MQ_UYR_\ H#5_+Y9_=?\ WJ_J#\5?\BSK'_7G+_Z U?R^6?W7_P!Z@">BBB@
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MH_L=ZMK^O?!Q;[Q0+[^V+C4KJ6=]4\-)H%Q+N?[[VJLWWO[_ /%0![Q1110
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M*VJQ?&W_ ")7B#_KQN/_ $"@#[W_ ."/?_)H*_\ 8PWO_H,5?<-?#W_!'O\
MY-!7_L8;W_T&*ON&@ HHHH R/%7_ "+.L?\ 7G+_ .@-7\OEG]U_]ZOZ@_%7
M_(LZQ_UYR_\ H#5_+Y9_=?\ WJ )Z*** "BBB@ HHHH **** "OJ/_@EW_R?
M%X'_ .N5_P#^D4M?+E?4?_!+O_D^+P/_ -<K_P#](I: /WPHHHH **** "BB
MB@#X0_;>UGQCX=^*FBZQ-/XT_P"$7L6TF[T6+PC%/+:^>M]_Q,/M\47S._D;
M/*W?)]]?O5]"?LP:IXK\3>!=<UOQ1%JMLFK>(]2O=)M-9XN[;3GN/]'BE7^'
MY?X/X%(7M7,_$WP7\4?!'QLO?B7\-]"TOQRFL:/;Z/J&A:MJAL'MF@E=TE@E
MVNNUO-;>I_NBNP_9J^''B#X;>!]33Q3<VA\1:YKE]X@O[33V9K6RENI=_P!G
MB9_F=5_O?Q,6H Z_XE:AXRT_01_P@VEZ5JNNRR;%&M7CV]K NQCYK;$9V^8*
MNU>?GKR)?VFM?A^ >G>+=3\%_P!G>-M1UC_A'++PVUPS)/J'VM[;>C;-[P?*
M\ORKN\M&KT[XI>.O"_A>QM-(\4:E>:1'KOF6T%Q9"XC92J[F_?Q?ZKC^(LM?
M,2?"/Q;\//A'HM_J-WK_ (MTGP1\1_\ A(=(@N5:?4_[$3?%L;?\[[/-FE_O
M,FU: /H/X2?%'6/$GBSQAX)\4V=E8>*O#$L#R2:>SK;7UK.A>*>)9/G'\2-U
M&]&^:O#O^"MG_)F.N_\ 84L/_1M='X5\"V?[0GQ1^,'B6[BU*U\$:WI%AX6T
M^]MGEM9+]8/-EFGB?Y779++Y?]QO+_BKY?\ ^"@W[&7@SX*_LSZIXGT;7_&&
MI7]O?6<26^L:Y)=6^'EV_P"J:@#]+/ __(EZ!_V#K?\ ]%+6[6%X'_Y$O0/^
MP=;_ /HI:W: /PL^.'_*0;XP?]?5Q_Z!%6G69\;O^4@WQ?\ ^OJX_P#:5:=
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MYTQ?%EQ\0/&.C^)=<O-35_[/T /]BT=5MXE^SIO^=>F_YO[]?)G[;?BKX?\
MQ<O/[2\+_$;X;ZMJ]OHM[X=FTGQ)K:0?8WEEBE^UVK_,JSJT6UO[R?Q?)7O'
M[%MY#XIL_B#XV?Q+X8U[5_$VN+=7UKX1O#=V6G>7:PQ10^:P7?+L179MO5J
M/IRBBB@ KXQ_X*V_\F8ZY_V%;#_T;7V=7QC_ ,%;?^3,=<_["MA_Z-H ^L?
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M-_X*L>*M#UC]CO7(++6;"\N!J=@WDV]TCO\ ZW^ZK4 ?8G@?_D2] _[!UO\
M^BEK=K"\#_\ (EZ!_P!@ZW_]%+6[0!^%GQN_Y2#?%_\ Z^KC_P!I5JUE?&[_
M )2"_&#_ *^;C_VE6K0 4VBG4 %-IU% !3:*=0 4VG44 9OPQ_Y/F^!G_83M
M_P#T:U?NA7X7?"__ )/F^!G_ &$[?_T:]?NC0 4444 %?G7_ ,%L/^2 ^!O^
MQF_]M)Z_12OSK_X+8?\ ) ? W_8S?^VD] 'R7IO_ ""[+_KA%_Z!5JJFF_\
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M (+8?\D!\#?]C-_[:3T ?)>E?\@NR_ZX1?\ H"5:JIIO_(+LO^N$7_H"59H
M=1110 VG444 %%%% !6+XV_Y$O7?^O&X_P#0*VJQ?&W_ ")7B#_KQN/_ $"@
M#[W_ ."/?_)H*_\ 8PWO_H,5?<-?#W_!'O\ Y-!7_L8;W_T&*ON&@ HHHH R
M/%7_ "+.L?\ 7G+_ .@-7\OEG]U_]ZOZ@_%7_(LZQ_UYR_\ H#5_+Y9_=?\
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M"5:H **;3J "FTZB@ HHIM #JQ?&_P#R)OB#_KQG_P#0*V*QO&W_ ")NN_\
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MW'_H#T ??'_!'O\ Y-!7_L8;W_T&*ON&OA[_ ((]_P#)H*_]C#>_^@Q5]PT
M%%%% &1XJ_Y%G6/^O.7_ - :OY?+/[K_ .]7]0?BK_D6=8_Z\Y?_ $!J_E\L
M_NO_ +U $]%%% !1110 4444 %%%% !7U'_P2[_Y/B\#_P#7*_\ _2*6OERO
MJ/\ X)=_\GQ>!_\ KE?_ /I%+0!^^%%%% !1110 4444 %%%% !1110 5\8_
M\%;?^3,=<_["MA_Z-K[.KXQ_X*V_\F8ZY_V%;#_T;0!]8^!_^1+T#_L'6_\
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M1\ /^BM>%_\ P.6@#W:OSK_X+8?\D!\#?]C-_P"VD]?3W_#='P _Z*UX7_\
M Y:^'?\ @K#^T/\ #/XQ?!?PEI?@KQOHWB74;7Q MQ/;Z?<^8Z1?9Y5+?[NY
MEH \/TW_ )!=E_UPB_\ 0*L5RNG_ !&\+1:=9*_B*PC=((D=/,_V*G_X65X3
M_P"ACTW_ +^T ='3JYK_ (65X3_Z&/3_ /O[1_PLKPG_ -#'IO\ W]H Z.G5
MS7_"RO"?_0QZ;_W]H_X65X3_ .ACT_\ [^T =+3:YS_A97A/_H8]-_[^T?\
M"RO"?_0QZ;_W]H Z.L;QM_R)NN_]>%Q_Z!57_A97A/\ Z&/3?^_M9?B[X@>&
M;SPKK4$&NV$UQ-9RJB))\[MM^Y0!^BW_  1[_P"305_[&&]_]!BK[AK\T/\
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MV_-A2%KK_P#AG#X3?]$M\%_^$_:?_&J](HH \W_X9P^$W_1+?!?_ (3]I_\
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MM.NY;@*$E=X$E#1_[.UQ7H- 'F__  SC\)_^B7>#/_!!:_\ QJD_X9Q^$_\
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MT6@#SG_AG'X4?]$Q\'?^""U_^(IO_#./PG;K\+_!O_@@M?\ XU7I%% 'F_\
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M@_9^)]2TWQ-<ZCXE2V\6IX+UU/%_A]H]9;4-4NFM6_X^%G7[*LL4OW?L_P#
MWR_)7ZKT4 ?GE\-_A[/\*=2^ 5WX<D\16TWBSP%J*>)%N+RZN(IY8M-BEBW(
M_P L3)+]W;L_NUR_@B[T6XT?X7)\?+CQ5%\/W^']DVD.KW_V675/-?[;Y[6O
M[WS]OE;=_P#!OK]-:* /S,^*,/BG38OBW+X;@NH?"%UX_P!&_MBX*WB(^C?V
M1%M>5K?_ $CR-_E>:T7S_P#CU?0_[%O]HZ#\)?%]]#KEOXNT1=1GN-%TO21?
M%+-5B5VM(FO$65MS_,OWOOU]644 ?E=\(_$%]K7CC6+W2!>:9:^(_ GB!]:\
M-6=MJC16=XD2/%#/<7COY]RN]O\ 5(NW_:WUK6L>@VOA+PY!\7_^$NL]*B^&
M>@KX$BT1;U%^V?8O]*\I8/\ E\\WRO\ 6_[%?IW10!^=?AWX6^(/BQXTO+/X
MM2>)'UJP^$NEWMS%!J%Q:HNJ;[C]ZWE.JM.OR_\  M]>;^.=8\;>+-&^&5Q\
M0M8DL]!O?A[9O9:EKQU:.%-7WO\ :)O] 7=]I5?*_P!;_#7ZN44 <+\&[?5[
M7X3^$(]:UM?$FL+I5M]IUA8V07CB)1YNUMK?/][YN>:[JBB@ HHHH **** "
MOEK]M58-)U;X-^*-?LY+WX?>'?%JWWB';'OBM5\ATM[N5?\ GE%.R,U?4M03
MP1743Q2QK+%(NUE9=RLM 'PY\=/'GA;XS?&_PGJ/PZU2V\3MX9\+^(I_$>MZ
M/+YMM!82V3)%;RRK\K,\VUD3_89JX;]CN37/A&/#2:O)I6J>*/B+X-L'\"^)
M]866*TB\BW3&AOLW>4J?ZWY/];O;^.OT,TWPWI&CV,MGI^E65A;2<R6]M;I$
MC?[RJ*>VA::T-E%]@M3%9LK6R>2NV!E^Z4_N_A0!\O?M=6OB:Y_8M\:77C^T
M\.GQ/;B';+H/FR6\*->P#*-.FY6V_>K.\:^-_"OPA_;,\9Z_\2+NWT;1=9\"
M6]II&H:HP6WG6*XE>[M8G;^-MT3>5_%7UU?:?;:E:O;7<$=S X^:*5-ZM_P&
MJ^K:#INO1Q1ZEI]KJ*Q-OC2Z@67:W]Y=U 'P=X7\,W'AO]D']F@:KI;:=J7_
M  G6C>4EW%_I,5K+J4LMO%_>7]T\7RU^@M4KG3[:\2)+F%+@1.LJ^:N[:Z_=
M;_>J[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>formf-1a_011.jpg
<TEXT>
begin 644 formf-1a_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 ?$# 2(  A$! Q$!_\0
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M:A$C-.OWXN6^^NY?EZC-2<WLJGV8G9T4@.:6D9A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %)2TE 'S=\8=3B^&/[1W@OXBZV)(O"4NCW7A^\U
M+:S1:=(\J2Q2R_W58KLW5F^-_&&C?';XU?#'2/!%];^(+3PUJ$NNZMJVG/YU
MM:*L+I%$95^7?*S_ '<]$KZ:FMXIXS')&KKT*MWJ*PTVTTV'R[.WBM8>NV%
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M2S*Z]V/X_P!VVAP/QZ\'WOC[X+^,_#>F_P#'_J.E3V]MSMS(4.Q?SKROPO\
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MVMK=3MJ3O*[K+=2Q2A96E7:RI'\OW]S/MI[?&[Q3J7AR]EU*VL42XLUO[/\
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M3;'N_>")Y6_W?DB>M*.XM?+\U98O*^[O5EV?G0!\M^+OC7XI\6^%]=T^PO\
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M] '745Q>C_$[0=5M]4EFO8=+&FSW44Z7TR1L$@G:)YOO?ZO<GWJ[2@ HHHH
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MUV7@WXH^(-:^(7]E:C;:8FC7EUK%O9FU\T7$?V&X6+=*S-M;=O\ X/N[?KM
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M)67S8MZHVS>B[JNZ7^U9I T>+5=?T#5/#6GWFAW&OZ?+>M$WVRWB*[D3:_\
MK6#HRKWW4 >]T5\[^+?VQ/#O@O5/L.IZ/?0O96MK=:PKW-JDFG>>J/Y7E-+N
MG9%;Y_*W[:]^L[R*_MXKF"198)562-U_B5NE %JBBB@ HHHH **** "BBB@
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M?PJU.A\)CGR_VB-OY3H:*3-+6Y\N%)2TE #%ZGZ5\??M@?\ )3M-_P"P4O\
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MRR*VW:C-]W=_X[7F/A?X@^*+J=7O]&N)HEAE=K:UM&623;]R569MOS?=V?\
M J .D\$_\CE\0/\ L*0?^D%K7:5YU\,=4EUC7O'=U)I]YI;/JL ^RWR(LJ_Z
M#:]=KLM>BT 4]0_Y!]W_ -<V_P#037YIP_\ 'NG^[7Z6:A_R#[O_ *YM_P"@
MFOS3A_X]T_W:YZQ]EP_\-7Y"MX]N?A;-!XMM+2._GTF19XK25]B2_P 'W_\
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M6FYMJLW\2-[,I->2>$O"'BCQ%K5HFMZ3<:9IMK(CRBZV+Y[+]R)?[WS?>?\
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M-!L];T?PZUUI=WN^S7#7EO%YFUMK;?-E5OO*RUO0^$_6,IKPAAN:K+E/HO\
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M3^[73+<^9XKVPOO<WN_J.R:*,^U%9GP8ZBBB@ HHHH *2EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BO,_BI\3+GX=:AX8MX-%COHM8O_L<M[=W
MIM;:U/\ "K/L;YWYVJVU6V[=X^6LK1_VCO#EP^NIK NM&N=)N+Y'\RUE:*>.
MUNOLY,3[/WK;GA^1/FW2JM 'L-49K'=(TL,ABE;[W]UO]Y:\HU[]ICPSINA7
M]S96FK7^K6MC>W;:2VGS130?9D5G2X^7]Q]^+YG_ +]:WB'XIW\<?A*S\/\
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M1Y55IPI582ER\QYQ^T6LZP>-5N88+2X^V-NM[?[B_O?NK73_  C\27=A\,O
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MFW<VW;\O1FJ+P_\ $OQ3XHAM'MO#4*PSK$?M;22>4K,^U_X/X?\ T)?[OST
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MOOLGS;2O-2+^S[X$5PBZ"(K=6B=+:.YG6&,*RLBK'OVHN]$=E7 9E5FJS9_
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>formf-1a_012.jpg
<TEXT>
begin 644 formf-1a_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' G # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#YZ_MO4_\
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M'^+_ ('1M0NW1]=L]R/._P#S\)7!5V?P6_Y+#X%_[#MG_P"E"4'-BHQ]A/\
MPR_])9^R$G^L>F4]O]:_^]3*[3^:WN%%%% @HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HH1=_P!VN$\;?'#P5X 9XM4UR)[U?^7&Q_TB
M7_OA?N_\#JZ=.567+&)$I1A\1W=%?+GBC]M)OGB\.>&E3_IXU:7?_P"0D_\
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MT4?_ +5&]75&5UV-]UJ "BHFN8(94BEGC1V^ZCRHCM4M !11]_[K44 %%%%
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M!J6GR_=N+=MZ5>K\WO!?C[7OA_J?VW0M0EL)?^6L/WHI_P#9E7[K5]@?"/\
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MO#K2W47B#1[R6PNDNI]WVAHI4;>JLK;=O]U5KW*BCVM0CV<3GH/ >@P^!?\
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M35^(_P /K^\\1>-;VQTF^UFTU33=)%U;^?N^V)!?RO<6L2N^U?W'\/RJV_\
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M;):W4:RQ2K_MHU?(GQ:_8[U7P3JW_"<?!B]N=*U2US+_ &)%)\W^WY#?Q?\
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M?LK_ +WX9_$R%?FE:#"K_P!NLM?/FM^&]5\-RQ1ZK8R6#R[MJ2_Q;?OU[_\
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MLE-MK.*VEEE7[\NU=_\ =5?N)5BBN4Z#SS4O!_E^%Y8/LJ_:M4UJ6]GWKO\
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MTO\ 9D_Y.0^%_P#V,EA_Z-2L:O\ "F72^.!^Z'\5%'\5%?"GUX4444 %%%%
M!1110 4444 %%%% !1110!XY^U-X#?QA\-9=0MHM^I:(WVI=GWV@_P"6J?\
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MEM_:=E]HNMWV6'[4N^?;]_:G\6S_ &*KOXNT%8GE;7-+2**?[(SM?1;%N/\
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MM=5M_(OK:"_M_P#GE=Q)*G_CU>>:]^S?\//$+%F\/K83?W],E>W_ /'/N_\
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M2KU%>'6Q%?$?Q9';&E&'PA1117(:A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5+9_\ 'U%_O5%4MG_Q]1?[U '\[]%%%?H!\8%%
M%% !1110 4444 %%%% !1110 4444 %%%% !7I?[,G_)R'PO_P"QDL/_ $:E
M%%8U?X4S2E\<#]T/XJ***^%/KPHHHH **** #<U'F444 0M;P2:@ERT,4E[
MCQI,R_O$1MF]5;_:VI_WS4VY_P"]110 >91110 4;G_O444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4MG_Q]1?[U%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>formf-1a_013.jpg
<TEXT>
begin 644 formf-1a_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !J 1H# 2(  A$! Q$!_\0
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M_=2>"?-9?]I;I=G_ *&]9W[%W_)U_P ,?^PK_P"TI:M_LV_\B!^T'_V(C_\
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M  3Z_:@U3XH:'J?P^\>7DQ^('AIV1WOO]?>0*^QM_P#TUB?Y']?D;^]7S/\
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M-IHVFCGES<UP]G$%C"K@5SGCCP3HWQ$\*ZKX<\062ZAH^IP-:W-LV<.C _\
M?)Y^]72T4KEGEGP/_9_\*_L\Z'?Z/X-6^M]+O)_M3VM[>R7"++M"LZ[ONEL+
MN_W:]0I!3MU3)RD[BLHZ(=1113&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex23-1_001.jpg
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 'T# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#!U[PSXR\
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MN,9ZYK0^$/\ R K_ /Z^1_Z"*NK5<L*ZM^9QDK.UOZ1%*DHXE4K64HNZO?\
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MJG/S7ULC*I1I\EK:795'A*PR/WUU_P!]C_"NM\=^'K&X\+07[B07-G;JB.I
MW*%R W'//TZT445*]1U:=Y=14Z%-4JEH]#&\'>&K'4O"UYJ%TTTD_P!G>),N
M"(QSRHQP>*Z+X?:9#I1OXH))61]C$.0<$9Z8%%%9XNK-^UBWI<UPM*"]E)+6
MQGOH%J?B$+_S)O.^UA\;AC.?I7>ZCIUKJUA+97L0E@E&&4\?B#V-%%<>)J3;
M@[[+0Z\-3@E-6W9X5XHT*VT3Q NGVLDQA<@'>P)Z^P%>L>%/"FE:3I*M%!YK
CW #N\^&/L!Q@#DT45WX^M4>&IZ[[^9P8&C36(J:;;>1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex23-1_002.jpg
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 'T# 2(  A$! Q$!_\0
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?54Z=9G4QJ/V=/M@B\GSL?-LSG'TS5JB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
